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Summary 
 
Spasticity is one of the most commonly seen complications after stroke, affecting 
around 20–50% of stroke survivors (Watkins et al. 2002; Zorowitz, Gillard and 
Brainin 2013; Kwah et al. 2012). The relatively short duration of therapeutic effects, 
heavy financial burden and unwanted risks in relation to current management have 
raised great concern (Wu, Mills et al. 2010; Fan et al. 2015; Nair and Marsden 2014). 
Therefore, these patients are in need of new or additional therapy to better manage 
spasticity with fewer adverse events. Chinese medicine has long been used in stroke 
patients, with some evidence indicating potential benefits for treating post-stroke 
spasticity (Qi et al. 2009; Rodriguez-Mansilla, Espejo-Antunez and Bustamante-
Lopez 2016; Lim et al. 2015). 
The objective of this project has been to systematically evaluate the add-on effects 
and safety of Chinese medicine, specifically Chinese herbal medicine and 
acupuncture, for post-stroke spasticity. Under the “whole evidence approach” 
framework, this research comprises four major components: 
Data mining of classical literature 
First, a search for relevant literature on treatments for post-stroke spasticity was 
conducted in Zhong Hua Yi Dian (ZHYD 中华医典 Version 5.0) (Zhong Hua Yi Dian 
2014), one of the largest Chinese medicine collections. Statistical analyses were 
conducted using the Statistical Package for the Social Sciences software version 23.0 
for Windows (IBM SPSS Statistics, IBM Corp, Somers, New York, USA) (SPSS 
23.0). Although the frequently reported formulas used for post-stroke spasticity in 
ancient times were different from those used in current clinical practice, the 
2 
 
commonly used herbs then are similar to what we use today, such as dang gui 当归 
and chuan xiong 川芎. In addition, acupuncture and moxibustion were also used in 
ancient China for symptoms similar to spasticity, with LI15 Jianyu 肩髃, LI11 Quchi 
曲池, LI4 Hegu 合谷 and GB30 Huantiao 环跳 the most common acupuncture 
points. 
Systematic review of Chinese herbal medicine clinical evidence 
Second, five major English and four key Chinese databases were searched. The 
Cochrane ‘risk of bias’ tool was used to access the methodological quality of the 
included studies. Review Manager (RevMan) 5.3 was employed for statistical 
analysis. A total of 35 trials including 2,309 participants were included in the 
systematic review. Although based on evidence of limited qulity, it was found that 
Chinese herbal medicine may be a potentially effective and well-tolerated adjunct 
therapy to reduce the severity of spasticity, improve motor function and enhance the 
activities of daily living for stroke patients with spasticity. Further studies of high 
methodological and reporting quality are needed to confirm its effects and safety, and 
to explore the adequate and optimal protocols for these interventions for post-stroke 
spasticity, incorporating a group of comprehensive outcome measures in different 
populations. 
Systematic reviews of acupuncture clinical evidence 
Third, a comprehensive literature review was conducted to evaluate the effects and 
safety of acupuncture, covering manual acupuncture, acupressure, moxibustion and 
electro-acupuncture, for treating post-stroke spasticity. As an adjunct therapy to 
routine care for stroke patients with spasticity, acupuncture, and particularly electro-
3 
 
acupuncture, has been widely researched and concluded to be a promising treatment. 
We then conducted a systematic review and meta-analysis of adjunct electro-
acupuncture for the treatment of post-stroke spasticity. The results of this component 
provided evidence to inform the design of a randomised controlled trial of adjunct 
electro-acupuncture for post-stroke spasticity. 
Pilot trial of adjunct electro-acupuncture for post-stroke spasticity 
Finally, based on the findings of the comprehensive literature review, a trial protocol 
was developed for a two-arm, parallel-design randomised controlled trial evaluating 
the effects and safety of electro-acupuncture as an adjunct therapy for post-stroke 
spasticity. A pilot study was then conducted to assess the feasibility of the full-scale 
trial. Thirty (30) participants were recruited and 22 completed the trial. Electro-
acupuncture was administered for 20 to 30 minutes, three times each week, for four 
weeks. The primary outcome measure (Modified Ashworth Scale) and secondary 
outcome measures (Fugl-Meyer Assessment [motor function] and Barthel Index) were 
recorded at baseline, the end of treatment (Week 4) and the end of the follow-up 
(Week 8). Adverse events were monitored, recorded, reported and assessed.  
The pilot trial suggested that a full-scale randomised controlled trial is feasible and 
manageable. The preliminary results showed that there was no significant between-
group difference in terms of changes in total scores of the Modified Ashworth Scale, 
Fugl-Meyer Assessment or Barthel Index at Week 4 or Week 8. Seventeen (17) mild 
to moderate adverse events were reported, but none of them were deemed to be 
related to electro-acupuncture. Future studies are warranted in order to determine the 
effectiveness and safety of adjunct electro-acupuncture for post-stroke spasticity.  
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Chapter 1 General introduction 
 
This chapter consists of an introduction to the rationale, objectives and research 
questions, and an introduction to the research methods, expected deliverables and 
major components of the project (Figure 1.1). 
 
Figure 1.1 Structure of the research project 
1.1. Background and rationale 
1.1.1 Clinical uncertainty 
Spasticity is one of the most commonly seen complications after stroke, affecting 
around 20–50% of survivors (Watkins et al. 2002; Sommerfeld et al. 2004; Kwah et 
al. 2012; Zorowitz, Gillard and Brainin 2013). However, its pathophysiology is not 
yet completely understood (Sheean 2002; Schindler-Ivens and Shields 2000; Reese et 
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al. 2006; Ivanhoe and Reistetter 2004; Hultborn et al. 1996; Mayer and Esquenazi 
2003; Thilmann, Fellows, and Garms 1991). Spasticity not only adversely affects 
patients’ physical functions, but also negatively impacts on their quality of life 
(Esquenazi and Mayer 2001; Lundstrom et al. 2010). 
Nearly all clinical guidelines consider non-pharmacological rehabilitation therapy the 
basic treatment in the management of spasticity, but the initial duration of therapy and 
the treatment protocol for each method have not been specified (Australian National 
Stroke Foundation 2017; Chinese Society of Neurology and Stroke Prevention Project 
Committee of National Health and Family Planning Commission in China 2012; 
Chinese Society of Neurology et al. 2017; Hebert et al. 2016; Lindsay et al. 2014; 
Royal College of Physicians Intercollegiate Stroke Working Party 2016; Simpson et 
al. 2016; Stroke Foundation of New Zealand and New Zealand Guidelines Group 
2010; Winstein et al. 2016).  
Oral medication and invasive therapies, such as oral Baclofen, tizanidine, intrathecal 
Baclofen injection and chemical neurolysis, should be considered for more 
generalised or severe spasticity affecting physical function or leading to pain, 
discomfort and loss of independence or limitation of activities (Australian National 
Stroke Foundation 2017; Chinese Society of Neurology and Stroke Prevention Project 
Committee of National Health and Family Planning Commission in China 2012; 
Chinese Society of Neurology et al. 2017; Hebert et al. 2016; Lindsay et al. 2014; 
Royal College of Physicians Intercollegiate Stroke Working Party 2016; Simpson et 
al. 2016; Stroke Foundation of New Zealand and New Zealand Guidelines Group 
2010; Winstein et al. 2016). However, their relatively short-term beneficial effects and 
unwanted risks, such as an increase in muscle weakness, are cause for concern (Nair 
and Marsden 2014).  
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Due to these limitations and the uncertainty in current clinical practice, patients are in 
need of additional new therapies to better control spasticity with fewer adverse events. 
1.1.2 Conflicting evidence 
Chinese medicine has long been used for stroke survivors (Zhang and Xue 2012). 
However, in the context of conflicting original studies, its effects have not been 
comprehensively evaluated and summarised, although some systematic reviews have 
been published in English (Lim et al. 2015; Park et al. 2014) and Chinese (Qi et al. 
2009) as identified by database searches on the use of acupuncture for post-stroke 
spasticity. The results of these systematic reviews are inconclusive. Further, none of 
these reviews covered all the major English and Chinese databases, and all focused on 
acupuncture only while the effects of Chinese herbal medicine have not been 
addressed. 
Moreover, Chinese medicine has long been used for stroke patients with symptoms 
similar to spasticity as recorded in various classical literatures (Wang and Xie 2010). 
Therefore, in addition to the relevant studies in modern literature, data mining of the 
classical literature of Chinese medicine is needed. This has been done in the current 
study with the help of Zhong Hua Yi Dian (ZHYD 中华医典 Version 5.0) (Zhong 
Hua Yi Dian 2014). 
Furthermore, summarising the commonly used Chinese herbal medicine formulas, 
herbs and acupuncture points used in ancient China, and comparing these therapies to 
those described in the modern literature may discover changes in the most prevalent 
Chinese medicine therapies over times and suggest new research directions. 
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1.1.3 Variation in practice and research 
It is probable that a variety of therapies are applied to patients with post-stroke 
spasticity, since instructions or recommendations on treatment specifically for 
spasticity are inconsistent from guidelines (Australian National Stroke Foundation 
2017; Chinese Society of Neurology and Stroke Prevention Project Committee of 
National Health and Family Planning Commission in China 2012; Chinese Society of 
Neurology et al. 2017; Hebert et al. 2016; Lindsay et al. 2014; Royal College of 
Physicians Intercollegiate Stroke Working Party 2016; Simpson et al. 2016; Stroke 
Foundation of New Zealand and New Zealand Guidelines Group 2010; Winstein et al. 
2016). Moreover, treatments may also differ in relation to time of initial intervention, 
herbal formulas, acupuncture points, stimulation intensity and frequency, etc. 
Similarly, variation is also observed in the clinical research on Chinese medicine for 
post-stroke spasticity, as a large number of diverse studies have been identified 
through the database search for this thesis project.  
Therefore, in order to evaluate a Chinese medicine therapy for patients with post-
stroke spasticity, it is critical to develop a rigorously designed and clinically 
meaningful protocol based on the findings of the currently available evidence about 
Chinese medicine therapies. 
1.2 Objectives and research questions 
1.2.1 Objectives 
Since rehabilitation therapies are recommended as the fundamental management 
technique in post-stroke recovery, the objectives of this research project are to 
evaluate the add-on effects and safety of Chinese medicine, specifically Chinese 
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herbal medicine and acupuncture (covering manual acupuncture, acupressure, 
moxibustion and electro-acupuncture), for treatment of post-stroke spasticity by 
systematically reviewing the classical and modern literature, and to seek evidence of 
high methodological and reporting quality for one of the promising therapies in 
Chinese medicine for post-stroke spasticity, electro-acupuncture. 
1.2.2 Research questions 
This thesis intended to address the following questions based on the currently 
available evidence: 
1) What are the understanding and evidence of Chinese medicine for post-stroke 
spasticity in classical literature? 
2) What are the add-on effects and safety of Chinese herbal medicine for post-stroke 
spasticity? 
3) What are the add-on effects and safety of acupuncture (including manual 
acupuncture, acupressure, moxibustion and electro-acupuncture) for post-stroke 
spasticity? 
4) What are the details of a rigorously designed randomised controlled trial of adjunct 
electro-acupuncture for post-stroke spasticity? Is it feasible to conduct a full-scale 
trial? 
1.3 Expected deliverables 
 Comprehensive evaluation of interventions for post-stroke spasticity found in the 
Chinese classical literature 
 A literature review and a systematic review of Chinese herbal medicine for post-
stroke spasticity 
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 A literature review and a systematic review of acupuncture for post-stroke 
spasticity 
 A protocol for a randomised controlled trial of adjunct electro-acupuncture for 
post-stroke spasticity 
 A pilot study of adjunct electro-acupuncture for post-stroke spasticity 
1.4 Organisation of the thesis 
This thesis contains eight chapters. 
Chapter 1 provides an introduction to the research background, rationale, objectives, 
research questions, expected deliverables of this project and the organisation of the 
thesis. 
Chapter 2 reviews the definitions, epidemiology, aetiology, pathogenic mechanisms, 
clinical characteristics, diagnosis, management, impacts and prognosis of post-stroke 
spasticity. 
Chapter 3 examines the understanding of post-stroke spasticity from a perspective of 
Chinese medicine. Besides, existing reviews of Chinese medicine for post-stroke 
spasticity are summarized in this chapter. 
Chapter 4 summarises the evidence of Chinese medicine (including Chinese herbal 
medicine and acupuncture) for post-stroke spasticity from classical literature. 
Chapter 5 systematically reviews the add-on effectiveness and safety of Chinese 
herbal medicine for post-stroke spasticity. 
Chapter 6 evaluates the add-on effectiveness and safety of acupuncture, including 
manual acupuncture, electro-acupuncture, acupressure and moxibustion, for post-
stroke spasticity. 
10 
 
Chapter 7 develops a protocol of a randomised controlled trial of a promising Chinese 
medicine therapy, electro-acupuncture, for post-stroke spasticity; and presents the 
results of a pilot study of the trial. 
Chapter 8 summarises the main findings of the project, discusses the strengths and 
limitations and draws a conclusion from the thesis. 
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Chapter 2 General review of post-stroke spasticity 
 
This chapter reviews the definitions, epidemiology, aetiology, pathogenic 
mechanisms, clinical characteristics, diagnosis, management, impacts and prognosis 
of post-stroke spasticity. 
2.1 Definitions 
2.1.1 Definition of stroke 
The World Health Organization (WHO) defined stroke as ‘developing clinical signs of 
focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or 
longer or leading to death, with no apparent cause other than of vascular origin’ 
(WHO Task Force on Stroke and Other Cerebrovascular Disorders 1989). Although 
published in 1989, this definition is still widely used today. A recent update (Sacco et 
al. 2013) of the definition emphasises that the imaging or autopsy of focal infarction 
or haemorrhage still requires consensus and further endorsement, especially in regions 
where magnetic resonance imaging is unavailable.  
From the above definitions, ischaemic stroke caused in the arterial and venous 
systems, intracerebral haemorrhage and subarachnoid haemorrhage are the three 
common vascular origins of stroke (Department of Veterans Affairs, Department of 
Defense, American Heart Association and American Stroke Association 2010; 
Australian National Stroke Foundation 2017; Lindsay et al. 2014; Royal College of 
Physicians Intercollegiate Stroke Working Party 2016; Sacco et al. 2013; Winstein et 
al. 2016). Thus transient ischaemic attack and stroke symptoms caused by tumour, 
subdural haemorrhage, trauma and poisoning are excluded from the scope of the 
concept. 
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2.1.2 Definition of spasticity 
Spasticity was initially defined in 1980 as ‘a motor disorder characterized by a 
velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated 
tendon jerks resulting from hyper-excitability of the stretch reflex as one component 
of the upper motor neuron syndrome’ (Lance 1980), with a focus on the difficulty of 
passive movement. In 1994, neurophysiological factors were added to the definition 
of spasticity as ‘a motor disorder characterized by a velocity-dependent increase in 
tonic stretch reflexes that results from abnormal intra-spinal processing of primary 
afferent input’ (Young 1994). In 2005, spasticity was defined as ‘a disordered 
sensorimotor control, resulting from an upper motor neuron lesion, presenting as 
intermittent or sustained involuntary activation of muscles’ (Pandyan et al. 2005). To 
date there has been no universally consistent definition of spasticity, which suggests 
the complexity and diversity of its manifestations and incompletely understood 
mechanisms. Spasticity is one of the most significant impairments after stroke and 
may lead to body pain, problems with skin hygiene and, most severely, contractures 
(Duncan et al. 2005). 
2.1.3 Scope of rehabilitation 
Rehabilitation is defined as ‘a problem-solving and educational process aimed at 
reducing the disability and handicap experienced by someone as a result of disease, 
always within the limitations imposed by both available resources and the underlying 
disease’ (Stroke Foundation of New Zealand and New Zealand Guidelines Group 
2010). The goal of post-stroke rehabilitation is to prevent deterioration of function 
and/or to improve function, and to bring about the highest possible levels of physical, 
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psychological, social and financial independence (Australian National Stroke 
Foundation 2017). 
2.2 Epidemiology 
2.2.1 Stroke 
Stroke has become a huge burden across the globe. According to WHO reports on its 
epidemiology, around 6.7 million deaths were caused by stroke in 2012; thus it is the 
third most common cause of death in developed countries, exceeded only by coronary 
heart disease and cancer (World Health Organization 2014). Worldwide, 15 million 
people suffer stroke each year; one third of them die and another third are left 
permanently disabled (World Health Organization 2014). The following figures 
(Figure 2.1 and Figure 2.2) adapted from Thrift et al. (2014) summarise the incidence 
of stroke worldwide, with statistics showing that its incidence rates ranged from a low 
of 41 per 100,000 population per year in Nigeria (1971–74) to a high of 
316/100,000/year in urban Dar es Salaam, Tanzania (Thrift et al. 2014). With the 
increase in ageing populations it is expected that the global burden of stroke will also 
rise, which will become a huge burden on families and communities. It is worth 
noting that, based on data from recently published research (Bejot et al. 2016; Ekker 
et al. 2018; Griffiths and Sturm 2011), an increase in the incidence of stroke of up to 
40% has been reported over the past decades, potentially lengthening the 
rehabilitation period post-stroke. 
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Figure 2.1 Heat map of stroke incidence adjusted to WHO world population 
Notes: figure adapted from Thrift et al. (2014). This is a heat map showing stroke incidence 
adjusted to the World Health Organization world population by quartiles. 
 
Figure 2.2 Incidence of stroke adjusted to WHO world population 
Notes: figure adapted from Thrift et al. (2014). 
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2.2.2 Spasticity 
Spasticity is one of the most commonly seen complications after stroke (Miller et al. 
2010; Lim et al. 2015), affecting around 20–50% of survivors (Zorowitz, Gillard and 
Brainin 2013; Kwah et al. 2012; Bethoux 2015; Kong, Lee and Chua 2012; Opheim et 
al. 2014; Shin et al. 2018; Wissel, Manack and Brainin 2013). Further, there is a 
variation in the time of onset of spasticity after stroke, which has an impact on the 
prevalence of post-stroke spasticity. Related evidence shows that, at the early stage 
(zero to three months) after stroke, the occurrence rate of spasticity is between 19% 
and 28% (Sommerfeld et al. 2004), while the percentage of survivors suffering 
spasticity increases slightly to 43% in the medium term (three months to one year) 
after stroke (Lundstrom et al. 2010). But in terms of its occurrence in the long term 
(more than one year after stroke), the data vary between 17% and 46% (Bhattacharya 
et al. 2005; Watkins et al. 2002; Lundstrom, Terent and Borg 2008). 
It has been reported that the direct cost for patients with spasticity following stroke is 
nearly four times higher than for stroke survivors without spasticity (Lundstrom et al. 
2010). Accordingly, the long-term financial burden of post-stroke spasticity increases 
the costs for both families and society. Moreover, the consequences and comorbidities 
following post-stroke spasticity, such as falls and fractures, not only require higher 
treatment costs but also increase the burden on caregivers (Francisco et al. 2017; 
Ganapathy et al. 2015). 
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2.3 Aetiology and pathogenic mechanisms 
2.3.1 General understanding of aetiology 
The following explanations are put forward in order to uncover the underlying 
mechanisms of how spasticity develops after stroke, even though the pathophysiology 
of spasticity itself is not yet completely understood. 
Spasticity is one of the positive features of upper motor neurone syndrome, resulting 
from afferent-dependent abnormal spinal reflexes (Marinelli et al. 2017). The 
occurrence of upper motor neurone syndrome is largely due to parapyramidal fibre 
dysfunction, with both excitatory and inhibitory pathways. The dorsal reticulospinal 
tract is the main tract that inhibits spinal reflex activity, while the excitatory pathways 
arise in the bulbopontine tegmentum, descending in the medial reticulospinal tract 
(Marinelli et al. 2017).  
Spinal reflexes seem to be the cause of the features of upper motor neurone syndrome. 
Many pathophysiological changes related to the regulation of spinal reflexes have 
been observed, such as decreased presynaptic inhibition, the failure of reciprocal 
inhibition from antagonist muscles, decreased homosynaptic depression and changes 
in motor neurone properties. Among these changes, it is the abnormal processing of 
proprioceptive input in the spinal cord, mediated by Ia afferents, that seems to be the 
key to the development of spasticity, in enhancing central excitability (Trompetto et 
al. 2014). But how these changes work together in the development of spasticity 
remains poorly understood (Ward 2012). 
Moreover, the negative features of upper motor neuron syndrome, such as muscle 
weakness, may lead to muscle immobilisation in the short term and further result in 
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hypertonia, stiffness and contracture, which in turn contribute to the development and 
worsening of spasticity (Trompetto et al. 2014). 
2.3.2 Contributing factors 
2.3.2.1 Risk factors for post-stroke spasticity 
Certain risks are considered potential factors in the development and progression of 
spasticity in stroke survivors (Ward 2012). These are: stroke lesions in the brain stem; 
haemorrhagic stroke; younger age; a low Barthel Index at baseline; early arm or leg 
weakness or paresis from days to 16 weeks; left-sided weakness; smoking; hemi-
spasticity most often in the arm, ≥ two joints affected; and a modified Ashworth Score 
≥ Lever Two from baseline to first follow-up (median time=6 weeks) (Urban et al. 
2010; Ward 2012; Lundstrom, Terent and Borg 2008; Wissel et al. 2010). 
However, there is uncertainty about the above factors due to contradictory evidence. 
For instance, Urban et al. (2010) discovered that patients with severe paresis at the 
acute stage had higher spasticity scores than patients with slight paresis, which is 
inconsistent with other observations (Ward 2012; Lundstrom, Terent and Borg 2008). 
Further, unlike the results from Leathley et al. (Ward 2012), the research from Wissel 
et al. (2010) showed that a history of smoking and other baseline factors such as 
gender and age were not associated with severe spasticity. 
2.3.2.2 Triggers of post-stroke spasticity 
Spasticity may be aggravated by triggers such as visceral or somatic stimuli below the 
level of injury (Phadke et al. 2013). Specifically, the triggers for worsening of 
spasticity include: 1) skin problems, such as ulcers, ingrown toenails, boils and skin 
infections; 2) visceral disorders, such as constipation, urinary tract infections, urinary 
tract calculi and menstrual pain; 3) device-related problems, such as improper seating, 
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ill-fitting orthotics and failure of intrathecal Baclofen pumps; 4) medication issues, 
such as rapid withdrawal of anti-spasticity drugs; and 5) others problems, such as 
infections, injuries, deep vein thrombosis and stress. 
2.3.2.3 Worsening of post-stroke spasticity 
In summary, the worsening of spasticity in stroke survivors, which often presents as 
aggravation of pain, stiffness, involuntary movement, deterioration of mobility, 
increase in care needs and sexual dysfunction (Nair and Marsden 2014), may result 
from spasticity triggers, primary neurological disease progression and the occurrence 
and development of new diseases. Therefore, comprehensive review of the 
abovementioned factors is needed in order to identify the reasons for worsening of 
spasticity. 
2.4 Clinical characteristics 
2.4.1 Typical clinical features 
Although the precise natural history of how spasticity develops is diverse and 
currently not completely understood, there are symptoms and signs that are clinical 
characteristics indicating spasticity in stroke survivors. The typical feature of 
spasticity is increased muscle tone that varies with the speed of movement such that, 
where the resistance becomes greater, the stretch goes faster (Li 2017). It is said that 
the resistance is ‘felt like a catch after an initial few degrees of movement’ (Nair and 
Marsden 2014). In most cases, the manifestations of post-stroke spasticity are 
accompanied by other post-stroke dysfunctions and changes in motor functions. 
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2.4.2 Upper-limb spasticity 
In upper-limb spasticity, the antigravity muscle groups are characteristically affected 
by the increased muscle tone, which is usually high in the adductors of the shoulders, 
flexors of the elbows, wrists and fingers, and pronators of the forearms. The typical 
clenched fist with ‘thumb in palm deformity’ is generally considered to be the result 
of excessive flexion of the fingers and adduction of the thumb that may be associated 
with upper-limb spasticity (Nair and Marsden 2014).  
In addition, patients with upper-limb spasticity are usually observed with a group of 
symptoms and signs that constitute upper motor neurone syndrome and therefore may 
be diagnosed with different terms rather than upper-limb spasticity, such as 
hemiplegic shoulder pain (Robert et al. 2015). Specifically, two commonly seen 
causes of hemiplegic shoulder pain are subscapularis spasticity disorder and pectoralis 
spasticity disorder. Subscapularis spasticity disorder is characterised by motion being 
very limited and pain being produced on external rotation, and pectoralis spasticity 
disorder is characterised by motion being very limited and pain being produced on 
abduction (Bates et al. 2005). 
2.4.3 Lower-limb spasticity 
In lower-limb spasticity, increased muscle tone resulting from spasticity is commonly 
seen in the adductors of the hips, flexors of the knees and plantar flexors and invertors 
of the ankles (Bethoux 2015; Kheder and Nair 2012; Nair and Marsden 2014). 
Specifically: 1) the adductor under spasticity resulting in plantar flexion and inversion 
at the knee forms part of the lower limb pattern in hemiplegia, pulls the knees and 
ankles together and limits the range of movement; 2) spasticity of the gastrocnemius 
and tibialis posterior muscles is a common cause of spastic equinovarus foot after 
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stroke, whose patients suffer deformity and difficulty with their gait; 3) spasticity and 
the persistent high tone of extensor hallucis longus may cause difficulty in wearing 
footwear (Nair and Marsden 2014); and 4) paretic lower limbs with muscle spasticity 
are at considerable risk of developing contractures, which not only restrict the 
movement of the involved joints but also lead to significant pain (Bates et al. 2005). 
2.4.4 Complications and coexisting disorders 
It is believed that spasticity can also induce changes in rheological muscle properties, 
such as stiffness, fibrosis and atrophy, and a number of complications, such as falls, 
pain, pressure ulcers, infections and contractures, are considered to be associated with 
spasticity although it is unclear whether these complications are caused by spasticity 
or coexist independently (Dietz and Sinkjaer 2007). It is often difficult to clearly 
separate spasticity from other post-stroke somatic discomforts in clinical practice 
(Bethoux 2015; Kheder and Nair 2012; Nair and Marsden 2014). 
2.5 Diagnosis and differential diagnosis 
2.5.1 Diagnosis of stroke 
Before identifying the specific stroke type, clinicians should first ask whether the 
clinical findings could be caused by a nonvascular process, such as a brain tumour, 
metabolic disorder, infection, demyelination, intoxication or traumatic injury that 
mimics stroke (Sacco et al. 2013). 
The classification of stroke includes different conditions, such as cerebral infarction, 
cerebral haemorrhage and subarachnoid haemorrhage. Brain imaging is required for 
confirmation of the classification (Goldstein and Simel 2005; Hand et al. 2006). 
Further, radiographic imaging can also help determine the lesions and the size, shape, 
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extent, nature and severity of the vascular area of stroke, as well as its relation to brain 
perfusion abnormalities and whether a nonvascular stroke mimic exists (Sacco et al. 
2013). 
Generally, CT has high specificity but low sensitivity, while magnetic resonance 
imaging diffusion-weighted imaging has high sensitivity as well as specificity 
(Brazzelli et al. 2009). Further, CT is sensitive to intra-cerebral hemorrhage in the 
acute phase but not after eight to ten days when Magnetic Resonance Imaging is 
required to differentiate intra-cerebral hemorrhage and ischemic stroke. Though 
Magnetic resonance imaging is currently considered a better choice for imaging 
modality, the limits in availability and relatively long imaging time restrict its use in 
routine application (Wardlaw et al. 2004). In the foreseeable future, CT is still likely 
to be the routine imaging modality for diagnosis of stroke (Sacco et al. 2013). 
To sum up, clinical and radiographic manifestations remain the key to the diagnosis of 
stroke, and review by physicians and even special expertise in stroke is often also 
required. 
2.5.2 Assessment of post-stroke spasticity 
The assessment of patients suffering spasticity generally includes focal muscle 
evaluation, as well as its impact on limb function and activities as a whole. 
Appendices 1–6 provide details of the scales introduced in this section. 
2.5.2.1 Outcome measures of spasticity 
The assessment of spasticity mainly requires the neurological examination of muscle 
tone, motor power, reflexes and sensory level. Quantification through a validated 
scoring system is necessary. The most frequently used is the Ashworth Scale or the 
Modified Ashworth Scale (Bohannon and Smith 1987; Ashworth 1964). 
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Several other scales are used in the focal muscle evaluation of spasticity: 1) the 
Tardieu Scale and Modified Tardieu Scale can be used to evaluate the passive range of 
motion, quality of muscle reaction to passive stretch at the fastest stretching velocity 
and angle of muscle reaction at the point of resistance to the fastest stretching velocity 
when the overactive stretch reflex produces a first catch (Tardieu, Shentoub and 
Delarue 1954; Fosang et al. 2003; Mehrholz et al. 2005); 2) the Composite Spasticity 
Index is a measure of extremity spasticity that is suitable for stroke survivors with 
hemiparesis by assessing the tendon jerk, clonus and tonic stretch reflex (Calota and 
Levin 2009); 3) other less used scales include the one developed by Priebe and Penn 
counting spasm frequency (Penn et al. 1989; Priebe et al. 1996) and the Pendulum 
Test assessing knee spasticity (Wartenberg 1951; Biering-Sorensen, Nielsen and 
Klinge 2006), etc. The scales mentioned above, however, are based on the examiner’s 
feeling of passive movement and therefore questions have been raised about their 
reliability and validity (Malhotra et al. 2009; Fleuren et al. 2010). There is no scale 
available to objectively quantify the degree or severity of spasticity. 
2.5.2.2 Related functional outcome measures 
Considering the fact that post-stroke spasticity is often accompanied by other 
dysfunctions or may lead to secondary complications, in order to comprehensively 
access the impact of spasticity on motor function in patients with stroke the Fugl-
Meyer Assessment is commonly used (Fugl-Meyer et al. 1975; Gladstone, Danells 
and Black 2002). It assesses stroke impairment based on motor function, particularly 
joint functioning (Fugl-Meyer et al. 1975; Gladstone, Danells and Black 2002). 
There are some other scales that may provide additional information on patients with 
post-stroke spasticity, such as scales for the activities of daily living (e.g. Barthel 
Index, Functional Independence Measure), scores for limb function (Fugl-Meyer 
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Assessment) and scales for neurological outcome and degree of recovery (National 
Institutes of Health Stroke Scale). These scales alone, however, are not specifically 
designed for clinical assessment of spasticity (Lechner, Frotzler and Eser 2006; Hsieh 
et al. 2008). Objective outcome measures such as electromyography and blood tests 
have been reported in some clinical assessments (Andersson and Lundeberg 1995; 
Liu, Bao and Dong 2014; Zhang et al. 2016; Zhu et al. 2014). 
2.5.3 Differential diagnosis of spasticity 
As one of the most commonly seen complications in patients after stroke, spasticity is 
usually observed in combination with other dysfunctions. Therefore, differentiating 
spasticity from other similar conditions after stroke may not be possible in clinical 
practice and no consensus has been reached in regards to the differential diagnosis of 
post-stroke spasticity. 
Krishnan et al. (Nair and Marsden 2014) discussed three related, yet different 
conditions whose typical common feature was increased muscle tone. They are 
contractures, rigidity and catatonia. 
Characterised as an abnormal shortening and reduction in the elasticity of tendons, 
muscles, joint capsules, ligaments and skin, contracture is accompanied by an increase 
in the resistance to passive stretch (Yelnik et al. 2010; Malhotra et al. 2011). The main 
difference between spasticity and contracture lies in the dynamic changes in muscle 
tone according to the speed of movement. But in post-stroke patients, contraction can 
also be one of the results of the worsening of spasticity. 
As for rigidity, its pathological changes are associated with the basal ganglia. The 
increased muscle tone affects all the muscles acting on a joint equally and is therefore 
non-selective (Bethoux 2015; Burke, Wissel and Donnan 2013; Kheder and Nair 
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2012; Lindsay et al. 2015; Nair and Marsden 2014; Sheean 2002). But spasticity 
usually affects only certain muscle groups of a joint. Further, rigidity can lead to 
resistance to passive movement throughout the whole range of movement without 
changing the speed (Nair and Marsden 2014). 
Catatonia is a neuropsychiatric syndrome that can be caused by several psychiatric, 
neurological and medical conditions, such as stroke and phencyclidine intoxication 
(Daniels 2009). It is characterised by gegenhalten, abnormal posturing and ‘waxy 
flexibility’ (Daniels 2009). Unlike spasticity, patients with catatonia often present with 
an increase in muscle tone proportional to the force applied (Daniels 2009).  
The differences between the four conditions are summarised in Table 2.1. 
Table 2.1 Differential diagnoses of spasticity 
 Spasticity Contracture Rigidity Catatonia 
Dynamic changes in 
muscle tone with speed 
of movement 
Yes No No No 
Shortening of tendons 
and muscles 
No Yes No No 
Affects muscle 
selectively 
Yes No No No 
Psychiatric factor 
involved 
No No No Yes 
Waxy flexibility No No No Yes 
Moreover, clinical manifestations of spasticity in stroke survivors vary partly due to 
the combination with other signs of upper motor neurone syndrome. Table 2.2 
summarises the six commonly seen features in upper motor neurone syndrome (Nair 
and Marsden 2014).
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Table 2.2 Positive signs of upper motor neurone syndrome 
 Spasticity Flexor spasms Clasp knife 
phenomenon 
Spastic dystonia Associated 
reactions 
Co-
contraction 
Key features of 
clinical 
manifestation 
Velocity-dependent 
increase in tonic 
stretch reflex 
A sudden 
stiffening of a 
muscle which 
may cause a 
limb to kick 
out or jerk 
towards the 
body 
A stretch reflex 
with a rapid 
decrease in 
resistance when 
attempting to flex 
a joint 
Continuous 
muscle 
contraction 
Involuntary 
movement of a 
body part 
associated with 
the resisted 
movement of 
another body part 
Simultaneous 
contraction of 
agonist and 
antagonist 
muscle groups 
Pathophysiology Abnormal 
processing of 
proprioceptive 
input in the spinal 
cord 
Disinhibited 
afferents of 
normal flexor 
withdrawal 
reflexes  
Afferent-modified 
stretch reflex 
underlying 
spasticity 
Afferent-
mediated tonic 
supraspinal drive 
to the α motor 
neurones 
Failure to inhibit 
the spread of 
motor activity 
through 
propriospinal 
pathways in the 
spinal cord 
Reduced or 
excessive 
reciprocal 
inhibition 
controlled at 
the cortical or 
spinal levels 
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2.6 Post-stroke spasticity management 
2.6.1 Treatment aims and principles 
The general aim of therapy is to limit the impact of spasticity on stroke survivors and 
to prevent secondary complications. The specific goals of therapy include (Nair and 
Marsden 2014): 
 Relief of pain and discomfort 
 Improvement of posture 
 Facilitation of sitting, standing and walking 
 Reduction in burden of care 
 Improvement of hygiene in areas such as the palms, axillae and groin 
 Improvement in body image and self-esteem 
 Prevention of complications such as pressure ulcers 
Generally, a multidisciplinary stroke rehabilitation team comprises the following 
professionals (National Institute for Health and Care Excellence 2013): 
 Consultant physicians 
 Nurses 
 Pharmacists 
 Physiotherapists 
 Speech and language therapists 
 Occupational therapists 
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 Rehabilitation assistants 
 Social workers 
 Clinical psychologists 
 Dietitians 
 Orthoptists 
Moreover, because of the diversity and complexity of post-stroke dysfunctions and 
complications, rehabilitation programs need to be individualised according to each 
patient’s activities, care needs and access to physical therapy (Nair and Marsden 
2014). Long-term comprehensive therapies including drug and non-drug interventions 
may be beneficial for patients with spasticity (National Institute for Health and Care 
Excellence 2013). 
2.6.2 Initial therapies 
It is generally believed that early initiation of rehabilitation is the key to preventing 
disabling complications. However, the exact intervention and initiation times for 
treatment of spasticity at an early stage following stroke are not clear, with expert 
opinions divided (Winstein et al. 2016; Simpson et al. 2016; Royal College of 
Physicians Intercollegiate Stroke Working Party 2016; National Institute for Health 
and Care Excellence 2013; Nair and Marsden 2014; Lindsay et al. 2014; Kheder and 
Nair 2012; Hebert et al. 2016; Chinese Society of Neurology et al. 2017; Chinese 
Society of Neurology and Stroke Prevention Project Committee of National Health 
and Family Planning Commission in China 2012; Bethoux 2015; Australian National 
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Stroke Foundation 2017; Department of Veterans Affairs, Department of Defense, 
American Heart Association and American Stroke Association 2010).  
Guidelines vary in relation to mild, moderate or severe spasticity that interferes with 
patients’ mobility, activities of daily living and sleep or requires personal care 
(European Stroke Organisation [ESO] Executive Committee and ESO Writing 
Committee 2008; Australian National Stroke Foundation 2017; Bates et al. 2005; 
Duncan et al. 2005; Miller et al. 2010; National Institute for Health and Care 
Excellence 2013; Robert et al. 2015; Smith et al. 2010; Stroke Foundation of New 
Zealand and New Zealand Guidelines Group 2010; Chinese Society of Neurology et 
al. 2017). 
2.6.3 Pharmacotherapy and rehabilitation 
Recommendations from guidelines differ in relation to therapeutic methods, target 
users and the intensity of rehabilitation (ESO Executive Committee and ESO Writing 
Committee 2008; Department of Veterans Affairs, Department of Defense, American 
Heart Association and American Stroke Association 2010; Schulz, Altman and Moher 
2010; Stroke Foundation of New Zealand and New Zealand Guidelines Group 2010; 
Bian and Shang 2011; China Academy of Chinese Medical Sciences and Chinese 
Association of Acupuncture-moxibustion 2011; Chinese Society of Neurology and 
Stroke Prevention Project Committee of National Health and Family Planning 
Commission in China 2012; National Institute for Health and Care Excellence 2013; 
Lindsay et al. 2014; Hebert et al. 2016; Royal College of Physicians Intercollegiate 
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Stroke Working Party 2016; Simpson et al. 2016; Winstein et al. 2016; Australian 
National Stroke Foundation 2017; Chinese Society of Neurology et al. 2017).  
It is believed that interventions without physical therapy can only temporarily reduce 
spasticity, but cannot lead to functional gains (Bates et al. 2005). Therefore, 
combining physical rehabilitation with pharmacotherapy, and even more aggressive 
and invasive therapies in severe cases when necessary, is widely accepted (ESO 
Executive Committee and ESO Writing Committee 2008; Department of Veterans 
Affairs, Department of Defense, American Heart Association and American Stroke 
Association 2010; Schulz, Altman and Moher 2010; Stroke Foundation of New 
Zealand and New Zealand Guidelines Group 2010; Bian and Shang 2011; China 
Academy of Chinese Medical Sciences and Chinese Association of Acupuncture-
moxibustion 2011; Chinese Society of Neurology and Stroke Prevention Project 
Committee of National Health and Family Planning Commission in China 2012; 
National Institute for Health and Care Excellence 2013; Lindsay et al. 2014; Hebert et 
al. 2016; Royal College of Physicians Intercollegiate Stroke Working Party 2016; 
Simpson et al. 2016; Winstein et al. 2016; Australian National Stroke Foundation 
2017; Chinese Society of Neurology et al. 2017).  
Further, management of the triggers that may exacerbate spasticity, such as infections, 
constipation and deep vein thrombosis is also needed in patients with post-stroke 
spasticity (ESO Executive Committee and ESO Writing Committee 2008). 
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2.6.3.1 Physical rehabilitation 
Although physical therapy is generally considered the routine treatment for post-
stroke spasticity (Stroke Foundation of New Zealand and New Zealand Guidelines 
Group 2010), currently there is no reliable evidence that confirms its benefits 
(Australian National Stroke Foundation 2017; Chinese Society of Neurology et al. 
2017; Royal College of Physicians Intercollegiate Stroke Working Party 2016; ). 
Conventionally, a series of stepwise therapies are applied to the treatment for post-
stroke spasticity with the most conservative forms at the beginning, such as 
positioning, gradually progressing to less conservative forms, including passive 
stretching, a range of motion exercises and corrective measures for contractures, 
including splinting, serial casting and surgical correction (Bates et al. 2005). 
However, evidence for these therapies in treating post-stroke spasticity is inconclusive 
and even conflicting (Sheehan, Winzeler-Mercay and Mudie 2006; Bovend’Eerdt et 
al. 2008; ESO Executive Committee and ESO Writing Committee 2008; Department 
of Veterans Affairs, Department of Defense, American Heart Association and 
American Stroke Association 2010; Schulz, Altman and Moher 2010; Stroke 
Foundation of New Zealand and New Zealand Guidelines Group 2010; Bian and 
Shang 2011; China Academy of Chinese Medical Sciences and Chinese Association 
of Acupuncture-moxibustion 2011; Chinese Society of Neurology and Stroke 
Prevention Project Committee of National Health and Family Planning Commission 
in China 2012; National Institute for Health and Care Excellence 2013; Lindsay et al. 
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2014; Hebert et al. 2016; Royal College of Physicians Intercollegiate Stroke Working 
Party 2016; Simpson et al. 2016; Winstein et al. 2016; Australian National Stroke 
Foundation 2017; Chinese Society of Neurology et al. 2017).  
In patients who already demonstrate contracture owing to spasticity, stretching using 
splints, machines or prolonged positioning may not be beneficial and is sometimes 
even harmful if accompanied by poor compliance and increased pain (Gustafsson and 
McKenna 2006; Harvey et al. 2006; Robinson et al. 2008; Rydwik, Eliasson and 
Akner 2006; Turton and Britton 2005). 
As for electrical stimulation, published studies also show inconsistent results 
(Bakhtiary and Fatemy 2008; Yan and Hui-Chan 2009), although electromyogram 
biofeedback was reported to be effective in combination with electrical stimulation in 
reducing spasticity and well tolerated during exercise (Hara, Ogawa and Muraoka 
2006). 
2.6.3.2 Oral medication 
It is suggested by the guidelines that patients with post-stroke spasticity should not 
receive routine pharmacological treatment, either orally or by injection, unless 
significant symptoms or interference with rehabilitation occur (Stroke Foundation of 
New Zealand and New Zealand Guidelines Group 2010; ESO Executive Committee 
and ESO Writing Committee 2008; Department of Veterans Affairs, Department of 
Defense, American Heart Association and American Stroke Association 2010; Schulz, 
Altman and Moher 2010; Bian and Shang 2011; China Academy of Chinese Medical 
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Sciences and Chinese Association of Acupuncture-moxibustion 2011; Chinese Society 
of Neurology and Stroke Prevention Project Committee of National Health and 
Family Planning Commission in China 2012; National Institute for Health and Care 
Excellence 2013; Lindsay et al. 2014; Hebert et al. 2016; Royal College of Physicians 
Intercollegiate Stroke Working Party 2016; Simpson et al. 2016; Winstein et al. 2016; 
Australian National Stroke Foundation 2017; Chinese Society of Neurology et al. 
2017). 
Oral medication can be considered depending on the response to non-pharmacological 
therapies. Evidence on oral medications for post-stroke spasticity treatment is limited 
and controversial; the conclusions focus on spasticity and pain relief, but functional 
benefits may be disappointing (Australian National Stroke Foundation 2017; Bethoux 
2015). It is said that oral anti-spastic medication is limited, with various side effects 
(Bethoux 2015). The commonly used oral medications include Baclofen, tizanidine 
and dantrolene. 
One of the commonly accepted pathophysiological features of spasticity is the 
imbalanced regulation of the activity of the alpha motor neurones, where the 
inhibitory impulses are insufficient or cut off in stroke patients (Ertzgaard, Campo and 
Calabrese 2017). Baclofen works on the γ-aminobutyric acid (GABA) ergic system 
through selectively binding to presynaptic GABA-B receptors to reduce the 
hyperactivity of the muscle stretch reflexes (Ertzgaard, Campo and Calabrese 2017). 
However, Baclofen has the difficulty in crossing the blood–brain barrier because it is 
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mainly water soluble. Consequently, a high dose is generally required, which can lead 
to intolerable side effects, such as muscle weakness, nausea, drowsiness and 
paraesthesia, affecting between 25% and 75% of patients (Jose de et al. 2013). 
Tizanidine acts on the α2-adrenoceptor agonist to inhibit motor neurons 
presynaptically and therefore blocks nerve impulses and reduces spasticity where the 
release of the excitatory amino acids glutamate and aspartate is decreased (Dai, Aksoy 
and Demiryurek 2016). Substance P released from small sensory afferents is also 
reduced (Wagstaff and Bryson 1997). Tizanidine also works on the imidazoline 
receptors, whose effects are relatively minor, compared to those of the α2-
adrenoceptor (Dai, Aksoy and Demiryurek 2016). Therefore, tizanidine is usually 
used to decrease muscle tone and reduce spasm frequency, as well as for 
hyperreflexia. However, due to its adrenergic action and impact on the imidazoline 
receptors, associated adverse events include hypotension and increased sedation (Dai, 
Aksoy and Demiryurek 2016). 
As for dantrolene, its exact molecular mechanisms are still incompletely understood. 
Traditionally dantrolene works as a skeletal muscle relaxant that can block 
intracellular calcium release from the sarcoplasmic reticulum and so prevent cytosolic 
calcium overload (Perez-Arredondo et al. 2016). It also demonstrates effects on anti-
inflammatory and neuroprotective properties in ischaemia models (Gwak et al. 2008; 
Perez-Arredondo et al. 2016). However, adverse events such as muscle weakness and 
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gastrointestinal discomfort have been observed and reported with dantrolene 
administration (Brandom and Larach 2002). 
Although these medications are commonly used in clinical practice, their efficacy is 
still uncertain (Bethoux 2015). Specifically, because diazepam and other 
benzodiazepines may interfere with cerebral functions and induce sedation that can 
reduce patients’ ability to become involved in post-stroke rehabilitation effectively, 
they should be avoided during the stroke recovery period (Hebert et al. 2016; Royal 
College of Physicians Intercollegiate Stroke Working Party 2016; Simpson et al. 
2016; Winstein et al. 2016; Australian National Stroke Foundation 2017; Chinese 
Society of Neurology et al. 2017). 
2.6.3.3 Botulinum toxin 
Botulinum toxin-A can be used to target specific muscles or muscle groups (ESO 
Executive Committee and ESO Writing Committee 2008). It has proven effects on 
decreasing muscle tone and increasing active and passive ranges of motion in the 
extremities (Australian National Stroke Foundation 2017). There is high-quality 
evidence suggesting that combing botulinum toxin injections and physiotherapy can 
improve extremity function (Bhakta, O’Connor and Cozens 2008; Francis et al. 2004; 
Childers et al. 2004; Brashear et al. 2002). Moreover, botulinum toxin seems to be 
well tolerated, with no severe adverse events reported (Australian National Stroke 
Foundation 2017).  
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However, its clinical effect is usually limited and lasts only two to three months, at a 
relatively high price (Stroke Foundation of New Zealand and New Zealand 
Guidelines Group 2010). Additionally, its impacts on activity level and quality of life 
have not been well studied (Jahangir et al. 2007; McCrory et al. 2009). With regards 
to shoulder spasticity and pain, results from several randomised controlled trials show 
conflicting conclusions (de Boer et al. 2008; Kong, Neo and Chua 2007; Lim, Koh 
and Paik 2008; Marco et al. 2007; Yelnik et al. 2007). The indication for use of 
botulinum toxin is mainly patients with localised moderate to severe spasticity after 
stroke whose Modified Ashworth Scale scores are no less than 3, when standard 
management has failed or as an adjunct to physiotherapy (Australian National Stroke 
Foundation 2017). 
2.6.3.4 Intrathecal Baclofen 
For severe spastic hemiplegia, intrathecal Baclofen is an option (Paciaroni et al. 
2007). It has been shown that intrathecal Baclofen can be beneficial for chronic stroke 
patients with spasticity (Sampson et al. 2002). Adverse events, such as drowsiness, 
weakness in the lower extremities, dizziness and seizures, have been reported in a 
small number of cases (Steinbok and O’Donnnell 2000; Kofler et al. 2009). 
2.6.3.5 Neurosurgical procedures 
Another option for severe spasticity is neurosurgical procedures, although current 
evidence from clinical trials does not support routine application of neurosurgical 
therapies such as selective dorsal rhizotomy or dorsal root entry zone lesions. These 
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are rarely used in clinical practice, probably because of the significant risks of these 
invasive treatments, including operative complications and unintended spinal cord 
damage (Bates et al. 2005). 
2.7 Impacts and prognosis of post-stroke spasticity 
Patients with post-stroke spasticity are not only affected by the problems of negative 
physical impacts, but also psychological and social problems in life (Morley et al. 
2013). Poor posture can result in difficulty in changing position and transfers. Patients 
with severe spasticity can suffer from hygiene problems, such as difficulty in cleaning 
hands, axillae, elbows and especially genital areas. In addition, bowel and bladder 
functions and sexual relationships may be affected by spasticity (Nair and Marsden 
2014). 
Interestingly, it is not uncommon that spasticity sometimes serves as a compensation 
for muscle weakness. For example, stiffness in the weak muscles of the lower limbs 
can assist with sitting, standing, transfers and walking, and spasticity of the long 
finger flexor muscles can help patients with implements like cutlery and toothbrushes 
(Nair and Marsden 2014). 
If left untreated, spasticity can have a devastating effect on physical functions and 
activities, comfort, care delivery and participation in daily living, and may even lead 
to musculoskeletal complications such as contracture in the long term (Miller et al. 
2010). The prognosis varies dramatically depending on spasticity location, access to 
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post-stroke management and compliance with rehabilitation plans (ESO Executive 
Committee and ESO Writing Committee 2008; Department of Veterans Affairs, 
Department of Defense, American Heart Association and American Stroke 
Association 2010; Schulz, Altman and Moher 2010; Stroke Foundation of New 
Zealand and New Zealand Guidelines Group 2010; Bian and Shang 2011; China 
Academy of Chinese Medical Sciences and Chinese Association of Acupuncture-
moxibustion 2011; Chinese Society of Neurology and Stroke Prevention Project 
Committee of National Health and Family Planning Commission in China 2012; 
National Institute for Health and Care Excellence 2013; Lindsay et al. 2014; Hebert et 
al. 2016; Royal College of Physicians Intercollegiate Stroke Working Party 2016; 
Simpson et al. 2016; Winstein et al. 2016; Australian National Stroke Foundation 
2017; Chinese Society of Neurology et al. 2017). 
2.8 Chapter summary 
Overall, although the underlying mechanism of post-stroke spasticity is not yet fully 
understood, post-stroke spasticity is generally diagnosed with a Modified Ashworth 
Scale score higher than zero. As for the treatments, non-pharmacotherapies are 
fundamental, while oral medications and more invasive treatments are recommended 
for severer cases. However, insufficient and conflicting evidence, as well as unwanted 
risks with these therapies, suggests an uncertainty in relation to their clinical efficacy. 
Therefore, further study and exploration of treatment on the basis of current 
management are needed. 
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Chinese medicine, mainly Chinese herbal medicine and acupuncture, has long been 
applied to stroke patients in clinical practice in Asian countries, with increasing 
amounts of research in recent years (Lim et al. 2015; Park et al. 2014; Qi et al. 2009). 
However, Chinese medicine is practised and developed based on theories different 
from those that underlie modern medicine. Additionally, the evidence for Chinese 
medicine in the treatment of post-stroke spasticity has not been comprehensively 
evaluated.  
Therefore, Chapter 3 presents a brief introduction to the basic theories of Chinese 
medicine, and Chapters 4 to 6 summarise the evidence for Chinese herbal medicine 
and acupuncture (covering manual acupuncture, acupressure, moxibustion and 
electro-acupuncture) in order to provide a synthesis of the evidence and suggest 
promising therapies for post-stroke spasticity. 
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Chapter 3 Understanding post-stroke spasticity with Chinese 
medicine 
 
This chapter introduces the understanding of post-stroke spasticity from a perspective 
of Chinese medicine. Besides, existing reviews of Chinese medicine for post-stroke 
spasticity are summarized in this chapter. 
3.1 Fundamental Chinese medicine theories 
Chinese medicine therapies, such as Chinese herbal medicine and acupuncture, 
originated in ancient China and are used based on the fundamental theories of Chinese 
medicine. 
Chinese medicine is based on the following fundamental theories: 1) the yin 阴 and 
yang 阳 theory; 2) the five element theory; 3) the visceral manifestation theory; 4) the 
qi 气, Blood, Fluid and Humour substance theory; and 5) the meridian and collateral 
theory (Sun and Zheng 2012). 
3.2 Terminology of post-stroke spasticity in Chinese medicine 
The (Huangdi) Internal Classic 黄帝内经 first described conditions whose symptoms 
were similar to stroke with medical terms such as ‘pu ji 仆击’, ‘da jue 大厥’, ‘bo jue 
薄厥’, ‘pian ku 偏枯’ and ‘feng fei 风痱’ around the B.C.300–110. Not until the Han 
Dynasty did the now widely known term ‘Wind Stroke’ (zhong feng 中风) appear and 
40 
 
it has been defined as a condition similar to stroke in modern medicine (Zhang and 
Xue 2012). 
The term ‘‘Wind Stroke’’ gradually became the prevalent and typical name for stroke 
in the classical literature. Stroke in Chinese medicine can be classified into two 
subtypes, ‘Visceral and Bowel Stroke’ (zhong zang fu 中脏腑) and ‘Meridian and 
Collateral Stroke’ (zhong jing luo 中经络), which refer to stroke with and without 
disorders of consciousness respectively. 
Similar to the modern understanding of spasticity after stroke, spasticity is generally 
regarded as one of the complications of limb dysfunction in stroke survivors 
accompanied by muscle weakness and skin numbness or pain, instead of being a 
clearly specified and independent condition in Chinese medicine. 
Therefore, post-stroke spasticity is generally discussed within the scope of ‘Meridian 
and Collateral Stroke’ in Chinese medicine. Because spasticity is often accompanied 
by other motor dysfunctions following stroke, description of post-stroke spasticity can 
also be found under the terms ‘ban shen bu sui 半身不遂’ , ‘bi cu luan pi 痹瘁挛僻’ 
and ‘jing mai luan ji 筋脉挛急’ etc. (Zhang and Xue 2012). 
3.3 Aetiology and pathogenesis 
The aetiology and pathogenesis of post-stroke spasticity has long been explored under 
the concept of ‘Wind Stroke’. This term originally meant ‘hit by Wind’. It can also be 
interpreted as the primary and fundamental understanding of the aetiology of stroke in 
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Chinese medicine. This understanding later switched in the Tang Dynasty from 
external Wind to internal Wind, suggesting the focus was now on internal causes 
(Zhang and Xue 2012). The aetiology and pathogenesis were then gradually 
developed to a wider perspective, including qi 气, Blood, yin 阴 and yang 阳 
deficiency, Wind (Liver Wind), Fire (Liver Fire and Heart Fire), Phlegm (Wind 
Phlegm and Wet Phlegm), reversed flow of qi 气 and Blood Stasis. The occurrence of 
stroke was originally attributed to a deficiency of qi 气, Blood, yin 阴 and yang 阳 
which generated pathological products such as Wind, Fire and Phlegm within the 
body, and in return substantially and continuously impacted on the normal function of 
qi 气 and Blood. An accumulated and worsening qi 气 and Blood malfunction might 
eventually result in a sudden block or crash within the brain collaterals, which is 
clinically the occurrence of stroke (Zhang and Xue 2012). 
3.4 Diagnosis 
Similarly, as one of the complications of stroke, post-stroke spasticity is diagnosed 
under the meridian and collateral theory according to its clinical manifestations 
(Zhang and Xue 2012). However, there are no specific diagnostic criteria for post-
stroke spasticity in Chinese medicine. Instead, diagnosis is established based on 
symptoms and correspondent treatment is selected based on Chinese medicine 
syndrome differentiation (see 3.6). 
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3.5 Differential diagnosis 
Post-stroke spasticity needs to be differentiated in Chinese medicine from convulsive 
disease (jing bing 痉病), whose clinical characteristics are limb convulsion, back 
stiffness and opisthotonos, usually accompanied by hyperpyrexia and 
unconsciousness without facial paralysis or hemiplegia. Similar conditions in modern 
medicine might be meningeal irritation or extrapyramidal diseases, which might cause 
paroxysmal tonic contraction or convulsion in all the muscles of the body, while 
spasticity is observed in increased muscular tone which results in focal muscle 
contraction, sometimes accompanied by muscle vibration (Zhang and Xue 2012). 
3.6 Syndrome differentiation 
The following textbooks and guidelines were used and summarized for the syndrome 
differentiation and management in the following sections. They include: 1) Chinese 
Internal Medicine (中医内科学) [book in Chinese] (China Traditional Medicine 
Press) (Zhang and Xue 2012); 2) Guidelines for Diagnosis and Treatment of Cerebral 
Infarction in China with Integrated Traditional Chinese and Western Medicine 2017 
(中国脑梗死中西医结合诊治指南) (Neurology Specialized Committee of Chinese 
Association of Integrative Medicine 2017); 3) China Post-Stroke Rehabilitation 
Guideline (中国脑卒中康复治疗指南) (Chinese Society of Neurology and Stroke 
Prevention Project Committee of National Health and Family Planning Commission 
in China 2012); 4) Guidelines for Early Rehabilitation of Stroke in China (中国脑卒
中早期康复治疗指南) (Chinese Society of Neurology et al. 2017). 
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Admittedly, there are variations in syndrome differentiation and correspondent 
treatment recommendations. Syndromes of the same or similar syndrome factors 
(such as Wind, Phlegm, Blood Stasis and qi 气 deficiency) and correspondent 
recommendations were synthesised after consultation and discussion with experts 
from Guangdong Provincial Hospital of Chinese Medicine. 
The differential diagnoses of ‘Meridian and Collateral Stroke’ in Chinese medicine 
can be clustered into five syndromes: Wind Phlegm and Stasis Blood; sudden 
hyperactivity of the Liver yang 阳; Phlegm Heat and Bowel excess; qi 气 deficiency 
and Stasis Blood; and yin 阴 deficiency with stirring Wind. Table 3.1 summarises the 
clinical manifestations and features of the five syndromes. 
Table 3.1 Syndromes differential diagnoses of ‘meridian and collateral stroke’ 
 Key symptoms Tongue Pulse 
Common 
symptoms 
Hemiplegia, dizziness, wry mouth and tongue, speech difficulty, 
hemianesthesia 
Wind Phlegm 
and Stasis 
Blood 
Dizziness Pale and dark tongue 
with thin white fur 
String-like 
and slippery 
pulse 
Sudden 
hyperactivity 
of the Liver 
yang 阳 
Dizziness, headache, 
reddened complexion and 
eyes, bitter taste in the mouth 
and dry throat, vexation and 
irritability, constipation 
Red or crimson 
tongue with thin 
yellow fur 
String-like 
and strong 
pulse 
Phlegm heat 
and bowel 
excess 
Dizziness, headache, 
constipation 
Red or pale and dark 
tongue with yellow 
slimy coating 
String-like 
and slippery 
pulse 
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 Key symptoms Tongue Pulse 
Qi 气 
deficiency 
and Stasis 
Blood 
Bright or pale complexion, 
shortness of breath, lack of 
strength, spontaneous 
sweating, palpitations, 
drooling 
Pale and dark tongue 
with thin white fur 
String-like 
and fine 
pulse or 
sunken and 
fine pulse 
Yin 阴 
deficiency 
with stirring 
Wind 
Dizziness, headache, tinnitus, 
blurred vision, aching lumbus 
and leg weakness, vexation 
and insomnia 
Crimson or dark red 
tongue with a little 
or no fur 
String-like 
and fine 
pulse or fine 
and rapid 
pulse 
Notes: Data are based on Chinese Internal Medicine (中医内科学) [book in Chinese] (China 
Traditional Medicine Press) (Zhang and Xue 2012) 
3.7 Management 
Traditionally, according to Chinese medicine, managing a condition requires dealing 
with the excessive or deficient nature based on the Chinese medicine syndrome 
diagnosis. Because Chinese medicine management targets the overall condition 
instead of the symptoms, the treatment principle for post-stroke spasticity is the same 
to that for ‘Meridian and Collateral Stroke’ because post-stroke spasticity is one 
complication after stroke, although specific therapies for spasticity were cited in the 
classical literature of Chinese medicine. Specific treatments from the textbooks and 
guidelines mentioned above in ‘3.6 Syndrome differentiation’ are presented under the 
categories of Chinese herbal medicine and acupuncture respectively below.  
3.7.1 Chinese herbal medicine 
3.7.1.1 Wind Phlegm and Blood Stasis 
Therapeutic principle: promoting Blood circulation to remove Blood Stasis, eliminate 
Phlegm and free the channels 
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Formula: modified ban xia bai zhu tian ma tang 半夏白术天麻汤 
Main herbs: ban xia 半夏, tian ma 天麻, fu ling 茯苓, ju hong 橘红, bai zhu 白术, 
gan cao 甘草 plus Blood-activating herbs 
Analysis of formula: ban xia 半夏 and Ju hong 橘红 eliminate Dampness and Phlegm 
and promote the flow of qi 气; bai zhu 白术 and fu ling 茯苓 tonify the Spleen to 
remove dampness and water retention; tian ma 天麻 expels the Liver Wind; and gan 
cao 甘草 regulates the middle energiser and mediates the properties of the other 
herbs. 
3.7.1.2 Liver yang 阳 hyperactivity 
Therapeutic principle: calming the Liver, discharging Fire and freeing the channels 
Formula: modified tian ma gou teng yin 天麻钩藤饮 
Main herbs: tian ma 天麻，gou teng 钩藤, chuan niu xi 川牛膝, shi jue ming 石决
明, shan zhi zi 山栀子, du zhong 杜仲, huang qin 黄芩 , yi mu cao 益母草 , san ji 
sheng 桑寄生 , ye jiao teng 夜交藤, fu shen 茯神 
Analysis of formula: tian ma 天麻 and gou teng 钩藤 are used as monarch drugs to 
expel the Liver Wind; shi jue ming 石决明 expels endogenous Wind and suppresses 
hyperactive yang 阳; chuan niu xi 川牛膝 directs the Blood downwards. These two 
herbs are used together to enhance the monarch herbs’ ability to suppress the 
hyperactive yang 阳 and expel endogenous Wind; du zhong杜仲 and sang ji sheng 桑
寄生 nourish the Liver and Kidney; zhi zi 栀子 and huang qin 黄芩 clear heat from 
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the Liver meridian, yi mu cao 益母草 and chuan niu xi川牛膝 promote Blood flow 
and induce diuresis so as to treat the hyperactive yang 阳; and ye jiao teng 夜交藤 
and fu shen 茯神 tranquilise the mind. 
3.7.1.3 Phlegm heat and bowel repletion 
Therapeutic principle: eliminating Phlegm and facilitating bowel movement 
Formula: modified xing lou cheng qi tang 星蒌承气汤 
Main herbs: dan nan xing 胆南星, gua lou 瓜蒌, sheng da huang 生大黄, mang xiao 
芒硝, bai wei 白薇, di gu pi 地骨皮 
Analysis of formula: dan nan xing胆南星 and gua lou 瓜蒌 eliminate dampness and 
Phlegm; sheng da huang 生大黄 and mang xiao 芒硝 free the bowels; and bai wei 白
薇 and di gu pi 地骨皮 eliminate pathogenic heat from the Blood. 
3.7.1.4 Qi 气 deficiency and Blood Stasis 
Therapeutic principle: benefiting qi 气 to activate Blood circulation and remove 
Blood Stasis to free the channels 
Formula: modified bu yang huan wu tang 补阳还五汤 
Main herbs: huang qi 黄芪, dang gui wei 当归尾, chi shao 赤芍, di long 地龙, tao 
reng 桃仁, chuan xiong 川芎, hong hua 红花 
Analysis of formula: huang qi 黄芪 tonifies qi 气; dang gui wei 当归尾, chi shao 赤
芍, di long 地龙, tao reng 桃仁, chuan xiong 川芎 and hong hua 红花 activate the 
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Blood and remove Stasis; and di long 地龙 clears and activates the channels and 
collaterals. 
3.7.1.5 Wind formation from yin 阴 deficiency 
Therapeutic principle: nourishing the Liver and Kidney, and suppressing yang 阳 to 
quench Wind 
Formula: modified zhen gan xi feng tang 镇肝熄风汤 
Main herbs: huai niu xi 怀牛膝, sheng zhe shi生赭石, sheng long gu生龙骨, sheng 
mu li 生牡蛎, gui ban 龟板, sheng hang shao 生杭芍, xuan shen 玄参, tian dong 天
冬, chuan lian zi 川楝子, sheng mai ya 生麦芽, yin chen 茵陈, gan cao 甘草 
Analysis of formula: huai niu xi 怀牛膝 ensures proper downward flow of the Blood 
and tonifies the Liver and Kidney; sheng zhe shi 生赭石, sheng long gu 生龙骨, 
sheng mu li 生牡蛎 and gui ban 龟板 settle the Liver and extinguish Wind; sheng 
hang shao 生杭芍, xuan shen 玄参, tian dong 天冬, chuan lian zi 川楝子 and yin 
chen 茵陈 nourish yin 阴 and suppress hyperactive yang 阳; sheng mai ya 生麦芽 
harmonises the Stomach; and gan cao 甘草 regulates and mediates the properties of 
the other herbs. 
3.7.2 Acupuncture 
The application of acupuncture for stroke may date back to the dynasty when the 
‘Yellow Emperor’s Inner Canon’ (Huang Di Nei Jing, 黄帝内经), one of the 
fundamental doctrinal sources for Chinese medicine for more than two millennia, was 
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written. From then on, a variety of acupuncture methods and acupuncture points were 
used in patients with motor dysfunctions post-stroke. Some possible therapies for 
post-stroke dysfunction are cited in the classical literature, such as manual 
acupuncture, point-to-point therapy and fire needling. 
Although acupuncture has been widely used in stroke survivors, no guideline specifies 
what acupuncture protocol, acupuncture points and initial time after stroke or therapy 
course should be applied to spasticity. 
3.8 Existing reviews of Chinese medicine for post-stroke spasticity 
Since the number of randomised controlled trials on Chinese medicine for post-stroke 
spasticity has grown in recent years, increasing numbers of systematic reviews 
examining these could provide a general summary of the effectiveness and limits of 
some Chinese medicine therapies. 
In the current study, a literature search was conducted in four English databases 
(PubMed, EMBASE, Cochrane Library, Cumulative Index to Nursing and Allied 
Health Literature) and four Chinese databases (Chinese Biomedical Database, 
Chinese National Knowledge Infrastructure, Chongqing VIP Database and Wanfang 
Database) from their inceptions to April 2015 and was later updated to February 2018. 
The search terms are listed in Appendices 7 and 8. Four systematic reviews were 
identified, two in English, one in Chinese and one in German. The search results for 
systematic reviews are listed in Table3.2. 
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Table 3.2 Summary of existing systematic reviews 
Notes: Acup, acupuncture; BI, Barthel Index; C, results of control group; CBM, Chinese Biomedical Database; CINAHL, Cumulative Index to 
Nursing and Allied Health Literature; CNKI, Chinese National Knowledge Infrastructure; CQVIP, Chongqing VIP Database; CSI, Composite 
Spasticity Index; EA, electro-acupuncture; FIM, Functional Independent Measure (motor); FMA, Fugl-Meyer Assessment of Sensorimotor Recovery 
Review Country Searched databases Included 
trials  
 Comparisons Outcome 
measures 
Results 
Qi et al. 
2009 
China Cochrane central of 
controlled trials, 
Cochrane library, CBM, 
CNKI, CQVIP, Wanfang 
Database 
14  1) Acup + Rehab vs. 
Rehab 
2) Acup vs. oral 
medications 
3) Acup vs. Rehab 
4) Acup vs. Mox 
AS, NIHSS, Motor 
Assessment Scale 
No significant 
difference 
Brunnstrom Stage I > C 
BI I > C except in Acup vs. 
Rehab 
FMA No significant 
difference except I > C 
in Acup vs. Mox 
CSI I > C 
AEs No report 
Park et 
al. 2014 
Korea PubMed, EMBASE, 
ProQuest, EBSCO, host, 
SCOPUS, CINAHL, 
CNKI, KoreaMed, 
RISS, KISTI, Dbpia  
8 1) Acup vs sham acup 
2) Acup+Rehab vs. Rehab 
3) EA+Rehab vs. Rehab 
MAS, FMA, BI, H-
reflex/M-response 
ratio, FIM 
No significant 
difference 
Lim et 
al. 2015 
Korea Cochrane library, 
PubMed, EMBASE, 
CNKI, National 
Research Foundation of 
Korea 
5 1) Acup or EA vs. placebo 
acup 
2) Acup  or EA vs. oral 
medication+Rehab  
MAS I > C 
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(motor function); I, results of intervention group; (M)AS, (Modified) Ashworth Scale; NIHSS, National Institutes of Health Stroke Scale; MA, meta-
analysis; Mox, moxibustion; Rehab, rehabilitation; TCM, traditional Chinese medicine; WM, Western medicine.
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Table 3.3 Conclusions of existing systematic reviews 
Reviews Comments 
Qi et al. 
2009 
A reliable conclusion cannot be drawn because of the defects in 
methodological quality and insufficient numbers of trials, especially 
the lack of long-term outcomes. Therefore, it is necessary to perform 
randomised control trials of high quality in future. 
Park et al. 
2014 
The effect of acupuncture for spasticity in patients with stroke 
remains uncertain because of the poor quality of the included 
studies. Larger and more methodologically sound trials are needed to 
confirm or refute the effect of acupuncture as a treatment for 
spasticity after stroke. 
Lim et al. 
2015 
Acupuncture could be effective in decreasing spasticity after stroke, 
but long-term studies are needed to determine the longevity of 
treatment effects. 
Table 3.2 and Table 3.3 only summarises the three systematic reviews in English and 
Chinese. There was no systematic review of Chinese herbal medicine for post-stroke 
spasticity. All the systematic reviews identified from the above databases focus on the 
effectiveness of acupuncture (Lim et al. 2015; Park et al. 2014; Qi et al. 2009). 
It was found that of the English databases searched by these systematic reviews, 
PubMed, EMBASE, Cochrane library and Cumulative Index to Nursing and Allied 
Health Literature were the most frequently used, while the Chinese Biomedical 
Database, Chinese National Knowledge Infrastructure, Chongqing VIP Database and 
Wanfang database were the key Chinese medical databases. However, none of the 
above systematic reviews covered all of these important English and Chinese 
databases. 
In terms of the interventions, manual acupuncture and electro-acupuncture were 
included. But the co-intervention therapies varied greatly, which might both increased 
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the heterogeneity and reduced the reliability of evidence when the data were pooled 
for meta-analysis. The same problem is found in the variety of comparators. 
In regards to the outcome measures, the Ashworth Scale and Modified Ashworth 
Scale were the most widely and consistently used as primary outcome measures in the 
systematic reviews. In order to evaluate the function of the affected limbs and quality 
of life for stroke survivors with spasticity, other outcome measures such as the Fugl-
Meyer Assessment and Barthel Index are required in future studies. 
The results of the systematic reviews on the effectiveness and safety of acupuncture 
for spasticity after stroke are inconclusive, partly because of the heterogeneity in 
participants, interventions, comparators and outcome measures, as well as the limited 
numbers of databases and search terms. It is worth noting that one of the reviews 
suggests that, compared to manual acupuncture, electro-acupuncture might result in 
better therapeutic effects on post-stroke spasticity (Lim et al. 2015). Therefore, to 
summarise the existing evidence (from both modern and classical literature) on 
promising Chinese medicine therapies for post-stroke spasticity and to inform the 
design of the randomised controlled trial for our study, we then conducted our own 
systematic reviews of Chinese medicine clinical trials, covering Chinese herbal 
medicine and electro-acupuncture, with up-to-date and comprehensive searches in 
databases from the modern literature and data mining of the classical literature.  
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Chapter 4 Data mining of classical literature 
 
This chapter summarises the evidence of Chinese medicine (including Chinese herbal 
medicine and acupuncture) for post-stroke spasticity from classical literature. 
4.1 Methods 
4.1.1 Brief introduction to classical literature database 
Zhong Hua Yi Dian (ZHYD 中华医典 Version 5.0) (Zhong Hua Yi Dian 2014), is one 
of the largest classical literature databases on Chinese medicine. Over 1,000 books of 
Chinese medicine are included on CD-ROM of Zhong Hua Yi Dian (ZHYD 中华医
典) from ancient times to the period of Republic of China. 
4.1.2 Identifying search terms for post-stroke spasticity in classical literature 
As one of the common complications of post-stroke motor dysfunction, spasticity has 
not yet been clearly defined nowadays, let alone used as a medical term in ancient 
China. The description and discussion of spasticity can usually be seen in references 
to related terms, such as ban shen bu sui 半身不遂 and zhong jing luo 中经络, 
following stroke onset. Therefore, related terms and references to stroke were 
identified first.  
The following steps describe how the search terms for stroke in the classical 
literatures were identified: 1) the Zhong Yao Fang Ji Da Ci Dian 中药方剂大辞典 
and relevant classical texts were checked to collect terms used in ancient China for 
stroke; 2) the terms that were used to describe stroke in textbooks and monographs 
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were identified; 3) clinical guidelines, systematic reviews and general reviews of 
stroke were searched and the terms used were recorded. 
Test searches for each term were then carried out in the Zhong Hua Yi Dian (ZHYD 
中华医典 Version 5.0) (Zhong Hua Yi Dian 2014), to check for accuracy in 
identifying citations relating to stroke. Considering the large number of citations 
found in the classical literature in the following screening, we only included terms 
with an accuracy rate higher than 50% in identifying stroke-related citations after 
consultation with rehabilitation experts and researchers in Guangdong Provincial 
Hospital of Chinese Medicine. Once the search terms were confirmed, a 
comprehensive search for citations related to stroke was conducted in Zhong Hua Yi 
Dian (ZHYD 中华医典 Version 5.0) (Zhong Hua Yi Dian 2014). The number of hits 
was recorded in a table for each term. 
4.1.3 Screening relevant citations 
All citations were reviewed to determine whether they were relevant to stroke and 
spasticity and contained therapeutic information during the search and screening on 
Zhong Hua Yi Dian (ZHYD 中华医典 Version 5.0) (Zhong Hua Yi Dian 2014). 
Citations were excluded from further analysis if they were: 1) not about stroke; 2) on 
paediatric diseases; 3) not related to motor functional impairment; 4) related to post-
stroke motor functional impairment but mentioning symptoms likely referring to 
hypomyotonia; 4) not containing information on treatment. Citations included in the 
final dataset were considered ‘possibly related to post-stroke spasticity’ with 
descriptions of Chinese medicine therapies (Chinese herbal medicine and 
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acupuncture) and were grouped according to Chinese medicine interventions for 
further analysis. 
Further screening and analysis were conducted to identify the citations that contained 
descriptions of treatment specifically for symptoms like those of post-stroke 
spasticity. Examples of these symptoms are: arm and leg muscular contracture (shou 
zu ju luan 手足拘挛), contracture or limb spasm (ju ji 拘急), spasm of muscle (jin 
luan 筋挛), spasm and contracture (luan suo 挛缩, luan bi挛躄), muscle spasm and 
contracture (jin mai luan ji 筋脉挛急, jin ji 筋急, jin ji 筋急, chi cong 瘛疭), muscle 
contracture and stiffness of limbs (ju luan qu shen bu de 拘挛屈伸不得) and muscle 
contracture and atrophy after Wind attack (jiu feng ku zhi 久风枯挚). 
Finally, the frequencies of herbal formulas, ingredients and acupuncture points were 
calculated and presented at two levels: all of the included citations and the citations 
that were likely about post-stroke spasticity. 
4.1.3 Data extraction and data analysis 
The following items were extracted and presented as different columns in a pre-
designed Excel spreadsheet: search terms, book name, dynasty of the book, citation 
ID on Zhong Hua Yi Dian (ZHYD 中华医典 Version 5.0) (Zhong Hua Yi Dian 2014), 
formula name, herb name, acupuncture point, needling techniques and other 
therapeutic methods. 
Statistical analysis was conducted using SPSS 23.0 software. Frequency analyses 
were used to identify the most commonly reported herbs, formulas and acupuncture 
points used to treat post-stroke spasticity in the ancient Chinese literature. The 
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historical changes in terminology and treatment methods were also explored by 
frequency analysis at each time point. 
4.2 Search results 
We conducted the initial search on Zhong Hua Yi Dian (ZHYD 中华医典 Version 5.0) 
(Zhong Hua Yi Dian 2014) with the 12 search terms and obtained a total of 27,460 
hits. The highest number of hits (19,150) was detected by the term zhong feng 中风. 
Details of the search results are presented in Table 4.1. 
Table 4.1 Hit frequency by search term 
Pin yin Chinese characters  Hit number (%) 
Zhong feng  中风 19,150 (69.7%) 
Tan huan 瘫痪 1,532 (5.6%) 
Pian ku 偏枯 1,521 (5.5%) 
Ban shen bu sui (1) 半身不遂 1,380 (5.0%) 
Cu zhong (2) 卒中 1,261 (4.6%) 
Pian feng 偏风 907 (3.3%) 
Zhong zang 中脏 611 (2.2%) 
Zhong jing 中经 435 (1.6%) 
Bo jue 薄厥 208 (0.8%) 
Cu zhong (1) 猝中 206 (0.8%) 
Feng fei 风痱 204 (0.7%) 
Ban shen bu sui (2) 半身不随 45 (0.2%) 
Total 27,460 (100%) 
Notes: The above Chinese characters in classical literature have the meanings similar to 
‘stroke’ or ‘paralysis’ in English. 
4.3 Citations included for analysis 
A total of 1,190 citations were included in a pool deemed to be ‘possibly related to 
post-stroke spasticity’. Of these, 1,028 focused on Chinese herbal medicine and 162 
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on acupuncture or similar therapies. In this ‘possible’ pool, 48 citations were records 
of cases. 
Among the citations possibly related to post-stroke spasticity, 264 were further judged 
to be ‘likely related to post-stroke spasticity’ because they reported symptoms similar 
to muscle spasm, stiffness, contracture or hypermyotonia; in ancient China, spasticity 
was not well defined and tools to measure velocity-dependent stretch reflexes had not 
yet been developed. In this ‘likely’ pool, ten (10) citations were records of cases. 
4.4 Definitions and aetiology of post-stroke spasticity 
In the classical literature on Chinese medicine, post-stroke spasticity was not 
considered an independent clinical condition. It has long been considered one of the 
manifestations or complications of stroke (zhong feng 中风). 
The definition of stroke (zhong feng 中风) in ancient China was somewhat similar to 
the modern concept. In particular, medical literature from the Ming and Qing 
Dynasties recorded detailed symptoms caused by zhong feng中风. Examples are: 
1. The condition exhibiting sudden falls, facial paralysis, hemiplegia and a stiff 
tongue with aphasia is commonly named zhong feng中风. But its manifestations 
may differ among patients. Specifically, ji pu 击仆 or cu zhong 卒中 usually refer 
to sudden falls, which is similar to a Wind attack in Chinese medicine, while pian 
ku 偏枯 or zuo tan you huan 左瘫右痪 often suggest facial paralysis and 
58 
 
hemiplegia (Ji Yang Gang Mu 济阳纲目•论风分在腑在脏在经浅深之异 (A.D. 
1626)). 
2. Hemiplegia, bilateral limb paralysis or unconsciousness may occur after a sudden 
fall, with the body slowly becoming still. Patients who suffer these symptoms may 
or may not die. This is called zhong feng 中风 (Yi Jing Su Hui Ji 医经溯洄集•中
风辨 (A.D. 1368)). 
3. A patient who suffers from zhong feng中风 often undergoes sudden falls, 
unconsciousness and a large amount of sputum accumulated in the throat with 
snoring sound, as well as facial paralysis, bilateral limb paralysis or hemiplegia, 
the mouth closed with lockjaw, a stiff tongue and aphasia (Yi Bian 医碥•中风
(A.D. 1751)). 
In addition to symptom description, the aetiology of zhong feng 中风 was also 
discussed in historical documents. An external pathogen was once considered the 
origin of zhong feng中风, but this was later reconsidered to be due to internal factors. 
As cited in Ling Shu 灵枢•刺节真邪, when there was a deficiency of qi 气, an 
external Wind would attack and this might result in zhong feng中风. The constitution 
of a patient could also play an important role in the occurrence of stroke. For instance, 
Su Wen 素问•通评虚实论 said that overweight or obesity could be the cause of pian 
ku 偏枯 and some other conditions. Back in the Yuan and Ming Dynasties, the 
aetiology of zhong feng 中风 could include the following internal factors: an internal 
deficiency, Phlegm and Heat. 
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 Internal deficiency虚 
As discussed in Yi Xue Fa Ming 医学发明•中风有三 in the Song and Yuan Dynasties, 
qi 气 may gradually become weaker as people age, particularly in those over 40 years 
old. If emotions accumulate at the same time, qi 气 will be further damaged. 
Therefore, zhong feng中风 is more commonly seen in the elderly population than 
younger people. Also, as qi 气 deficiency is more common in overweight people, they 
are more likely to suffer zhong feng中风. 
 Internal Phlegm 痰 
Dan Xi Xin Fa 丹溪心法•论中风 from the Song and Yuan Dynasties believed that the 
Wind disorder was in fact not an external Wind invasion. The underlying pathogen 
was Phlegm caused by jiao 焦 Dampness. It was the Heat generated from Phlegm 
which caused the internal Wind that eventually caused zhong feng中风. 
 Internal Heat热 
If there is not enough rest, internal heat may grow. Further, as said in He Jian Liu Shu 
河间六书•素问玄机原病式 (Ming Dynasty), uncontrolled Heat could also result in 
yin 阴 deficiency and excess yang 阳. Worse, the Heat might lead to stagnated qi 气 
and unclear shen 神, which would present as sudden falls and unconsciousness. 
Consistent with the current understanding of stroke aetiology, as cited in Lin Zheng 
Zhi Nan 临证指南•中风 (Qing Dynasty), a rise in the internal Wind of the Liver yang 
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阳 resulting from Blood and Essenes deficiency was the real cause of zhong feng 中
风. 
4.5 Chinese herbal medicine 
Chinese herbal medicine treatment was discussed in 1,028 included citations from 226 
books. The most productive books were: Pu Ji Fang 普济方 (Ming Dynasty) 
(n=105), Sheng Ji Zong Lu 圣济总录 (Song Dynasty) (n=89), Tai Ping Sheng Hui 
Fang 太平圣惠方 (A.D. 992) (n=72), Ji Yang Gang Mu 济阳纲目 (A.D. 1626) 
(n=49), Qi Xiao Liang Fang 奇效良方 (A.D. 1470) (n=27), Gu Jin Yi Tong Da Quan 
古今医统大全 (A.D. 1556) (n=19), Wai Tai Mi Yao 外台秘要 (A.D. 752) (n=18), Bei 
Ji Qian Jin Yao Fang 备急千金要方 (A.D. 652) (n=16), Tai Ping Hui Min He Ji Ju 
Fang 太平惠民和剂局方 (Song Dynasty) (n=15) and Yi Xue Gang Mu 医学纲目 
(A.D. 1565) (n=14). 
4.5.1 Frequency of Chinese herbal medicine citation by dynasty 
Books from the Ming Dynasty (A.D. 1369–1644) and Qing Dynasty (A.D. 1645–
1911) (Table 4.2) recorded 66.3% of the included Chinese herbal medicine treatment 
citations. Table 4.2 presents the details of the dynastic distribution of the citations. 
Two citations were identified from a Chinese herbal medicine book published in 
Japan (A.D. 1780) and two were from books without known years of publication.  
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Table 4.2 Dynastic distribution of Chinese herbal medicine–related citations 
Dynasty No. of treatment citations 
Before Tang Dynasty (before 618) 4 
Tang and the Five Dynasties (618–960) 44 
Song and Jin Dynasties (961–1271) 240 
Yuan Dynasty (1272–1368) 31 
Ming Dynasty (1369–1644) 416 
Qing Dynasty (1645–1911) 266 
Ming Guo/Republic of China (1912–1949) 23 
Others 2 unknown, 2 Japan* 
Total 1,028 
* Chinese medicine books published in Japan 
4.5.2 Treatment with Chinese herbal medicine 
Chinese herbal medicine treatments recorded in the above citations were included in 
frequency analysis. If ingredients were not specifically cited, the books where the 
citations were found were searched to identify the ingredients. 
4.5.2.1 Formulas in all included Chinese herbal medicine citations 
Combinations of herbs without a formula name were described in 117 treatments with 
Chinese herbal medicine. There were 162 out of the 472 included named formulas 
recorded in multiple citations. Table 4.3 presents the 10 most frequently cited 
formulas. It is worth noting that the formula ingredients in Table 4.3 are taken from 
the earliest citation because the ingredients of a formula may change over time or 
differ in different books. 
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Table 4.3 Most frequently reported formulas in all included Chinese herbal 
medicine citations 
Formula 
name 
Herb ingredients No. of 
citations  
Da qin jiu 
tang 大秦艽汤 
Qin jiao 秦艽, gan cao 甘草, chuan xiong 川芎, dang 
gui 当归, bai shao 白芍, xi xin 细辛, qiang huo 羌活, 
fang feng 防风, huang qin 黄芩, shi gao 石膏, bai zhi 
白芷, bai zhu 白术, shu di huang 熟地黄, fu ling 茯苓, 
du huo 独活 
25 
Modified Si 
wu tang 四物
汤加减 
Dang gui 当归, chuan xiong 川芎, bai shao 白芍, shu 
di huang 熟地黄, tao ren 桃仁, hong hua 红花, zhu li 
竹沥, sheng jiang 生姜 
22 
Modified Xiao 
xu ming tang 
小续命汤 
Ma huang 麻黄, rou gui 肉桂, gan cao 甘草, ren shen 
人参, bai shao 白芍, chuan xiong 川芎, huang qin 黄芩
, fang feng 防风, dang gui 当归, shi gao 石膏, bai zhu 
白术, sheng jiang 生姜, fu zi 附子, xing ren 杏仁, hai 
zao 海藻, zhu rou 猪肉 (pork) 
17 
Modified Liu 
jun zi tang 六
君子汤加减 
Ren Shen 人参, Bai Zhu 白术, Fu Ling 茯苓, Gan Cao 
甘草, Chen Pi 陈皮, Ban Xia 半夏, etc.  
11 
Xu ming tang 
续命汤 
Ma huang 麻黄, gui zhi 桂枝, ren shen 人参, dang gui 
当归, chuan xiong 川芎, shi gao 石膏, xing ren 杏仁, 
sheng jiang 生姜, gan cao 甘草 
10 
Di huang yin 
zi 地黄饮子 
Sheng di huang 生地黄, shu di huang 熟地黄, shi 
chang pu 石菖蒲, ba ji tian 巴戟天, fu zi 附子, rou gui 
肉桂, shi hu 石斛, fu ling 茯苓, yuan zhi 远志, mai 
dong 麦冬, wu wei zi 五味子, bo he 薄荷, shan zhu yu 
山茱萸 
9 
San huang 
tang 三黄汤 
Ma huang 麻黄, huang qi 黄芪, huang qin 黄芩, du huo 
独活, xi xin 细辛, 
8 
Wu yao shun 
qi san 乌药顺
气散 
Wu yao 乌药, chen pi 陈皮, ma huang 麻黄, jiang can 
僵蚕, chuan xiong 川芎, zhi shi 枳实, gan cao 甘草, jie 
geng 桔梗, bai zhi 白芷, sheng jiang 生姜, da zao 大枣 
8 
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Formula 
name 
Herb ingredients No. of 
citations  
Tian ma wan 
天麻丸 
1. Tian ma 天麻, di yu 地榆, mo yao 没药, xuan shen 玄
参, fu zi 附子, she xiang 麝香, feng mi 蜂蜜, jiu 酒 (rice 
wine) 
2. Tian ma 天麻, xuan shen 玄参, fang feng 防风, di yu 
地榆, bo he 薄荷, fu zi 附子, niu xi 牛膝, zao jiao 皂荚, 
niu huang 牛黄, long nao 龙脑, jiu 酒 (rice wine), feng 
mi 蜂蜜, fu ping 浮萍 
8 
Hu jing gu jiu 
虎胫骨酒 
Gou ji 狗脊, hu jing 虎胫 (tiger shin), niu xi 牛膝, ba ji 
tian 巴戟天, shi hu 石斛, shi nan 石楠, fang feng 防风, 
dang gui 当归, yin yu 茵芋, du zhong 杜仲, chuan 
xiong 川芎, xu duan 续断 
8 
Notes: the use of some herbs such as fu zi 附子, wu tou 乌头, xi xin 细辛 may be restricted in 
some countries. The use of some herbs may be restricted under the provisions of CITES (such 
as she xiang 麝香 and hu jing 虎胫). The Chinese names, pin yin names, scientific names and 
common English names of the herbs were listed in Appendix 9. Readers are advised to 
comply with relevant regulations. 
All these formulas were orally administered. However, none of them is recommended 
in current textbooks and clinical practice guidelines (ESO Executive Committee and 
ESO Writing Committee 2008; Department of Veterans Affairs, Department of 
Defense, American Heart Association and American Stroke Association 2010; Schulz, 
Altman and Moher 2010; Stroke Foundation of New Zealand and New Zealand 
Guidelines Group 2010; Bian and Shang 2011; China Academy of Chinese Medical 
Sciences and Chinese Association of Acupuncture-moxibustion 2011; Chinese 
Society of Neurology and Stroke Prevention Project Committee of National Health 
and Family Planning Commission in China 2012; National Institute for Health and 
Care Excellence 2013; Lindsay et al. 2014; Hebert et al. 2016; Royal College of 
Physicians Intercollegiate Stroke Working Party 2016; Simpson et al. 2016; Winstein 
et al. 2016; Australian National Stroke Foundation 2017; Chinese Society of 
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Neurology et al. 2017). The reasons for this might be: 1) understanding of zhong feng 
中风 aetiology changed from external Wind attack to internal pathological factors 
such as qi 气 deficiency, Phlegm and Heat over time; and 2) the included formulas 
may not specifically focus on spasticity, as those summarised at this level for analysis 
are formulas for general treatment of stroke. 
4.5.2.2 Ingredients in all included Chinese herbal medicine citations 
There are 473 ingredients used in the included citations. Table 4.4 presents the 20 
most frequently cited herbs. dang gui 当归, usually used to nourish Blood and cure 
Blood Stasis, was the most commonly used herb among the included citations, 
followed by fang feng 防风, which could be used to eliminate Wind. The frequently 
cited herbs can be categorised into the following groups based on their functions: 1) 
nourishing Blood and curing Blood Stasis e.g. dang gui 当归, chuan xiong 川芎 and 
di huang地黄; 2) qi 气, Spleen or Kidney tonifying e.g. fu zi 附子, wu tou 乌头, rou 
gui 肉桂, ren shen 人参, bai zhu 白术, fu ling 茯苓 and ginger 生姜; 3) Wind 
eliminating e.g. fang feng 防风, qiang huo 羌活, ma huang 麻黄 and xi xin 细辛; 4) 
Meridian opening e.g. tian ma 天麻 and niu xi 牛膝. Because of their toxicity, the use 
of fu zi 附子, wu tou 乌头 and xi xin 细辛, although they are listed among the 20 most 
frequently used herbs, is restricted in some countries. The Chinese names, pin yin 
names, scientific names and common English names of the above herbs were listed in 
Appendix 9. 
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Table 4.4 Most frequently reported ingredients in possibly post-stroke spasticity–
related citations 
Herb name Scientific name No. of 
citations (n) 
dang gui 当归 Angelica sinensis (Oliv.) Diels 429 
fang feng 防风 Saposhnikovia divaricata (Turcz.) 
Schischk. 
414 
gan cao 甘草 Glycyrrhizae Radix et Rhizoma 396 
jiang 生姜, 姜 Zingiber officinale (Willd.) Rosc. (fresh 
or dried rhizome) 
376 
chuan xiong 川芎 Ligusticum chuanxiong Hort. 368 
fu zi 附子 Aconitum carmichaeli Debx. 333 
rou gui 肉桂, 肉桂枝, 官
桂 
Cinnamomum cassia Presl 293 
ren shen 人参 Panax ginsng C.A. Mey. 288 
ma huang 麻黄 Ephedrae Herba 271 
di huang (shu di huang/ 
sheng di huang/ di 
huang) 地黄 (熟地黄/生
地黄/地黄) 
Rehmannia glutino a Libosch. 258(172/73/1
3) 
bai zhu 白术 Atractylodes macrocephala Koidz. 251 
qiang huo 羌活 Notopterygium incisum Ting ex H. T. 
Chang 
237 
fu ling 茯苓 Poria cocos (Schw.) Wolf 222 
jiu 酒 Alcohol 215 
du huo 独活 Angelica pubescens Maxim. f. biserrata 
Shan et Yuan 
215 
bai shao 白芍 Paeonia lactiflora Pall. 210 
tian ma 天麻 Gastrodia elata Bl. 204 
wu tou 乌头, 川乌, 草乌 1. Aconitum carmichaeli Debx. 
2. Aconitum kusnezoffii Reichb. 
167 
xi xin 细辛 1. Asarum heterotropoides Fr. Schmidt 
var. mandshuricum (Maxim) Kitag. 
2. Asarum sieboldii Miq. var. seoulense 
Nakai 
3. Asarum sieboldii Miq. 
151 
niu xi 牛膝 Cyathula officinalis Kuan 150 
Notes: The use of certain herbs such as fu zi 附子, wu tou 乌头, xi xin 细辛 may be restricted 
in some countries. Readers are advised to comply with relevant regulations. The Chinese 
names, pin yin names, scientific names and common English names of the above herbs were 
listed in Appendix 9. 
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4.5.2.3 Formulas in likely post-stroke spasticity citations 
Citations were judged to be ‘likely post-stroke spasticity citations’ if treatment of 
post-stroke motor dysfunction focused particularly on spasticity symptoms. A total of 
232 citations from 76 books were defined as likely post-stroke spasticity citations, 
with the most frequently cited ones being: Pu Ji Fang 普济方 (Ming Dynasty) (n=34), 
Tai Ping Sheng Hui Fang 太平圣惠方 (A.D. 992) (n=27), Sheng Ji Zong Lu 圣济总
录 (Song Dynasty) (n=16), Ji Yang Gang Mu 济阳纲目 (A.D. 1626) (n=9), Tai Ping 
Hui Min He Ji Ju Fang 太平惠民和剂局方 (Song Dynasty) (n=8), Ru Men Shi Qin 
儒门事亲 (A.D. 1228) (n=7), Yi Xue Gang Mu 医学纲目 (A.D. 1565) (n=7), Bei Ji 
Qian Jin Yao Fang 备急千金要方 (A.D. 652) (n=7), Qi Xiao Liang Fang 奇效良方 
(A.D. 1470) (n=7), Wai Tai Mi Yao 外台秘要 (A.D. 752) (n=5). 
Thirty out of 151 formulas cited more than twice were identified from 232 citations. 
Twelve (12) formulas were cited multiple times (> 3 times). They were: san huang 
tang 三黄汤 (n=7), Xu ming tang 续命汤 (n=7), Xiao xu ming tang 小续命汤 (n=6), 
Hu jing gu jiu 虎胫骨酒 (n=6), Qian jin san huang tang 千金三黄汤 (n=5), Xing 
feng tang 省风汤 (n=5), Tie dan wan 铁弹丸 (n=4), Fang feng san 防风散 (n=4), Da 
jin ya jiu 大金牙酒 (n=3), Zuo jing wan 左经丸 (n=3), Du huo san 独活散 (n=3), 
Qin jiu sheng ma tang 秦艽升麻汤 (n=3). 
4.5.2.4 Herbs in likely post-stroke spasticity citations 
Table 4.5 presents the 20 most frequently recorded ingredients. There are 298 
ingredients identified from the 232 citations. This list is consistent with that from all 
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included citations (Table 4.4). Quan xie 全蝎 is the most frequently cited ingredient; 
its main function is to relieve spasm and pain in Chinese medicine. But it should be 
noted that buthotoxin is contained in Quan xie全蝎 so a small dosage is suggested. 
Table 4.5 Most frequently reported ingredients in likely post-stroke spasticity–
related citations 
Name of ingredient Scientific name No. of 
citations (n) 
fang feng 防风 Saposhnikovia divaricata (Turcz.) Schischk. 115 
dang gui 当归 Angelica sinensis (Oliv.) Diels 96 
chuan xiong 川芎 Ligusticum chuanxiong Hort. 94 
fu zi 附子 Aconitum carmichaeli Debx. 86 
gan cao 甘草 Glycyrrhizae Radix et Rhizoma 86 
ma huang 麻黄 Ephedrae Herba 78 
rou gui 肉桂, 肉桂
枝, 官桂 
Cinnamomum cassia Presl 72 
jiang 生姜, 姜 Zingiber officinale (Willd.) Rosc. (fresh or 
dried rhizome) 
68 
du huo 独活 Angelica pubescens Maxim. f. biserrata 
Shan et Yuan 
65 
ren shen 人参 Panax ginsng C.A. Mey. 64 
qiang huo 羌活 Notopterygium incisum Ting ex H. T. Chang 52 
jiu 酒 Alcohol 51 
bai zhu 白术 Atractylodes macrocephala Koidz. 50 
huang qin 黄芩 Scutellaria baicalensis Georgi 49 
niu xi 牛膝 Cyathula officinalis Kuan 46 
wu tou 乌头, 川乌, 
草乌 
1. Aconitum carmichaeli Debx. 
2. Aconitum kusnezoffii Reichb. 
44 
tian ma 天麻 Gastrodia elata Bl. 42 
bai shao 白芍 Paeonia lactiflora Pall. 39 
xi xin 细辛 1. Asarum heterotropoides Fr. Schmidt var. 
mandshuricum (Maxim) Kitag. 
2. Asarum sieboldii Miq. var. seoulense 
Nakai 
3. Asarum sieboldii Miq. 
39 
quan xie 全蝎 Buthus martensii Karsch 36 
Notes: the use of certain herbs such as fu zi 附子, wu tou 乌头, xi xin 细辛 may be restricted 
in some countries. Readers are advised to comply with relevant regulations. The Chinese 
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names, pin yin names, scientific names and common English names of the above herbs were 
listed in Appendix 9. 
4.5.3 Representative case report 
Six case reports with different formulas were identified as using Chinese herbal 
medicine to manage symptoms likely caused by post-stroke spasticity. One citation 
from the book Shou Shi Bao Yuan 寿世保元 (Ming Dynasty) reported a patient 
recovering from hemiplegia and spasticity 10 years post-stroke due to a Chinese 
herbal medicine formula (Shi Guo Gong Jin Jiu Liang Fang 史国公浸酒良方), but its 
effects have not been confirmed by the literature review and were probably 
exaggerated, as this formula was not recorded in other books identified by our search. 
4.5.4 Discussion 
A total of 1,028 citations of Chinese herbal medicine possibly for the treatment of 
post-stroke motor function impairment were included in a ‘‘possible pool’’ after 
searching and screening the classical literature of Chinese medicine. Of these, 232 
were judged to be likely addressing spasticity or related symptoms and were put into a 
‘‘likely pool’’. There were 472 named Chinese herbal medicine formulas with 473 
different ingredients identified from the ‘‘possible pool’’. 
In the ‘likely pool’, 151 formulas were identified from 232 citations. The most 
frequently reported ones are: San huang tang 三黄汤, Xu ming tang 续命汤, Xiao xu 
ming tang 小续命汤, Hu jing gu jiu 虎胫骨酒, Qian jin san huang tang 千金三黄汤, 
Xing feng tang 省风汤, Tie dan wan 铁弹丸, Fang feng san 防风散, Da jin ya jiu 大
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金牙酒, Zuo jing wan 左经丸, Du huo san 独活散, Qin jiu sheng ma tang 秦艽升麻
汤.  
Probably due to the developing understanding of the aetiology of post-stroke 
spasticity over time, the above formulas are inconsistent with those recommended by 
mainstream guidelines, textbooks and monographs (Zhang and Xue 2012). Further, 
the main functions of the ingredients identified above can be categorised into 
nourishing the Blood and curing Blood Stasis, tonifying qi 气, Spleen or Kidney, 
eliminating Wind and opening up meridians, somewhat similar to the treatment 
principles used in clinical practice nowadays (ESO Executive Committee and ESO 
Writing Committee 2008; Department of Veterans Affairs, Department of Defense, 
American Heart Association and American Stroke Association 2010; Schulz, Altman 
and Moher 2010; Stroke Foundation of New Zealand and New Zealand Guidelines 
Group 2010; Bian and Shang 2011; China Academy of Chinese Medical Sciences and 
Chinese Association of Acupuncture-moxibustion 2011; Chinese Society of 
Neurology and Stroke Prevention Project Committee of National Health and Family 
Planning Commission in China 2012; National Institute for Health and Care 
Excellence 2013; Lindsay et al. 2014; Hebert et al. 2016; Royal College of Physicians 
Intercollegiate Stroke Working Party 2016; Simpson et al. 2016; Winstein et al. 2016; 
Australian National Stroke Foundation 2017; Chinese Society of Neurology et al. 
2017). It should be noted that certain herbs frequently reported in the classical 
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literature are no longer used in clinical practice today due to their toxicity or their 
sources coming from endangered animals. 
4.6 Acupuncture 
We identified 162 citations of acupuncture from 46 books discussing post-stroke 
motor function impairment possibly including spasticity. The most commonly cited 
are: Pu Ji Fang – Zhen Jiu 普济方•针灸 (Ming Dynasty) (n=20), Gu Jin Yi Tong Da 
Quan 古今医统大全 (A.D. 1556) (n=15), Lei Jing Tu Yi 类经图翼 (Ming Dynasty) 
(n=10), Zhen Jiu Da Cheng 针灸大成 (Ming Dynasty) (n=10), Tai Ping Sheng Hui 
Fang 太平圣惠方 (A.D. 992) (n=9), Zhen Jiu Ji Cheng 针灸集成 (Qing Dynasty) 
(n=9), Zhen Jiu Ju Ying 针灸聚英 (A.D. 1529) (n=8), Sheng Ji Zong Lu 圣济总录 
(Song Dynasty) (n=7), Mian Xue Tang Zhen Jiu Ji Cheng 勉学堂针灸集成 (A.D. 
1874) (n=6), Zhen Fang Liu Ji 针方六集 (A.D. 1618) (n=6). 
4.6.1 Frequency of acupuncture citation by dynasty 
Similar to the Chinese herbal medicine citations, the majority of these citations were 
from the Ming Dynasty (A.D. 1369–1644) and Qing dynasty (A. D.1645–1911). The 
earliest treatment citations were from Huang Di Ming Tang Jiu Jing 黄帝明堂灸经 
(Tang dynasty), and the most recent were from the book Jin Zhen Mi Zhuan 金针秘传 
(A.D. 1937). Five citations were from books without known years of publication and 
one was from a Japanese acupuncture textbook published during the Qing Dynasty 
(Table 4.6). 
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Table 4.6 Dynastic distribution of acupuncture-related citations 
Dynasty No. of treatment citations 
Before Tang Dynasty (before 618) 0 
Tang and the Five Dynasties (618–960) 6 
Song and Jin Dynasties (961–1271) 25 
Yuan Dynasty (1272–1368) 8 
Ming Dynasty (1369–1644) 79 
Qing Dynasty (1645–1911) 36 
Ming Guo/Republic of China (1912–1949) 2 
Others 5 unknown, 1 Japan* 
Total 162 
* Chinese medicine book published in Japan 
4.6.2 Treatment with acupuncture-related therapies 
Among the included citations, 111 out of 162 recorded that a particular acupuncture 
point could be used for treating certain clinical conditions or symptoms. Two citations 
recorded clinical case reports. 
4.6.2.1 Interventions in all included acupuncture citations 
A total of 96 acupuncture points were found in all included acupuncture citations, 
with the top 20 presented in Table 4.7.  
72 
 
Table 4.7 Most frequently reported acupuncture points in possibly post-stroke 
spasticity–related citations 
Acupuncture 
point 
Point location* No. of 
citations 
(n) 
LI11 Quchi 曲池  On the lateral aspect of the elbow, at the midpoint of 
the line connecting LU5 with the lateral epicondyle 
of the humerus 
41 
LI15 Jianyu 肩髃  On the shoulder girdle, in the depression between the 
anterior end of lateral border of the acromion ad the 
greater tubercle of the humerus 
32 
GV20 Baihui 百会  On the head, 5.5 B-cun superior to the posterior 
hairline, on the posterior median line. 
24 
LI10 Shousanli 手
三里  
On the posterolateral aspect of the forearm on the 
line connecting LI5 with LI11, 3 B-cun inferior to 
the cubital crease. 
22 
GB31 Fengshi 风
市  
On the lateral aspect of the thigh, in te depression 
posterior to the iliotibial band where the tip of the 
middle finger rests, when standing up with the arms 
hanging alongside the thigh. 
20 
GB30 Huantiao 环
跳  
In the buttocks region, at the junction of the lateral 
one third and medial two thirds of the line 
connecting the prominence of the greater trochanter 
with the sacral hiatus. 
19 
GB39 Xuanzhong 
悬钟  
On the fibular aspect of the leg, anterior to the fibula, 
3 B-cun proximal to the prominence of the lateral 
malleolus 
18 
LI4 Hegu 合谷  On the dorsum of the hand, in the depression radial 
and proximal to the second metacarpophalangeal 
joint. 
15 
GB34 
Yanglingquan 阳
陵泉  
On the fibular aspect of the leg, in the depression 
anterior and distal to the head of the fibula. 
15 
BL60 Kunlun 昆仑  On the posterolateral aspect of the ankle, in the 
depression between the prominence of the lateral 
malleolus and the calcaneal tendon. 
12 
CV24 Chengjiang 
承浆  
In the anterior region of the neck, superior to the 
superior border of the thyroid cartilage, in the 
depression superior to the hyoid bone, on the anterior 
median line. 
11 
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* Location was adapted from World Health Organization Western Pacific Region. 2010 
Acupuncture 
point 
Point location* No. of 
citations 
(n) 
ST36 Zusanli 足三
里  
On the anterior aspect of the leg, on the line 
connecting ST35 with ST 41, 3 B-cun inferior to 
ST35. 
11 
GB21 Jianjing 肩
井  
In the posterior region of the nek, at the midpoint of 
the line connecting the spinous process of the 
seventh cervical vertebra (C7) with the lateral end of 
the acromion. 
10 
BL40 Weizhong 委
中  
On the posterolateral aspect of the knee, just medial 
to the biceps femoris tendon in the popliteal crease. 
7 
GB3 Shangguan 
上关  
On the head, in the depression superior to the 
midpoint of the zygomatic arch. 
7 
ST4 Dicang 地仓  On the face, 0.4 F-cun lateral to the angle of the 
mouth. 
6 
KI6 Zhaohai 照海  On the medial aspect fo the foot, 1 B-cun inferior to 
the prominence of the medial malleolus, in the 
depression inferior to the medial malleolus. 
6 
GV16 Fengfu 风府  In the posterior region of the neck, directly inferior 
to te external occipital protuberance, in the 
depression between the trapezius muscles. 
5 
GB40 Qiuxu 丘墟  On the anterolateral aspect of the ankle, in the 
depression lateral to the extensor digitorum longus 
tendon, anterior and distal to the lateral malleolus. 
5 
ST6 Jiache 颊车  On the face, one fingerbreadth (middle finger) 
anterosuperior to the angle of the mandible. 
5 
BL15 Xinshu 心俞  In the upper back region, at the same level as the 
inferior border of the spinous process of the fifth 
thoracic vertebra (T5), 1.5 B-cun lateral to the 
posterior median line. 
5 
GB2 Tinghui 听会 On the face, in the depression between the intertragic 
notch and the condylar process of the mandible. 
5 
GB20 Fengchi 风
池  
In the anterior region of the neck, inferior to the 
occipital bone, in the depression between the orgins 
of the sternocleidomastoid and the trapezius muscles. 
5 
GB38 Yangfu 阳辅  On the fibular aspect of the leg, anterior to the fibula, 
4 b-cunproximal to the prominence of the lateral 
malleolus. 
5 
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The above acupuncture points can be grouped according to their locations and 
functions as follows: 
Upper limbs: LI11 Quchi 曲池, LI15 Jianyu 肩髃, LI10 Shousanli 手三里, LU7 
Lieque 列缺, LI4 Hegu 合谷, GB21 Jianjing 肩井 
Lower limbs: GB31 Fengshi 风市, GB30 Huantiao 环跳, B34 Yanglingquan 阳陵泉, 
BL60 Kunlun 昆仑, ST36 Zusanli 足三里, BL40 Weizhong 委中, GB39 Xuanzhong 
悬钟, KI6 Zhaohai 照海, GB38 Yangfu 阳辅, GB40 Qiuxu 丘墟 
Facial area: CV24 Chengjiang 承浆, GB3 Shangguan 上关, ST4 Dicang 地仓, GB2 
Tinghui 听会, ST6 Jiache 颊车 
Other points reflect treatment principles based on their functions: 
To clear the mind and Shen 神: GV20 Baihui 百会, BL15 Xinshu 心俞 
To eliminate Wind: GV16 Fengfu 风府, GB20 Fengchi 风池 
It should be noted that the above citations are not limited to post-stroke spasticity. 
These points are used for patients with stroke in general. 
Most of these included citations (n=111) were extracted from books specifically on 
acupuncture. In the classical literature, acupuncture points were introduced under each 
meridian, with information on locations, disease to be treated, depth of needling and 
moxibustion. 
75 
 
4.6.2.2 Interventions in likely post-stroke spasticity citations 
By adding the criterion of ‘spasticity-specific symptoms’, the included acupuncture 
citation pool was reduced to a total of 30 citations from 13 books: Pu Ji Fang – Zhen 
Jiu 普济方•针灸 (Ming Dynasty) (n=10), Zhen Jiu Da Cheng 针灸大成 (n=5), Sheng 
Ji Zong Lu 圣济总录 (Song Dynasty) (n=2), Bian Que Shen Ying Zhen Jiu Yu Long 
Jing 扁鹊神应针灸玉龙经 (n=2), Pu Ji Ben Shi Fang 普济本事方 (n=2), Zhen Jiu 
Wen Da 针灸问答 (n=2), Wai Tai Mi Yao 外台秘要 (A.D. 752) (n=1), Tai Ping 
Sheng Hui Fang 太平圣惠方 (A.D. 992) (n=1), Wu Ju Tong Yi An 吴鞠通医案 (n=1), 
Jiu Fang Mi Zhuan 灸法秘传 (n=1), Bing Ji Sha Zhuan 病机沙篆 (n=1), Xi Fang Zi 
Ming Tang Jiu Jing 西方子明堂灸经 (n=1), Zhen Fang Liu Ji 针方六集 (A.D. 1618) 
(n=1). Further, we identified 36 acupuncture points from these citations (Table 4.8). 
Of the points identified from the citations possibly related to post-stroke spasticity, 13 
points are repeated in this list (Tables 4.7 and 4.8). 
Table 4.8 Most frequently reported acupuncture points in likely post-stroke 
spasticity–related citations 
Acupuncture point No. of citations 
LI15 Jianyu 肩髃 11 
LI11 Quchi 曲池 7 
LI4 Hegu合谷 5 
GB30 Huantiao环跳 5 
LI10 Shousanli手三里 4 
GV20 Baihui 百会 4 
BL60 Kunlun 昆仑 4 
GB31 Fengshi 风市 3 
GB34 Yanglingquan 阳陵泉 3 
BL40 Weizhong 委中 3 
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Acupuncture point No. of citations 
GB21 Jianjing 肩井 2 
LI9 Shanglian 上廉 2 
ST36 Zusanli 足三里 2 
LU7 Lieque 列缺 2 
PC6 Neiguan 内关 2 
SI4 Wangu 腕骨 2 
4.6.3 Discussion 
Our research found that the acupuncture treatment for Zhong Feng 中风 could date 
back to the Tang Dynasty and has been continually used. Our review found that the 
earliest description of likely post-stroke spasticity treated with acupuncture is from a 
book published in the Tang Dynasty, Wai Tai Mi Yao 外台秘要(A.D. 752). 
There are a total of 162 citations identified as acupuncture treatment for post-stroke 
functional impairment possibly including symptom of spasticity. When limiting the 
criterion to ‘spasticity-specific symptoms’, 30 citations were included in the pool. 
A total of 96 acupuncture points were identified from all included citations. 
Somewhat similar to current clinical practice, the principle of selecting acupuncture 
points in the treatment of post-stroke functional impairment is based on choosing 
points in the affected areas, assisted by the Chinese medicine syndrome differentiation. 
Further, 16 acupuncture points were found in the 30 citations which specifically 
mentioned spasticity-like symptoms. These points are commonly used in acupuncture 
treatment for hemiplegia. Our analysis of these citations did not locate any special 
acupuncture point carrying an anti-spasticity function.  
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Chapter 5 Chinese herbal medicine for post-stroke spasticity 
 
This chapter systematically reviews the add-on effectiveness and safety of Chinese 
herbal medicine for post-stroke spasticity. The protocol was registred on PROSPERO 
(registration number: PROSPERO 2016: CRD42016043281). 
5.1 Methods 
To identify relevant studies on Chinese medicine, a comprehensive search of the 
modern literature was conducted. According to the predefined inclusion and exclusion 
criteria, only randomised controlled trials were screened. 
5.1.1 Search methods for study identification 
A literature search was conducted in April 2015 and later updated to February 2018 
following the instructions of the Cochrane Handbook for Systematic Reviews of 
Interventions 5.1.0 (Cochrane Collaboration 2011). A total of nine electronic 
databases were searched from their respective inceptions to April 2015. Five of these 
were English databases and four were Chinese databases. The digital databases are 
listed in Table 5.1. 
Table 5.1 Databases searched in the research project 
English databases Chinese databases 
PubMed Chinese Biomedical Database 
EMBASE Chinese National Knowledge Infrastructure 
Cumulative Index to Nursing and 
Allied Health Literature 
Chongqing VIP Database 
Cochrane Library Wanfang Database 
Allied and Complementary 
Medicine Database 
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The search strategies used were combinations of the following key terms and their 
synonyms: stroke, spasticity, Chinese herbal medicine and acupuncture. The search 
strategy for PubMed is presented in Table 5.2 as an example. Similar search strategies 
were applied to the other digital databases. 
Table 5.2 Search strategy for systematic reviews of Chinese herbal medicine in 
PubMed 
Search Search strategy 
#1 stroke OR brain infarction OR intracranial embolism and thrombosis OR 
intracranial hemorrhages OR cerebrovascular accident OR cerebral 
infarction OR intracranial haemorrhage OR cerebral 
#2 muscle spasticity OR muscle hypertonia OR muscle tonus OR spasm OR 
dystonia OR paraparesis, spastic* OR high tone OR hypermyotonia OR 
contracture 
#3 traditional Chinese medicine OR Chinese traditional medicine OR Chinese 
herbal drugs OR Chinese drugs, plant OR medicine, traditional OR 
ethnopharmacology OR ethnomedicine OR ethnobotany OR medicine, 
kampo OR kampo OR TCM OR medicine, ayurvedic OR phytotherapy OR 
herbologia OR plants, medicinal OR plant preparation OR plant extract OR 
plants, medicine OR materia medica OR single prescription OR herbs OR 
Chinese medicine herb OR herbal medicine 
#4 acupuncture OR meridians OR electroacupuncture OR Moxibustion OR 
auriculotherapy OR plum blossom OR acupressure OR ear acupuncture OR 
ear acupressure OR acupuncture, ear OR acupuncture therapy OR moxa 
OR laser acupuncture OR seven star needle OR acupuncture analgesia OR 
acupuncture points OR electro-acupuncture OR electro acupuncture OR 
TENS OR transcutaneous nerve stimulation OR transcutaneous electric 
nerve stimulation OR transcutaneous electrical nerve stimulation OR 
electro-stimulation OR electro stimulation OR pharmacopuncture OR point 
injection OR catgut embedding 
#5 random* AND controlled trial 
#7 #1 AND #2 AND #3 AND #5 
#8 #1 AND #2 AND #4 AND #5 
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5.1.2 Study selection 
Two reviewers independently screened the titles and abstracts of all studies based on 
the search results from the electronic databases. Studies were included or excluded 
according to the predefined selection criteria. If inadequate information was obtained 
from the titles and abstracts, full text checking was needed for screening. Any 
disagreement between the two reviewers was resolved through discussion or by a 
third researcher when no agreement could be reached. The selection criteria were: 
5.1.2.1 Inclusion criteria 
 Randomised controlled trial 
 Patients after stroke, was diagnosed according to guidelines and confirmed by 
computed tomography (CT) or magnetic resonance imaging 
 No limitation on patient age or gender 
 Ashworth Scale or Modified Ashworth Scale score ≥ 1 
 Intervention: Chinese herbal medicine or acupuncture (covering manual 
acupuncture, acupressure, moxibustion and electro-acupuncture) 
 Control: sham or placebo, no intervention 
 Co-intervention: co-interventions were allowed as long as all the arms of the trial 
used the same co-interventions, which were therapeutic strategies regarded as 
routine care for stroke patients, including blood pressure control, proper 
positioning of extremities, physiotherapy and occupational therapies 
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 Outcome measures: study reported at least one of the following outcome 
measures: primary outcome measure Ashworth Scale or Modified Ashworth 
Scale or Modified Modified Ashworth Scale; secondary outcome measures Fugl-
Meyer Assessment (motor function), Barthel Index; safety outcome measure: 
adverse events. 
5.1.2.2 Exclusion criteria 
 Animal studies 
 Patients with subdural hematoma, brain tumour or parasites 
 Spasticity caused not by stroke but by other conditions, such as spinal cord 
injury/compression, multiple sclerosis, motor neurone disease or tuberculosis of 
the spine 
 Complex treatment was adopted without specifying the add-on effects of Chinese 
medicine 
5.1.3 Data collection and analysis 
5.1.3.1 Data extraction and management 
Data from studies that met the selection criteria were extracted into a pre-designed 
Excel spread sheet with the following domains: 1) characteristics of the studies – 
author(s), publication year, journal, study design, country, randomisation, blinding 
(participants, intervention providers, assessors), follow-up duration; 2) participant 
characteristics – age, post-stroke stage, stroke type, time of stroke, sample size, 
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syndrome differentiation; 3) interventions and control treatments – principles of 
treatment, formula, herb, acupuncture point, frequency and duration, etc.; 4) outcome 
measures. 
Where there were missing or incomplete data, the trial authors were contacted in order 
to obtain additional information or to seek clarification. 
5.1.3.2 Methodological quality assessment 
The risk of bias of the following domains were assessed by two reviewers 
independently using the Cochrane Collaboration tool for assessing risk of bias in the 
Cochrane Handbook for systematic reviews of interventions (Version 5.1.0): 
 Selection bias (random sequence generation, allocation concealment) 
 Performance bias (blinding of participants and intervention providers) 
 Detection bias (blinding of outcome assessment) 
 Attrition bias (incomplete outcome data) 
 Reporting bias (selective reporting) 
 Other bias (e.g. bias related to the specific study design used being fraudulent) 
The risk of bias in each domain was judged as high, low or unclear risk. Any 
disagreement between the two reviewers was resolved through discussion or by a 
third researcher. 
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5.1.3.3 Statistical analysis 
Statistical analysis was carried out in RevMan 5.3. Effect size analyses were 
performed to explore the differences between groups. To present the results, 
dichotomous data are expressed as the risk ratio (RR) with a 95% confidence interval 
(CI) and continuous data are reported as the mean difference (MD) or standardised 
mean difference (SMD). Further, subgroup analyses and sensitivity analyses had been 
planned and were carried out when applicable. The source of clinical heterogeneity 
among included trials was explored through subgroup analyses for baseline 
differences in terms of stroke onset (1 or > 1 times), history of stroke (≤ 180 days or > 
180 days), treatment duration (≤ 4 weeks or > 4 weeks) and preparation of herbal 
interventions (such as compression and steaming therapy). In consideration of the 
methodological quality, sensitivity analyses were performed based on the results of 
risk of bias judgements (only studies assessed as low risk of bias in sequence 
generation, allocation concealment, blinding, incomplete data or selective reporting 
were included). The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist of Chinese herbal medicine systematic reviews is 
attached as an appendix (Appendix 10). Moreover, publication bias was explored by 
visual inspection of funnel plots for asymmetry and with Egger’s linear regression test 
if ten or more studies were included in a meta-analysis. 
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5.2 Results 
5.2.1 Study selection 
There were 46,304 studies identified through the comprehensive search (Figure 5.1). 
A total of 2,309 possibly relevant studies were obtained for full-text screening. Thirty-
five (35) randomised controlled trials meeting our criteria were included for 
systematic review; 24 of these were included in the meta-analyses. 
Of these 35 trials, the results of five randomised controlled trials (Chen 2013; Huang 
et al. 2011; Zhang, Qiao and Chen 2008; Zhao 2013; Zhao 2010) could not be 
synthesised in the meta-analysis because their reported data were incorrect or could 
not be pooled. Another six studies (Zhu, Jin, et al. 2013; Zhu, Hu, and Zhou 2002; 
Zhu et al. 2007; Zhang 2009; Xie et al. 2011; Weng 2014) evaluated oral plus topical 
Chinese herbal medicine interventions and their results were not pooled for meta-
analysis due to the diversity of interventions. 
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Figure 5.1 PRISMA flow chart of Chinese herbal medicine systematic review 
Notes: CHM, Chinese herbal medicine; MAS, Modified Ashworth Scale; RCT, randomised 
controlled trial. 
5.2.2 Basic characteristics 
All randomised controlled trials included in this review were conducted in China and 
published between 2002 and 2016 (Table 5.3). Sample sizes of the included studies 
ranged from 29 to 120. A total of 2,457 stroke patients with an average age of 61.72 
years were included. 
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Table 5.3 Summary of basic characteristics in Chinese herbal medicine systematic review 
Interventions Author, 
year 
Sample 
size 
(I/C)  
Age 
(years) 
Gender 
(% 
male) 
Stroke type First 
onset 
of 
stroke 
Time from 
stroke 
onset  
Spasticity 
severity 
Outcome measures  
Oral CHM Cai 
2016 
47/46 65.9 65.6 Cerebral 
infarction & 
haemorrhage 
N/A ≤ 3 months MAS > 0 MAS, CSS, ER 
Oral CHM Chen 
2014 
25/25 59.1 68.0 Cerebral 
infarction 
N/A 10–42 days AS ≥ 2 AS, FMA, BI 
Oral CHM Chen 
2013 
30/30 64.6 54.9 Cerebral 
infarction & 
haemorrhage 
Yes ≤ 3 months MAS: 1–3 EMG, TCM 
syndrome score 
Oral CHM He 
2016 
50/50 60.7 61.0 N/A N/A 4–87 days MAS > 0 FMA, BI, ER 
Oral CHM Huang 
W 2011 
20/15 68.6 57.1 N/A N/A ≥ 3 months MAS: 2–3 wrist & ankle ROM 
Oral CHM Li Y 
2011 
40/40 N/A 65.0 Cerebral 
infarction 
N/A 2–82 days MAS > 0 FMA, BI, ER 
Oral CHM Li 2015 40/40 N/A 66.3 Cerebral 
infarction 
N/A ≤ 90 days MAS > 0 FMA, BI, ER 
Oral CHM Liu 
2014 
34/34 67.6 55.9 Cerebral 
infarction & 
haemorrhage 
N/A 18–90 days MAS ≥ 1+ MAS, BI 
Oral CHM Murat 
2016 
36/36 61.5 62.5 Cerebral 
infarction & 
haemorrhage 
Yes 2–5 weeks MAS ≥ 1 BI, ER, TCM 
syndrome score 
86 
 
Interventions Author, 
year 
Sample 
size 
(I/C)  
Age 
(years) 
Gender 
(% 
male) 
Stroke type First 
onset 
of 
stroke 
Time from 
stroke 
onset  
Spasticity 
severity 
Outcome measures  
Oral CHM Wang 
2013 
35/34 N/A 60.9 Cerebral 
infarction & 
haemorrhage 
N/A 30–180 
days 
MAS ≥ 1 MAS, FMA 
Oral CHM Wei 
2011 
30/30 56.2 65.0 Cerebral 
infarction & 
haemorrhage 
N/A 2 weeks–6 
months 
MAS > 0 MAS, FMA, ER 
Oral CHM Zhang 
2008 
35/31 65.8 72.7 Cerebral 
infarction & 
haemorrhage 
N/A 2 weeks–6 
months 
MAS: 1–3 integrated EMG 
Oral CHM Zhang 
2012 
60/40 64.14 68.0 Cerebral 
infarction & 
haemorrhage 
Yes 14–180 
days 
MAS: 1–3 MAS, ER, VAS, 
Swelling score (upper 
limb), Berg balance 
score 
Oral CHM Zhao 
2013 
30/30 63.5 65 Cerebral 
infarction 
N/A N/A MAS ≥ 1 ER, AEs, neurological 
deficit score, 
Brunnstrom, motor 
patterns, TCM 
syndrome score 
Oral CHM Zhong 
2016 
41/41 62.56 56.1 Cerebral 
infarction & 
haemorrhage 
N/A 3–9 days MAS ≥ 1 BI, ER 
Topical CHM Cao 
2015 
32/32 57.7 61.3 Cerebral 
infarction & 
haemorrhage 
N/A < 365 days MAS ≥ 1+ MAS, CSS, BI 
Topical CHM Chen 
2010 
25/25 60 54 Cerebral 
infarction 
N/A ≤ 6 months MAS: 1–3 AS, AEs 
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Interventions Author, 
year 
Sample 
size 
(I/C)  
Age 
(years) 
Gender 
(% 
male) 
Stroke type First 
onset 
of 
stroke 
Time from 
stroke 
onset  
Spasticity 
severity 
Outcome measures  
Topical CHM Ding 
2016 
59/50 57.1 56.0 Cerebral 
infarction & 
haemorrhage 
Yes 10–100 
days 
MAS ≥ 2 MAS, ROM, ER 
Topical CHM Huang 
JX 2011 
45/45 60.8 61.1 Cerebral 
infarction & 
haemorrhage 
N/A N/A MAS ≥ 2 MAS, BI, AEs 
Topical CHM Jia 2012 44/42 65.5 61.6 Cerebral 
infarction & 
haemorrhage 
N/A 6–20 days MAS ≥ 1+ MAS, FMA, BI, ER, 
VAS 
Topical CHM Lai 
2016 
30/30 68.5 59.3 Cerebral 
infarction 
N/A N/A MAS ≥ 1 MAS, CSS, FMA, BI, 
ER, AEs 
Topical CHM Li 2008 30/30 57.2 58.3 Cerebral 
infarction & 
haemorrhage 
N/A N/A MAS ≥ 1+ MAS, ER 
Topical CHM Ou 
2007 
15/14 N/A N/A Cerebral 
infarction & 
haemorrhage 
Yes < 1 year MAS ≥ 2 MAS, step, walking 
speed 
Topical CHM Ou 
2014 
20/21 59.4 53.7 Cerebral 
infarction & 
haemorrhage 
Yes < 1 year MAS ≥ 2 MAS, FMA, FIM, 
AEs 
Topical CHM Shen 
2007 
31/30 60 55.7 Cerebral 
infarction 
N/A ≤ 6 months MAS: 1–3 AS, AEs 
Topical CHM Wang 
2014 
24/24 57 62.5 Cerebral 
infarction & 
haemorrhage 
N/A 30–151 
days 
MAS > 0 MAS, BI 
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Interventions Author, 
year 
Sample 
size 
(I/C)  
Age 
(years) 
Gender 
(% 
male) 
Stroke type First 
onset 
of 
stroke 
Time from 
stroke 
onset  
Spasticity 
severity 
Outcome measures  
Topical CHM Zhang 
2016 
60/60 62.1 60.0 Cerebral 
infarction & 
haemorrhage 
Yes 17–180 
days 
MAS ≥ 1 MAS, BI 
Topical CHM Zhang 
2007 
30/30 66.0 65.0 N/A N/A 2–12 weeks MAS: 1–3 FMA, FIM, ER 
Topical CHM Zhao 
2010 
28/27 N/A 63.6 Cerebral 
infarction & 
haemorrhage 
N/A N/A MAS ≥ 2 MAS (unclear 
description) 
Oral plus 
topical CHM 
Weng 
2014 
35/38 55.42 47.95 Cerebral 
infarction & 
haemorrhage 
Yes N/A MAS: 1–3 MAS, FMA, BI, AEs 
Oral plus 
topical CHM 
Xie 
2011 
60/60 59.25 60.83 Cerebral 
infarction & 
haemorrhage 
N/A < 60 days MAS > 1 MAS, FMA, BI 
Oral plus 
topical CHM 
Zhang 
2009 
38/36 54.49 56.76 Cerebral 
infarction 
N/A N/A AS > 0 FMA, BI, ER, TCM 
syndrome score, AEs 
Oral plus 
topical CHM 
Zhu 
2002 
30/30 63.5 71.67 Cerebral 
infarction & 
haemorrhage 
N/A 1–2 months MAS ≥ 2 MAS, ER, AEs 
Oral plus 
topical CHM 
Zhu 
2007 
31/31 63.1 59.68 Cerebral 
infarction & 
haemorrhage 
N/A 1–2 months MAS: 2–4 AS, BI, ER, AEs 
Oral plus 
topical CHM 
Zhu 
2013 
30/30 64.35 51.67 N/A N/A N/A AS: 1–3 AS, FMA, sEMG 
Notes: AEs, adverse events; AS, Ashworth Scale; BI, Barthel Index; CHM, Chinese herbal medicine; CSS, Composite Spasticity Scale; EMG, 
Electromyography; ER, effective rate; FIM, Functional Independent Measure; FMA, Fugl-Meyer Assessment of Sensorimotor Recovery; MAS, 
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Modified Ashworth Scale; N/A, not available; ROM, range of motion; sEMG, surface electromyography; TCM, traditional Chinese medicine; VAS, 
Visual Analogue Scale.
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Fifteen studies (Cai 2016; Chen et al. 2014; Chen 2013; He 2016; Huang et al. 2011; 
Li and Wang 2011; Li et al. 2015; Liu et al. 2014; Murat 2016; Wang 2013b; Wei et 
al. 2011; Zhang, Qiao and Chen 2008; Zhang, Yang and Gao 2012; Zhao 2013; Zhong 
2016) investigated the add-on effects of oral Chinese herbal medicine, 14 studies were 
of topical Chinese herbal medicine (Cao and Han 2015; Chen, Zhang et al. 2010; 
Ding 2016; Huang 2011; Jia et al. 2012; Lai 2016; Li, Zhong and Wang 2008; Ou et 
al. 2014; Ou et al. 2007; Shen, Wang and Zhu 2007; Wang et al. 2014; Zhang 2016; 
Zhang, Gao and Chen 2007; Zhao 2010) and six studies were of oral plus topical 
Chinese herbal medicine (Weng 2014; Xie et al. 2011; Zhang 2009; Zhu et al. 2007; 
Zhu, Hu and Zhou 2002; Zhu, Jin et al. 2013). 
The stroke history of included patients was reported up to one year. Eight studies 
(Chen 2013; Ding 2016; Murat 2016; Ou et al. 2014; Ou et al. 2007; Weng 2014; 
Zhang 2016; Zhang, Yang and Gao 2012) only enrolled participants with a first stroke. 
Nine trials (Chen et al. 2014; Ding 2016; Huang 2011; Huang et al. 2011; Ou et al. 
2014; Ou et al. 2007; Zhao 2010; Zhu et al. 2007; Zhu, Hu and Zhou 2002) included 
stroke patients whose Ashworth Scale or Modified Ashworth Scale score was ≥ Level 
Two at baseline. 
Reported Chinese herbal medicine formulas varied greatly among the included 
studies, with a treatment duration ranging from 20 days to three months (Table 5.4). 
Table 5.5 presents the details of rehabilitation treatment used in the included studies. 
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A variety of rehabilitation therapies were used as co-interventions. Duration in each 
treatment section ranged from 30 to 90 minutes with a treatment frequency once per 
day. However, most of the included studies did not adequately reported the dose, 
frequency and treatment period of pharmacotherapy used in the studies. Placebos 
were not used in any of the included trials. Twenty-five (25) studies reported data on 
the Ashworth Scale or Modified Ashworth Scale, 19 reported on the Barthel Index and 
16 reported on the Fugl-Meyer Assessment (Table 5.3).
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Table 5.4 Summary of intervention treatment in Chinese herbal medicine systematic review 
Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Cai 
2016 
Decoction 200 ml bid 12 
weeks 
N/A N/A N/A (oral) Gua 
lou gui zhi 
tang 瓜蒌
桂枝汤 
Gua lou gen 瓜蒌根, gui 
zhi 桂枝, bai shao 白芍, 
sheng jiang 生姜, da zao 大
枣, gan cao 甘草 
Chen 
2014 
Decoction 0.5 dose bid 4 
weeks 
N/A N/A N/A (oral) Jia 
wei bu 
yang huan 
wu tang 加
味补阳还
五汤 
Huang qi 黄芪, chuan 
xiong 川芎, dang gui 当归, 
di long 地龙, tao ren 桃仁, 
hong hua 红花, jiang can 
僵蚕, chi shao 赤芍, tian 
zhu huang 天竺黄, gua lou 
瓜蒌 
Chen 
2013 
Decoction 200 ml bid 4 
weeks 
N/A N/A N/A (oral) Gua 
lou gui zhi 
tang 瓜蒌
桂枝汤 
Gua lou gen 瓜蒌根, gui 
zhi 桂枝, bai shao 白芍, 
gan cao 甘草, sheng jiang 
生姜, da zao 大枣 
He 
2016 
Decoction 1 dose qd 28 days N/A N/A N/A (oral) Tong 
luo jie jing 
tang 通络
解痉汤 
Dang gui 当归, shu di 
huang 熟地黄, niu xi 牛膝, 
tian ma 天麻, quan xie 全
蝎, chuan shan jia 穿山甲, 
shen jin cao 伸筋草, bai 
shao 白芍, sang zhi 桑枝, ji 
xue teng 鸡血藤, gou teng 
钩藤, wu shao she 乌梢蛇, 
di long 地龙, mu gua 木瓜 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Huang 
W 2011 
Capsule 3 g tid 3 
months 
N/A N/A N/A (oral) Wen 
jing shu jin 
jiao nang 
温经舒筋
胶囊 
Shu di huang 熟地黄, lu 
jiao jiao 鹿角胶, ma huang 
麻黄, bai jie zi 白芥子, 
sheng jiang 生姜, rou gui 
肉桂, huang qi 黄芪, chuan 
xiong 川芎, dang gui 当归, 
chi shao 赤芍, tao ren 桃
仁, hong hua 红花, ji xue 
teng 鸡血藤, niu xi 牛膝, di 
long 地龙, mu gua 木瓜, 
shen jin cao 伸筋草, bai 
shao 白芍, gan cao 甘草 
Li Y 
2011 
Decoction 1 dose qd 28 days N/A N/A N/A (oral) Tong 
luo jie jing 
tang 通络
解痉汤 
Dang gui 当归, bai shao 白
芍, shu di huang 熟地黄, 
sang zhi 桑枝, niu xi 牛膝, 
ji xue teng 鸡血藤, tian ma 
天麻, gou teng 钩藤, quan 
xie 全蝎, wu shao she 乌梢
蛇, chuan shan jia 穿山甲, 
di long 地龙, shen jin cao 
伸筋草, mu gua 木瓜 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Li 2015 Decoction 1 dose qd 28 days N/A N/A N/A (oral) Yi qi 
rou jin tang 
益气柔筋
汤 
Huang qi 黄芪, bai zhu 白
术, tao ren 桃仁, hong hua 
红花, dang gui 当归, chi 
shao 赤芍, chuan xiong 川
芎, shi chang pu 石菖蒲, 
dan nan xing 胆南星, niu xi 
牛膝, ji xue teng 鸡血藤, 
shen jin cao 伸筋草, sang 
zhi 桑枝, ren dong teng 忍
冬藤, di long 地龙, shan 
zha 山楂 
Liu 
2014 
Decoction 0.5 dose bid 2 
months 
N/A N/A N/A (oral) 
Decoction 
without a 
name 
Huang qi 黄芪, dang gui 当
归, bai shao 白芍, shan zhu 
yu 山茱萸, sheng di huang 
生地黄, shan yao 山药, di 
long 地龙, quan xie 全蝎, 
gou qi 枸杞, sang ji sheng 
桑寄生 
Murat 
U 2016 
Decoction 200 ml bid 4 
weeks 
N/A N/A N/A (oral) 
Decoction 
without a 
name 
Sheng di huang 生地黄, 
shu di huang 熟地黄, bai 
shao 白芍, gan cao 甘草, 
quan xie 全蝎, wu gong 蜈
蚣, tao ren 桃仁, hong hua 
红花, dan shen 丹参, di 
long 地龙, tu bie chong 土
鳖虫, ji xue teng 鸡血藤, 
gui ban 龟板 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Wang 
2013 
Capsule N/A tid 4 
weeks 
N/A N/A N/A (oral) Bu 
chang nao 
xin tong 
jiao nang
步长脑心
通胶囊 
Huang qi 黄芪, dang gui 当
归, chi shao 赤芍, chuan 
xiong 川芎, tao ren 桃仁, 
hong hua 红花, di long 地
龙, mu gua 木瓜, shen jin 
cao 伸筋草, jiang can 僵
蚕, wu gong 蜈蚣, quan xie 
全蝎 
Wei 
2011 
Decoction 100 ml bid 4 
weeks 
N/A N/A N/A (oral) Rou 
jin tang 柔
筋汤 
Sheng di huang 生地黄, bai 
shao 白芍, shan zhu yu 山
茱萸, shi hu 石斛, shen jin 
cao 伸筋草, mu gua 木瓜, 
lu lu tong 路路通, sang zhi 
桑枝, gan cao 甘草 
Zhang 
2008 
Decoction 1 dose qd 4 
weeks 
N/A N/A N/A (oral) 
Decoction 
without a 
name 
Bai shao 白芍, sheng di 
huang 生地黄, gan cao 甘
草, dang gui 当归, ji xue 
teng 鸡血藤, ru xiang 乳香, 
mo yao 没药, di long 地龙, 
mu gua 木瓜, shen jin cao 
伸筋草 
Zhang 
2012 
Decoction 0.5 dose bid 3 
weeks 
N/A N/A N/A (oral) Shao 
yao gan 
cao tang 芍
药甘草汤 
Bai shao 白芍, gan cao 甘
草, shu di huang 熟地黄, 
dang gui 当归 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Zhao 
2013 
Decoction 250 ml bid 4 
weeks 
N/A N/A N/A (oral) Zi ni 
wen shen yi 
qi huo xie 
tang 自拟
温肾益气
活血汤 
Fu zi 附子, huang qi 黄芪, 
gui zhi 桂枝, tao ren 桃仁, 
hong hua 红花, du zhong 
杜仲, dang shen 党参, xi 
xin 细辛, chuan xiong 川
芎, dang gui 当归, di long 
地龙, fu ling 茯苓, bai shao 
白芍, shen jin cao 伸筋草, 
gan cao 甘草 
Zhong 
2016 
Decoction 0.5 dose bid 4 
weeks 
N/A N/A N/A (oral) Shao 
yao gan 
cao tang 芍
药甘草汤 
Bai shao 白芍, gan cao 甘
草 
Cao 
2015 
N/A N/A N/A N/A 30 min bid 30 days (compressi
on) 
Decoction 
without a 
name 
Jiang can 僵蚕, chi shao 赤
芍, shen jin cao 伸筋草, 
gui zhi 桂枝, ge gen 葛根, 
mu gua 木瓜, hong hua 红
花, ze xie 泽泻, fu ling pi 
茯苓皮, di long 地龙, gan 
cao 甘草 
Chen 
2010 
N/A N/A N/A N/A 30 min qd 30 days (steaming) 
Decoction 
without a 
name 
Bai shao 白芍, mu gua 木
瓜, shen jin cao 伸筋草, 
dan shen 丹参, gui zhi 桂
枝, dang gui 当归, chuan 
xiong 川芎, di long 地龙, 
gan cao 甘草, bing pian 冰
片 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Ding 
2016 
N/A N/A N/A N/A 30 min qd 8 weeks (compressi
on) 
Decoction 
without a 
name 
Wu tou 乌头, cao wu 草乌, 
ji xue teng 鸡血藤, tou gu 
cao 透骨草, chuan xiong 
川芎, su mu 苏木, shen jin 
cao 伸筋草, hong hua 红
花, gui zhi 桂枝, ma huang 
麻黄, sang zhi 桑枝, you 
song jie 油松节, dang gui 
当归, hua jiao 花椒 
Huang 
JX 2011 
N/A N/A N/A N/A 15–30 min bid/tid 4 weeks (steaming) 
Shu jin 
tong luo 
fang 赎金
通络方 
Bai shao 白芍, mu gua 木
瓜, ge gen 葛根, xi xian cao 
豨莶草, shen jin cao 伸筋
草, tu bie chong 土鳖虫, 
chuan xiong 川芎, xue jie 
血竭, hong hua 红花, niu xi 
牛膝, quan xie 全蝎, wu 
gong 蜈蚣, dan shen 丹参, 
sheng di huang 生地黄, 
dang gui 当归, tou gu cao 
透骨草, gan cao 甘草 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Jia 2012 N/A N/A N/A N/A 40 min qd 4 weeks (steaming) 
Decoction 
without a 
name 
Hong hua 红花, dan shen 
丹参, dang gui 当归, chuan 
xiong 川芎, ji xue teng 鸡
血藤, mu gua 木瓜, xi xian 
cao 豨莶草, shen jin cao 伸
筋草, wei ling xian 威灵仙, 
qiang huo 羌活, du huo 独
活, sang zhi 桑枝, gui zhi 
桂枝, cang zhu 苍术, bai 
zhu 白术, di long 地龙, bai 
shao 白芍, gan cao 甘草 
Ou 
2007 
N/A N/A N/A N/A 20 min qd 20 days (steaming) 
Shu jin huo 
luo xi ji 舒
筋活络洗
剂 
Huang qi 黄芪, dang gui 当
归, dang shen 党参, tao ren 
桃仁, hong hua 红花, 
chuan xiong 川芎, su mu 苏
木, sang zhi 桑枝, shen jin 
cao 伸筋草, ji xue teng 鸡
血藤, mu gua 木瓜, wei 
ling xian 威灵仙, dan shen 
丹参, ma qian zi 马钱子 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
OU 
2014 
N/A N/A tid N/A 20 min qd 20 days (steaming) 
Shu jin huo 
luo xi ji 舒
筋活络洗
剂 
Huang qi 黄芪, dang gui 当
归, dang shen 党参, tao ren 
桃仁, hong hua 红花, 
chuan xiong 川芎, su mu 苏
木, sang zhi 桑枝, shen jin 
cao 伸筋草, ji xue teng 鸡
血藤, mu gua 木瓜, wei 
ling xian 威灵仙, dan shen 
丹参, ma qian zi 马钱子 
Shen 
2007 
N/A N/A N/A N/A 20–30 min qd 30 days (compressi
on) 
Decoction 
without a 
name 
Dang gui 当归, chuan 
xiong 川芎, bing pian 冰片, 
niu xi 牛膝, tou gu cao 透
骨草, wei ling xian 威灵仙, 
hong hua 红花, fang feng 
防风, ai ye 艾叶, gui zhi 桂
枝, tu bie chong 土鳖虫, 
huang jiu 黄酒 (rice wine), 
cu 醋 (vinegar), tong you 桐
油 
Wang 
2014 
N/A N/A N/A N/A 20 min qd 28 days (compressi
on) 
Decoction 
without a 
name 
Shen jin cao 伸筋草, bai 
shao 白芍, gan cao 甘草, 
dang gui 当归, di long 地
龙, mai dong 麦冬, fang 
feng 防风, wu gong 蜈蚣 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Zhang 
2016 
N/A N/A N/A N/A 60 min 6 times/ 
week 
4 weeks (compressi
on) Jie jing 
shu jin tang 
解痉舒筋
汤 
Tian ma 天麻, gou teng 钩
藤, wu gong 蜈蚣, fang 
feng 防风, shen jin cao 伸
筋草, ji xue teng 鸡血藤, 
wei ling xian 威灵仙, bai 
shao 白芍, mai dong 麦冬, 
dang gui 当归, tao ren 桃
仁, hong hua 红花 
Zhang 
2007 
N/A N/A N/A N/A 20 min qd 4 weeks (steaming) 
Decoction 
without a 
name 
Bai shao 白芍, wang jiang 
nan 望江南, shen jin cao 伸
筋草, mu gua 木瓜, sang 
zhi 桑枝, gui zhi 桂枝, 
hong hua 红花, dang gui 当
归, ru xiang 乳香, mo yao 
没药 
Zhao 
2010 
N/A N/A N/A N/A 40 min qd 28 days (foot bath) 
Decoction 
without a 
name 
Hong hua 红花, tao ren 桃
仁, dang gui 当归, dan 
shen 丹参, mu gua 木瓜 
Weng 
2014 
Decoction 100 ml bid 4 
weeks 
N/A bid 4 weeks (oral+comp
ression) Jie 
jing he ji 解
痉合剂 
Bai shao 白芍, gan cao 甘
草, wang jiang nan 望江南, 
mu gua 木瓜, ru xiang 乳
香, mo yao 没药, quan xie 
全蝎, dan shen 丹参, huang 
jiu 黄酒 (rice wine) 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Xie 
2011 
Decoction 150 ml qd 28 days 20 min qd 28 days (oral) Rou 
jin tang 柔
筋汤 
Huang qi 黄芪, dang gui 当
归, ji xue teng 鸡血藤, shan 
zhu yu 山茱萸, wu gong 蜈
蚣 
(bath) 
Decoction 
without a 
name 
Bing pian 冰片, tan xiang 
檀香, dang gui 当归, bai 
shao 白芍, wu mei 乌梅 
Zhang 
2009 
Decoction 150 ml bid 28 days 15–30 min bid 28 days (oral) 
Decoction 
without a 
name 
Bai shao 白芍, gan cao 甘
草, shen jin cao 伸筋草, mu 
gua 木瓜, ji xue teng 鸡血
藤, chuan shan jia 穿山甲, 
niu xi 牛膝, sang zhi 桑枝, 
tian ma 天麻, jiang can 僵
蚕 
(compressi
on) 
Decoction 
without a 
name 
Wu tou 乌头, fang feng 防
风, gui zhi 桂枝, hua jiao 
花椒, hong hua 红花, dang 
gui 当归, huang qi 黄芪, 
tou gu cao 透骨草, shen jin 
cao 伸筋草, wei ling xian 
威灵仙 
Zhu 
2002 
CHM syrup 10 ml tid 30 days N/A qid 30 days (oral+comp
ression) Jie 
jing he ji解
痉合剂 
Bai shao 白芍, gan cao 甘
草, wang jiang nan 望江南, 
mu gua 木瓜, quan xie 全
蝎, dan shen 丹参, huang 
jiu 黄酒 (rice wine) 
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Author, 
year 
Oral CHM Topical CHM Formula Ingredients* 
Preparation Dosage Frequency Period Duration Frequency Period 
Zhu 
2007 
CHM syrup 10 ml tid 30 days N/A qid 30 days (oral+comp
ression) Jie 
jing he ji解
痉合剂 
Bai shao 白芍, gan cao 甘
草, wang jiang nan 望江南, 
mu gua 木瓜, ru xiang 乳
香, mo yao 没药, quan xie 
全蝎, dan shen 丹参, huang 
jiu 黄酒 (rice wine) 
Zhu 
2013 
CHM syrup 10 ml tid 30 days N/A qid 30 days (oral+comp
ression) 
Shao yao 
gan cao 
tang芍药
甘草汤 
Bai shao 白芍, gan cao 甘
草 
Notes: bid, twice per day; min, minutes; N/A, not available; qd, once per day; qid, four times per day; tid, three times per day; * The ingredients of 
formulas were presented in Chinese pin yin. Correspondent scientific names were available in the book: ‘Dan Bensky (Ed.). 2004. Chinese Herbal 
Medicine, Materia Medica (Third Edition), WA, Eastland Press’. The Chinese names, pin yin names, scienrific names and common English names of 
the herbs were listed in Appendix 9.  
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Table 5.5 Summary of rehabilitation treatment in Chinese herbal medicine systematic review 
Study ID Control method Pharmacotherapy Rehabilitation therapy 
Dose Frequency Treatment 
period 
Duration in each 
treatment 
section 
Frequency Treatment 
period 
Cai 2016 Rehabilitation programs 
& Baclofen 
Increased 
from 10 mg 
to 75 mg 
qd 12 weeks 45 minutes 1 time/day; 7 times/week 12 weeks 
Cao 2015 Rehabilitation programs N/A N/A N/A N/A N/A 30 days 
Chen 2010 Baclofen Increased 
from 5 mg 
to 10 mg 
tid 30 days N/A N/A 30 days 
Chen 2014 Rehabilitation programs N/A N/A N/A 60 minutes 1 time/day; 6 times/week 4 weeks 
Chen 2013  Rehabilitation programs N/A N/A N/A N/A 1 time/day; 6 times/week 4 weeks 
Ding X 2016 Rehabilitation programs N/A N/A N/A 40 minutes 1 time/day; 7 times/week 8 weeks 
He YC 2016 Rehabilitation programs N/A N/A N/A 40 minutes 1 time/day; 6 times/week 28 days 
Huang JX 
2011 
Rehabilitation programs N/A N/A N/A 60 minutes 1 time/day; 5 times/week 4 weeks 
Huang W 
2011 
Rehabilitation programs N/A N/A N/A N/A N/A 3 months 
Jia 2012 Rehabilitation programs N/A N/A N/A 45 minutes 1 time/day; 6 times/week 4 weeks 
Lai 2016 Rehabilitation programs N/A N/A N/A N/A 1 time/day; 7 times/week 30 days 
Li 2008 Rehabilitation programs N/A N/A N/A N/A N/A 6 weeks 
Li Y 2011 Rehabilitation programs N/A N/A N/A 40 minutes 1 time/day; 6 times/week 28 days 
Liu 2015 Rehabilitation programs N/A N/A N/A N/A N/A 3 months 
Liu 2014 Rehabilitation programs N/A N/A N/A 30 minutes 1 time/day; 7 times/week 2 months 
Murat 2016 Rehabilitation programs N/A N/A N/A N/A N/A 4 weeks 
Ou 2007 BTXA and rehabilitation 
programs 
100–300 
units in total 
N/A N/A 30–60 minutes (1–2) time/day; 7 
times/week  
2 months 
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Study ID Control method Pharmacotherapy Rehabilitation therapy 
Dose Frequency Treatment 
period 
Duration in each 
treatment 
section 
Frequency Treatment 
period 
OU 2014 BTXA and rehabilitation 
programs 
20–40 units/ 
injection 
point 
N/A N/A N/A N/A 2 months 
Shen 2007 Rehabilitation programs N/A N/A N/A N/A N/A 30 days 
Wang 2014 Rehabilitation programs N/A N/A N/A 45 minutes 1 time/day; 6 times/week 28 days 
Wang 2013 Rehabilitation programs N/A N/A N/A N/A N/A; 6 times/week 4 weeks 
Wei 2011 Rehabilitation programs N/A N/A N/A 1 hour 2 time/day; 7 times/week 4 weeks 
Weng 2014 Tizanidine and 
rehabilitation programs 
2–4 mg tid 4 weeks 45 minutes 1 time/day; 5 times/week 4 weeks 
Xie 2011 Rehabilitation programs N/A N/A N/A 90 minutes 2 time/day; 7 times/week 28 days 
Zhang 2016 Rehabilitation programs N/A N/A N/A N/A 1 time/day; 5 times/week 4 weeks 
Zhang 2009 Rehabilitation programs N/A N/A N/A 45–60 minutes (1–2) time/day; 6 
times/week 
28 days 
Zhang 2007 Rehabilitation programs N/A N/A N/A 45 minutes 1 time/day; 6 times/week 4 weeks 
Zhang 2008 Rehabilitation programs N/A N/A N/A 45 minutes 1 time/day; 6 times/week 4 weeks 
Zhang 2012 Rehabilitation programs N/A N/A N/A 45 minutes 1 time/day; 6 times/week 3 weeks 
Zhao 2013 Rehabilitation programs N/A N/A N/A N/A N/A 4 weeks 
Zhao 2010 Rehabilitation programs N/A N/A N/A 40 minutes 1 time/day; 7 times/week 28 days 
Zhong 2016 Rehabilitation programs N/A N/A N/A 30 minutes 1 time/day; 7 times/week 4 weeks 
Zhu 2002 Rehabilitation programs N/A N/A N/A N/A N/A 30 days 
Zhu 2007 Rehabilitation programs N/A N/A N/A N/A N/A 30 days 
Zhu 2013 Rehabilitation programs N/A N/A N/A 30 minutes 1 time/day; 6 times/week 4 weeks 
Notes: N/A, not available; qd, once per day; bid, twice per day; tid, three times per day. 
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5.2.3 Risk-of-bias assessment 
Eighteen studies (Cao and Han 2015; Chen, Zhang et al. 2010; Chen 2013; Ding 
2016; Lai 2016; Li, Zhong and Wang 2008; Li and Wang 2011; Liu et al. 2014; Murat 
2016; Ou et al. 2014; Ou et al. 2007; Shen, Wang and Zhu 2007; Xie et al. 2011; 
Zhang 2016; Zhang 2009; Zhang, Yang and Gao 2012; Zhong 2016; Zhu, Jin et al. 
2013) were assessed as having a low risk of bias in random sequence generation with 
appropriate methods; two trials (Zhu et al. 2007; Zhang 2009) were assessed as 
having a high risk of bias because they allocated patients based on the date of 
admission; others were of unclear risk due to lack of information. Allocation was well 
concealed in only two studies (Chen 2013; Lai 2016) whereas another two (Zhu et al. 
2007; Zhang 2009) were assessed as having a high risk of bias because participants 
were allocated based on their case record numbers. 
Blinding of participants and intervention providers was attempted in none of the 
included trials, but three trials (Liu et al. 2014; Weng 2014; Zhang, Gao and Chen 
2007) performed blinding in outcome assessors. None of the included studies had 
protocols registered prospectively and ten studies (He 2016; Jia et al. 2012; Li and 
Wang 2011; Li et al. 2015; Murat 2016; Zhang, Gao and Chen 2007; Zhang, Qiao and 
Chen 2008; Zhao 2013; Zhong 2016; Zhu, Jin et al. 2013) did not report results for all 
predefined outcomes mentioned in their method sections. 
The results of the risk-of-bias assessment are summarised in Figure 5.2. 
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Figure 5.2 Summary of risk-of-bias assessment in Chinese herbal medicine 
systematic review 
Notes: The green, yellow and red circles indicate that the results of the risk-of-bias 
assessment were low, unclear and high, respectively. 
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5.2.4 Reporting quality of included studies 
The information reported in the included studies was compared with items 
recommended by Consolidated Standards of Reporting Trials (CONSORT) 2010 
(Schulz, Altman and Moher 2010) and the extension for herbal interventions (Gagnier 
et al. 2006) and Chinese herbal medicine formulas (Cheng et al. 2017). We found that 
only the following four items were described by all the included trials: the allocation 
ratio; eligibility criteria for participants; the number of participants included in each 
analysis; and whether the analysis was by original assigned group. 
Structured summaries of trial design, methods, results and conclusions, specific 
objectives or hypotheses, settings and locations where the data were collected, 
random allocation sequence, type of randomisation, details of any restriction, dates 
defining the periods of recruitment and follow-up, each primary and secondary 
outcome, results for each group, and the estimated effect size and its precision were 
available in most of the included studies, while the other items were either 
insufficiently described or reported by less than half of the included studies. Table 5.6 
presents the details of the reporting quality of each included study.  
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Table 5.6 Reporting quality of included studies in Chinese herbal medicine 
systematic review 
Study ID Title and abstract Introduction 
Background and 
objectives 
1a 1b 1c 2a 2b 
Cai 2016 No Yes No Insufficient reporting Yes 
Cao 2015 No Yes No Insufficient reporting Yes 
Chen 2010 No Yes Insufficient reporting No Yes 
Chen 2014 No Yes No Insufficient reporting Yes 
Chen 2013 No Yes No Yes Yes 
Ding 2016 No Yes No Insufficient reporting Yes 
He 2016 No Yes No Insufficient reporting Yes 
Huang JX 2011 No Yes No Insufficient reporting Yes 
Huang W 2011 No Yes No Insufficient reporting Yes 
Jia 2012 No Yes Insufficient reporting Insufficient reporting Yes 
Lai 2016 No Yes No Yes Yes 
Li 2008 No Yes Insufficient reporting No Yes 
Li Y 2011 No Yes Insufficient reporting No Yes 
Li 2015 No Yes No Insufficient reporting Yes 
Liu 2014 No No Insufficient reporting Insufficient reporting No 
Murat 2016 No Yes No Yes Yes 
Ou 2007 No Yes No Insufficient reporting Yes 
Ou 2014 No Yes No Insufficient reporting Yes 
Shen 2007 No No No No No 
Wang 2014 No Yes No Insufficient reporting Yes 
Wang 2013 No Yes No Insufficient reporting Yes 
Wei 2011 No Yes Insufficient reporting Insufficient reporting Yes 
Weng 2014 No Yes No Yes Yes 
Xie 2011 No Yes Insufficient reporting No Yes 
Zhang 2016 No Yes No Yes Yes 
Zhang 2009 No Yes Insufficient reporting Yes Yes 
Zhang 2007 No Yes Insufficient reporting Insufficient reporting Yes 
Zhang 2008 No Yes Insufficient reporting Insufficient reporting Yes 
Zhang 2012 No Yes No Yes Yes 
Zhao 2013 No Yes No Yes Yes 
Zhao 2010 No No No No No 
Zhong 2016 No Yes No Insufficient reporting Yes 
Zhu 2002 No Yes No Insufficient reporting Yes 
Zhu 2007 No Yes No Insufficient reporting Yes 
Zhu 2013 No Yes No Insufficient reporting Yes 
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Study ID Methods 
Trial design Participants Interventions Outcomes 
3a 3b 4a 4b 5 6a 6b 
Cai 2016 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Cao 2015 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Chen 2010 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Chen 2014 Yes No Yes Insufficient reporting Insufficient reporting Protocol unavailable No changes 
Chen 2013 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Ding 2016 Yes No Yes Insufficient reporting Insufficient reporting Protocol unavailable No changes 
He 2016 Yes No Yes Insufficient reporting Insufficient reporting No Insufficient reporting 
Huang JX 2011 Yes Yes Yes Yes Insufficient reporting Protocol unavailable No changes 
Huang W 2011 Yes No Yes Yes Insufficient reporting No No 
Jia 2012 Yes No Yes Yes Insufficient reporting No Insufficient reporting 
Lai 2016 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Li 2008 Yes No Yes No Insufficient reporting Protocol unavailable No changes 
Li Y 2011 Yes No Yes Yes Insufficient reporting No Insufficient reporting 
Li 2015 Yes No Yes Yes Insufficient reporting No Insufficient reporting 
Liu 2014 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Murat 2016 Yes No Yes Yes Insufficient reporting No Insufficient reporting 
Ou 2007 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Ou 2014 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Shen 2007 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Wang 2014 Yes No Yes No Insufficient reporting Protocol unavailable No changes 
Wang 2013 Yes No Yes No Insufficient reporting protocol unavailable No changes 
Wei 2011 Yes No Yes No Insufficient reporting Protocol unavailable No changes 
Weng 2014 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
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Study ID Methods 
Trial design Participants Interventions Outcomes 
3a 3b 4a 4b 5 6a 6b 
Xie 2011 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Zhang 2016 Yes No Yes Insufficient reporting Insufficient reporting Protocol unavailable No changes 
Zhang 2009 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Zhang 2007 Yes No Yes Yes Insufficient reporting No Insufficient reporting 
Zhang 2008 Yes No Yes Insufficient reporting Insufficient reporting No Insufficient reporting 
Zhang 2012 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Zhao 2013 Yes No Yes Yes Insufficient reporting No Insufficient reporting 
Zhao 2010 Yes No Yes Yes Insufficient reporting Protocol unavailable No changes 
Zhong 2016 Yes No Yes Insufficient reporting Insufficient reporting No Insufficient reporting 
Zhu 2002 Yes No Yes Insufficient reporting Insufficient reporting Protocol unavailable No changes 
Zhu 2007 Yes No Yes Insufficient reporting Insufficient reporting Protocol unavailable No changes 
Zhu 2013 Yes No Yes Yes Insufficient reporting No Insufficient reporting 
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Study ID Methods 
Sample size Randomisation Blinding Statistical methods 
Sequence 
generation 
Allocation 
concealment 
mechanism 
Implementation 
7a 7b 8a 8b 9 10 11a 11b 12a 12b 
Cai 2016 No No No No No No No No Insufficient reporting No 
Cao 2015 No No Yes Yes No No No No Insufficient reporting No 
Chen 2010 No No Yes Yes No No No No Insufficient reporting No 
Chen 2014 No No No No No No No No Insufficient reporting No 
Chen 2013 No No Yes Yes Yes No No No Insufficient reporting No 
Ding 2016 No No Yes Yes No No No No Insufficient reporting No 
He 2016 No No No No No No No No Insufficient reporting No 
Huang JX 2011 No No No No No No No No Insufficient reporting No 
Huang W 2011 No No No No No No No No Insufficient reporting No 
Jia 2012 No No No No No No No No Insufficient reporting No 
Lai 2016 No No Yes Yes Yes No No No Insufficient reporting No 
Li 2008 No No Yes Yes No No No No Insufficient reporting No 
Li Y 2011 No No Yes Yes No No No No Insufficient reporting No 
Li 2015 No No No No No No No No Insufficient reporting No 
Liu 2014 No No Yes Yes No No Yes No Insufficient reporting No 
Murat 2016 No No Yes Yes No No No No Insufficient reporting No 
Ou 2007 No No Yes Yes No No No No Insufficient reporting No 
Ou 2014 No No Yes Yes No No No No Insufficient reporting No 
Shen 2007 No No Yes Yes No No No No Insufficient reporting No 
Wang 2014 No No No No No No No No Insufficient reporting No 
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Study ID Methods 
Sample size Randomisation Blinding Statistical methods 
Sequence 
generation 
Allocation 
concealment 
mechanism 
Implementation 
7a 7b 8a 8b 9 10 11a 11b 12a 12b 
Wang 2013 No No Yes No No No No No Insufficient reporting No 
Wei 2011 No No No No No No No No Insufficient reporting No 
Weng 2014 No No No No No No Yes No Insufficient reporting No 
Xie 2011 No No Yes Yes No No No No Insufficient reporting No 
Zhang 2016 No No Yes Yes No No No No Insufficient reporting No 
Zhang 2009 No No Yes Yes No No No No Insufficient reporting No 
Zhang 2007 No No No No No No Yes No Insufficient reporting No 
Zhang 2008 No No No No No No No No Insufficient reporting No 
Zhang 2012 No No Yes Yes No No No No Insufficient reporting No 
Zhao 2013 No No No No No No No No Insufficient reporting No 
Zhao 2010 No No No No No No No No No No 
Zhong 2016 No No Yes Yes No No No No Insufficient reporting No 
Zhu 2002 No No No No No No No No Insufficient reporting No 
Zhu 2007 No No Yes No No No No No Insufficient reporting No 
Zhu 2013 No No Yes Yes No No No No Insufficient reporting No 
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Study ID Results 
Participant 
flow  
Recruitment Baseline 
data 
Numbers 
analysed 
Outcomes and 
estimation 
Ancillary 
analyses 
Harms 
13a 13b 14a 14b 15 16 17a 17b 18 19 
Cai 2016 No No Yes Not applicable No Yes Yes Not applicable No No 
Cao 2015 No No Yes Not applicable No Yes Yes Not applicable No No 
Chen 2010 No No Yes Not applicable No Yes Yes Not applicable No Yes 
Chen 2014 No No Yes Not applicable No Yes Yes Not applicable No No 
Chen 2013 No No Yes Not applicable Yes Yes No Not applicable No No 
Ding 2016 No No Yes Not applicable No Yes Yes Not applicable No No 
He 2016 No No Yes Not applicable No Yes Yes Not applicable No No 
Huang JX 2011 No No Yes Not applicable No Yes Yes Not applicable No Yes 
Huang W 2011 No No Yes Not applicable No Yes No Not applicable No No 
Jia 2012 No No No Not applicable No Yes Yes Not applicable No No 
Lai 2016 No No Yes Not applicable Yes Yes Yes Not applicable No Yes 
Li 2008 No No Yes Not applicable No Yes Yes Not applicable No No 
Li Y 2011 No No No Not applicable No Yes Yes Not applicable No No 
Li 2015 No No No Not applicable No Yes Yes Not applicable No No 
Liu 2014 No No Yes Not applicable No Yes Yes Not applicable No No 
Murat 2016 No No Yes Not applicable Yes Yes Yes Yes Yes Yes 
Ou 2007 No No Yes Not applicable No Yes Yes Not applicable No No 
Ou 2014 No No Yes Not applicable Yes Yes Yes Not applicable No No 
Shen 2007 No No Yes Not applicable No Yes Yes Not applicable No Yes 
Wang 2014 No No Yes Not applicable No Yes Yes Not applicable No No 
Wang 2013 No No No Not applicable No Yes Yes Not applicable No No 
Wei 2011 No No Yes Not applicable No Yes Yes Not applicable No No 
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Study ID Results 
Participant 
flow  
Recruitment Baseline 
data 
Numbers 
analysed 
Outcomes and 
estimation 
Ancillary 
analyses 
Harms 
13a 13b 14a 14b 15 16 17a 17b 18 19 
Weng 2014 No No Yes Not applicable Yes Yes Yes Not applicable No Yes 
Xie 2011 No No Yes Not applicable No Yes Yes Not applicable No No 
Zhang 2016 No No Yes Not applicable No Yes Yes Not applicable No No 
Zhang 2009 No No Yes Not applicable Yes Yes Yes Not applicable No Yes 
Zhang 2007 No No Yes Not applicable No Yes Yes Not applicable No No 
Zhang 2008 No No Yes Not applicable Yes Yes No Not applicable No No 
Zhang 2012 No No Yes Not applicable Yes Yes Yes Not applicable No No 
Zhao 2013 No No Yes Not applicable Yes Yes No Not applicable No Yes 
Zhao 2010 No No Yes Not applicable No Yes No Not applicable No No 
Zhong 2016 No No Yes Not applicable No Yes Yes Not applicable No No 
Zhu 2002 No No No Not applicable No Yes Yes Not applicable No Yes 
Zhu 2007 No No No Not applicable No Yes Yes Not applicable No Yes 
Zhu 2013 No No Yes Not applicable Yes Yes Yes Not applicable No No 
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Study ID Discussion Other information 
Limitations Generalisability Interpretation Registration Protocol Funding 
20 21 22 23 24 25 
Cai 2016 No No No No No No 
Cao 2015 No No No No No No 
Chen 2010 No No No No No No 
Chen 2014 No No No No No Yes 
Chen 2013 Insufficient discussion No No No No No 
Ding 2016 No No No No No No 
He 2016 No No No No No No 
Huang JX 2011 No No No No No No 
Huang W 2011 No No No No No No 
Jia 2012 No No No No No No 
Lai 2016 Insufficient discussion No insufficient discussion No No No 
Li 2008 No No No No No No 
Li Y 2011 No No No No No No 
Li 2015 No No No No No No 
Liu 2014 No No No No No No 
Murat 2016 Yes No No No No No 
Ou 2007 No No No No No No 
Ou 2014 No No No No No No 
Shen 2007 No No No No No No 
Wang 2014 No No No No No No 
Wang 2013 No No No No No No 
Wei 2011 No No No No No No 
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Study ID Discussion Other information 
Limitations Generalisability Interpretation Registration Protocol Funding 
20 21 22 23 24 25 
Weng 2014 No No No No No No 
Xie 2011 No No No No No No 
Zhang 2016 No No No No No No 
Zhang 2009 No No No No No No 
Zhang 2007 No No No No No No 
Zhang 2008 No No No No No No 
Zhang 2012 No No No No No No 
Zhao 2013 No No No No No No 
Zhao 2010 No No No No No No 
Zhong 2016 No No No No No No 
Zhu 2002 No No No No No No 
Zhu 2007 No No No No No No 
Zhu 2013 No No No No No No 
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Notes: CONSORT 2010 and Extension for Herbal Intervention and Chinese Herbal Medicine 
Formula Checklist Items 
1a Identification as a randomised trial in the title 
1b Structured summary of trial design, methods, results, and conclusions 
1c Determination of appropriate keywords, including ‘Chinese herbal medicine formula’ and 
‘randomised controlled trial’ 
2a Scientific background and explanation of rationale 
2b Specific objectives or hypotheses 
3a Description of trial design including allocation ratio 
3b Important changes to methods after trial commencement, with reasons 
4a Eligibility criteria for participants 
4b Settings and locations where the data were collected 
5 The interventions for each group with sufficient details to allow replication, including how 
and when they were actually administered 
6a Completely defined pre-specified primary and secondary outcome measures 
6b Any changes to trial outcomes after the trial commenced, with reasons 
7a How sample size was determined 
7b When applicable, explanation of any interim analyses and stopping guidelines 
8a Method used to generate the random allocation sequence 
8b Type of randomisation; details of any restriction 
9 Mechanism used to implement the random allocation sequence 
10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
11a If done, who was blinded after assignment to interventions 
11b If relevant, description of the similarity of interventions 
12a Statistical methods used to compare groups for primary and secondary outcomes 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 
13a For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
13b For each group, losses and exclusions after randomisation, together with reasons 
14a Dates defining the periods of recruitment and follow-up 
14b Why the trial ended or was stopped 
15 A table showing baseline demographic and clinical characteristics for each group 
16 For each group, number of participants included in each analysis and whether the analysis 
was by original assigned groups 
17a For each primary and secondary outcome, results for each group, and the estimated effect 
size and its precision 
17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses 
19 All important harms or unintended effects in each group 
20 Trial limitations, addressing sources of potential bias, imprecision and, if relevant, 
multiplicity of analyses 
21 Generalisability of the trial findings 
22 Interpretation consistent with results, balancing benefits and harms, and considering other 
relevant evidence 
23 Registration number and name of trial registry 
24 Where the full trial protocol can be accessed, if available 
25 Sources of funding and other support, role of funders  
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5.2.5 Effects of interventions 
Results of the meta-analyses are presented below for oral Chinese herbal medicine 
and topical Chinese herbal medicine separately. 
5.2.5.1 Oral Chinese herbal medicine add-on to routine care 
Change in Ashworth Scale or Modified Ashworth Scale 
Significant add-on effects of oral Chinese herbal medicine were found for the changes 
in scores of the Ashworth Scale or Modified Ashworth Scale for upper limbs (three 
studies (Cai 2016; Liu et al. 2014; Zhang, Yang and Gao 2012), SMD −1.79, 95% CI 
[−3.00, −0.57], I2=94%) and lower limbs (three studies (Cai 2016; Liu et al. 2014; 
Wang 2013b), SMD −1.01, 95% CI [−1.43, −0.59], I2=55%) although with high and 
moderate heterogeneity (Table 5.7, Figure 5.3).  
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Table 5.7 Summary of effect results in Chinese herbal medicine systematic 
review 
 
Outcome measure No. of 
studies 
Effects I2 
(%) 
Oral 
CHM 
Change of AS or MAS 
upper limbs 
3 SMD −1.79, 95% CI [−3.00, 
−0.57]* 
94 
Change of AS or MAS 
lower limbs 
3 SMD −1.01, 95% CI [−1.43, 
−0.59]* 
55 
Change of FMA overall 3 MD 12.14, 95% CI [1.57, 
22.71]* 
89 
Change of FMA upper 
limbs 
3 MD 7.64, 95% CI [−1.29, 
16.57] 
97 
Change of FMA lower 
limbs 
2 MD 4.03, 95% CI [1.90, 6.17]* 61 
Change of BI 7 MD 13.15, 95% CI [4.37, 
21.93]* 
98 
Topical 
CHM 
Change of AS or MAS 
upper limbs 
8 SMD −1.06, 95% CI [−1.40, 
−0.72]* 
72 
Change of AS or MAS 
lower limbs 
5 SMD −1.16, 95% CI [−1.83, 
−0.49]* 
84 
Change of FMA upper 
limbs 
2 MD 5.88, 95% CI [4.09, 7.68]* 0 
Change of FMA overall 2 MD 5.56, 95% CI [2.38, 8.74]* 0 
Change of BI 6 MD 12.01, 95% CI [2.81, 
21.22]* 
99 
Notes: AS, Ashworth Scale; BI, Barthel Index; CHM, Chinese herbal medicine; CI, 
confidence interval; FMA, Fugl-Meyer Assessment (motor function); I2, chi-squared test to 
estimate heterogeneity; MAS, Modified Ashworth Scale; MD, mean difference; SMD, 
standardised mean difference; *: significant add-on effect was detected by meta-analysis. 
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Figure 5.3 Forest plot of (Modified) Ashworth Scale in Chinese herbal medicine 
systematic review 
Notes: CHM, Chinese herbal medicine; CI, confidence, interval; RC, routine care; SD, 
standard deviation; Std., standardised. 
 
Change in Fugl-Meyer Assessment 
In terms of overall motor function measurement with the Fugl-Meyer Assessment, 
combining oral Chinese herbal medicine and routine care was estimated to be 
significantly better than routine care alone (three studies (He 2016; Li and Wang 
2011; Wang 2013b), MD 12.14, 95% CI [1.57, 22.71], I2=89%) (Table 5.7, Figure 
5.4). Similarly, benefits of adding oral Chinese herbal medicine to routine care were 
seen in Fugl-Meyer Assessment changed scores for the lower extremities (two studies 
(Chen et al. 2014; Wei et al. 2011), MD 4.03, 95% CI [1.90, 6.17], I2=61%), but not in 
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the upper limbs (three studies (Chen et al. 2014; Li et al. 2015; Wei et al. 2011), MD 
7.64, 95% CI [−1.29, 16.57], I2=97%). 
 
Figure 5.4 Forest plot of Fugl-Myer Assessment in Chinese herbal medicine 
systematic review 
Notes: CHM, Chinese herbal medicine; CI, confidence interval; RC, routine care; SD, 
standard deviation. 
Change in Barthel Index 
Seven included trials (Chen et al. 2014; He 2016; Li and Wang 2011; Li et al. 2015; 
Liu et al. 2014; Murat 2016; Zhong 2016) reported results for the Barthel Index and 
were pooled for meta-analysis. Results show that the combination of oral Chinese 
herbal medicine and routine care received improvement in the Barthel Index 
compared to routine care alone (MD 13.15, 95% CI [4.37, 21.93]), although with high 
heterogeneity (I2=98%) (Table 5.7, Figure 5.5). 
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Figure 5.5 Forest plot of Barthel Index in Chinese herbal medicine systematic 
review 
Notes: CHM, Chinese herbal medicine; CI, confidence interval; RC, routine care; SD, 
standard deviation. 
5.2.5.2 Topical Chinese herbal medicine add-on to routine care 
Change in Ashworth Scale or Modified Ashworth Scale 
Compared to routine care alone, adding topical Chinese herbal medicine further 
decreased the Ashworth Scale or Modified Ashworth Scale scores in the upper limbs 
(eight studies (Chen, Zhang et al. 2010; Ding 2016; Huang 2011; Lai 2016; Li, Zhong 
and Wang 2008; Shen, Wang and Zhu 2007; Wang et al. 2014; Zhang 2016), SMD 
−1.06, 95% CI [−1.40, −0.72], I2=72%) and the lower limbs (five studies (Chen, 
Zhang et al. 2010; Huang 2011; Ou et al. 2007; Shen, Wang and Zhu 2007; Wang et 
al. 2014), SMD −1.16, 95% CI[−1.83, −0.49], I2=84%) (Table 5.7, Figure 5.3), though 
with high heterogeneity detected in both analyses. 
Change in Fugl-Meyer Assessment 
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Synthesis results for the Fugl-Meyer Assessment (total motor function) from two 
trials (Jia et al. 2012; Zhang, Gao and Chen 2007) show superior effects of topical 
Chinese herbal medicine combined with routine care compared to routine care alone 
(MD 5.56, 95% CI [2.38, 8.74], I2=0%) (Figure 5.4). Similarly, meta-analysis results 
of another two studies (Lai 2016; Ou et al. 2014) show greater improvement in Fugl-
Meyer Assessment scores (upper-limb motor function) with topical Chinese herbal 
medicine added to routine care (MD 5.88, 95% CI [4.09, 7.68], I2=0%) (Table 5.7, 
Figure 5.4). 
Change in Barthel Index 
Compared to routine care alone, a combination of topical Chinese herbal medicine 
and routine care further improved Barthel Index results as shown in the meta-analysis 
with six studies (Cao and Han 2015; Huang 2011; Jia et al. 2012; Lai 2016; Wang et 
al. 2014; Zhang 2016) (MD 12.01, 95% CI [2.81, 21.22], I2=99%) (Table 5.7, Figure 
5.5). 
5.2.5.3 Safety assessment 
In total, ten of the included studies discussed safety issues in Chinese herbal 
medicine, while the other 25 studies did not provide information on adverse events. 
One study (Jia et al. 2012) reported a case of skin allergy in the intervention group 
with topical Chinese herbal medicine; although the symptom was evaluated as mild 
by a physician and disappeared after three days, the patient dropped out due to this 
event without further confirmation of its causality. Another study reported a patient in 
the treatment group with topical Chinese herbal medicine experiencing transient 
influenza-like symptoms after the Botox injection (Ou et al. 2014), which was 
considered not related to the use of Chinese herbal medicine. 
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5.2.5.4 Subgroup analyses and sensitivity analyses 
Oral Chinese herbal medicine add-on to routine care 
Due to the limited number of included studies, there were insufficient data for 
subgroup analysis. In terms of sensitivity analysis of the Barthel Index synthesis 
results, when only studies of low risk of bias in sequence generation were included, 
significant results remained and heterogeneity reduced to 66% (four studies (Li and 
Wang 2011; Liu et al. 2014; Murat 2016; Zhong 2016), MD 7.81, 95% CI [4.31, 
11.31]) (Table 5.8).  
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Table 5.8 Sensitivity analyses in Chinese herbal medicine systematic review 
 Oral CHM add-on 
to RC 
Risk of 
bias 
No. of 
studies 
Effects I2 (%) 
Oral 
CHM 
AS or MAS (upper 
limb) 
  3 SMD −1.79, 95% CI 
[−3.00, −0.57] 
94 
Sequence generation low N/A N/A N/A 
Blinding of assessors low 1 SMD −3.44, 95% CI 
[−4.20, −2.68] 
/ 
AS or MAS (lower 
limb) 
 3 SMD −1.01, 95% CI 
[−1.43, −0.59] 
55 
Sequence generation  low 1 SMD −1.48, 95% CI 
[−2.02, −0.94] 
/ 
Blinding of assessors low 1 SMD −1.48, 95% CI 
[−2.02, −0.94] 
/ 
FMA (total motor 
function) 
 3 MD 12.14, 95% CI 
[1.57, 22.71] 
89 
Sequence generation low 1 MD 17.30, 95% CI 
[8.38, 26.22] 
/ 
Blinding of assessors low N/A N/A N/A 
BI  7 MD 13.15, 95% CI 
[4.37, 21.93] 
98 
Sequence generation low 4 MD 7.81, 95% CI 
[4.31, 11.31]* 
66 
Blinding of assessors low N/A N/A N/A 
Topical 
CHM 
AS or MAS (upper 
limb) 
 8 SMD −1.06, 95% CI 
[−1.40, −0.72] 
72 
Sequence generation low 6 SMD −0.86, 95% CI 
[−1.14, −0.58]* 
50 
Blinding of assessors low N/A N/A N/A 
AS or MAS (lower 
limb) 
 5 SMD −1.16, 95% CI 
[−1.83, −0.49] 
84 
Sequence generation low 3 SMD −0.61, 95% CI 
[−0.96, −0.27]* 
0 
Blinding of assessors low N/A N/A N/A 
BI  6 MD 12.01, 95% CI 
[2.81, 21.22] 
99 
Sequence generation low 3 MD 9.16, 95% CI 
[−2.37, 20.69] 
99 
Blinding of assessors low N/A N/A N/A 
Notes: AS or MAS, Ashworth Scale or Modified Ashworth Scale; BI, Barthel Index; CHM, 
Chinese herbal medicine; CI, confidence interval; FMA, Fugl-Meyer Assessment (motor 
function); I2, chi-squared test to estimate heterogeneity; MD, mean difference; N/A, not 
applicable; RC, routine care; SMD, standardised mean difference; *, heterogeneity reduced. 
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Topical Chinese herbal medicine add-on to routine care 
For Ashworth Scale or Modified Ashworth Scale scores in the upper limbs, 
heterogeneity reduced to 0% in the subgroup where only patients with first stroke 
were included. Due to the limited number of studies, subgroup analysis on Fugl-
Meyer Assessment scores was not applicable. With regards to the Barthel Index, the 
subgroup where patients were within 180 days after stroke (three studies (Jia et al. 
2012; Wang et al. 2014; Zhang 2016), SMD 19.14, 95% CI [17.29, 20.98], I2=43%) 
demonstrated a greater effect than the subgroup of patients with a post-stroke period 
longer than 180 days (three studies (Cao and Han 2015; Huang 2011; Lai 2016), SMD 
3.53, 95% CI [0.51, 6.54], I2=43%) (Table 5.9). 
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Table 5.9 Subgroup analyses and post-hoc analyses with herbal ingredients in Chinese herbal medicine systematic review 
Analysis Subgroups (M)AS (upper limb)a (M)AS (lower limb) a Barthel Indexb 
Subgroup 
analysis 
All studies  −1.06 [−1.40, −0.72], I2=72%, 8 
(300/292) 
−1.16 [−1.83, −0.49], I2=84%, 5 
(140/138) 
12.01 [2.81, 21.22], I2=99%, 6 
(231/231) 
First onset of 
stroke 
Yes −1.19 [−1.48, −0.91], I2=0%, 2 
(119/110)▲ 
N/A N/A 
Unspecified −1.01 [−1.50, −0.53], I2=79%, 6 
(181/182) 
N/A N/A 
Treatment 
duration 
> 4 weeks N/A N/A N/A 
≤ 4 weeks N/A N/A N/A 
Post-stroke 
period 
≤ 180 days −1.10 [−1.48, −0.71], I2=67%, 5 
(199/189) 
−0.99 [−1.80, −0.18], I2=82%, 3 
(80/79) 
19.14 [17.29, 20.98], I2=43%, 
3 (128/126)▲ 
> 180 days −0.99 [−1.75, −0.24], I2=84%, 3 
(101/103) 
−1.41 [−2.60, −0.22], I2=85%, 2 
(60/59) 
3.53 [0.51, 6.54], I2=43%, 3 
(103/105)▲ 
Preparation Compression −1.12 [−1.54, −0.69], I2=60%, 4 
(140/132) 
−1.09 [−2.52, 0.34], I2=91%, 2 
(55/54)● 
8.98 [−2.81, 20.76], I2=99%, 3 
(82/84)● 
Fumigation −0.99 [−1.58, −0.41], I2=83%, 4 
(160/160) 
−1.22 [−2.06, −0.39], I2=82%, 3 
(85/84) 
17.12 [11.92, 22.32], I2=82%, 
3 (149/147) 
Post-hoc 
analysis 
with herbal 
ingredients 
BS Included −1.15 [−1.69, −0.61], I2=82%, 5 
(184/184) 
−1.55 [−2.29, −0.82], I2=79%, 3 
(94/94) 
18.01 [14.91, 21.12], I2=75%, 
4 (173/171) 
Excluded −0.96 [−1.24, −0.68], I2=0%,  
3 (116/108)▲ 
−0.50 [−0.92, −0.08], I2=0%, 2 
(44/44)▲ 
3.79 [−0.33, 7.91], I2=70%, 2 
(58/60)● 
DG Included −1.21 [−1.58, −0.83], I2=71%, 4 
(244/234) 
N/A 18.01 [14.91, 21.12], I2=75%, 
4 (173/171) 
Excluded −0.61 [−0.99, −0.23], I2=0%, 2 
(56/58)▲ 
N/A 3.79 [−0.33, 7.91], I2=70%, 2 
(58/60)● 
BS+DG Included −1.30 [−1.90, −0.71], I2=81%, 4 
(154/154) 
−1.55 [−2.29, −0.82], I2=79%, 3 
(94/94) 
18.01 [14.91, 21.12], I2=75%, 
4 (173/171) 
Not included −0.86 [−1.13, −0.59], I2=16%, 4 
(146/138)▲ 
−0.50 [−0.92, −0.08], I2=0%, 2 
(44/44)▲ 
3.79 [−0.33, 7.91], I2=70%, 2 
(58/60)● 
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Analysis Subgroups (M)AS (upper limba (M)AS (lower limb) a Barthel Indexb 
Post-hoc 
analysis 
with herbal 
ingredients 
BS+SJC Included −1.15 [−1.69, −0.61], I2=82%, 5 
(184/184) 
−1.55 [−2.29, −0.82], I2=79%, 3 
(94/94) 
18.01 [14.91, 21.12], I2=75%, 
4 (173/171) 
Not included −0.96 [−1.24, −0.68], I2=0%,  
3 (116/108)▲ 
−0.50 [−0.92, −0.08], I2=0%, 2 
(44/44)▲ 
3.79 [−0.33, 7.91], I2=70%, 2 
(58/60)● 
DG+SJC Included −1.26 [−1.70, −0.82], I2=75%, 5 
(213/204) 
N/A 18.01 [14.91, 21.12], I2=75%, 
4 (173/171) 
Not included −0.72 [−1.02, −0.41], I2=0%, 3 
(87/88)▲ 
N/A 3.79 [−0.33, 7.91], I2=70%, 2 
(58/60)● 
BS+DG+HH Included −1.56 [−1.94, −1.17], I2=43%, 3 
(129/129)▲ 
−1.93 [−2.34, −1.53], I2=0%, 2 
(69/69)▲ 
18.01 [14.91, 21.12], I2=75%, 
4 (173/171) 
Not included −0.77 [−1.04, −0.49], I2=32%, 5 
(171/163)▲ 
−0.61 [−0.96, −0.27], I2=0%, 3 
(71/69)▲ 
3.79 [−0.33, 7.91], I2=70%, 2 
(58/60)● 
BS+DG+SJC Included −1.30 [−1.90, −0.71], I2=81%, 4 
(154/154) 
−1.55 [−2.29, −0.82], I2=79%, 3 
(94/94) 
18.01 [14.91, 21.12], I2=75%, 
4 (173/171) 
Not included −0.86 [−1.13, −0.59], I2=16%, 4 
(146/138)▲ 
−0.50 [−0.92, −0.08], I2=0%, 2 
(44/44)▲ 
3.79 [−0.33, 7.91], I2=70%, 2 
(58/60)● 
Notes: BI: Barthel Index; BS: bai shao 白芍 (Paeonia lactiflora Pall.); CHM: Chinese herbal medicine; DG: dang gui 当归 (Angelica sinensis (Oliv.) 
Diels); FMA: Fugl-Meyer Assessment; HH: hong hua 红花 (Carthamus tinctorius L.); (M)AS: (Modified) Ashworth Scale; MG: mu gua 木瓜 
(Chaenomeles speciosa (Sweet) Nakai); N/A: Not applicable; SJC: shen jin cao 伸筋草 (Lycopodium japonicum Thunb.); a: Results were presented as 
‘SMD, 95% CI, I2, No. of studies (No. of participants of I/C groups)’; b: Results were presented as ‘MD, 95% CI, I2, No. of studies (No. of 
participants of I/C groups)’; ●: No statistically significant difference; ▲: Heterogeneity reduced.
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In terms of the administration of Chinese herbal medicine, an add-on effect was 
detected in terms of when the Chinese herbal medicine was used as steaming therapy 
for the outcomes of lower-limb Ashworth Scale or Modified Ashworth Scale (SMD 
−1.22, 95% CI [−2.06, −0.39], I2=82%) and Barthel Index (MD 17.12, 95% CI [11.92, 
22.32], I2=82%) scores, while there was no add-on benefit when Chinese herbal 
medicine was used for compression in Ashworth Scale or Modified Ashworth Scale 
scores for the lower limbs (SMD −1.09, 95% CI [−2.52, 0.34], I2=91%) or in the 
Barthel Index (MD 8.98, 95% CI [−2.81, 20.76], I2=99%). 
Sensitivity analysis of studies at low risk of bias in sequence generation shows that 
significant treatment effects remained while heterogeneity reduced for the changed 
scores in upper-limb Ashworth Scale or Modified Ashworth Scale (six studies (Chen, 
Zhang et al. 2010; Ding 2016; Lai 2016; Li, Zhong and Wang 2008; Shen, Wang and 
Zhu 2007; Zhang 2016), SMD −0.86, 95% CI [−1.14, −0.58], I2=50%) (Table 5.8), as 
well as that of the lower limbs (three studies (Chen, Zhang et al. 2010; Ou et al. 2007; 
Shen, Wang and Zhu 2007), SMD −0.61, 95% CI [−0.96, −0.27], I2=0%) (Table 5.8). 
5.2.5.5 Publication bias 
None of the above meta-analyses included more than ten trials; therefore, publication 
bias was not evaluated. 
5.2.5.6 Herb analysis 
Bai shao 白芍 (Paeonia lactiflora Pall.) was the most frequently used oral herb 
reported by 17 studies followed by gan cao 甘草 (Glycyrrhiza uralensis Fisch.) 
(Table 5.10), while shen jin cao 伸筋草 (Lycopodium japonicum Thunb.) and dang 
gui 当归 (Angelica sinensis (Oliv.) Diels) were at the top of the most frequently 
reported topically used herbs among the included studies (Table 5.10). In fact, the 
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combination of bai shao 白芍 and gan cao 甘草 is a traditional oral Chinese herbal 
medicine formula named Shao yao gan cao tang 芍药甘草汤, which is recorded to 
have the function of relieving spasticity (Zhang, Yang et al. 2015). 
Table 5.10 Frequently used herbs reported by included studies in Chinese herbal 
medicine systematic review  
 Herbs Academic names Frequency 
Oral 
herbs 
bai shao 白芍 Paeonia lactiflora Pall. 17 
gan cao 甘草 Glycyrrhiza uralensis Fisch. 13 
dang gui 当归 Angelica sinensis (Oliv.) Diels 12 
quan xie 全蝎 Buthus martensii Karsch 10 
di long 地龙 Pheretima aspergillum (E.Perrier) 
or Pheretima vulgaris Chen or 
Pheretima guillelmi (Michaelsen) 
or Pheretima pectinifera 
Michaeken 
9 
mu gua 木瓜 Chaenomeles speciosa (Sweet) 
Nakai 
9 
ji xue teng 鸡血藤 Spatholobus suberectus Dunn 8 
shen jin cao 伸筋草 Lycopodium japonicum Thunb. 7 
huang qi 黄芪 Astragalus membranaceus (Fisch.) 
Bge. var. mongholicus (Bge.) 
Hsiao or Astragalus 
membranaceus (Fisch.) Bge. 
7 
tao reng 桃仁 Prunus persica (L). Batsch or 
Prunus davidiana (Carr.) Franch 
6 
hong hua 红花 Carthamus tinctorius L. 6 
Topical 
herbs 
shen jin cao 伸筋草 Lycopodium japonicum Thunb. 13 
dang gui 当归 Angelica sinensis (Oliv.) Diels 13 
bai shao 白芍 Paeonia lactiflora Pall. 12 
hong hua 红花 Carthamus tinctorius L. 12 
mu gua 木瓜 Chaenomeles speciosa (Sweet) 
Nakai 
11 
gui zhi 桂枝 Cinnamomum cassia Presl 9 
dan shen 丹参 Salvia miltiorrhizaBge. 9 
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 Herbs Academic names Frequency 
Topical 
herbs 
gan cao 甘草 Glycyrrhiza uralensis Fisch. 9 
chuan xiong 川芎 Ligusticum chuanxiong Hort. 8 
ji xue teng 鸡血藤 Spatholobus suberectus Dunn 7 
wei ling xian 威灵仙 Clematis chinensis Osbeck or 
Clematis hexapetala Pall. or 
Clematis manshurica Rupr. 
7 
For topical herbs, post-hoc subgroup analysis was conducted to estimate the effects of 
individual and combinations of the five most frequently reported herbal ingredients in 
the included studies. Table 5.7 summarises the results with significant between-
subgroup difference in post-hoc analysis of these herbs. Superior effects detected in 
the subgroup of studies whose formulas involved bai shao 白芍 seem greater 
compared to the subgroups of studies without bai shao 白芍 in terms of the Ashworth 
Scale or Modified Ashworth Scale in the lower limbs (SMD −1.55, 95% CI [−2.29, 
−0.82], I2=79%) and the Barthel Index (MD 18.01, 95% CI [14.91, 21.12], I2=75%). 
Similarly, subgroups of studies that used dang gui 当归 might have benefited more 
than those without it in terms of the upper-limb Ashworth Scale or Modified 
Ashworth Scale (SMD −1.21, 95% CI [−1.58, −0.83], I2=71%) and Barthel Index 
(MD 18.01, 95% CI [14.91, 21.12], I2=75%). 
It is worth noting that formulas containing the three ingredients (bai shao 白芍, dang 
gui 当归 and hong hua 红花) were observed to have a trend of greater effects in terms 
of all three outcome measures: Ashworth Scale or Modified Ashworth Scale in upper 
limbs (SMD −1.56, 95% CI [−1.94, −1.17], I2=43%), Ashworth Scale or Modified 
Ashworth Scale in lower limbs (SMD −1.93, 95% CI [−2.34, −1.53], I2=0%) and 
Barthel Index (MD 18.01, 95% CI [14.91, 21.12], I2=75%), than the formulas without 
them with reduced heterogeneity.  
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5.3 Discussion 
5.3.1 Summary of main results 
The results suggest that adding oral or topical Chinese herbal medicine to routine care 
for post-stroke spasticity is beneficial for reducing muscle spasticity in the upper and 
lower extremities. For the overall and lower-limb motor scores of the Fugl-Meyer 
Assessment and the Barthel Index, significant add-on effects of both oral and topical 
Chinese herbal medicine were observed, while no significant effects of adding oral 
Chinese herbal medicine to routine care for upper-limb motor function was detected. 
Mild, self-healing adverse events were reported in intervention groups with topical 
Chinese herbal medicine, but the association between Chinese herbal medicine and 
adverse events had not been explored. 
5.3.2 Overall completeness and applicability of evidence 
5.3.2.1 Clinical importance of results 
In our analyses, the Ashworth Scale or Modified Ashworth Scale change scores were 
merged for analysis using SMD; therefore, minimal detectable difference (MDD) or 
minimal clinically important difference (MCID) was not applied to its clinical 
interpretation. With regards to the upper-limb Fugl-Meyer Assessment, both MDD 
and MCID were explored and rated 5.2 (Page, Fulk and Boyne 2012; Wagner, Rhodes 
and Patten 2008). The MCID of overall, upper-limb and lower-limb Fugl-Meyer 
Assessment was explored and rated 6.0, 4.58 and 3.31 respectively in another study 
(Chen, Wu and Shen 2015). In fact, the changes in total motor, upper-limb and lower-
limb scores of the Fugl-Meyer Assessment in intervention groups (oral or topical 
Chinese herbal medicine plus routine care) and control groups (routine care alone) 
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were all greater than the MCID (Figure 5.4). In terms of the Barthel Index, the MDD 
(4.02 points) (Hsieh et al. 2007) was established and used for interpretation of our 
results. The use of oral Chinese herbal medicine with routine care demonstrated 
clinical advantages for post-stroke spasticity in terms of the Barthel Index when 
compared to routine care alone (Figure 5.5). 
The inconsistent effects among different outcomes should be interpreted with caution. 
The reasons could be: first, the relatively small numbers of participants and included 
studies and the high heterogeneity limited our confidence in the results; second, the 
decrease in spasticity severity might not necessarily have led to improvement in motor 
function (Li 2017); and third, other factors, such as muscle strength, might also have 
contributed to changes in the results, particularly motor function and activities of 
daily living (Harvey 2015; Langhammer, Lindmark and Stanghelle 2007; Nunes et al. 
2016). 
5.3.2.2 Implications for practice 
This review has attempted to explore the characteristics of post-stroke spasticity 
patients who would benefit from adding Chinese herbal medicine therapies to routine 
care, such as time of stroke onset and post-stroke period. The results of subgroup 
analyses suggest that spasticity patients within 180 days post-stroke might benefit 
more from additional topical Chinese herbal medicine treatment. 
As for specific Chinese herbal medicine treatment, further exploration of potential 
formulas was not possible because of the diversity of formulas used in the included 
studies (Table 5.3). Therefore, we have summarised the most frequently reported 
herbs and conducted subgroup analyses for individual and combinations of herbal 
ingredients used in the included studies. For oral Chinese herbal medicine, bai shao 
白芍 and gan cao 甘草 were the most frequently reported herbs, although subgroup 
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analysis results of better effects to support the use of these two herbs were not 
forthcoming. With regards to topical Chinese herbal medicine, a combination of bai 
shao 白芍, dang gui 当归 and hong hua 红花 demonstrated a promising therapeutic 
add-on effect for spasticity reduction and improvement in activities of daily living. 
Specifically, for the preparation of topical Chinese herbal medicine, steaming therapy 
with Chinese herbal medicine showed a trend of better improvement than Chinese 
herbal medicine compression therapy (Table 5.9). It is worth noting that confounding 
variables might also have had an impact on the results due to the complexity in the 
application of topical Chinese herbal medicine. For instance, the overall treatment 
effects of steaming may be a combined result of Chinese herbal medicine, steam and 
heat. 
Therefore, to distinguish and confirm individual therapeutic effects of Chinese herbal 
medicine requires further assessment. Treatment duration was reported ranging from 
20 days to three months among the included trials (Table 5.4). But subgroup analysis 
of treatment with the predefined cut-off four-week duration was not possible. 
Moreover, all the participants enrolled in the included studies had already developed 
spasticity with the Ashworth Scale or Modified Ashworth Scale ≥ 1. The effects of 
Chinese herbal medicine on patients at a very early stage post-stroke when spasticity 
is not yet detected with the Modified Ashworth Scale are not known based on the 
results of this review. In addition, all participants enrolled in the included trials were 
Chinese; additional evidence of using Chinese herbal medicine therapy on non-
Chinese populations is needed in order to generalise the results. 
5.3.2.3 Potential pharmacological mechanisms 
Neuroprotective activity was observed with paeoniflorin extracted from bai shao by 
activating the adenosine A1 receptor (Liu et al. 2005; Tang et al. 2010; Zhang et al. 
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2009; Zhang et al. 2017). In terms of gan cao 甘草, potential neuroprotection with 
one of its major ingredients, glycyrrhizin, was mediated by anti-inflammatory effects 
via inhibiting HMGB1 secretion and neurotoxicity by suppression of glutamate-
induced apoptosis (Kim et al. 2012). Triterpene saponins and Licochalcone E in gan 
cao 甘草 were observed with protection effects against neurotoxicity through 
suppression of the glutamate-induced apoptosis (Cherng et al. 2006; Hwang et al. 
2006) and activating the Nrf2/antioxidant response element signalling pathway (Kim 
et al. 2012). Another bioactive component, Licochalcone A, was detected with anti-
spasmodic activity alone and when combined with paeoniflorin, potentially through 
inhibition of phosphodiesterase (Nagai et al. 2007; Sato et al. 2006) and decreasing 
excitatory amino acids content respectively (Kimura et al. 1984; Zhang, Yang, et al. 
2015). 
The ingredients with an anti-neurotoxicity effect in dang gui 当归 include 
polysaccharides, organic acids and phthalides. Potential mechanisms include 
decreasing expression of nicotinic acetylcholine receptors (Gu et al. 2008) and 
increasing brain-derived neurotrophic factor and nerve growth factor protein 
expression (Chen et al. 2009). Similarly, a neuroprotective function could also be 
observed with the ingredients from hong hua 红花 (He et al. 2012; Yu, Chen et al. 
2013; Zhang et al. 2016). A combination of topically used dang gui 当归, hong hua 
红花 and bai shao 白芍 demonstrated a promising benefit for post-stroke spasticity 
(Table 5.9), but the underlying mechanism is yet to be uncovered. Representative 
examples of major neurological effects and potential mechanisms are summarised in 
Table 5.11.
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Table 5.11 Major neurological effects and potential mechanisms of herbs frequently reported in Chinese herbal medicine 
systematic review 
Herbs Bioactive 
ingredients 
Related 
formulations 
Beneficial effects Potential mechanisms Experimental 
models 
Dang gui 当
归 (Angelica 
sinensis 
(Oliv.) Diels) 
1) 
Polysaccharides 
2) Organic acids 
3) Phthalides 
1) Jia wei bu yang 
huan wu tang 加味
补阳还五汤 
2) Tong luo jie jing 
tang 通络解痉汤 
3) Shu jin huo luo xi 
ji 舒筋活络洗剂 
Neuroprotective 
effects 
Increasing brain-derived neurotrophic factor and 
nerve growth factor protein expression 
Rats 
Inhibit 
neurotoxicity 
Decreased expression of nicotinic acetylcholine 
receptors induced by β-amyloid protein 
Human 
neuroblastoma 
cells 
Bai shao 白
芍 (Paeonia 
lactiflora 
Pall.) 
Paeoniflorin 1) Shao yao gan cao 
tang 芍药甘草汤 
2) Gua lou gui zhi 
tang 瓜蒌桂枝汤 
3) Tong luo jie jing 
tang 通络解痉汤 
4) Jie jing he ji 
解痉合剂 
 
Neuroprotective 
activity  
Activating adenosine A1 receptor: 
1) Scavenging superoxide anions, inhibiting 
microglial activation and IL-1β, NF-κB, TNF-α 
expressions 
2) Attenuated neuronal apoptosis by regulating the 
Ca2+/ CaMKII/CREB signaling pathway 
Rats 
Anti-spasmodic 
activity  
(Combined with paeoniflorin and glycyrrhizin): 
1) Decrease excitatory amino acids content 
2) Inhibit muscle contraction 
1) Frogs & 
mice 
2) Rats  
Analgesic 
activity 
Paeoniflorin (180 mg/kg): inhibiting extracellular 
signal-regulated protein kinase (ERK) pathway 
Rats  
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Herbs Bioactive 
ingredients 
Related 
formulations 
Beneficial effects Potential mechanisms Experimental 
models 
Gan cao 甘草 
(Glycyrrhiza 
uralensis 
Fisch.) 
Glycyrrhizin 
(glycyrrhizic 
acid) 
1) Shao yao gan cao 
tang 芍药甘草汤 
2) Gua lou gui zhi 
tang 瓜蒌桂枝汤 
3) Shu jin tong luo 
fang 舒筋通络方 
4) Jie jing he ji 解痉
合剂 
Neuroprotective 
effects 
Anti-inflammatory effects by inhibiting HMGB1 
secretion, 
Anti-excitotoxic and anti-oxidative 
Rats 
Gan cao 甘草 
(Glycyrrhiza 
uralensis 
Fisch.) 
Triterpene 
saponins 
1) Shao yao gan cao 
tang 芍药甘草汤 
2) Gua lou gui zhi 
tang 瓜蒌桂枝汤 
3) Shu jin tong luo 
fang舒筋通络方 
4) Jie jing he ji 解痉
合剂 
Inhibit 
neurotoxicity 
Suppression of glutamate-induced apoptosis by  
1) inhibiting Ca2+ influx activated through NMDA 
receptor by glutamate 
2) diminishing DNA fragmentation and cleavage of 
PARP 
3) inhibiting binding activity of NF-κB 
4) maintaining SOD1 levels 
Rat neuronal 
cultures & 
meriones 
unguiculatus 
Licochalcone A Anti-spasmodic 
activity 
Inhibit pdes, especially isozyme 3, followed by 
accumulation of intracellular camp 
Mouse 
jejunum 
Licochalcone E Neuroprotection Activates Nrf2/antioxidant response element 
signalling pathway 
Mouse cells 
Hong hua 红
花 
(Carthamus 
tinctorius L.) 
Hydroxysafflor 
yellow A 
1) Bu yang huan wu 
tang 补阳还五汤 
2) Yi qi rou jin tang 
益气柔筋汤 
3) Shu jin huo luo xi 
ji 舒筋活络洗剂 
Neuroprotective 
function 
Suppression of apoptosis by regulation of Bcl-2 
and Bax protein expression 
Rats 
Kaempferol-3-O-
rutinoside 
Prevent ischemic 
brain injury and 
inflammation 
Inhibit activation of NF-κB & STAT3 
 
Rats 
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Herbs Bioactive 
ingredients 
Related 
formulations 
Beneficial effects Potential mechanisms Experimental 
models 
Mu gua 木瓜 
(Chaenomeles 
speciosa 
(Sweet) 
Nakai) 
Oleanolic acid 
Ursolic acid 
1) Tong luo jie jing 
tang 通络解痉汤 
2) Rou jin tang 柔筋
汤 
3) Shu jin huo luo xi 
ji 舒筋活络洗剂 
4) Jie jin he ji 解痉
合剂 
Inhibit 
neurotoxicity 
Inhibit neuronal death by elevating intracellular 
Ca2+ concentration and generation of ROS 
Rat cortical 
neurons 
Notes: Bax protein: Bcl-2-associated X protein; Bcl-2: B-cell lymphoma 2; Ca2+: calcium ion; CaMKII: calmodulin-dependent protein kinase II; 
cAMP: Cyclic adenosine monophosphate; CREB: cAMP response element-binding; HMGB1: high mobility group box1protein; IL-1β: interleukin-
1beta; NF-κB: nuclear factor-kappa B; NMDA: N-methyl-D-aspartate; Nrf2: nuclear factor E2-related factor 2; PARP: poly-ADP-ribose polymerase; 
PDE: phosphodiesterase; Ref: references; ROS: reactive oxygen species; SOD1: superoxide dismutase 1; STAT3: signal transducer and activator of 
transcription 3; TNF-α: tumour necrosis factor-alpha. 
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However, various formulas with complex compounds were used in the included 
studies and the potentially active ones isolated from Chinese herbal medicine usually 
act via different mechanisms and pathways. There is no direct research evidence of 
human skeletal muscles with these bioactive ingredients specifically exploring the 
underlying mechanisms of spasticity, which is characterised by a velocity-dependent 
increase in tonic stretch reflexes (Lance 1980). Therefore, the causal relationship 
between the observed therapeutic effects on post-stroke spasticity and the individual 
components or monomolecular substance targeting a few known cellular or molecular 
pathways cannot be confirmed.  
Further mechanism and clinical studies to discover how bioactive Chinese herbal 
medicine ingredients work individually and interactively are also needed to optimise 
and even standardise Chinese herbal medicine components and treatment protocols in 
the future. 
5.3.3 Limitations 
There are concerns around the safety and long-term tolerance of therapy in the 
treatment of spasticity after stroke (Nair and Marsden 2014). Our systematic review 
suggests that oral and topical Chinese herbal medicine were well tolerated during 
treatment periods for as long as three months, with mild adverse events in 10 studies 
(Chen, Zhang et al. 2010; Huang 2011; Lai 2016; Ou et al. 2014; Shen, Wang and Zhu 
2007; Weng 2014; Zhang 2009; Zhao 2013; Zhu et al. 2007; Zhu, Hu and Zhou 2002). 
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However, the remaining 25 studies did not address safety issues and none of the 
included studies covered a follow-up period, making the assessment of long-term 
safety impossible based on the results of our systematic review. 
Proper randomisation and allocation are essential to reduce selection bias in 
randomised controlled trials. However, in this systematic review only 51.4% of the 
included studies applied appropriate methods for sequence generation and only 5.7% 
for allocation concealment (Figure 5.2), both might have led to underestimation or 
overestimation of the treatment effects (Pildal et al. 2007). It is worth noting that none 
of the included trials attempted to blind participants or intervention providers with the 
use of appropriate placebos, and outcome assessors were blinded in only three studies 
(Liu et al. 2014; Weng 2014; Zhang, Gao and Chen 2007).  
Admittedly there is no easy way to perform double blinding with oral or topical 
Chinese herbal medicine therapies, whose preparation, appearance, taste and smell are 
so diverse that placebo control might be difficult. In the context of this challenge, tests 
of blinding with placebos are needed before conducting a randomised controlled trial, 
and evaluation of Chinese herbal medicine efficacy compared with placebos added 
onto rehabilitation therapies or pharmacotherapies is required, especially for non-
objective outcome assessment. 
Another limitation of the synthesis results is the reporting quality of the included 
studies. None of them reported all of the key items recommended by CONSORT 2010 
and its extensions for herbal intervention and Chinese herbal medicine formulas 
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(Cheng et al. 2017; Gagnier et al. 2006; Schulz, Altman and Moher 2010) and even 
among those key items that were reported, ambiguous terms were frequently used. For 
example, eight studies only reported dosage information as ‘1 dose’ or ‘0.5 dose’ but 
without actual amounts of the decoction, and 3 studies named their oral Chinese 
herbal medicine ‘syrup’ but without the actual manufacturing method being provided. 
Therefore, future trials need to improve reporting quality, and specific definitions and 
standardisation of Chinese herbal medicine interventions require further research and 
agreement. 
5.3.4 Disagreement with existing reviews 
We identified one published systematic review and meta-analysis investigating the 
effects of the oral Chinese herbal medicine formula Shao yao gan cao tang 芍药甘草
汤 for post-stroke spasticity (Chen and Tan 2016). Ten randomised controlled trials 
involving 732 participants were included in this meta-analysis through a database 
search covering January 1990 to November 2015. The Jadad scale was used to assess 
the methodological quality of the included studies. Although potential benefits of the 
decoctions were detected with regards to the Fugl-Meyer Assessment and Barthel 
Index in this meta-analysis, the pooled data from different comparisons in one 
synthesis result (such as Shao yao gan cao tang 芍药甘草汤 vs. routine care and 
Shao yao gan cao tang 芍药甘草汤 add-on to routine care vs. routine care) prevented 
us from drawing conclusions based on the synthesis results for Shao yao gan cao tang 
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芍药甘草汤. Moreover, this review did not evaluate outcomes related to the severity 
of spasticity. 
Our systematic review and meta-analysis is different from the above systematic 
review in the following ways: first, our review focuses specifically on the add-on 
effects of Chinese herbal medicine, including oral and topical Chinese herbal 
medicine for post-stroke spasticity; second, comprehensive outcome measures were 
evaluated in terms of spasticity severity, motor function and activities of daily living; 
third, our research provides up-to-date evidence via the search from database 
inception to February 2018; fourth, the Cochrane risk-of-bias tool was used for 
methodological quality assessment since the total score from the Jadad scale is 
increasingly being challenged in relation to its validity (Emerson et al. 1990; Juni et 
al. 1999; Schulz et al. 1995). 
5.4 Conclusion 
Noting the quality concerns of the included trials, this review suggests that Chinese 
herbal medicine may be a potentially effective and well-tolerated add-on therapy to 
reduce spasticity and improve daily activities. Specifically, oral Chinese herbal 
medicine with bai shao 白芍 and gan cao 甘草 is most commonly reported, while 
topical Chinese herbal medicine containing bai shao 白芍, dang gui 当归 and hong 
hua 红花 used in steaming therapy seems the best option. Future trials of high 
methodological quality with prospectively registered protocols, valid placebo controls 
and follow-up periods are needed.  
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Chapter 6 Acupuncture for post-stroke spasticity 
 
This chapter evaluates the add-on effectiveness and safety of acupuncture, including 
manual acupuncture, electro-acupuncture, acupressure and moxibustion, for post-
stroke spasticity. The protocol of electro-acupuncture systematic review was registred 
on PROSPERO (registration number PROSPERO 2015:CRD42015027894): 
6.1 Introduction 
Acupuncture has been practised in China for a long time and become increasingly 
popular in Western countries in recent decades (Lim et al. 2015). Traditionally, 
manual acupuncture refers to insertion of acupuncture needles into acupuncture 
points. When electrical stimulation is applied through a small electric current passing 
between pairs of acupuncture needles, it is known as electro-acupuncture (Liu et al. 
2015). This is different from transcutaneous electrical nerve stimulation which is a 
technique that involves the delivery of mild pulsed electrical currents across the intact 
surface of the skin to stimulate low-threshold nerves in order to relieve pain (Johnson 
and Jones 2017). Other acupuncture-related therapies include acupressure (different 
manual pressures applied to acupuncture points), moxibustion (burning herbs, usually 
ai ye, 艾叶, Artemesia vulgaris L., close to or on the skin to induce a warming 
sensation), scalp acupuncture (applying acupuncture on acupuncture points located in 
lines on the scalp) and wrist-ankle acupuncture (applying acupuncture on acupuncture 
points located at the wrists and ankles). 
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In this chapter, we report on a general review conducted to evaluate the effects and 
safety of acupuncture and its related therapies, covering manual acupuncture, 
acupressure, moxibustion and electro-acupuncture, for post-stroke spasticity, followed 
by a systematic review and meta-analysis focusing on the effects and safety of 
electro-acupuncture. Compared with manual acupuncture, electro-acupuncture can 
provide a constant stimulation whose intensity, frequency and duration are 
quantifiable (Liu et al. 2015). Therefore, electro-acupuncture enables clinicians to 
apply a standardised treatment in clinical practice. Also, electro-acupuncture can be 
used as a study intervention that is specifically defined, which enables studies to 
examine different parameters and achieve a relatively higher quality of reporting. 
To start with, we identified six systematic reviews (three published in English and 
three published in Chinese) evaluating the effects of acupuncture for post-stroke 
spasticity in the database search. 
Qi et al. (2009) included 14 randomised controlled trials, all of which were clinical 
trials conducted in China with a total number of 978 Chinese participants. 
Intervention therapies among these studies included manual acupuncture, electro-
acupuncture, acupuncture point injection with Chinese herbal medicine, Chinese body 
massage or Tuina and plum-blossom needling. The risk of bias of the included studies 
was assessed as low. As for the results of the meta-analyses, there were no significant 
between-group differences detected in terms of AS, Carr-Shepherd scores, nerve 
defect scores and hip adductor tension scores; but superior results were obtained for 
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the Fugl-Meyer Assessment (one study) and the Barthel Index (three studies). Due to 
the relatively low methodological quality of the included studies, a firm conclusion 
cannot be drawn based on the results of this systematic review. 
Liu et al. (Liu, Bao and Dong 2014) generally reviewed the effects of acupuncture 
point-to-point penetrative needling therapy for spastic paralysis after stroke. There 
were 19 randomised controlled trials published in Chinese included in this systematic 
review, but assessment of methodological quality and meta-analysis were not 
performed and therefore it concluded that the efficacy of this type of acupuncture 
could not be confirmed. 
Park et al. (2014) included eight studies with a total of 339 participants evaluating the 
effects of both manual acupuncture and electro-acupuncture for post-stroke spasticity. 
The results of this systematic review suggested that adding acupuncture to traditional 
rehabilitation brought no additional benefits in terms of the Modified Ashworth Scale 
or H-reflex/M-response ratio. Moreover, due to the limited methodological quality of 
the included studies, this systematic review concluded that the effects of acupuncture 
for post-stroke spasticity were not confirmed. 
Lim et al. (2015) conducted a systematic review and meta-analysis including 5 studies 
(three in English, one in Chinese and one in Korean). The results of this review 
demonstrated that acupuncture or electro-acupuncture could significantly reduce 
spasticity as measured by the Modified Ashworth Scale post-stroke. Specifically, the 
results of subgroup analysis suggested that spasticity was reduced in wrists, knees and 
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elbows with acupuncture. This review also explored the sources of heterogeneity, 
which to some extent could be explained by the diversity in acupuncture treatment 
protocols and control methods among the included trials. The authors concluded that 
acupuncture could decrease post-stroke spasticity but that future studies to evaluate 
the long-term effects of acupuncture and electro-acupuncture are needed. 
Another systematic review and meta-analysis conducted by Lin and Liu (2015) 
evaluated the effects of acupuncture for hemiplegic gait. This review involved eight 
randomised controlled trials and 14 controlled clinical trials with a total number of 
1,519 participants after stroke. Acupuncture was compared to routine care in all 
included studies. The most frequently reported outcome measures, including lower-
limb Fugl-Meyer Assessment, gait assessment, Modified Ashworth Scale, Composite 
Spasticity Index or Composite Spasticity Scale and Barthel Index or Modified Barthel 
Index, were generally described and summarised. Meta-analysis was also performed 
in terms of Fugl-Meyer Assessment in the lower extremities and additional benefits 
were observed with acupuncture compared to routine care for patients with 
hemiplegic gait after stroke. Because meta-analysis of spasticity-related outcome 
measures such as Modified Ashworth Scale, Composite Spasticity Scale and 
Composite Spasticity Index was not performed, the effects of acupuncture for post-
stroke spasticity could not be confirmed. 
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6.2 Manual acupuncture, acupressure and moxibustion for post-stroke spasticity 
6.2.1 Search results 
A comprehensive initial search was conducted in both English and Chinese databases 
from their inception to April 2015 and 37,141 citations were identified. Eventually, 77 
manual acupuncture–related, three acupressure-related and seven moxibustion-related 
randomised controlled trials, and 17 electro-acupuncture–related randomised 
controlled trials were identified for meta-analysis (Figure 6.1). 
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Figure 6.1 Screening flow chart of acupuncture and related studies 
Notes: RCT, randomised controlled trial. 
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6.2.2 Descriptive analysis 
All but one trial (Fink et al. 2004) were conducted in China with more than 13,000 
patients involved. The effects of acupuncture and its related therapies were explored 
and are summarised below, covering acupuncture, electro-acupuncture, moxibustion, 
acupressure and their combinations. 
The average age of the included patients was 60.5 years. In terms of the gender of 
participants, the number of males (n=6,256) was greater than that of females 
(n=4,314). The intervention treatment period ranged from two weeks to three months. 
Syndromes of Chinese medicine were reported in 8 of the included studies (Han 2010; 
Jia 2009; Lang 2011; Yang et al. 2014; Yu, Zheng et al. 2013; Zhan 2009; Zhao, Wang 
and Yang 2013; Zhuang et al. 2010), among which the ‘Liver yang 阳 uprising, Wind 
and Phlegm blocking the meridians, with qi 气 deficiency and Blood Stasis’ syndrome 
was the most frequently reported. 
A total of 116 two-arm randomised controlled trials were identified, among which 92 
evaluated the additional effects of acupuncture added to routine care, while 24 
compared the acupuncture therapies with different comparators. In addition, 23 trials 
included three treatment arms consisting of both a direct comparison and a treatment 
group with an add-on treatment of acupuncture. However, due to the complex 
comparisons in the included studies, only the results for two treatment arms were used 
for meta-analyses in two studies (Hu 2011; Zhang and Tang 2011). Another ten three-
armed studies compared the effects of a newly developed acupuncture technique with 
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traditional manual acupuncture in two of the treatment groups. For these trials, only 
the results of the group with the new acupuncture technique are analysed and pooled 
in meta-analysis in this chapter. In summary, comparisons of the included trials in this 
review and meta-analysis include: 1) acupuncture vs. placebo or sham needling (n=2); 
2) acupuncture vs. routine medications and/or rehabilitation therapies (n=47); 3) 
acupuncture vs. electrical stimulation (n=1); and 4) acupuncture added onto various 
treatments, including medication and/or rehabilitation therapy (n=123). 
In terms of the acupuncture points identified from the included studies, a total of 170 
body acupuncture points were used by the included studies, among which the most 
frequently reported ones were: LI4 Hegu 合谷 (n=39), LI11 Quchi 曲池 (n=38), SJ5 
Waiguan 外关 (n=36), SP6 Sanyinjiao 三阴交 (n=32), LI15 Jianyu肩髃 (n=27), LI10 
Shousanli 手三里 (n=26), GB34 Yanglingquan 阳陵泉 (n=25), SP9 Yinlingquan 阴陵
泉 (n=24), ST36 Zusanli 足三里 (n=24), LU5 Chize 尺泽 (n=24), PC6 Neiguan 内关 
(n=20), HT1 Jiquan极泉 (n=20), SP10 Xuehai 血海 (n=17), KI6 Zhaohai照海 
(n=17), LV3 Taichong 太冲 (n=15), GB40 Qiuxu 丘墟 (n=15), BL40 Weizhong 委中 
(n=15), GV20 Baihui 百会 (n=12), ST41 Jiexi 解溪 (n=12), BL37 Yinmen 殷门 
(n=11). Some special acupuncture points or treatment zones, such as scalp 
acupuncture, were also reported but not pooled in the calculations. 
6.2.3 Risk-of-bias assessment 
Appropriate methods of sequence generation were reported by only 69 trials among 
the included studies, and only 12 randomised controlled trials were assessed as having 
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a low risk of bias in allocation concealment as they used sealed envelopes; the 
remaining 139 studies were assessed as having an unclear risk of bias in this domain 
due to the lack of information reported.  
As for the blinding of participants, only two studies were judged as having a low risk 
of bias because they adapted sham/placebo acupuncture, while the other 149 studies 
were assessed as having a high risk of bias in this domain since no blinding of 
participants was attempted. All included studies were assessed as having a high risk of 
bias in relation to blinding of intervention providers because no blinding was applied 
to intervention providers; this is particularly challenging for manual acupuncture. 
Seven trials were assessed as having a low risk of bias due to blinding of outcome 
assessors, while the others were judged as having an unclear risk of blinding in this 
area.  
In terms of completeness of outcome data, all included studies were assessed as 
having a low risk of bias. With regards to selective outcome reporting, all included 
trials were assessed as having an unclear risk of bias as none of their research 
protocols were registered or published.  
Table 6.1 summarises the results of the methodological quality assessment of the 
included studies.  
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Table 6.1 Risk of bias assessment results in acupuncture-related systematic 
reviews 
Risk of bias domain Low risk  
No. (%) 
Unclear risk 
No. (%) 
High risk 
No. (%) 
Sequence generation 69 (45.7%) 78 (51.7%) 4 (2.6%) 
Allocation concealment 12 (7.9%) 139 (92.1%) 0 (0%) 
Blinding of participants 2 (1.3%) 0 (0%) 149 (98.7%) 
Blinding of intervention 
providers 
0 (0%) 0 (0%) 151 (100%) 
Blinding of outcome assessors 7 (4.6%) 144 (95.4 %) 0 (0%) 
Incomplete outcome data 151 (100%) 0 (0%) 0 (0%) 
Selective outcome reporting 0 (0%) 151 (100%) 0 (0%) 
6.2.4 Effects of interventions 
As for the primary outcome measure, results for the Ashworth Scale or Modified 
Ashworth Scale were reported by 96 of the included trials. Fifty-five (55) of these 
reported the average scores for the Ashworth Scale or Modified Ashworth Scale and 
the other 41 studies reported the number of participants in each level of the Ashworth 
Scale or Modified Ashworth Scale. For these 41 trials, their results were converted to 
average scores for synthesis and further analysis. Moreover, the results from the 
Ashworth Scale and Modified Ashworth Scale can be categorised into measurement 
of spasticity in the upper extremities, lower extremities and specific joints, as well as 
unspecified regions.  
Considering the availability and diversity of result reporting in the included studies, 
we conducted meta-analyses for the Ashworth Scale and Modified Ashworth Scale in 
the upper limbs, lower limbs and unspecified regions. Results for the Ashworth Scale 
and Modified Ashworth Scale were reported using different grades or scales, 
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including [0, 1, 2, 3, 4, 5] for AS scores and [0, 1, 1.5, 2, 3, 4] or [1, 2, 3, 4, 5, 6] for 
Modified Ashworth Scale scores. Therefore, the synthesis results for these scores are 
pooled and presented with the SMD in the meta-analyses. The effects of acupuncture 
for post-stroke spasticity are summarised below based on the differences between 
interventions and comparisons. 
6.2.4.1 Manual acupuncture vs. sham/placebo needling 
Placebo or sham acupuncture was used in two included trials (Fink et al. 2004; Li et 
al. 2014). One (Fink et al. 2004) used blunt needles on non-acupuncture points, while 
the other one (Li et al. 2014) employed superficial needling with short needles, also 
on non-acupuncture points, as control methods. 
Results for the Modified Ashworth Scale were reported with average scores by the 
two studies, but neither reported specific methods for calculation of Modified 
Ashworth Scale scores. Moreover, suspected data with incorrect calculations were 
observed in one trial (Li et al. 2014), and no between-group differences (MD 0.00, 
95% CI [−0.79, 0.79]) were detected by the other study (Fink et al. 2004), although 
with a relatively small sample size (13 in intervention group vs. 12 in control group). 
In terms of Fugl-Meyer Assessment, one study (Li et al. 2014) reported results for the 
total motor function of the Fugl-Meyer Assessment at the end of treatment and at the 
end of follow-up. No significant between-group differences were detected at the end 
of a four-week treatment phase comparing manual acupuncture with sham 
acupuncture (MD 4.50, 95% CI [−1.33, 10.33]). However, the difference was 
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statistically significant at the end of the follow-up period (MD 11.48, 95% CI [5.68, 
17.28]). 
Similarly, the results for the Barthel Index were not significantly different between 
groups at the end of treatment (MD 0.21, 95% CI [−5.19, 5.61]) as reported by one 
study (Li et al. 2014), but significant between-group differences were obtained at the 
end of follow-ups (MD 10.00, 95% CI [4.54, 15.46]). 
In summary, because of the limited number of participants in the included studies, 
further research is needed to compare the effects of acupuncture with place or sham 
acupuncture for post-stroke spasticity with regards to spasticity severity, motor 
function and activities of daily living. 
6.2.4.2 Acupuncture used as integrative medicine 
The effects of acupuncture added onto routine care were assessed in 75 of the 
included studies (Cao and Qiao 2012; Chen et al. 2015; Chen, Chen et al. 2010; Chen 
2009, 2010; Cheng 2012; Feng, Zhao and Yu 2012; Guo 2015; Han 2010; He et al. 
2011; He et al. 2009; Hu and Peng 2013; Hu 2011; Jia 2009; Jiang et al. 2010; Jiang 
and Zheng 2013; Jin 2010; Jin 2012; Lang 2011; Lang et al. 2013; Lang et al. 2011; 
Li, Luo et al. 2011; Li et al. 2008; Li, Yan and Song 2014; Lu et al. 2013; Luo 2007; 
Ni et al. 2012; Ni et al. 2011; Qiu and Liu 2014; Qu 2014; Shen, Sun and Zhuang 
2010; Song 2012; Sun 2003; Ta, Wu and Ma 2011; Tong et al. 2013; Wang 2013a; 
Wang 2014; Wang, Liu and Wang 2011; Wang and Yao 2014; Wang 2012; Wang 
2013c; Wu 2014; Wu et al. 2009; Wu, Liang et al. 2010; Xi 2012; Xia 2011; Xiao 
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2011; Xu et al. 2015; Xu 2014; Xue 2014; Yan, Huo and Yin 2003; Yin et al. 2013; 
Yang et al. 2014; Yang 2013; Yang, Zhuang and Liu 2013; Yang 2011; Yang et al. 
2008; Zeng et al. 2005; Zhan 2009; Zhang, Zhang and Ma 2011; Zhang 2013; Zhang 
et al. 2007; Zhang and Zheng 2011; Zhang et al. 2012; Zhang et al. 2014; Zhang 
2011; Zhao, Wang and Yang 2013; Zhao 2009; Zhong, Wei and Lu 2014; Zhou et al. 
2013; Zhou 2013; Zhou 2010; Zhu 2003; Zhuang, Xu and Zhuang 2009; Zhuang et al. 
2010). Table 6.2 summarises the synthesis results. Overall, additional benefits could 
be detected in all the outcome measures, including Ashworth Scale or Modified 
Ashworth Scale, Fugl-Meyer Assessment and Barthel Index. 
Data of upper-limb Ashworth Scale or Modified Ashworth Scale scores were reported 
by 8 randomised controlled trials (Chen et al. 2015; Jin 2010; Shen, Sun and Zhuang 
2010; Wang 2014; Wang 2013c; Xiao 2011; Yan, Huo and Yin 2003; Yang et al. 
2008), whose synthesis results demonstrated that adding acupuncture to routine care 
could result in superior effects to routine care alone (SMD −0.56, 95% CI [−0.84, 
−0.28], I2=58%). As for lower-limb Ashworth Scale or Modified Ashworth Scale, 
scores the meta-analysis results synthesised from five trials suggested that the 
combination of acupuncture and routine care could benefit more than routine care 
alone (SMD −0.38, 95% CI [−0.64, −0.13], I2=0%).  
With regards to Ashworth Scale or Modified Ashworth Scale scores in unspecified 
regions, synthesis results of 21 randomised controlled trials (Cao and Qiao 2012; 
Chen, Chen et al. 2010; Chen 2010; Cheng 2012; He et al. 2011; He et al. 2009; Jiang 
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et al. 2010; Jin 2012; Li, Luo et al. 2011; Li et al. 2008; Li, Yan and Song 2014; Luo 
2007; Qiu and Liu 2014; Song 2012; Xu 2014; Zeng et al. 2005; Zhan 2009; Zhang, 
Zhang and Ma 2011; Zhang et al. 2014; Zhang 2011; Zhao, Wang and Yang 2013) 
showed that additional benefits could be received by adding acupuncture to routine 
care compared to routine care alone (SMD −0.48, 95% CI [−0.58, −0.38], I2=0%). 
The total motor scores for the Fugl-Meyer Assessment were reported by 25 included 
studies (Chen, Chen et al. 2010; Chen 2010; Han 2010; He et al. 2009; Hu 2011; Jin 
2012; Lang 2011; Lang et al. 2011; Lu et al. 2013; Qu 2014; Song 2012; Tong et al. 
2013; Wu 2014; Yan, Huo and Yin 2003; Yang 2013; Yang, Zhuang and Liu 2013; 
Zeng et al. 2005; Zhan 2009; Zhang, Zhang and Ma 2011; Zhang et al. 2007; Zhang 
and Zheng 2011; Zhang et al. 2012; Zhang 2011; Zhou 2010; Zhu 2003). The results 
of meta-analysis suggest that the combination of acupuncture and routine care could 
benefit patients more compared to routine care alone (MD 11.98, 95% CI [8.59, 
15.36], I2=95%) at the end of treatment. One randomised controlled trial (Yang 2013) 
also reported the end-of-treatment results, which showed that the combined effects of 
acupuncture and routine care were superior to routine care alone (MD 38.30, 95% CI 
[30.09, 46.51]).  
As for the Fugl-Meyer Assessment in the upper extremities, the synthesis results of 17 
randomised controlled trials (Cao and Qiao 2012; Han 2010; He et al. 2011; Jia 2009; 
Jin 2010; Lang 2011; Lang et al. 2013; Ni et al. 2012; Ni et al. 2011; Qiu and Liu 
2014; Sun 2003; Wang 2013c; Xiao 2011; Yan, Huo and Yin 2003; Zhan 2009; 
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Zhuang, Xu and Zhuang 2009; Zhuang et al. 2010) demonstrated that adding 
acupuncture to routine care could bring additional benefits compared to routine care 
alone (MD 5.59, 95% CI [3.98, 7.20], I2=60%). The results for lower-limb Fugl-
Meyer Assessment were reported by 15 included trials (Chen 2009; He et al. 2011; Jia 
2009; Lang 2011; Lang et al. 2013; Qiu and Liu 2014; Sun 2003; Xi 2012; Yan, Huo 
and Yin 2003; Yang et al. 2014; Yin et al. 2013; Zhan 2009; Zhao 2009; Zhou 2013; 
Zhuang et al. 2010). Similarly, the results of combining acupuncture with routine care 
were significantly better than routine care alone (MD 3.11, 95% CI [2.32, 3.90], 
I2=62%). 
In terms of the Barthel Index, the results of meta-analysis synthesised from 30 
randomised controlled trials (Chen, Chen et al. 2010; Cheng 2012; Han 2010; He et 
al. 2009; Hu 2011; Jia 2009; Jin 2012; Lang 2011; Lang et al. 2013; Lang et al. 2011; 
Li, Luo et al. 2011; Luo 2007; Qiu and Liu 2014; Qu 2014; Song 2012; Wang 2013a; 
Wang 2014; Wang 2012; Wu 2014; Wu et al. 2009; Yin et al. 2013; Zeng et al. 2005; 
Zhang, Zhang and Ma 2011; Zhang et al. 2007; Zhang and Zheng 2011; Zhang et al. 
2012; Zhang et al. 2014; Zhang 2011; Zhao 2009; Zhu 2003) suggested that adding 
acupuncture to routine care could bring additional treatment effects to routine care 
alone (MD 11.35, 95% CI [8.62, 14.08], I2=84%).  
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Table 6.2 Add-on effects of acupuncture for post-stroke spasticity at the end of 
treatment in meta-analyses 
Outcome No. of 
studies 
No. of 
participants 
Effect size (MD/SMD, 95% CI) I2 
(%) 
AS or MAS 
(unspecified) 
21 1,572 SMD −0.48, 95% CI [−0.58, −0.38]* 0 
AS or MAS 
(upper limb) 
8 498 SMD −0.56, 95% CI [−0.84, −0.28]* 58 
AS or MAS 
(lower limb) 
5 245 SMD −0.38, 95% CI [−0.64, −0.13]* 0 
FMA (motor) 25 2,013 MD 11.98, 95% CI [8.59, 15.36]* 95 
FMA (upper 
limb) 
17 1,298 MD 5.59, 95% CI [3.98, 7.20]* 60 
FMA (lower 
limb) 
15 1,156 MD 3.11, 95% CI [2.32, 3.90]* 62 
BI 30 2,326 MD 11.35, 95% CI [8.62, 14.08]* 84 
Notes: AS, Ashworth Scale; BI, Barthel Index; FMA, Fugl-Meyer Assessment; I2, chi-squared 
test to estimate heterogeneity; MAS, Modified Ashworth Scale; MD, mean difference; SMD, 
standardised mean difference; *statistically significant. 
6.2.4.3 Frequently reported acupuncture points in meta-analyses showing favourable 
effect 
Based on the information provided in the included randomised controlled trials, the 
most frequently reported acupuncture points showing favourable effects of 
acupuncture or integrative use of acupuncture in combination with routine care were 
calculated and are summarised in Table 6.3, regardless of specific comparisons. 
Acupuncture points are grouped based on outcome measures, including Ashworth 
Scale or Modified Ashworth Scale, Fugl-Meyer Assessment and Barthel Index.  
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Table 6.3 Frequently reported acupuncture points in meta-analyses showing 
favourable effects 
Outcome 
measure 
No. of meta-
analyses 
No. of 
studies 
Acupuncture point No. of 
studies using 
point 
Ashworth 
Scale or 
Modified 
Ashworth 
Scale 
4 34 LI4 Hegu 合谷 20 
SP6 Sanyinjiao 三阴交 19 
SJ5 Waiguan 外关 15 
LI11 Quchi 曲池 14 
ST36 Zusanli 足三里 12 
LU5 Chize 尺泽 11 
SP10 Xuehai 血海 11 
LV3 Taichong 太冲 10 
LI10 Shousanli 手三里 9 
SP9 Yinlingquan 阴陵泉 9 
Fugl-
Meyer 
Assessment 
5 54 SP6 Sanyinjiao 三阴交 19 
LI4 Hegu 合谷 18 
SJ5 Waiguan 外关 18 
LI11 Quchi 曲池 18 
LU5 Chize 尺泽 15 
LV3 Taichong 太冲 13 
SP9 Yinlingquan 阴陵泉 13 
PC6 Neiguan 内关 12 
HT1 Jiquan 极泉 12 
ST36 Zusanli 足三里 11 
Barthel 
Index 
1 30 SP6 Sanyinjiao 三阴交 16 
LI4 Hegu 合谷 14 
LI11 Quchi 曲池 12 
SP9 Yinlingquan 阴陵泉 11 
SJ5 Waiguan 外关 10 
LU5 Chize 尺泽 10 
LI10 Shousanli 手三里 8 
ST36 Zusanli 足三里 8 
SP10 Xuehai 血海 8 
HT1 Jiquan 极泉 8 
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As can be seen in the above table, seven acupuncture points were repeated in lists of 
all three outcome measures. They were: LI4 Hegu 合谷, SP6 Sanyinjiao 三阴交, SJ5 
Waiguan 外关, LI11 Quchi 曲池, ST36 Zusanli 足三里, LU5 Chize 尺泽, SP9 
Yinlingquan 阴陵泉. 
Additionally, scalp acupuncture and the Jin San Zhen (靳三针) technique were also 
observed to have positive effects based on the results of the meta-analyses. The most 
frequently reported points for Jin San Zhen (靳三针) included three points in the 
temporal area 颞三针 (n=15), three points on the upper limb 上肢挛三针 (n=5) and 
three points on the lower limb 下肢挛三针 (n=5). 
6.2.4.4 Acupressure for post-stroke spasticity 
Three trials evaluated the add-on effects of acupressure in combination with routine 
care compared to routine care alone for post-stroke spasticity (Li and Liu 2010; Ma et 
al. 2013; Pan et al. 2009). Superior effects were observed in terms of the upper-limb 
Modified Ashworth Scale (MD −0.37, 95% CI [−0.65, −0.09]), although this was 
reported by only one study (Ma et al. 2013). Another trial (Li and Liu 2010) reported 
additional benefits of adding acupressure to routine care compared with routine care 
alone for the Modified Ashworth Scale in unspecified regions (MD −0.80, 95% CI 
[−1.30, −0.30]).  
The total motor scores for the Fugl-Meyer Assessment were reported by two studies 
(Li and Liu 2010; Pan et al. 2009), their synthesis results showing that there were 
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superior effects with a combined therapy of acupressure and routine care compared to 
routine care alone (MD 18.98, 95% CI [1.85, 36.11], I2=92%).  
In terms of the Barthel Index, data from one study (Pan et al. 2009) suggested that 
patients with post-stroke spasticity would receive greater benefits from adding 
acupressure to routine care compared to routine care alone (MD 6.15, 95% CI [0.80, 
11.50]).  
None of these studies addressed the safety issues of acupressure, as none provided 
information on adverse events. 
6.2.4.5 Moxibustion for post-stroke spasticity 
There were seven studies (Chi et al. 2013; Zhou and Shi 2014; Feng et al. 2014; Huo 
2014; Huo et al. 2013; Li et al. 2013; Xu et al. 2013) including 529 participants 
evaluating the add-on effects of moxibustion therapy to routine care compared with 
routine care alone for post-stroke spasticity. Five trials (Huo 2014; Huo et al. 2013; Li 
et al. 2013; Xu et al. 2013; Feng et al. 2014) were two-arm studies and the other two 
(Zhou and Shi 2014; Chi et al. 2013) were three-armed studies whose treatment arms 
were routine care vs. moxibustion vs. moxibustion plus routine care. Synthesis 
therapeutic effects are presented below and summarised in Table 6.4. 
For the Modified Ashworth Scale, additional benefits were observed in terms of 
upper-limb Modified Ashworth Scale (SMD −0.38, 95% CI [−0.72, −0.04], I2=0%) 
(Huo et al. 2013; Huo 2014) and Modified Ashworth Scale scores in unspecified 
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regions (SMD −0.74, 95% CI [−1.15, −0.34], I2=0%) (Feng et al. 2014; Xu et al. 
2013) with moxibustion added to routine care compared to routine care alone. 
For the Fugl-Meyer Assessment, meta-analysis was applicable only for the total motor 
scores for the Fugl-Meyer Assessment in three randomised controlled trials (Feng et 
al. 2014; Li et al. 2013; Xu et al. 2013). Superior add-on effects of moxibustion to 
routine care could be detected compared to routine care alone (MD 9.32, 95% CI 
[7.45, 11.19], I2=0%). In terms of upper-limb Fugl-Meyer Assessment (MD 13.51, 
95% CI [12.72, 14.30]) and low-limb Fugl-Meyer Assessment (MD 2.97, 95% CI 
[2.61, 3.33]), additional benefits of moxibustion were also detected but only by a 
single study (Huo 2014). 
For the Barthel Index, meta-analysis of six studies (Chi et al. 2013; Zhou and Shi 
2014; Feng et al. 2014; Huo 2014; Huo et al. 2013; Xu et al. 2013) suggests that the 
combination of moxibustion and routine care demonstrated better effects than routine 
care alone (MD 14.04, 95% CI [10.90, 17.18], I2=89%). Moreover, meta-analysis 
results for two trials (Chi et al. 2013; Zhou and Shi 2014) show that positive results 
were also observed at the end of the follow-up periods (MD 14.94, 95% CI [9.08, 
20.81], I2=44%). 
As above, no information on adverse events was reported by any of the included 
studies evaluating the add-on effects of moxibustion for post-stroke spasticity. 
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Table 6.4 Add-on effects of moxibustion for post-stroke spasticity at the end of 
treatment in meta-analyses 
Outcome No. of 
studies 
No. of 
participants 
Effect size (MD/SMD, 95% CI) I2 
(%) 
MAS 
(unspecified) 
2 100 SMD −0.74, 95% CI [−1.15, −0.34]* 0 
MAS (upper 
limb) 
2 136 SMD −0.38, 95% CI [−0.72, −0.04]* 0 
FMA (motor) 3 213 MD 9.32, 95% CI [7.45, 11.19]* 0 
BI 6 356 MD 14.04, 95% CI [10.90, 17.18]* 89 
Notes: AS, Ashworth Scale; BI, Barthel Index; FMA, Fugl-Meyer Assessment; I2, chi-squared 
test to estimate heterogeneity; MAS, Modified Ashworth Scale; MD, mean difference; SMD, 
standardised mean difference; *statistically significant. 
6.2.5 Safety of acupuncture 
Only seven included randomised controlled trials (Ha et al. 2013; Wang 2014; Wu 
2014; Xue 2014; Zhang, Zhang and Ma 2011; Zhang 2006; Zhuang, Xu and Zhuang 
2009) using manual acupuncture addressed safety issue. Six events of temporary 
nerve pain or numbness and oedema in both intervention and control groups were 
reported in one study (Zhang, Zhang and Ma 2011); however, these events were 
considered to be related to nerve blocking therapy rather than of acupuncture. It 
should be noted that another trial (Zhuang, Xu and Zhuang 2009) reported one case of 
discomfort related to hematoma on the head caused by scalp acupuncture, without 
detailed information being provided. Therefore, particular caution should be paid to 
the safety of scalp acupuncture in future studies. The other five trials reported either 
that there were no adverse events observed in any of the treatment groups (Ha et al. 
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2013; Wang 2014; Wu 2014; Zhang 2006) or that there were no severe adverse events 
(Xue 2014). 
6.3 Adjunct electro-acupuncture for post-stroke spasticity 
Although the results of three published systematic reviews with meta-analyses (Lim et 
al. 2015; Park et al. 2014; Qi et al. 2009) of acupuncture for post-stroke spasticity 
suggested positive add-on effects of electro-acupuncture, their results cannot be 
confirmed, partly because of the small number of included studies. Additionally, there 
is no published systematic review focusing specifically on the effects of adjunct 
electro-acupuncture for post-stroke spasticity. Compared with the published 
systematic reviews, we conducted a more comprehensive search of five English and 
four Chinese databases and updated the search time to September 2016, with the aim 
of evaluating the add-on effects and safety of adjunct electro-acupuncture for post-
stroke spasticity. 
To carry out this evaluation, we conducted a systematic review following the 
methodology similar to that in Chapter 5 and updated the search to September 2016. 
Included trials compared any type of routine care combined with electro-acupuncture, 
to the same routine care without electro-acupuncture (or with placebo/sham/pseudo 
electro-acupuncture). The PRISMA checklist for electro-acupuncture systematic 
review is attached as an appendix (Appendix 11). 
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6.3.1 Search results 
Our search identified 31,833 studies (Figure 6.2). Full texts of 84 possibly relevant 
papers were obtained, with 22 clinical trials (Yu and Zhang 2007; Liu, Li and Ma 
2016; Fan et al. 2015; Cheng et al. 2015; Zhang, Lei et al. 2015; Huang et al. 2016; 
Yang, Lin and Yu 2007; Yan et al. 2010; Xue, Li and Huo 2008; Xing et al. 2015; Wu 
2011; Wang, Guan and Ma 2007; Lu 2003; Lu et al. 2010; Lu 2011; Li et al. 2007; Li, 
Yue et al. 2011; Guo 2003; Guo, Yang and Lu 2015; Cai et al. 2011; Yao, Zeng and 
Zhou 2012; Wu et al. 2008) meeting the selection criteria to be included in meta-
analysis.  
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Figure 6.2 PRISMA Flow Chart of electro-acupuncture systematic review 
Notes: MAS, Modified Ashworth Scale; RCT, randomised controlled trial. 
6.3.2 Descriptive analysis 
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All the included studies were conducted in China from 2003 to 2016 involving 1,425 
participants (Table 6.5). The sample size of the included studies ranged from 37 to 
132, with the participants’ average age being 65 years. Participants’ baseline 
characteristics varied among the included studies. Eight of them only included 
patients with a first stroke. The post-stroke period ranged from one day to four years. 
For spasticity severity at baseline, Modified Ashworth Scale scores ≥ 1 were reported 
in 11 studies. As for the selection of acupuncture points, most of the reported 
acupuncture points were located at the posterior aspect of the arm and forearm and the 
posterior and lateral aspects of the thigh and leg. On average, eight points were used 
for electro-acupuncture among the studies; however, the rationale for selecting these 
acupuncture points was not stated in any of the included studies.  
Treatment frequency was reported to be once or twice a day for a period of three to 12 
weeks. Diverse comprehensive rehabilitation programs, including Bobath therapy and 
the Rood approach, were reported as co-interventions in the included trials 
(supplemental table S1, available online only at www.archives-pmr.org). Seventeen 
(17) of the included studies reported the rehabilitation duration for each treatment 
section, which ranged from 20 to 120 minutes, with a treatment period of three to 12 
weeks (Table 6.6). None of the included studies used pseudo-electro-acupuncture 
(manual acupuncture with pseudo-electrical stimulation) as the control. The Modified 
Ashworth Scale was the most frequently reported outcome measure (22 studies), 
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followed by the Barthel Index (11 studies) and the Fugl-Meyer Assessment (10 
studies) (see Table 6.5). 
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Table 6.5 Basic characteristics of the included studies in electro-acupuncture systematic review 
Author, 
year 
Sample 
size (I/C) 
Age 
(years) 
Gender 
(% male) 
Stroke type First onset of 
stroke 
Spasticity 
severity 
Time from stroke 
onset (days) 
Comparisons  
Cai 2011 60 (30/30) 53–79 53.3 Not mentioned Not 
mentioned 
Not mentioned ≥ 30 EA + Rehab vs. 
Rehab 
Cheng 2015 37 (18/19) 40–70 51.4 Cerebral 
infarction & 
haemorrhage 
Not 
mentioned 
MAS: 1–3 Not mentioned EA + Rehab vs. 
Rehab 
Fan 2015 40 (20/20) 18–80 62.5 Cerebral 
infarction & 
haemorrhage 
Yes MAS: 0–4 0–60 EA + Rehab vs. 
Rehab 
Guo 2003 57 (29/28) 40–79 70.2 Cerebral 
infarction & 
haemorrhage 
Yes Not mentioned 0–21 EA + Rehab vs. 
Rehab 
Guo 2015 58 (28/30) 32–73 63.8 Cerebral 
infarction 
Yes Not mentioned < 7 EA + Rehab vs. 
Rehab 
Huang 2016 68 (33/35) 34–80 53.0 Not mentioned No MAS ≥ 1 14–147 EA + Rehab vs. 
Rehab 
Li 2007 58 (29/29) 53–75 60.3 Not mentioned Not 
mentioned 
MAS > 2 60–180 EA + Rehab + 
Baclofen vs. Rehab 
+ Baclofen 
Li H 2011 60 (30/30) 35–69 60.0 Not mentioned Not 
mentioned 
Not mentioned 10–90 EA + Rehab vs. 
Rehab 
Liu 2016 80 (40/40) 35–75 41.3 Cerebral 
infarction & 
haemorrhage 
Yes Not mentioned 20–60 EA + Rehab vs. 
Rehab 
Lu 2003 40 (20/20) 55–74 62.5 Not mentioned Not 
mentioned 
Not mentioned 0–180 EA + Rehab vs. 
Rehab 
Lu 2010 90 
(30/30/30) 
52–80 60.0 Not mentioned Not 
mentioned 
AS:1–3 
Brunstrom: 2–
3 
14–60 EA1 + Rehab vs. 
Rehab vs. EA2 + 
Rehab 
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Author, 
year 
Sample 
size (I/C) 
Age 
(years) 
Gender 
(% male) 
Stroke type First onset of 
stroke 
Spasticity 
severity 
Time from stroke 
onset (days) 
Comparisons  
Lu 2011 60 (30/30) 40–75 71.7 Cerebral 
infarction & 
haemorrhage 
Yes Not mentioned 14–180 EA + Rehab vs. 
Rehab 
Wang 2007 63 (31/32) 18–75 Not 
mentioned 
Cerebral 
infarction & 
haemorrhage 
Not 
mentioned 
Not mentioned Not mentioned EA + Rehab + 
Baclofen vs. Rehab 
+ Baclofen 
Wu 2008 60 (30/30) 46–75 61.7 Cerebral 
infarction & 
haemorrhage 
Yes Not mentioned 30–1461 EA + Rehab vs. 
Rehab 
Wu 2011 60 (30/30) 41–76 55.0 Cerebral 
infarction & 
haemorrhage 
Not 
mentioned 
MAS > 0 > 15 EA + Rehab vs. 
Rehab 
Xing 2015 60 (30/30) 40–76 61.7 Cerebra 
infarction 
Not 
mentioned 
MAS:1–4 14–180 EA + Rehab vs. 
Rehab 
Xue 2008 56 (28/28) N/A 82.1 Not mentioned Yes Not mentioned Not mentioned EA + Rehab vs. 
Rehab 
Yan 2010 81 (40/41) 40–75 49.4 Cerebral 
infarction 
Not 
mentioned 
MAS ≥ 1 Not mentioned EA + Rehab vs. 
Rehab 
Yang 2007 80 (42/38) < 75 62.5 Cerebral 
infarction 
Yes Not mentioned 14–90 EA + Rehab vs. 
Rehab 
Yao 2012 132 (66/66) 58–69 59.1 Cerebral 
infarction & 
haemorrhage 
Not 
mentioned 
MAS ≥ 1 ≤ 90 EA + Rehab vs. 
Rehab 
Yu 2007 60 (30/30) ≤ 80 60.0 Cerebral 
infarction & 
haemorrhage 
Not 
mentioned. 
MAS ≥ 1 30–120 EA + Rehab vs. 
Rehab 
Zhang 2015 65 (34/31) 46–75 63.1 Cerebral 
infarction & 
haemorrhage 
Not 
mentioned 
MAS: 1–4 30–365 EA + Rehab vs. 
Rehab 
 
171 
 
Author, 
year 
Acupuncture points  No. of 
electro-
stimulated 
acupuncture 
points 
Whether 
‘de qi 得
气’ was 
achieved 
Electrical 
stimulation 
frequency 
(Hz) 
Needle 
retention 
time 
(min)  
Treatment 
frequency 
(times/ day; 
days/ week) 
Length 
of 
treatme
nt 
Outcome 
measures  
Cai 2011 LI11, LI4, LI15, SJ5, GB30, 
GB31, ST36, GB39, BL60, 
DU20 
10 Yes 10 30 1 time/day; 
5 days/week 
4 weeks MAS, MBI, FMA, 
RSB 
Cheng 2015 Scalp acupuncture points 
(not specified) 
2 
(unspecified) 
Yes 60–80 20 1 time/day; 
6 days/week 
6 weeks MAS, FMA, RSB 
Fan 2015 HT1, LI15, LU5, PC7, SJ4, 
SJ10, BL62, KI6, LR8, 
SP10, ST34, ST41 
7 Yes Not 
mentioned 
30 1 time/day; 
7 days/week 
30 days MAS, FMA, BBS 
Guo 2003 Scalp acupuncture points 
(details unavailable), LI4, 
LR3, ST36, DU20 
Not available Yes 30 30  1 time/day; 
5 days/week 
4 weeks MAS, MBI, FMA, 
Clinical Nerve 
Function 
Limitation Score, 
secondary 
complications 
Guo 2015 LI10, LI14, LI15, SJ5 4  Yes 2 30 1 time/day; 
6 days/week 
3 weeks MAS, FMA 
Huang 2016 LI4, LI10, LI15, SJ5, SJ10, 
SJ14, GB34, SP9, SP10, 
EX-LE28 
10  Not 
mentione
d 
2 Not 
mentione
d 
1 time/day; 
6 days/week 
4 weeks MAS, BI, RSB 
Li 2007 LI4, LI11, LI14, LI15, SJ5, 
BL36, BL37, BL40, ST36, 
ST40, LR3 
11 Not 
mentione
d 
1–10 25 1 time/day; 
7 days/week 
8 weeks MAS, BI 
Li H 2011 ST36, ST37, ST39, GB34, 
BL62, KI6, GB41 
7 Yes Not 
mentioned 
30 1 time/day; 
7 days/week 
30 days MAS, MMT, Carr-
Shepherd walking 
and balance scores 
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Author, 
year 
Acupuncture points  No. of 
electro-
stimulated 
acupuncture 
points 
Whether 
‘de qi 得
气’ was 
achieved 
Electrical 
stimulation 
frequency 
(Hz) 
Needle 
retention 
time 
(min)  
Treatment 
frequency 
(times/ day; 
days/ week) 
Length 
of 
treatme
nt 
Outcome 
measures  
Liu 2016 LI10, LI11, SJ5, SJ8, SJ11, 
SJ12, SJ13, BL37, BL40, 
GB34, GB39 
4 Yes ‘Low 
frequency’ 
(not 
specified) 
30 1 time/day; 
7 days/week 
30 days MAS, FMA, BI 
Lu 2003 ST36, GB34, BL62, ST41, 
KI3, KI6, BL57, LR3 
4 
(unspecified) 
Yes 20–30 30 1 time/day; 
7 days/week 
12 
weeks 
MAS, MMT, Carr-
Shepherd walking 
and balance scores 
Lu 2010 DU16, DU14, DU4, DU3, 
SJ13, SJ11, LI10, SJ5, EX-
UE8, SJ3, BL36, BL37, 
GB34, ST40 
14 Not 
mentione
d 
2 30 1 time/ day; 
5 days/ week 
4 weeks MAS 
Lu 2011 meridian sinew nodal points 
of limbs (details 
unavailable) 
Not available Yes Not 
mentioned 
30 2 times/ day; 
6 days/ week 
4 weeks MAS, FMA, BI 
Wang 2007 LI15, SI9, EX-UE12, LI14, 
SJ10, LI10, SJ5, ST31, 
ST32, SP10, GB34, ST40, 
GB39 
13 Yes 100 40 1 time/day; 
7 days/week 
4 weeks MAS 
Wu 2008 LI10, SJ5, SJ10, EX-UE9, 
BL40, BL57, GB34, LR3, 
ST31, ST36, EX-LE28 
Not available Not 
mentione
d 
Not 
mentioned 
30 1 time/ day; 
6 days/ week 
4 weeks MAS, BI 
Wu 2011 DU20, DU24, BG13, EX-
HN1, GB20, LR3, KI6, SP9, 
LI15, LI11, LI10, SJ5, LI4, 
ST32, ST34, ST36, SP6, 
BL62, EX-LE28 
Not available Yes Not 
mentioned 
30 1 time/day; 
7 days/week 
12 
weeks 
MAS, FMA, BI 
Xing 2015 LI10, LI11, LI14, LI15, LI4, 
SJ5, SP10, GB34, ST40, 
SP6, ST41 
11 Not 
mentione
d 
Not 
mentioned 
30 1 time/day; 
7 days/week 
30 days MAS, CSI 
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Author, 
year 
Acupuncture points  No. of 
electro-
stimulated 
acupuncture 
points 
Whether 
‘de qi 得
气’ was 
achieved 
Electrical 
stimulation 
frequency 
(Hz) 
Needle 
retention 
time 
(min)  
Treatment 
frequency 
(times/ day;  
days/ week) 
Length 
of 
treatme
nt 
Outcome 
measures  
Xue 2008 LI11, LI15, LI10, LI4, 
SP10, SP9, SP6, KI3 
8 Not 
mentione
d 
10–100 30 1 time/day; 
6 days/week 
4 weeks MAS, FMA 
Yan 2010 PC2, EX-UE21, LU5, PC3, 
HT3, LU6, LU7, HT5, LI4, 
SI3, ST32, ST34, ST36, 
GB34, SP10, SP9, SP5, 
GB40, SP6, GB39 
4 Yes 100 30  1 time/day 
5 days/week 
6 weeks MAS, FMA, MBI 
Yang 2007 Scalp acupuncture points 
(not specified) 
Not available Not 
mentione
d 
‘High 
frequency’ 
(unspecifie
d) 
20 1 time/day; 
6 days/week 
4 weeks MAS 
Yao 2012 LI11, SJ5, SJ6, LI4, LI10, 
BL37, BL40, ST36, SP6, 
ST40, LR3 
Not available Yes Not 
mentioned 
20 1 time/day; 
7 days/week 
30 days MAS, BI 
Yu 2007 LI15, LI11, LI10, SJ5, LI4, 
GB31, ST34, ST36, GB34, 
ST40, GB39, SP6, SP9 
4 
(unspecified) 
Not 
mentione
d 
1 Not 
mentione
d 
1 time/day; 
6 days/week 
30 days MAS 
Zhang 2015 LI4, LI11, LI15, SJ5, BL40, 
BL57, GB40, SP6, SP9, 
ST41 
8 or 10 Yes Not 
mentioned 
30 1 time/day; 
7 days/week 
4 weeks MAS, BI, Motor 
Assessment Scale 
Notes: AS, Ashworth Scale; BI, Barthel Index; BBS, Berg Balance Scale; C, controlled group; CSI, Composite spasticity index; EA, electro-
acupuncture; FMA, Fugl-Meyer Assessment; I, intervention group; MAS, Modified Ashworth Scale; MD, mean difference; min, minutes; Rehab, 
rehabilitation; RSB, recovery stage of Brunnstrom; SMD, standardised mean difference.  
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Table 6.6 Summary of rehabilitation treatments in electro-acupuncture 
systematic review 
Author, year Rehabilitation 
duration in each 
treatment section 
Rehabilitation frequency Rehabilitation 
period times/day days/week 
Cai 2011 40 minutes 1 7 4 weeks 
Cheng 2015 60 minutes Not available Not available 6 weeks 
Fan 2015 120 minutes 1 5 30 days 
Guo 2003 40 minutes 1 5 4 weeks 
Guo 2015 Not available Not available Not available 3 weeks 
Huang 2016 60 minutes 1 6 4 weeks 
Li 2007 45 minutes 1 7 8 weeks 
Li H 2011 Not available Not available Not available 30 days 
Liu 2016 30–45 minutes 1 7 30 days 
Lu 2003 30 minutes 1 7 12 weeks 
Lu 2010 Not available Not available Not available 4 weeks 
Lu 2011 30 minutes 1 6 4 weeks 
Wang 2007 Not available Not available Not available 4 weeks 
Wu 2008 30 minutes 1 6 4 weeks 
Wu 2011 30 minutes 1 7 12 weeks 
Xing 2015 30 minutes 1 5 30 days 
Xue 2008 45 minutes 1 6 4 weeks 
Yan 2010 60 minutes 1 5 6 weeks 
Yang 2007 45 minutes 1 6 4 weeks 
Yao 2012 20–30 minutes 1 7 30 days 
Yu 2007 Not available 2 6 30 days 
Zhang 2015 30 minutes 1 7 4 weeks 
6.3.3 Risk-of-bias assessment 
Nine studies (Yan et al. 2010; Zhang, Lei et al. 2015; Wang, Guan and Ma 2007; Lu et 
al. 2010; Guo, Yang and Lu 2015; Liu, Li and Ma 2016; Huang et al. 2016; Cai et al. 
2011; Cheng et al. 2015) used adequate random sequence generation and were 
assessed as having a low risk of bias; the others were assessed as having an unclear 
risk of bias in this domain because of a lack of information. None of the included 
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studies described details of allocation concealment; therefore all were assessed as 
having an unclear risk of bias. None of the included studies attempted to achieve 
participant and intervention providers’ blinding, but three trials (Lu et al. 2010; Lu 
2003; Li, Yue et al. 2011) reported blinding of assessors. All but two trials (Wang, 
Guan and Ma 2007; Huang et al. 2016) were assessed as having a low risk of bias in 
incomplete outcome data. These two trials were assessed as having an unclear risk of 
bias because they did not provide reasons for the drop-outs and intention-to-treat 
(ITT) analysis was not undertaken. Information on selective reporting could not be 
assessed in all studies because they lacked research protocols. Therefore, the studies 
were assessed as having an unclear risk of bias, except for one study (Fan et al. 2015), 
which was assessed as having a high risk of bias because it did not report the results 
for the Composite Spasticity Scale and Gross Motor Function Measure. Baseline 
scores were presented in all studies except one (Xue, Li and Huo 2008); thus, this 
study was assessed as having a high risk of bias in relation to ‘‘other bias’’. 
Details of the risk-of-bias assessment are presented in Figure 6.3. 
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Figure 6.3 Summary of risk-of-bias assessment in electro-acupuncture systematic 
review 
Notes: The green, yellow and red circles indicate the results of the risk-of-bias assessment 
were low, unclear and high, respectively. 
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6.3.4 Effects of interventions 
Change in Modified Ashworth Scale 
Thirteen of the included trials (Cai et al. 2011; Guo 2003; Guo, Yang and Lu 2015; Lu 
2011; Wang, Guan and Ma 2007; Wu 2011; Xing et al. 2015; Yang, Lin and Yu 2007; 
Fan et al. 2015; Huang et al. 2016; Liu, Li and Ma 2016; Zhang, Lei et al. 2015; Yao, 
Zeng and Zhou 2012) reported Modified Ashworth Scale scores without specifying 
which joints or regions were measured. A significant between-group difference for the 
Modified Ashworth Scale was seen with high heterogeneity when comparing electro-
acupuncture plus routine care to routine care alone (SMD −1.16, 95% CI [−1.70, 
−0.61], I²=93%) (Figure 6.4, Table 6.7). 
Similar results were found in the meta-analysis for the Modified Ashworth Scale in 
the upper and lower limbs comparing electro-acupuncture plus routine care to routine 
care alone (4 studies (Li et al. 2007; Cheng et al. 2015; Xue, Li and Huo 2008; Yu and 
Zhang 2007), SMD −0.57, 95% CI [−0.84, −0.29], I²=0% and five studies (Li, Yue et 
al. 2011; Li et al. 2007; Lu 2003; Yu and Zhang 2007; Wu et al. 2008), SMD −0.88, 
95% CI [−1.42, −0.35], I²=78% respectively) (Figure 6.3).  
In addition, two studies (Lu et al. 2010; Yan et al. 2010) measured the Modified 
Ashworth Scale for different joints and reported the results separately, so their data 
were not pooled. 
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Figure 6.4 Forest plot of (Modified) Ashworth Scale in electro-acupuncture 
systematic review 
Notes: CI, confidence interval; EA, Electro-acupuncture, MAS, Modified Ashworth Scale; 
PSS, post-stroke spasticity; RC, routine care; SD, standard deviation; Std., standardised.
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Table 6.7 Summary of main results and subgroup analyses of electro-acupuncture systematic review 
Meta-analysis groups MAS 
(unspecified 
region) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants of 
I/C groups)) 
MAS (upper 
limb) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants 
of I/C 
groups)) 
MAS (lower 
limb) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants 
of I/C 
groups)) 
FMA (motor 
function) 
(MD, 95% 
CI, I2, No. of 
studies (No. 
of 
participants 
of I/C 
groups)) 
FMA (upper 
limb) (MD, 
95% CI, I2, 
No. of studies 
(No. of 
participants of 
I/C groups)) 
FMA (lower 
limb) (MD, 
95% CI, I2, 
No. of 
studies (No. 
of 
participants 
of I/C 
groups)) 
Barthel Index 
(MD, 95% CI, 
I2, No. of 
studies (No. of 
participants of 
I/C groups)) 
All studies −1.16 [−1.70, 
−0.61], I²=93%, 
13 (442/438) 
−0.57 [−0.84, 
−0.29], I²=0%, 
4 (105/106) 
−0.88 [−1.42, 
−0.35], 
I²=78%, 5 
(137/137) 
10.6 [8.67, 
12.53], I²=0%, 
4 (129/128) 
13.32 [−6.53, 
33.17], 
I²=100%, 4 
(116/120) 
4.42 [0.06, 
8.78], 
I²=90%, 3 
(88/89) 
6.85 [3.64, 
10.05], I²=80%, 
7 (262/260) 
Spasticity 
severity 
MAS ≥ 1 −1.24 [−2.43, 
−0.04], I²=96%, 
5 (183/182) 
Not available −0.43 [−0.79, 
−0.06], 
I²=0%, 2 
(59/59) 
Not available 4.43 [2.44, 
6.43], I²=0%, 2 
(58/60) 
Not 
available 
5.07 [1.23, 
8.91], I²=79%, 4 
(163/162) 
MAS 
unspecified 
−1.11 [−1.69, 
−0.54], I²=89%, 
8 (259/256) 
−1.22 [−1.99, 
−0.45], 
I²=79%, 3 
(78/78) 
21.86 [−6.29, 
50.00], 
I²=100%, 2 
(58/60) 
9.42 [7.30, 
11.55], I²=0%, 3 
(99/98) 
First onset 
of stroke 
Yes −0.48 [−0.90, 
−0.06], I²=75%, 
6 (189/186) 
Not available Not available Not available Not available Not 
available 
9.42 [7.30, 
11.55], I²=0%, 3 
(99/98) 
Unspecified −1.80 [−2.77, 
−0.83], I²=95%, 
7 (253/252) 
5.07 [1.23, 
8.91], I²=79%, 4 
(163/162) 
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Meta-analysis groups MAS 
(unspecified 
region) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants of 
I/C groups)) 
MAS (upper 
limb) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants 
of I/C 
groups)) 
MAS (lower 
limb) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants 
of I/C 
groups)) 
FMA (motor 
function) 
(MD, 95% 
CI, I2, No. of 
studies (No. 
of 
participants 
of I/C 
groups)) 
FMA (upper 
limb) (MD, 
95% CI, I2, 
No. of studies 
(No. of 
participants of 
I/C groups)) 
FMA (lower 
limb) (MD, 
95% CI, I2, 
No. of 
studies (No. 
of 
participants 
of I/C 
groups)) 
Barthel Index 
(MD, 95% CI, 
I2, No. of 
studies (No. of 
participants of 
I/C groups)) 
Number of 
acupuncture 
points 
≥ 10 −1.45 [−2.22, 
−0.68], I²=94%, 
9 (313/312) 
Not available −0.43 [−0.79, 
−0.06], 
I²=0%, 2 
(59/59) 
Not available Not available Not 
available 
6.05 [2.38, 
9.72], I²=84%, 5 
(203/202) 
< 10 & 
unspecified 
−0.56 [−1.09, 
−0.03], I²=77%, 
4 (129/126) 
−1.22 [−1.99, 
−0.45], 
I²=79%, 3 
(78/78) 
9.93 [3.19, 
16.68], I²=46%, 
2 (59/58) 
EA 
stimulation 
time 
< 30 min −1.23 [−2.54, 
0.08], I²=96%, 
3 (141/139) 
Not available Not available Not available Not available Not 
available 
3.83 [1.59, 
6.07], I²=2%, 2 
(99/101) 
≥ 30 min −1.14 [−1.79, 
−0.50], I²=92%, 
10 (301/299) 
8.33 [3.97, 
12.68], I²=80%, 
5 (163/159) 
Length of 
treatment 
period 
> 4 weeks −1.47 [−2.75, 
−0.18], I²=96%, 
5 (186/186) 
Not available Not available Not available Not available Not 
available 
7.92 [2.73, 
13.10], I²=87%, 
3 (136/136) 
≤ 4 weeks −0.99 [−1.51, 
−0.47], I²=87%, 
8 (256/252) 
5.79 [1.65, 
9.94], I²=67%, 4 
(126/124) 
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Meta-analysis groups MAS 
(unspecified 
region) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants of 
I/C groups)) 
MAS (upper 
limb) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants 
of I/C 
groups)) 
MAS (lower 
limb) (SMD, 
95% CI, I2, 
No. of studies 
(No. of 
participants 
of I/C 
groups)) 
FMA (motor 
function) 
(MD, 95% 
CI, I2, No. of 
studies (No. 
of 
participants 
of I/C 
groups)) 
FMA (upper 
limb) (MD, 
95% CI, I2, 
No. of studies 
(No. of 
participants of 
I/C groups)) 
FMA (lower 
limb) (MD, 
95% CI, I2, 
No. of 
studies (No. 
of 
participants 
of I/C 
groups)) 
Barthel Index 
(MD, 95% CI, 
I2, No. of 
studies (No. of 
participants of 
I/C groups)) 
Post-stroke 
period 
≤ 180 days −0.95 [−1.58, 
−0.31], I²=93%, 
9 (318/317) 
Not available Not available Not available 6.93 [5.01, 
8.85], I²=0%, 2 
(68/71) 
Not 
available 
6.97 [3.56, 
10.37] , I²=74%, 
5 (198/199) 
> 180 days −1.64 [−2.70, 
−0.59], I²=92%, 
4(124/121) 
20.06 [−11.61, 
51.73], 
I²=100%, 2 
(48/49) 
6.62 [−3.79, 
17.02] , I²=92%, 
2 (64/61) 
Notes: BI, Barthel Index; CI, confidence interval; EA, electro-acupuncture; FMA, Fugl-Meyer Assessment; I2, chi-squared test to estimate 
heterogeneity; I/C, intervention group/ control group; MAS, Modified Ashworth Scale; MD, mean difference; SMD, standardised mean difference.
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Subgroup analyses were conducted based on: 1) spasticity severity as measured by the 
Modified Ashworth Scale; (2) whether this was the participant’s first stroke; (3) the 
number of acupuncture points; (4) Electro-acupuncture stimulation time; (5) the 
length of the treatment period; and (6) the length of the post-stroke period. Some of 
the predefined subgroup analyses could not be conducted because of the limited 
number of included studies (Table 6.7). 
Of note, in the subgroup of electro-acupuncture treatment duration of < 30 minutes, 
adding electro-acupuncture was not beneficial for the Modified Ashworth Scale in 
unspecified regions (SMD 1.23, 95% CI [2.54, 0.08], I2=96%). All other subgroup 
analyses consistently showed favourable effects of the combination of electro-
acupuncture and routine care. Only two subgroups on the outcome of the Modified 
Ashworth Scale in the lower limbs showed no heterogeneity (I2=0%): 1) patients with 
a baseline Modified Ashworth Scale score ≥ 1; or 2) when > 10 acupuncture points 
were used in electro-acupuncture treatment (Table 6.7). 
Change in Fugl-Meyer Assessment 
For the total Fugl-Meyer Assessment motor function scores, the effects of combining 
electro-acupuncture and routine care were significantly better than using routine care 
alone (Guo 2003; Liu, Li and Ma 2016; Lu 2011; Wu 2011) (4 studies, MD 10.60, 
95% CI [8.67, 12.53], I²=0%) (Figure 6.5). 
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Figure 6.5 Forest plot of Fugl-Myer Assessment in electro-acupuncture 
systematic review 
Notes: CI, confidence interval; EA, electro-acupuncture; FMA, Fugl-Meyer Assessment; RC, 
routine care; SD, standard deviation. 
Subgroup analysis of Fugl-Meyer Assessment scores in the upper limbs showed that, 
of the two studies (Yan et al. 2010; Cheng et al. 2015) which recruited patients with 
baseline Modified Ashworth Scale scores ≥ 1, the heterogeneity reduced and the 
treatment effects were in favour of the combination of electro-acupuncture and routine 
care (2 studies, MD 4.43, 95% CI [2.44, 6.43], I²=0%). For the two studies (Guo, 
Yang and Lu 2015; Cai et al. 2011) that did not specify baseline Modified Ashworth 
Scale scores, no add-on effects of electro-acupuncture were detected and the 
heterogeneity was very high (MD 21.86, 95% CI [−6.29, 50.00], I2=100%).  
In addition, two studies (Yan et al. 2010; Guo, Yang and Lu 2015) that recruited 
patients within 180 days showed superior effects of adding electro-acupuncture to 
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routine care for the Fugl-Meyer Assessment in the upper limbs with low heterogeneity 
(MD 6.93, 95% CI [5.01, 8.85], I2=0%). However, no add-on effects of electro-
acupuncture were observed in the subgroup of patients with a post-stroke period > 
180 days (MD 20.06, 95% CI [−11.61, 51.73], I²=100%) (Table 6.7). Other subgroup 
analyses related to the Fugl-Meyer Assessment were not possible due to the limited 
number of included studies. 
Change in Barthel Index 
Eleven included trials (Cai et al. 2011; Huang et al. 2016; Liu, Li and Ma 2016; 
Zhang, Lei et al. 2015; Guo 2003; Li et al. 2007; Lu 2011; Wu 2011; Yan et al. 2010; 
Yao, Zeng and Zhou 2012; Wu et al. 2008) reported results for the Barthel Index or 
Modified Barthel Index, but only seven of them (Yao, Zeng, and Zhou 2012; Zhang, 
Lei et al. 2015; Liu, Li and Ma 2016; Huang et al. 2016; Guo 2003; Lu 2011; Wu 
2011) reported on the specific version of Barthel Index and so were pooled for meta-
analysis. There was greater improvement in Barthel Index scores in participants with 
electro-acupuncture than those without (7 studies, MD 6.85, 95% CI [3.64, 10.05] 
(Figure 6.6), but the heterogeneity was also high (I²=80%). 
 
Figure 6.6 Forest plot of Barthel Index in electro-acupuncture systematic review 
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Notes: CI, confidence interval; EA, Electro-acupuncture; RC, routine care; SD, standard 
deviation. 
With regards to subgroup analysis for the Barthel Index, in the subgroup of patients 
with a post-stroke period > 180 days, adding electro-acupuncture showed no benefit 
(2 studies (Zhang, Lei et al. 2015; Wu 2011), MD 6.62, 95% CI [−3.79, 17.02], 
I²=92%). Results for other subgroups favoured adding electro-acupuncture to routine 
care. In addition, heterogeneity could be reduced to 0% in the subgroups where 
baseline Modified Ashworth Scale scores were not specified or only patients after 
their first stroke were recruited, and heterogeneity could be reduced to 2% in the 
subgroup when electro-acupuncture stimulation lasted less than 30 minutes (Table 
6.7). 
6.3.5 Safety assessment and outcomes on follow-up 
No data on adverse events were reported in any of the included studies and none of 
the included trials involved a follow-up period. 
6.3.6 Sensitivity analysis 
For the Modified Ashworth Scale in the lower limbs, sensitivity analysis with a low 
risk of bias in outcome assessors reduced heterogeneity to 0%, while for the other 
outcome measures the cause of their high heterogeneity could not be detected. 
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6.3.7 Reporting quality of included studies 
We compared the key items reported in the included trials with those recommended 
by the Standards for Reporting Intervention in Clinical Trials of Acupuncture 
guidelines (Appendix 13, MacPherson et al. 2010) and found that only the style of 
acupuncture, the needle stimulation, the number of treatment sessions and the 
frequency and duration of treatment were reported by all of the included studies 
(Table 6.8). Details of variations in acupuncture point selection, needling and other 
interventions, as well as precise descriptions of the control methods, were available in 
most of the included studies.  
However, in terms of the reasons for the treatment provided and the depth of 
insertion, only four studies reported these items (Table 6.8). Only one study reported 
practitioner backgrounds and one other study reported the rationale for the control 
therapy (Table 6.8). The setting and context of treatment were mentioned in none of 
the included studies.
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Table 6.8 Reporting quality of included studies in electro-acupuncture systematic review 
Studies 1. Acupuncture rationale 2. Details of needling  
1a) Style of 
acupuncture  
1b) 
Reasoning 
for 
treatment 
provided 
1c) 
Extent to 
which 
treatment 
was 
varied  
2a) 
Number 
of needle 
insertions  
2b) 
Names 
of points 
used  
2c) 
Depth of 
insertion 
2d) 
Response 
sought  
2e) Needle 
stimulation 
2f) 
Needle 
retention 
time  
2g) 
Needle 
type  
Cai 2011 Yes No Yes Yes Yes No Yes Yes Yes Yes 
Cheng 
2015 
Yes No No No No No Yes Yes Yes Yes 
Fan 2015 Yes Yes Yes Yes Yes No Yes Yes Yes Yes 
Guo 
2003 
Yes Yes No No No No Yes Yes Yes No 
Guo 
2015 
Yes No Yes Yes Yes No Yes Yes Yes Yes 
Huang 
2016 
Yes No Yes Yes Yes Yes Yes Yes No Yes 
Li 2007 Yes No Yes Yes Yes No Yes Yes Yes No 
Li H 
2011 
Yes No Yes Yes Yes No Yes Yes Yes No 
Liu 2016 Yes Yes Yes Yes Yes No Yes Yes Yes Yes 
Lu 2003 Yes No Yes Yes Yes Yes Yes Yes Yes Yes 
Lu 2010 Yes No Yes Yes Yes Yes Yes Yes Yes No 
Lu 2011 Yes Yes No No No No Yes Yes Yes Yes 
Wang 
2007 
Yes No Yes Yes Yes No Yes Yes Yes Yes 
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Studies 1. Acupuncture rationale 2. Details of needling  
1a) Style of 
acupuncture  
1b) 
Reasoning 
for 
treatment 
provided 
1c) 
Extent to 
which 
treatment 
was 
varied  
2a) 
Number 
of needle 
insertions  
2b) 
Names 
of points 
used  
2c) 
Depth of 
insertion 
2d) 
Response 
sought  
2e) Needle 
stimulation 
2f) 
Needle 
retention 
time  
2g) 
Needle 
type  
Wu 2008 Yes No Yes Yes Yes No No Yes Yes No 
Wu 2011 Yes No Yes Yes Yes No Yes Yes Yes Yes 
Xing 
2015 
Yes No Yes Yes Yes No No Yes Yes No 
Xue 
2008 
Yes No Yes Yes Yes No Yes Yes Yes No 
Yan 
2010 
Yes No Yes Yes Yes No Yes Yes Yes Yes 
Yang 
2007 
Yes No No No No Yes Yes Yes Yes No 
Yao 
2012 
Yes No Yes Yes Yes No Yes Yes Yes No 
Yu 2007 Yes No Yes Yes Yes No Yes Yes No Yes 
Zhang 
2015 
Yes No Yes Yes Yes No Yes Yes Yes No 
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Studies 3. Treatment regimen  4. Other components of treatment 5. Practitioner 
background  
6. Control or comparator interventions 
3a) No. of 
treatment 
sessions  
3b) Frequency 
and duration of 
treatment 
sessions  
4a) Details of other 
interventions 
administered 
4b) Setting 
and 
context of 
treatment 
5) Description 
of participating 
acupuncturists 
6a) Rationale for 
control/comparator 
in context of research 
question 
6b) Precise 
description of 
control or 
comparator 
Cai 2011 Yes Yes Yes No No No Yes 
Cheng 2015 Yes Yes Yes No Yes No Yes 
Fan 2015 Yes Yes Yes No No No Yes 
Guo 2003 Yes Yes Yes No No No No 
Guo 2015 Yes Yes Yes No No No Yes 
Huang 2016 Yes Yes Yes No No No Yes 
Li 2007 Yes Yes Yes No No No Yes 
Li H 2011 Yes Yes Yes No No No Yes 
Liu 2016 Yes Yes Yes No No No Yes 
Lu 2003 Yes Yes Yes No No No No 
Lu 2010 Yes Yes Yes No No No Yes 
Lu 2011 Yes Yes Yes No No Yes Yes 
Wang 2007 Yes Yes Yes No No No Yes 
Wu 2008 Yes Yes Yes No No No Yes 
Wu 2011 Yes Yes Yes No No No Yes 
Xing 2015 Yes Yes No No No No Yes 
Xue 2008 Yes Yes Yes No No No Yes 
Yan 2010 Yes Yes Yes No No No Yes 
Yang 2007 Yes Yes Yes No No No Yes 
Yao 2012 Yes Yes Yes No No No Yes 
Yu 2007 Yes Yes Yes No No No Yes 
Zhang 2015 Yes Yes Yes No No No Yes 
6.3.8 Publication bias 
For the Modified Ashworth Scale scores for unspecified regions, the funnel plot is 
asymmetric around the mean effect size line (Figure 6.7). Then we conducted Egger’s 
test, whose results indicate potential publication bias (p=0.003). Publication bias can 
result from unpublished studies showing no treatment effect. However, in our meta-
analysis it is more likely to have been generated by the large effects of two trials 
(Xing et al. 2015; Wu 2011). The larger effects in these two trials are attributable to 
the greater reduction in Modified Ashworth Scale scores achieved in the trials. When 
these two trials were removed from the analysis, the results of Egger’s test were not 
significant (p=0.098). The limited number of trials for meta-analysis of other outcome 
measures prohibited meaningful funnel plots to detect publication bias. 
 
Figure 6.7 Funnel plot of (Modified) Ashworth Scale (unspecified regions) in 
electro-acupuncture systematic review 
Notes: SE, standard error; SMD, standaradisd mean difference. 
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6.4 Discussion 
6.4.1 Summary of main findings 
Based on the evidence collected from clinical research, body acupuncture and electro-
acupuncture are the most popular treatments among the included clinical trials. Other 
acupuncture-related therapies, acupressure and moxibustion have also been evaluated 
by a small number of studies. 
Considering the prevalence of various acupuncture therapies and the existing 
synthesis evidence on manual acupuncture, we have conducted general reviews of 
manual acupuncture, acupressure and moxibustion, and specifically performed a 
systematic review and meta-analysis of electro-acupuncture to evaluate the add-on 
effects and safety of electro-acupuncture, which is one of the most promising 
acupuncture-related therapies in clinical practice, in order to summarise currently 
available evidence and provide key information for the design of a following pilot 
study of electro-acupuncture. 
According to the synthesis results of our review of manual acupuncture for post-
stroke spasticity, when manual acupuncture was used as an integrative therapy, the 
results of meta-analyses suggest that additional benefits could be obtained by adding 
manual acupuncture to routine care compared to routine care alone with regards to 
scores for the upper-limb Ashworth Scale or Modified Ashworth Scale, lower-limb 
Ashworth Scale or Modified Ashworth Scale, Ashworth Scale or Modified Ashworth 
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Scale in unspecified regions, upper-limb Fugl-Meyer Assessment, lower-limb Fugl-
Meyer Assessment and total motor function of Fugl-Meyer Assessment, as well as the 
Barthel Index.  
Acupressure and moxibustion are less studied, with a limited number of studies 
included, although additional benefits were observed in scores for the Ashworth Scale 
or Modified Ashworth Scale, total motor score of Fugl-Meyer Assessment and Barthel 
Index. With regards to electro-acupuncture, the synthesis results suggest that adding 
electro-acupuncture to routine care for post-stroke spasticity might be superior to 
routine care alone in terms of muscle spasticity reduction as measured by the 
Modified Ashworth Scale, overall and lower-limb improvement of motor function as 
measured by the Fugl-Meyer Assessment, and activities of daily living as measured 
by the Barthel Index. 
As for the safety of manual acupuncture, although most of the included studies did not 
address this issue, among the reported trials there was one adverse event deemed to 
have been caused by scalp acupuncture. Other reported adverse events were 
considered unrelated to manual acupuncture. With regards to the safety of electro-
acupuncture, none of the included trials provided information about adverse events. 
Overall, based on our review, manual acupuncture and electro-acupuncture are safe if 
performed properly by trained practitioners, except for scalp acupuncture. Future 
studies are encouraged to record and report adverse events, as well as exploring the 
association between the adverse events and acupuncture and related therapies. 
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6.4.2 Clinical importance of results 
Since the add-on effects of acupuncture and related therapies for the reduction of 
spasticity as measured by the Modified Ashworth Scale were analysed with SMD, the 
minimal detectable difference (MDD) of Modified Ashworth Scale scores cannot be 
used to explain the results. Therefore, we have only compared between-group 
differences for the Modified Ashworth Scale.  
As for the Fugl-Meyer Assessment scores for the upper extremities, both the MDD 
and MCID are 5.2 (Page, Fulk and Boyne 2012; Wagner, Rhodes and Patten 2008). 
The MCID of overall, upper-limb and lower-limb Fugl-Meyer Assessment was rated 
as 6.0, 4.58 and 3.31 respectively in another study (Chen, Wu and Shen 2015). The 
changes in the total motor, upper-limb and lower-limb scores of the Fugl-Meyer 
Assessment in intervention groups and control groups (routine care alone) were all 
greater than the MCID.  
With regards to Barthel Index, although the MCID was not established, the MDD was 
4.02 (Hsieh et al. 2007). Therefore, we have used 4.02 points in the Barthel Index for 
the interpretation of our results in relation to clinical practice. However, the results of 
our meta-analysis support a clinically meaningful improvement in the Barthel Index 
when acupuncture and related therapies were added to routine care.  
Although clinically important results were obtained based on the synthesis results 
from the included studies, it should be noted that, first, in addition to spasticity, the 
motor function and activities of daily living of stroke patients might be affected by 
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various factors such as muscle strength and sensation disorders; and second, the 
relatively low methodological and reporting quality, small numbers of included 
studies and small total sample size all limit our confidence in the results. 
6.4.3 Implications for clinical practice 
In the general reviews of manual acupuncture, acupressure and moxibustion, 
frequently reported acupuncture points have been summarised. Seven acupuncture 
points were shown in all lists: LI4 Hegu 合谷, SP6 Sanyinjiao 三阴交, SJ5 Waiguan 
外关, LI11 Quchi 曲池, ST36 Zusanli 足三里, LU5 Chize 尺泽, SP9 Yinlingquan 阴
陵泉. 
In terms of electro-acupuncture, for the Modified Ashworth Scale in unspecified 
regions, patients with electro-acupuncture stimulation times of < 30 minutes did not 
benefit from adding electro-acupuncture to routine care. For the Fugl-Meyer 
Assessment in the upper limbs, ‘superior add-on effects of electro-acupuncture could 
only be detected in the subgroups where patients’ baseline Modified Ashworth Scale 
level was ≥ 1 and where the post-stroke period was ≤ 180 days. With regards to the 
Barthel Index, adding electro-acupuncture to routine care did not benefit those with a 
post-stroke period > 180 days.’ 
This review has attempted to find an adequate and even optimal electro-acupuncture 
treatment protocol and to provide suggestions for clinical practice and scientific 
research. Specifically, the results suggest that patients who are < 180 days post-stroke 
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and whose baseline Modified Ashworth Scale level ≥ 1 might benefit from electro-
acupuncture treatment. Electro-acupuncture treatment ≥ 30 days might also contribute 
to a better result. However, the above results of subgroup analysis cannot be 
confirmed because of the limitations in the numbers and the methodological quality of 
the included studies, as well as the high heterogeneity of the results. 
Although the electrical stimulation frequency reported in most of the included studies 
was < 20 Hz, the optimal frequency needs further exploration because of the uncertain 
impact of different frequencies of electro-acupuncture on the muscles (Koog 2016; 
McMakin and Oschman 2013). The number of acupuncture points that were electro-
stimulated among the included studies ranged from two to 14, with the average being 
eight (Table 6.5). Twenty (20) studies reported patient responses, such as the ‘de qi 得
气’ sensation (a composite of unique needling sensations, including soreness, 
numbness, distension, heaviness felt at the acupuncture point, with the practitioner’s 
feeling of mild needle grasping) (World Health Organization 2007) or muscle 
contraction during acupuncture treatment (Table 6.5). The reasoning for the treatment 
provided was given in only four of the included studies.  
Although recommendations are to at least conduct a subgroup analysis that includes 
only studies with an adequate protocol for electro-acupuncture treatment (White et al. 
2008), subgroup analysis based on adequate electro-acupuncture treatment protocols 
was not possible in our systematic review because of a lack of clinical consensus and 
of empirical evidence of adequate electro-acupuncture protocols. However, compared 
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with criteria on the adequacy of acupuncture applied to studies of other conditions 
such as fibromyalgia (Deare et al. 2013) and low back pain (White et al. 2008), the 
number of points needled and the treatment frequency suggest that the dose might be 
adequate. 
6.4.4 Measurement of spasticity 
Our reviews have not explored the underlying mechanism of how electro-acupuncture 
works in reducing spasticity. The conventional understanding of the pathophysiology 
of post-stroke spasticity can be summarised as the abnormal processing of 
proprioceptive input in the spinal cord resulting in the hyperexcitability of the stretch 
reflexes (Thibaut et al. 2013). Because of the complexity of the underlying 
pathophysiological basis of spasticity with neural and non-neural components 
(Thibaut et al. 2013), it is difficult to measure a change in spasticity with a single 
outcome measure.  
Currently the Modified Ashworth Scale is the most frequently and widely reported 
outcome measure, although it may not cover all key aspects of spasticity, such as a 
velocity-dependent increase in muscle tone, and might underestimate the effects of an 
intervention because of its limited ability to assess minor changes in spasticity 
(Fleuren et al. 2010). Future studies may need to incorporate a comprehensive group 
of outcome measures, including quantitative measures such as surface 
electromyography (Cousins et al. 2009; Lindsay et al. 2015) and electrophysiological 
evaluation (Zhao et al. 2009). 
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6.4.5 Control methods 
Since positive treatment effects of pseudo and sham acupuncture have been observed 
even if they are used appropriately, there have been concerns raised about 
acupuncture research (Dincer and Linde 2003; Koog 2016; Wong, Leung and Zhang 
2015; Zhu, Gao et al. 2013) and the treatment effects of acupuncture might be 
underestimated when compared with pseudo or sham acupuncture. Therefore, 
subgroup analysis of studies with and without pseudo or sham acupuncture is needed 
when conducting systematic reviews of acupuncture. However, in our systematic 
review, neither pseudo acupuncture nor sham acupuncture were used in any of the 
included studies. 
6.4.6 Differences from previous systematic reviews 
Compared with the three existing systematic reviews (Lim et al. 2015; Park et al. 
2014; Qi et al. 2009) of acupuncture for stroke, our study of adjunct electro-
acupuncture for post-stroke spasticity is different in the following main areas. First, 
the previous systematic reviews did not specifically evaluate the add-on effects of 
electro-acupuncture for post-stroke spasticity. Second, we conducted a more 
comprehensive search in five English and four Chinese databases. Because of the 
characteristics of Chinese characters, the indexing of keywords and subjects could not 
be clearly defined. Search terms should therefore not be limited to MeSH terms 
directly translated into Chinese, but use a more general and comprehensive 
combination of similar words and phrases with synonyms, which may have 
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contributed to a much larger number of search results in this systematic review 
compared with the previously published ones. Third, we updated the search to 
September 2016 with more up-to-date evidence in the English and Chinese databases. 
6.4.7 Study limitations 
6.4.7.1 Methodological quality 
The limited methodological quality of the included studies has prevented us from 
drawing firm conclusions on the effects of acupuncture and related therapies for post-
stroke spasticity with respect to spasticity reduction, improvement of motor function 
and activities of daily living. It is important for a randomised controlled trial to apply 
proper randomisation and allocation. However, we have noted that fewer than half of 
the included studies used a proper randomisation method to reduce selection bias, and 
allocation concealment was inadequately reported. These limitations in methodology 
can lead to exaggeration of the estimated efficacy (Pildal et al. 2007).  
In addition to randomisation and allocation concealment, insufficient blinding can 
also contribute to overestimation of the effects (Hrobjartsson et al. 2014). Placebo or 
sham acupuncture was used in only two included studies. Pseudo-electro-acupuncture 
or sham electro-acupuncture was not used in any of the included trials. Admittedly, 
blinding of participants and intervention providers is difficult in clinical trials of non-
pharmacotherapy. However, the attempt to reduce performance bias with sham, 
pseudo or placebo electro-acupuncture is needed in future research. Blinding 
assessors could also help reduce the detection bias with regards to non-objective 
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outcome measures, including the Modified Ashworth Scale, Fugl-Meyer Assessment 
and Barthel Index. However, fewer than ten studies in this systematic review reported 
clearly the methods used for blinding assessors, limiting our confidence in the results 
of this meta-analysis. 
6.4.7.2 High heterogeneity in results 
High heterogeneity across studies was observed in some of the meta-analyses in both 
the general review and the systematic review of electro-acupuncture. To gain a broad 
perspective on the overall evidence of acupuncture and related therapies for post-
stroke spasticity, randomised controlled trials with different basic characteristics and 
treatment protocols were included in the general and systematic reviews, which may 
have led to clinical heterogeneity. We also conducted subgroup and sensitivity 
analyses in the systematic review of electro-acupuncture. However, the cause of the 
high heterogeneity could not be determined (Table 6.7). 
6.4.7.3 Assessment of safety 
The evaluation of the safety of adjunct electro-acupuncture for post-stroke spasticity 
is also one of the objectives of this systematic review, but none of the included trials 
addressed the long-term effects or adverse events. Acupuncture and related therapies, 
including electro-acupuncture, acupressure and moxibustion, have been widely 
accepted as relatively safe if performed appropriately by competent practitioners even 
though some mild adverse events might occur, such as localised pain or slight 
bleeding from needling (Liu, Li and Ma 2016). Only one trial, of scalp acupuncture, 
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reported suspected acupuncture treatment-related discomfort caused by hematoma on 
the head, but no other adverse event was either reported or confirmed to be 
acupuncture-related.  
As for the safety issue in the electro-acupuncture systematic review, none of the 
included studies reported adverse events during their treatment periods and no follow-
up observations were provided. The lack of reporting of adverse events is a significant 
problem. Therefore, the safety of acupuncture and related therapies for post-stroke 
spasticity cannot be confirmed based on the studies included in this systematic review. 
6.4.7.4 Reporting quality 
In the systematic review of electro-acupuncture, we have further assessed the 
reporting quality of the included studies. None of the studies addressed all of the key 
items recommended by the Standards for Reporting Intervention in Clinical Trials of 
Acupuncture. Therefore, we recommend that future clinical trials be registered 
prospectively and that reporting quality be improved by adhering to the Standard for 
Reporting Intervention in Clinical Trials of Acupuncture and the CONSORT 
statement, in order to provide transparency for the study design, practice and analysis 
(Bian and Shang 2011; MacPherson et al. 2010). 
Thirteen of the 22 included studies did not specify which region was measured in their 
reporting for the Modified Ashworth Scale, making the interpretation of results less 
clinically relevant. Outcome measures need to be described in detail in future studies 
in order to improve reporting quality. 
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6.4.7.5 Generalisation of results 
Since all participants were restricted to the Chinese population, generalisation of the 
results to non-Chinese populations needs further evidence. In addition, contractures 
will inevitably develop in stroke patients with chronic spasticity (Ada, O’Dwyer and 
O’Neill 2006), where acupuncture might have a different impact (Botte, Nickel and 
Akeson 1988). Caution is needed in generalisation of the results to a general stroke 
population with both spasticity and contracture. 
6.5 Conclusion 
The general review of acupuncture, acupressure and moxibustion, together with the 
systematic review and meta-analysis of electro-acupuncture, suggest that acupuncture 
and related therapies combined with routine care have the potential to reduce 
spasticity in the upper and lower extremities, and to improve overall motor function 
and activities of daily living for patients with spasticity. Further studies of high 
methodological and reporting quality are needed to confirm the effects and safety of 
acupuncture and related therapies, and to explore the adequate and optimal treatment 
protocols for post-stroke spasticity, incorporating a group of comprehensive outcome 
measures in different populations.  
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Chapter 7 Pilot randomised controlled trial of adjunct electro-
acupuncture for post-stroke spasticity 
 
This chapter describes the design of a randomised controlled trial of electro-
acupuncture for post-stroke spasticity; and presents the results of a pilot study of the 
trial. The trial had been registered on WHO International Clinical Trials Registry 
Platform (registration number: ChiCTR-IOR-16010283). 
7.1 Background 
As one of the most commonly seen complications of stroke (Lim et al. 2015; Miller et 
al. 2010), spasticity can have a negative impact on around 20–50% of stroke survivors 
(Kwah et al. 2012; Zorowitz, Gillard, and Brainin 2013). The direct cost for patients 
with post-stroke spasticity is reported to be nearly four times higher than for those 
without it (Lundstrom, Terent and Borg 2008). 
In the clinical management of post-stroke spasticity, treatment options include 
pharmacological and non-pharmacological interventions. Medications including oral 
Baclofen, botulinum injection and chemical neurolysis may be considered for 
managing moderate or severe cases of post-stroke spasticity (Australian National 
Stroke Foundation 2017; Chinese Society of Neurology and Stroke Prevention Project 
Committee of National Health and Family Planning Commission in China 2012; 
Chinese Society of Neurology et al. 2017; Lindsay et al. 2014; Miller et al. 2010; 
National Institute for Health and Care Excellence 2013; Smith et al. 2010; Stroke 
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Foundation of New Zealand and New Zealand Guidelines Group 2010). Unwanted 
side effects, such as muscle weakness, may limit the use of oral anti-spasticity 
medications (Fan et al. 2015). Intrathecal Baclofen injection is effective but usually 
only used in generalised spasticity when there is no response with conservative 
options (Harned, Salles, and Grider 2011).  
Non-pharmacological interventions such as anti-spastic pattern positioning and range-
of-motion exercises are recommended as primary treatments (Australian National 
Stroke Foundation 2017; Chinese Society of Neurology and Stroke Prevention Project 
Committee of National Health and Family Planning Commission in China 2012; 
Chinese Society of Neurology et al. 2017; Lindsay et al. 2014; Miller et al. 2010; 
National Institute for Health and Care Excellence 2013; Smith et al. 2010; Stroke 
Foundation of New Zealand and New Zealand Guidelines Group 2010). 
Nevertheless, even after various treatments, moderate to severe disability is observed 
in more than half of stroke patients with spasticity (Sze et al. 2000). Concerns have 
been raised about the unsatisfactory long-term benefits and high costs of current 
therapies (Nair and Marsden 2014; Wu, Mills, et al. 2010). Due to these limitations of 
current clinical management for post-stroke spasticity, patients with stroke are in need 
of alternative treatment options for better control of spasticity with fewer side effects. 
Acupuncture has long been practised in China and in recent decades has become 
increasingly popular in Western countries (Lim et al. 2015). Electro-acupuncture 
involves the application of an electrical stimulus, where electric current passes 
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between pairs of acupuncture needles (Liu et al. 2015). One advantage of electro-
acupuncture over manual acupuncture is that the frequency and intensity can be 
standardised and repeated easily, ensuring participants in clinical studies receive the 
same amount of stimulation (Smith et al. 2010). Electro-acupuncture was also found 
to be more effective than manual acupuncture in a previous systematic review 
evaluating acupuncture for post-stroke spasticity (Lim et al. 2015). However, 
methodological issues and inadequate reporting of included studies limit the certainty 
of this finding (Lim et al. 2015). 
Prior to designing this clinical trial, we conducted a systematic review of adjunct 
electro-acupuncture for post-stroke spasticity (PROSPERO 2015: CRD42015027894) 
(Cai et al. 2017). Twenty-two (22) randomised controlled trials were included in the 
meta-analysis. The following limitations prevented us from drawing firm conclusions 
on the effects and safety of adjunct electro-acupuncture for post-stroke spasticity: 1) 
methodological quality – none of the included trials applied appropriate allocation 
concealment and only three studies implemented blinding of outcome assessors; 2) 
reporting quality – none of the included studies addressed all key items recommended 
by the Standards for Revised Reporting Intervention in Clinical Trials of Acupuncture 
(MacPherson et al. 2010); and 3) absence of safety data – none of the included trials 
evaluated the safety of adjunct electro-acupuncture for the treatment of post-stroke 
spasticity. 
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This study aims to evaluate the effects and safety profile of adjunct electro-
acupuncture for post-stroke spasticity and address the abovementioned limitations. 
The main hypothesis of this trial is that, compared to routine care (the usual 
pharmacotherapy and/or rehabilitation therapies) alone, adding electro-acupuncture to 
routine care will prove an additional benefit in relation to post-stroke spasticity in 
terms of muscle tone reduction, improvement of motor function of affected 
extremities and activities of daily living. The results of this trial will be reported in 
accordance with CONSORT 2010 (Schulz, Altman and Moher 2010) and Standards 
for Reporting Intervention in Clinical Trials of Acupuncture (MacPherson et al. 
2010). It has been designed following the instructions of the SPIRIT 2013 Checklist 
(Appendix 12) (Chan et al. 2013). Appropriate allocation concealment and blinding of 
outcome assessors/statisticians will be adopted in the design of this trial, with 
evaluation of the effects and safety of electro-acupuncture in a four-week treatment 
phase and a four-week follow-up phase. 
7.2 Study design 
This study is a single-centre outcome assessor–blinded parallel pilot randomised 
controlled trial consisting of a four-week treatment phase followed by a four-week 
follow-up phase. Figure 7.1 illustrates the trial procedure and Table 7.1 details the 
trial schedule. Specific research items will be reported in accordance with the Revised 
Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) 
(Appendix 13).  
 Figure 7.1 Study procedure of electro-acupuncture trial
Table 7.1 Schedule of enrolment, interventions and assessments of electro-
acupuncture randomised controlled trial 
Time point Screening Baseline 
assessment 
Treatment 
phase 
Follow-up  
phase 
Enrollment Week  
0 
Week 
1-3 
Week  
4 
Week 
6 
Week 
8 
Eligibility screening ●      
Informed consent ●      
Demographic 
characteristic 
 ●     
History and 
treatment of 
spasticity and 
comorbidities 
● ●     
MAS  ●  ●  ● 
FMA  ●  ●  ● 
BI  ●  ●  ● 
EA therapy    ● ●   
EA treatment record    ● ●   
RC (both groups)   ● ● ● ● 
AEs   ● ● ● ● 
Drop-outs   ● ● ● ● 
Record of clinic or 
hospital visits 
  ● ● ● ● 
Notes: AEs, adverse events; BI, Barthel Index; EA, electro-acupuncture; FMA, Fugl-Meyer 
Assessment; MAS, Modified Acworth Scale; RC, routine care; ●, items required. 
7.2.1 Setting, recruitment and participants 
This pilot study was conducted in the GPHCM, Guangzhou, China. Participants were 
introduced to the trial by their general practitioners, neurologists, physiotherapists or 
acupuncturists from the inpatient and outpatient Department of Rehabilitation, 
Department of Acupuncture and Department of Neurology of the hospital. 
The inclusion criteria were: 1) people with first stroke confirmed by Computed 
Tomography (CT) or/and Magnetic Resonance Imaging ; 2) 30 days to one year after 
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stroke onset; 3) aged ≥ 18 years; 4) baseline Modified Ashworth Scale ≥ 1; 5) willing 
to participate and be randomised to one of the groups. 
The exclusion criteria were: 1) people with spasticity due to other causes, such as 
multiple sclerosis, traumatic brain and spinal cord injuries; 2) severe and unstable 
clinical disorders; 3) inability to follow or respond to treatment instructions; 4) 
lactation, pregnancy or intention to become pregnant within six months; 5) pacemaker 
or implantable cardioverter defibrillator carrier; 6) currently enrolled in another 
clinical trial; 7) needle phobia. 
Written informed consent was sought from participants once their eligibility was 
confirmed. Written information and verbal explanation of the study (including the 
purpose, procedures, time commitment and potential risks and benefits of the trial) 
were provided before informed consent was obtained. 
All participants received a unique research identification number, which was the only 
identifier on data collection forms and in the electronic database. Electronic data were 
kept confidential and stored in password-protected electronic files, and all hard-copy 
files were stored in locked filing cabinets. Compensation for any harm related to the 
trial was provided by GPHCM on a case-by-case basis. Participants were permitted to 
withdraw from receiving the trial intervention at any time during the trial, with or 
without providing a reason. Participants were asked if they were willing to be 
contacted four weeks after withdrawal when they decided to cease taking the trial 
intervention, and this was also written in the informed consent form that had been 
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approved by the Ethic Committee of Guangdong Provincial Hospital of Chinese 
Medicine. The withdrawn cases that had received the intervention and had agreed to 
be contacted underwent a follow-up assessment four weeks after withdrawal in order 
to obtain information about their condition. 
7.2.2 Randomisation and allocation concealment 
Participants were randomly allocated to an intervention group (electro-acupuncture 
plus routine care) or control group (routine care alone) at a ratio of 1:1. An external 
statistician provided the computer-generated random sequences and allocation was 
implemented by a central web-based interactive randomisation service system at 
GPHCM. Block randomisation was used to ensure equal numbers of participants were 
allocated to the two groups. Participants were advised not to reveal their group 
allocation to the outcome assessors at any time during the trial. 
7.2.3 Blinding 
As previously described, based on the application of manual acupuncture, electro-
acupuncture is defined as electrical stimulation applied via a small electric current 
passing between pairs of acupuncture needles. Currently there is no control method 
for electro-acupuncture that can, on one hand, perfectly mimic the procedures of 
electro-acupuncture, while on the other hand producing no physiological effects 
(MacPherson et al. 2014). Due to the difficulty of blinding participants and 
acupuncturists in trials with electro-acupuncture, this study was designed as an open-
210 
 
label trial. Independent outcome assessors and statisticians were blinded to group 
allocation throughout the entire trial. 
7.2.4 Interventions 
In the four-week treatment phase, participants in both groups received routine care 
and those allocated to the intervention group also received electro-acupuncture 
treatments. 
7.2.4.1 Routine care in both groups 
Considering that recommendations for management of post-stroke spasticity vary 
across different clinical guidelines and that stroke patients have complex 
comorbidities and complications, the routine care therapies used in this trial were not 
strictly standardised. Routine care for spasticity which was tailored to the individual 
included pharmacological and non-pharmacological interventions. Treatments from 
general internal medicine (such as blood pressure control, lipid-lowering medications) 
and rehabilitation therapies were permitted. Details of routine care used during the 
trial were recorded, noting any change of routine care and the reasons. 
7.2.4.2 Electro-acupuncture in intervention group 
A total of 12 electro-acupuncture sessions, three per week, were performed for a 
period of four weeks. Acupuncturists who delivered the treatments were qualified 
traditional Chinese medicine practitioners with at least two years of acupuncture 
experience. They were required to be registered with the Chinese Medical Doctor 
Association and to hold a master’s degree in acupuncture. All electro-acupuncture 
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treatments were conducted in private rooms. The practitioner explained the electro-
acupuncture process and possible sensations during therapy to the participants before 
treatment. Immediately after each electro-acupuncture session, brief interviews were 
conducted to record participants’ feedback about the treatment. These records were 
checked regularly by the investigators to ensure consistency across different 
acupuncture therapists. 
In the electro-acupuncture treatment, needling could be bilateral or unilateral, at the 
acupuncturist’s discretion. Based on our systematic review of published electro-
acupuncture trials for post-stroke spasticity (Cai et al. 2017), a list of acupuncture 
points were identified and suggested to be used in this trial: LI4 Hegu 合谷, LI10 
Shousanli 手三里, LI11 Quchi 曲池, LI15 Jianyu 肩髃, TE5 Waiguan 外关, GB34 
Yanglingquan 阳陵泉, LR3 Taichong 太冲, SP6 Sanyinjiao 三阴交, ST36 Zusanli 足
三里, and ST40 Fenglong 丰隆 (World Health Organization Western Pacific Region 
2010). Details of these points are available in Table 7.2.  
The selection of acupuncture points depended on the treatment needed for the joints 
affected by spasticity, with LI4 Hegu 合谷, TE5 Waiguan 外关 (wrist), LI10 
Shousanli 手三里, LI11 Quchi 曲池 (elbow), LI15 Jianyu 肩髃 (shoulder), GB34 
Yanglingquan 阳陵泉, ST36 Zusanli 足三里, ST40 Fenglong 丰隆 (knee), SP6 
Sanyinjiao 三阴交 (ankle) and LR3 Taichong 太冲 (toe joint) as mandatory points.  
In addition, acupuncturists were permitted to select other points than those included in 
this list as optional points based on the individualised condition of patients. It is 
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important to note that all acupuncturists were required to select points located in the 
antagonist muscles and avoid those located in the spasticity muscles. A maximum of 
10 needles, including a maximum of three pairs for electro-acupuncture on the 
affected side, were inserted during each treatment session (Wang and Xie 2010). 
Details of each electro-acupuncture treatment session including the acupuncture 
points were documented.  
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Table 7.2 Locations of acupuncture points in electro-acupuncture trial 
Acupuncture 
points 
Affected 
joints 
Locations 
LI4 Hegu 合
谷 
Wrist On the dorsum of the hand, radical to the midpoint of the 
second metacarpal bone. 
TE5 Waiguan 
外关 
Wrist On the posterior aspect of the forearm, midpoint of the 
interosseous space between the radius and the ulna, two B-cun 
proximal to the dorsal wrist crease (2 B-cun proximal to TE4 
Yangchi 阳池, in the depression between the radius and the 
ulna, the anterior point correspondent to TE5 Waiguan 外关 is 
PC6 Neiguan 内关). 
LI10 
Shousanli 手
三里 
Elbow On the posterolateral aspect of the forearm, on the line 
connecting LI5 yangxi 阳溪 with LI11 Quchi 曲池, two B-cun 
inferior to the cubital crease. 
LI11 Quchi 曲
池 
Elbow On the lateral aspect of the elbow, at the midpoint of the line 
connecting LU5 Chize 尺泽 with the lateral epicondyle of the 
humerus (when the elbow is fully flexed, LI11 Quchi 曲池 is 
located in the depression on the lateral end of the cubital 
crease). 
LI15 Jianyu 
肩髃 
Shoulder On the shoulder girdle, in the depression between the anterior 
end of lateral border of the acromion and the greater tubercle of 
the humerus (when the arm is abducted, two depressions 
appear, anterior and posterior to the acromion, and LI15 Jianyu 
肩髃 is located in the deeper depression anterior to the 
acromion while TE14 Jianliao肩髎 is located in the posterior 
depression). 
GB34 
Yanglingquan 
阳陵泉 
Knee On the fibular aspect of the leg, in the depression anterior and 
distal to the head of the fibula. 
ST36 Zusanli 
足三里 
Knee On the anterior aspect of the leg, on the line connecting ST35 
with ST41, three B-cun inferior to ST35 Dubi 犊鼻 (ST36 
Zusanli 足三里 is located on the tibialis anterior muscle). 
ST40 
Fenglong 丰
隆 
Knee On the anterolateral aspect of the leg, lateral border of the 
tibialis anterior muscle, eight B-cun superior to the prominence 
of the lateral malleolus (ST40 Fenglong 丰隆 is one 
fingerbreadth (middle finger) lateral to ST38 Tiaokou 条口. 
SP6 
Sanyinjiao 三
阴交 
Ankle On the tibial aspect of the leg, posterior to the medial border of 
the tibia, three B-cun superior to the prominence of the medial 
malleolus (1B-cun superior to KI8 Jiaoxin 交信). 
LR3 Taichong 
太冲 
Toe joint On the dorsum of the foot, between the first and the second 
metatarsal bones, in the depression distal to the junction of the 
bases of the two bones, over the dorsalis pedis artery (LR3 
Taichong 太冲 can be felt in the depression when moving 
proximally from LR2 Xingjian 行间 in the gap between the first 
and the second metatarsal bones towards the base of two 
metatarsal bones). 
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Single-use stainless steel acupuncture needles of 0.25 mm in diameter (HanyiTCM, 
Beijing, China) were used for the electro-acupuncture treatments. Needle lengths 
varied from 25 mm to 40 mm, while needle insertion depth varied from 15 mm to 
25 mm according to the thickness of the muscles where the electro-acupuncture was 
conducted. The ‘de qi得气’ sensation, an elicited response from patients, was 
obtained before adding electrical stimulation. ‘de qi得气’ is a composite of unique 
needling sensations, including aching, numbness, distension or heaviness, felt by both 
patients and acupuncturists (Yang et al. 2013). Upon obtaining the needling sensation, 
electro-acupuncture was applied through a stimulator (G6805-I, Qing Dao Xinshen 
Industrial Co.LTD, Qingdao, China) with biphasic continuous waves at a frequency of 
50–100 Hz and at the maximum tolerable intensity for 20 to 30 minutes. 
7.2.5 Follow-up 
Participants in both groups continued to receive routine care during the four-week 
follow-up phase. Participants were contacted by phone at the end of Week Six for 
compliance assessment. At the end of the follow-up phase, participants attended the 
trial clinic for a final assessment, then their involvement in the trial ceased. 
7.2.6 Outcome measures and evaluation 
The primary outcome measure was changes in the Modified Ashworth Scale 
(Appendix 1) score of the major affected joint from baseline to the end of treatment. 
The Modified Ashworth Scale measures the resistance to passive movement on a six-
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point scale (Levels Zero, One, One plus, Two, Three and Four) (Bohannon and Smith 
1987). A lower score indicates a smaller resistance in the measured joint. Modified 
Ashworth Scale scores in six different joints (shoulder, elbow, wrist, hip, knee and 
ankle) on the hemiplegia side were measured and recorded at baseline (Week 0), the 
end of treatment (Week 4) and the end of follow-up (Week 8). 
The secondary outcome measures were the Fugl-Meyer Assessment (motor function) 
(Appendix 4) and the Barthel Index (Appendix 5). The Fugl-Meyer Assessment 
(motor function) sums the scores for the upper limb (maximum score of 66) and the 
lower limb (maximum score of 34) to obtain a total score (maximum 100) (Fugl-
Meyer et al. 1975). A higher score suggests a better recovery in motor function. The 
Barthel Index (Appendix 5) is a ten-item instrument that evaluates activities of daily 
living. Items include feeding, bathing, grooming, dressing, bowels, bladder, toilet use, 
transfers (bed to chair and back), mobility (on a level surface) and stairs (Mahoney 
and Barthel 1965). The Barthel Index establishes the degree of independence from 
physical assistance for important tasks. Scores range from zero to 100, with a higher 
score meaning less dependence on help. 
Baseline data were collected at the first visit by an independent outcome assessor, 
including each participant’s family history, medical history and presenting symptoms, 
potential risk factors and aggravating factors for spasticity, complications and 
comorbidities, as well as evaluation of the Modified Ashworth Scale, Fugl-Meyer 
Assessment and Barthel Index. At the end of the treatment and follow-up phases, the 
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Modified Ashworth Scale, Fugl-Meyer Assessment and Barthel Index were evaluated 
again by the same outcome assessor. 
7.2.7 Safety assessment 
All participants were requested to report information on any adverse event that 
occurred during the trial. All details of adverse events including the time of 
occurrence and the severity were recorded. The relationship between adverse events 
and the intervention was assessed according to the WHO Uppsala Monitoring Centre 
System for Standardised Case Causality Assessment (UPPSALA Monitoring Centre).  
If participants developed an adverse event during the trial, they would be advised to 
seek medical advice from their physicians and cease the electro-acupuncture treatment 
if the adverse event was considered to be electro-acupuncture–related and became 
intolerable. Severe adverse events or severe adverse reactions were defined according 
to the International Conference on Harmonised Tripartite Guideline (ICH Expert 
Working Group 2000) and had to be reported to the Ethics Committee of GPHCM and 
the research team. 
7.2.8 Discontinuing interventions 
The determination to discontinue the trial for a participant was made by the research 
team if: 1) a serious post-stroke complication developed; or 2) recurrent stroke or any 
other severe condition occurred, leaving the patient to a critical condition. Physicians 
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determined whether the participant should cease trial participation in the event of a 
severe adverse event or severe adverse reaction. 
7.3 Data collection, management and monitoring 
Information about the participants, instrument measures and other relevant data were 
collected at the baseline, post-treatment and follow-up assessments. Adverse events 
were observed and recorded during the eight-week duration of the trial. The case 
report form (CRF) including electro-acupuncture treatment records was paper-based. 
All corrections made to the CRFs had to be personally signed and dated by the person 
responsible. All data were then entered into a pre-designed, password-protected 
electronic dataset by two independent investigators who were blinded to group 
allocation. Double-checking of the entered data was performed by another researcher 
to ensure accuracy. The original CRFs and all other forms were kept securely at 
GPHCM. Only members of the trial research team had access to the final trial dataset. 
Data and progress monitoring were conducted by an independent researcher outside 
the research team every two weeks throughout the trial. The independent data 
management team monitored the safety and implementation of the trial, and had 
access to group allocation. 
7.4 Sample size calculation 
A pilot study of 30 participants was conducted to test the feasibility of the trial 
protocol prior to a full-scale trial. Sample size estimation for the full-scale trial was 
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based on meta-analysis of six trials reporting on the Modified Ashworth Scale (Liu, Li 
and Ma 2016; Lu 2011; Wu 2011; Xue, Li and Huo 2008; Yu and Zhang 2007; Zhang, 
Lei et al. 2015). The assumption was that adding electro-acupuncture to routine care 
was more effective than routine care alone. Accordingly, the electro-acupuncture 
group and control group would show decreases of 1.22 and 0.79 in scores on the 
Modified Ashworth Scale, respectively, with a standard deviation (SD) of 0.72 in each 
group.  
Sample size was estimated using Software Power Analysis & Sample Size 11.0 
(NCSS, LLC, Kaysville, Utah, USA) with a significance level (alpha) of a two-sided 
two-sample t-test of 0.05 and 80% power to detect any difference between the two 
groups. A total sample size of 136 was required, allowing for equal allocation to the 
two groups and 15% loss of follow-ups. Upon completion of the pilot study, results of 
the main outcomes could be used to adjust the sample size estimation for the full-scale 
trial. 
7.5 Statistical analysis 
SPSS 23.0 and SAS 9.2 (SAS Institute, Cary, North Carolina, USA) were used for 
data analysis. For all analyses, the statistical significance levels were set at 5% 
(ɑ=0.05). 
Demographic and other baseline characteristics were summarised for each group. 
Categorical variables were presented using frequencies and percentages, and 
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continuous variables using standard measures of central tendency and dispersion, with 
mean and SD if data were normally distributed. Data not normally distributed were 
presented using median or inter-quartile ranges. 
To compare the changes in the primary and secondary outcomes (Modified Ashworth 
Scale, Fugl-Meyer Assessment and Barthel Index) between groups, a superiority 
independent sample t-test with a 95% CI was conducted. Further, repeated measures 
of analysis of variance (rANOVA) or linear mixed models were applied in order to 
analyse the changes in scores for the Modified Ashworth Scale, Fugl-Meyer 
Assessment and Barthel Index across three testing time points (Weeks 0, 4 and 8) 
(Vickers and Altman 2001). Adverse events were expressed in tabulations and with 
descriptive statistics. Frequencies and percentages for adverse events were also 
analysed using a Chi-square test or Fisher’s exact test to detect between-group 
differences. 
Statistical analyses were performed using the intent-to-treat (ITT) approach. Missing 
data were replaced using the multiple imputation method. Ten imputed datasets were 
created under the assumption that the missing data were random. Results of the trial 
were then pooled as intervention effects based on the analyses of the datasets with 
multiple imputations. 
For the full-scaled study, sensitivity analyses would be performed to assess the non-
imputed and complete case analyses. In addition, to adjust for hypothesised residual 
baseline imbalances and to assess their impact on effect estimates, a multivariable 
220 
 
analysis would be performed. Moreover, subgroup analysis of muscle tone as 
measured by the Modified Ashworth Scale would be conducted in regards to age (< 
65 years and ≥ 65 years), gender, different types of stroke, baseline Modified 
Ashworth Scale, affected joints and length of post-stroke period, to specify the effects 
of electro-acupuncture in these domains. 
7.6 Ethics and dissemination 
The trial protocol was approved by the Ethics Committee of GPHCM (Appendix 14, 
15) and the RMIT University Human Research Ethics Committee (Appendix 16) in 
December 2016 in accordance with the related Chinese ethics audit regulations and 
the Australian National Health and Medical Research Council’s National Statement of 
Ethical Conduct in Human Research (‘Measures for the Ethical Review of Biomedical 
Research Involving Human Subjects’ 2010; ‘[Construction Specifications of Platform 
Construction Assessment of Ethics Review of Traditional Chinese Medicine] [article 
in Chinese]’ 2010; ‘National Statement on Ethical Conduct 2007 (Updated 2015)’ 
2015). 
No modifications to the protocol were expected unless necessary. Any changes in the 
selection criteria or methodology were discussed with the entire research team and re-
approved by the two ethics committees. The results would be published in a peer-
reviewed journal, written up in a PhD thesis and presented at conferences. Data would 
be published in aggregate to avoid individual participant identification and presented 
in such a way that identifiable data were removed. 
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7.7 Results 
7.7.1 Enrolment, screening and retention 
Between March 2017 and January 2018, we screened 72 patients for eligibility and of 
these, 30 were included and randomly assigned to two groups (15/15). Five of the 30 
participants decided not to proceed after being randomised, but before treatment 
started. The reason of not participating was relocating to other hospitals or cities. As a 
result, 25 participants (12 in the intervention group and 13 in the control group) from 
inpatient departments received allocated treatments and were included in final data 
analysis. Three participants from the control group dropped out during the follow-up 
phase because they relocated to other hospitals for further rehabilitation. All 12 
participants in the intervention group completed the follow-up phase. The trial 
procedure is shown Figure 7.2.
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Figure 7.2 Study flow chart of pilot electro-acupuncture trial 
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7.7.2 Basic characteristics and baseline comparison 
Participants’ baseline characteristics are summarised in Table 7.3. The average age of 
included patients was 63.50 years in the intervention group (intervention group) and 
56.23 years in the control group (control group). There were more male participants 
than female participants in both groups. Cerebral infarction was the most commonly 
seen stroke type (58.33% in intervention group vs. 61.54% in control group), followed 
by cerebral haemorrhage. One case of concurrent cerebral infarction and haemorrhage 
was reported in each group. In terms of lesion sites, participants with lesions in the 
left hemisphere made up the greatest proportion (41.67% in intervention group vs. 
61.54% in control group) as compared to right hemisphere, brain stem and multiple 
lesions. Consequently, the paralysed side of most was the right side. In addition, all 
the participants had undergone acupuncture therapy before they were recruited into 
the trial. 
Risk factors including infection (two in each group), constipation (zero in intervention 
group vs. one in control group), calculi (zero in intervention group vs. one in control 
group) and combinations of these (one in each group) were reported. As for other 
post-stroke complications, two patients in the control group were reported to have 
shoulder subluxation and five to have shoulder-hand syndrome (two in intervention 
group and three in control group). Moreover, seven participants (four in intervention 
group and three in control group) were undergoing anti-spasticity therapies, such as 
oral Baclofen, type A botulinum toxin injection and spasmodic machines, when 
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recruited and during the trial. The other 18 participants did not receive anti-spasticity 
medications or spasmodic machine rehabilitation treatment during the research 
project. 
Table 7.3 Baseline characteristics of participants in electro-acupuncture pilot 
trial 
Characteristics Intervention 
group (n=12) 
Control group 
(n=13) 
Age, year (mean ± SD) 63.50±15.03 56.23±11.58 
Gender (male) 8 (66.67%) 11 (84.62%) 
Setting (inpatient dept) 12 (100%) 13 (100%) 
Stroke type   
–Cerebral infarction 7 (58.33%) 8 (61.54%) 
–Cerebral haemorrhage 4 (33.33%) 4 (30.77%) 
–Cerebral infarction and Haemorrhage 1 (8.33%)  1 (7.69%) 
Lesion sites   
–Left hemisphere 5 (41.67%) 8 (61.54%) 
–Right hemisphere 3 (25.00%) 2 (15.38%) 
–Brain stem 1 (8.33%)  2 (15.38%) 
–Multiple 3 (25.00%) 1 (7.69%) 
Paretic side (right) 7 (58.33%) 8 (61.54%) 
Post-stroke period (months) (mean ± SD) * 1.92±1.38 4.77±2.80 
Risk factor or inducement 3 (25.00%) 5 (38.46%) 
–Infection 2 (16.67%) 2 (15.38%) 
–Constipation 0 (0.00%) 1 (7.69%) 
–Calculi 0 (0.00%) 1 (7.69%) 
–Multiple 1 (8.33%)  1 (7.69%) 
Other post-stroke complications 2 (16.67%) 5 (38.46%) 
–Shoulder subluxation 0 (0.00%) 2 (15.38%) 
–Shoulder-hand syndrome 2 (16.67%) 3 (23.08%) 
Anti-spasticity treatment 4 (33.33%) 3 (23.08%) 
–Baclofen 1 (8.33%)  2 (15.38%) 
–Type A botulinum toxin injection 1 (8.33%)  0 (0.00%) 
–Spasmodic machine 2 (16.67%) 0 (0.00%) 
–Multiple 0 (0.00%) 1 (7.69%) 
Note: * significant difference between the two groups (P<0.05). 
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Comparisons of the baseline assessments for the Modified Ashworth Scale, Fugl-
Meyer Assessment and Barthel Index are presented in Table 7.4. The total average 
scores of the MAS were 10.5 in the intervention group and 9.23 in the control group. 
As for the total motor function measured by the FMA, the scores of the intervention 
group and the control group were 27.92 and 33.00, respectively. In terms of BI, the 
intervention group scored 41.67, while the control group scored 53.85. In summary, 
no significant differences were found between the two groups on clinical 
characteristics or baseline demographic data except for a longer post-stroke period in 
the control group (1.92 vs. 4.77 months, p=0.00). 
Table 7.4 Baseline comparison of Modified Ashworth Scale, Fugl-Meyer 
Assessment and Barthel Index in electro-acupuncture pilot trial 
 Intervention group (n=12) Control group (n=13) 
MAS (mean±SD)   
–MAS (shoulder) 1.33±1.07 1.08±0.49 
–MAS (elbow) 1.75±0.97 1.85±0.80 
–MAS (wrist) 1.83±1.12 1.54±1.13 
–MAS (hip) 1.75±1.14 1.38±1.33 
–MAS (knee) 2.00±0.85 1.92±0.86 
–MAS (ankle) 1.83±1.03 1.46±0.88 
–MAS (total) 10.50±5.07 9.23±3.56 
FMA (mean±SD)   
–Upper-limb FMA 15.17±11.71 17.38±14.64 
–Lower-limb FMA 12.75±7.44 15.62±7.18 
–Total FMA 27.92±15.79 33.00±20.44 
BI (mean±SD) 41.67±22.80 53.85±18.16 
Notes: BI, Barthel Index; FMA, Fugl-Meyer Assessment (motor function); MAS, Modified 
Ashworth Scale; SD, standard deviation. 
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7.7.3 Clinical effects 
A general linear model was used to check if there was an interactive effect between 
the interventions and post-stroke period and between-group differences. Interactive 
effects were not detected in any of the comparisons. We did not detect an interactive 
effect in any of the comparisons. We found no significant differences between groups 
in relation to changes in MAS, FMA (motor) and BI scores from weeks 0–4, 0–8 or 
4–8 (Table 7.5). There was also no significant difference between groups after 
intention-to-treat analysis with multiple imputations or per-protocol analysis (Table 
7.5). We compared the total MAS, FMA (motor) and BI scores at weeks four and 
eight, but again found no differences between groups (Table 7.5).  
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Table 7.5 Treatment in electro-acupuncture pilot trial 
 Outcomes Groups (No. 
Participants) 
Mean a SD a F test b 
End-of-
treatment 
(Week 4) 
MAS (total score) IG (n=12) 10.42 4.83 F(1,22)=3.52, 
p=0.07 CG (n=13) 10.54 3.71 
FMA (total score) IG (n=12) 28.50 12.75 F(1,22)=1.17, 
p=0.29 CG (n=13) 35.92 20.89 
BI (total score) IG (n=12) 47.92 20.94 F(1,22)=0.65, 
p=0.43 CG (n=13) 57.31 20.58 
End-of-
follow-up 
(Week 8) 
Per 
protocol 
analysis 
MAS (total score) IG (n=12) 11.58 5.04 F(1,19)=2.24, 
p=0.15 CG (n=10) 12.50 4.33 
FMA (total score) IG (n=12) 32.08 13.62 F(1,19)=0.14, 
p=0.71 CG (n=10) 33.60 10.23 
BI (total score) IG (n=12) 50.00 21.74 F(1,19)=0.23, 
p=0.64 CG (n=10) 60.50 15.54 
End-of-
follow-up 
(Week 8) 
ITT 
analysis 
MAS (total score) IG (n=12) 11.58 5.04 F(1,22)=2.35, p= 
0.14 CG (n=13) 12.01 3.87 
FMA (total score) IG (n=12) 32.08 13.62 F(1,22)=0.13, 
p=0.72 CG (n=13) 37.40 19.47 
BI (total score) IG (n=12) 50.00 21.74 F(1,22)=0.41, 
p=0.53 CG (n=13) 59.88 20.58 
Notes: BI, Barthel Index; CG, controlled group; FMA total, total motor score of Fugl-Meyer 
Assessment; MAS total, total scores of Modified Ashworth Scale in six joints on hemiplegic 
side; IG, intervention group; SD, standard deviation; a: not adjusted by baseline value, b: 
results of ANCOVA with baseline value as a covariate.  
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7.7.4 Safety assessment 
Although a total of 37 adverse events (33 reports of post-stroke complications, 
including ten of respiratory tract infection; five of limb discomfort; three of urinary 
tract infection, insomnia and constipation respectively; two of itching skin and two of 
depression; one of dizziness, diarrhoea, poor appetite, fungal infection in left toe and 
transient elevation of blood pressure respectively; as well as four newly developed 
conditions [two events of periodontitis, one of blepharitis and one of otitis externa]) 
were observed in 18 participants (10 in intervention group and 8 in control group) in 
the pilot trials, none of these were assessed as related to the electro-acupuncture 
treatment. All of these 37 adverse events (23 in intervention group and 14 in control 
group) were relieved or healed when appropriate treatments were applied. Statistical 
analysis for electro-acupuncture–related adverse events was not performed due to 
insufficient data. 
7.8 Discussion 
7.8.1 Summary of the pilot trial 
Based on the synthesis results of a systematic review (Cai et al. 2017), this trial was 
designed to evaluate the effects and safety of electro-acupuncture plus routine care for 
post-stroke spasticity with a semi-pragmatic electro-acupuncture intervention 
protocol. Evaluations of Modified Ashworth Scale, Fugl-Meyer Assessment and 
Barthel Index scores, as well as adverse events, were recorded and reported over a 
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four-week treatment and four-week follow-up period. This study incorporated 
appropriate allocation concealment and blinding of assessors/statisticians, and has 
been reported in accordance with CONSORT 2010 and Standards for Reporting 
Intervention in Clinical Trials of Acupuncture 2010 (MacPherson et al. 2010; Schulz, 
Altman and Moher 2010). 
7.8.2 Electro-acupuncture treatment protocol 
The electro-acupuncture treatment protocol, including the electrical stimulation 
frequency, optional acupuncture points, number, frequency and duration of treatment, 
was designed based on the results of a systematic review (Cai et al. 2017). It is worth 
noting that, although there is no consensus on the selection of acupuncture points for 
electro-acupuncture in post-stroke spasticity, it has been reported that electrical 
stimulation might induce muscle contraction (Andersson and Lundeberg 1995). 
Acupuncture practitioners were required to avoid stimulating acupuncture points 
located in the spasm muscles, and the maximum number of acupuncture points for 
electro-acupuncture on the affected side of the body was limited to three pairs (Wang 
and Xie 2010).  
Selection of an appropriate electrical stimulation frequency was one of the major 
challenges in the study design. We referred to the results of our systematic review 
(Cai et al. 2017) and selected a biphasic continuous waveform (50–100 Hz) at 
patients’ maximum tolerable intensity for the following reasons: first, there is no 
specific instruction or consensus for electrical stimulation frequency and waveform 
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from existing publications that could guide the selection of electro-acupuncture 
parameters for spasticity; second, it has been reported that visible muscle contraction 
is likely to be induced at a low electrical stimulation frequency (Andersson and 
Lundeberg 1995); and third, all published randomised controlled trials included in the 
meta-analysis (Cai et al. 2017) used a biphasic continuous waveform. After discussion 
with acupuncturists at GPHCM, where the trial was conducted, we decided to use a 
biphasic continuous waveform (50–100 Hz) in this trial. 
7.8.3 Control method for electro-acupuncture trial 
In order to achieve a more pragmatic control method, routine care including 
pharmacotherapy and rehabilitation treatment was not strictly standardised. Pseudo-
acupuncture, sham acupuncture and placebo acupuncture were considered 
inappropriate choices for the control. On one hand, positive physiological effects of 
pseudo and sham acupuncture with needle insertion have been observed (Koog 2016; 
Wong, Leung and Zhang 2015; Zhu, Gao et al. 2013). In this situation, treatment 
effects of acupuncture are underestimated when compared with pseudo or sham 
acupuncture. On the other hand, this pilot trial recruited stroke patients from a 
hospital in mainland China, where electro-acupuncture is well accepted and widely 
used. Patients were generally familiar with electro-acupuncture, making participant 
blinding difficult (Lim et al. 2015). 
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7.8.4 Selection of outcome measures 
Due to the complex relationship between post-stroke pathological lesions and various 
complications, it is difficult to attribute changes in impairment, function and activity 
after stroke to spasticity alone (Johnson 2002). Spasticity can impact on stroke 
patients in various ways (Nair and Marsden 2014). Therefore, the assessment of 
stroke patients with spasticity should not be limited to the severity of spasticity but 
should include a comprehensive measurement of motor function and the activities of 
daily living in general. 
The Modified Ashworth Scale in the upper and lower extremities has demonstrated 
adequate to excellent test–retest reliability among stroke patients (Blackburn, van 
Vliet and Mockett 2002). In terms of inter-rater reliability, high agreement is detected 
with the Modified Ashworth Scale when assessment is made by a single rater, but 
there is poor reliability between different examiners, particularly for the Modified 
Ashworth Scale in the lower limbs (Blackburn, van Vliet and Mockett 2002).  
With regards to validity, the Modified Ashworth Scale has been criticised for 
producing a global assessment of the resistance to passive movement of an extremity 
rather than a specific assessment of stretch-reflex hyperexcitability (Kamper, Schmit 
and Rymer 2001; Scholtes et al. 2006). While the ability of the Modified Ashworth 
Scale to distinguish between functional and mechanical properties of muscle has been 
questioned (van Wijck et al. 2001), it is considered the primary measure of muscle 
spasticity with widespread clinical acceptance. In fact, the Modified Ashworth Scale 
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is considered the current clinical gold standard, recommended by the American 
Physical Therapy Association, in the absence of objective clinical tools for measuring 
spasticity that are clinically feasible and easily interpreted by clinicians (Aloraini et 
al. 2015; Neurology Section of American Physical Therapy Association 2011). 
Although there are not yet officially translated Chinese versions of the Modified 
Ashworth Scale and Fugl-Meyer Assessment, the outcome assessor for our trial is a 
professional rehabilitation therapist with many years’ experience in using the 
Modified Ashworth Scale and Fugl-Meyer Assessment in clinical practice, so we 
consider the use of these outcome measures acceptable in this trial. 
The Fugl-Meyer Assessment is one of the most widely accepted and recommended 
quantitative assessment tools for evaluating the recovery of stroke patients in both 
clinical and research settings. It has excellent performance in reliability and validity 
(Page, Hade and Persch 2015) in relation to motor function, although criticism has 
been made of the representation of distal fine motor function and finger movement 
(Gladstone, Danells and Black 2002).  
The Barthel Index was originally published in 1965 and has been widely accepted, 
used and studied with adequate to excellent validity and reliability (Leung, Chan and 
Shah 2007; Lin et al. 2010; Rollnik 2011). More recently, a new outcome measure, 
the Functional Independence Measure, was developed to replace the Barthel Index for 
accessing activities of daily living (Dromerick, Edwards and Diringer 2003). Uptake 
of this new assessment tool in trials involving Chinese people with post-stroke 
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spasticity is low. Given that the Barthel Index is widely accepted, used, studied and 
reported in China (Leung, Chan and Shah 2007) and that the psychometric properties 
of the Functional Independent Measure instrument and the Barthel Index are similar 
(Hsueh et al. 2002; Neurology Section of American Physical Therapy Association 
2011), the Barthel Index was selected for this trial. This allows for comparison of our 
results with other studies. 
Results of the study might provide evidence of high methodological and reporting 
quality related to the effects and safety of adjunct electro-acupuncture for post-stroke 
spasticity, with comprehensive evaluations of muscle tone, motor function and 
activities of daily living. 
7.8.5 Feasibility 
The findings from our pilot trial suggest that a full-scale randomised controlled trial is 
feasible and manageable. However, future studies are needed to confirm the 
effectiveness and safety of adjunct electro-acupuncture for treating post-stroke 
spasticity. Although a statistically meaningful result was not obtained in this study, 
there are several reasons why a full-scale randomised controlled trial is feasible. 
Firstly, in terms of recruitment and compliance, around 80% (58 out of 72) of the 
people we screened were interested in participating in the study, and more than half of 
them (30 out of 58) met the selection criteria and were recruited (Figure 7.2). Of those 
who declined to remain involved at the stage of screening (19.4%, 14 out of 72) and 
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group allocation (16.7%, five out of 30) (Figure 7.2), the main reason was their 
relocating to other hospitals for further rehabilitation. This indicates that recruiting 
eligible participants from clinical departments is feasible. Based on the recruitment 
rate of this pilot study, to achieve an estimated sample size of 136 for a trial, around 
392 people would need to be screened. Considering the pilot study was completed 
within 10 months, recruiting people from multiple sites would help to reduce the time 
required to recruit a larger cohort. 
Second, participants and acupuncturists accepted the electro-acupuncture treatment 
protocol well. No one dropped out in the treatment phase, and loss of participants in 
the follow-up phase was just 12%, with the main reason for this being the 
participant’s relocation to another hospital. The treatment frequency (three sessions 
each week) was well managed by two acupuncture practitioners. The duration and 
number of acupoints for electrical stimulation in each treatment session was also well 
tolerated since there were no acupuncture-related adverse events. 
Third, this pilot trial was well implemented in accordance with its study design in 
terms of randomisation, allocation concealment and blinding of outcome assessors. To 
ensure trials are implemented in accordance with the study design, the researchers at 
each trial site must be well trained. We also recommend regular inspections of trial 
implementation and data monitoring are done. 
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7.8.6 Effectiveness 
As noted, we found no significant differences between the intervention and control 
groups for any outcome measure in this study (Tables 7.5, Figures 7.3–7.5). Several 
possible reasons might explain the negative results. Firstly, this may be due to the 
small sample size, or because the periods of intervention and assessment were not 
long enough to detect electro-acupuncture’s potential sustained therapeutic effects 
(Figure 7.3). Based on this pilot trial’s results and the overall positive trend towards 
the intervention group of total MAS score (Figure 7.3), future studies should include a 
longer therapeutic and observation period. Specifically, during the treatment phase 
(Weeks 0 to 4) of this pilot trial, the intervention group’s MAS score remained steady, 
but gradually increased during the follow-up phase (Weeks 4 to 8). Although no 
statistical between-group differences were detected during the follow-up phase, the 
increase in MAS scores in the intervention group was smaller than that of the control 
group. The MAS score of the control group continued increasing in a similar manner 
in both the treatment phase and follow-up phase. Therefore, as suggested in Figure 
7.3, during the treatment phase electro-acupuncture therapy might have helped to 
minimise the worsening of spasticity in the follow-up phase. With a longer 
observation period, we may see this change further increase to suggest that electro-
acupuncture is superior to usual care alone, due to electro-acupuncture’s potential 
sustained therapeutic effects (Figure 7.3, Armour et al. 2017; Kumnerddee and 
Pattapong 2012). In addition, electro-acupuncture had no superior additional 
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therapeutic effects over traditional rehabilitation treatments for post-stroke spasticity. 
The hypothesis of the adjunct treatment effects of electro-acupuncture was mainly 
based on the systematic review (Cai et al. 2017) summarising existing evidence, 
which has been assessed to be of low methodological quality and so might have 
biased the results. Considering the limitations of this trial, further research with a 
rigorous study design exploring the efficacy of electro-acupuncture for specific 
muscle spasticity in stroke survivors is needed. 
 
Figure 7.3 Change in (Modified) Ashworth Scale in electro-acupuncture pilot 
trial 
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Figure 7.4 Change in Fugl-Myer Assessment in electro-acupuncture pilot trial 
238 
 
 
Figure 7.5 Change in Barthel Index in electro-acupuncture pilot trial 
7.8.7 Safety 
In this pilot trial, 18 participants reported various adverse events. However, all 
adverse events were relieved or healed when appropriate treatments were used. None 
of these adverse events were considered to be caused by electro-acupuncture, 
although the relationship between these adverse events and electro-acupuncture was 
mostly a subjective process based on the assessors’ clinical experience and judgement. 
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7.8.8 Comparison with other trials and interventions 
By comparing the results of this pilot study with the results of our meta-analysis (Cai 
et al. 2017), it has been found that the synthesised results were much more favourable 
than the treatment effects of the intervention and control groups in our pilot study. As 
mentioned in the systematic review, previously published trials had methodological 
flaws in terms of sequence generation, allocation concealment and blinding. Our 
study was rigorous in its methodology, which might have reduced potential selection 
and performance bias, and produced more conservative results. 
Moreover, as mentioned above, electro-acupuncture is a modified type of acupuncture 
with electrical current passing through pairs of inserted needles on acupoints. 
Therefore, it shares the features of electrical stimulation and acupuncture, so 
potentially integrates the effects of adjustable and quantifiable electrical stimulation 
with the effects of manual acupuncture. Evidence has been synthesised for electrical 
stimulation, such as neuromuscular electric stimulation or transcutaneous electrical 
stimulation (Stein et al. 2015) and recommendations have been made for its use in the 
management of spasticity (Australian National Stroke Foundation 2017; Chinese 
Society of Neurology et al. 2017; Chinese Society of Neurology and Stroke 
Prevention Project Committee of National Health and Family Planning Commission 
in China 2012; Hebert et al. 2016; Royal College of Physicians Intercollegiate Stroke 
Working Party 2016; Winstein et al. 2016). But evidence around the use of manual 
acupuncture in the management of spasticity is inconsistent and poor quality (Lim et 
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al. 2015; Wu, Mills et al. 2010; Australian National Stroke Foundation 2017; Chinese 
Society of Neurology et al. 2017; Chinese Society of Neurology and Stroke 
Prevention Project Committee of National Health and Family Planning Commission 
in China 2012; Hebert et al. 2016; Royal College of Physicians Intercollegiate Stroke 
Working Party 2016; Winstein et al. 2016). Therefore, further research is needed to 
assess acupuncture’s effects on post-stroke spasticity, and to compare different 
therapies for post-stroke spasticity and explore their underlying mechanisms of action. 
7.8.9 Limitations 
As discussed above, the limitations of this pilot trial include the small sample size, 
which was inadequate to confirm the effectiveness of adjunct electro-acupuncture for 
post-stroke spasticity. Moreover, subgroup analysis was not conducted due to the 
small sample size. Therefore, related information on how age, gender, type of stroke, 
baseline Modified Ashworth Scale score and post-stroke period would affect the 
effects of electro-acupuncture, and which affected joint might benefit most from 
electro-acupuncture treatment, remains unknown. These data are yet to be produced 
by the full-scale trial.  Another concern is the increase in statistical heterogeneity and 
the difficulty in interpretation of the results caused by the diversity in acupoint 
selection. Considering the complexity of spasticity in different muscles among stroke 
survivors in clinical practice, difference and flexibility in acupoint selection were 
permitted in this pragmatic randomised controlled trial. Additionally, in this pilot trial 
we measured the overall change of spasticity severity with the Modified Ashworth 
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Scale, adding the results for six different joints in the upper and lower limbs, in an 
attempt to provide an overall, rather than specific, assessment of change in the 
severity of spasticity. The potential specific treatment effects of individual acupoints 
for specific areas of muscle spasticity should be explored in future research. In 
addition, a relatively short period of treatment and assessment might have limited the 
trial in exploring the possible sustained effects of electro-acupuncture. 
7.9 Conclusions 
Based on this pilot trial’s findings, a full-scaled RCT is can be appropriately 
conducted and would allow us to evaluate the effectiveness and safety of EA for 
treating post-stroke spasticity. Cost-effectiveness studies are also needed to weigh up 
the risks and benefits of this intervention in different populations and regions. 
7.10 Trial status 
The pilot study began recruiting participants in March 2017 and was completed in 
January 2018. 
7.11 Funding 
This trial has been supported by the Specific Research Fund for TCM Science and 
Technology of Guangdong Provincial Hospital of Chinese Medicine (2016)’ (No. 
YN2016QL01) and the ‘National Key Technology R&D Program for the 12th Five-
year Plan of Ministry of Science and Technology, China’ (No. 2013BAI02B10).  
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Chapter 8 Main findings, discussion and conclusion 
 
This chapter summarises the main outcomes of the research project and discusses the 
strengths and limitations of Chinese medicine for post-stroke spasticity. Suggestions 
for future studies and clinical practice are also provided. 
This research project has systematically evaluated the effects and safety of Chinese 
medicine interventions for the management of post-stroke spasticity by: 
1) Data mining of the classical literature to identify citations about symptoms possibly 
or likely related to post-stroke spasticity and summarisation of frequently recorded 
Chinese herbal medicine therapies, formulas, herbs, acupuncture therapies and 
acupuncture points; 
2) Systematic review and meta-analysis of the add-on effects and safety of Chinese 
herbal medicine for post-stroke spasticity with a comprehensive search, screening and 
evaluation of the evidence of modern studies from five English and four Chinese 
databases; 
3) Systematic review and meta-analysis of the effects and safety of acupuncture and 
its related therapies (covering manual acupuncture, acupressure, moxibustion and 
electro-acupuncture) for post-stroke spasticity, also with the same search, screening 
and evaluation of evidence of modern studies from five English and four Chinese 
databases; and 
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4) Development of a protocol of and conduct of a pilot randomised controlled trial of 
adjunct electro-acupuncture for post-stroke spasticity with a rigorous study design, 
aiming to address the limitations in methodology and reporting quality in previously 
published studies, and to assess the feasibility of a full-scale trial. 
8.1 Main achievements 
8.1.1 Data mining of classical literature 
Based on the search and screening results from Zhong Hua Yi Dian (ZHYD 中华医典
Version 5.0) (Zhong Hua Yi Dian 2014), citations were extracted and ranked on two 
levels according to their relevance to post-stroke spasticity. Classical understanding of 
the post-stroke spasticity aetiology was summarised by dynasty with a general change 
from external Wind to internal factors, such as internal deficiency, Phlegm and Heat.  
In addition, various therapies, formulas, herbs and acupuncture points were identified 
and frequencies were calculated. Specifically, San huang tang 三黄汤, Xu ming tang 
续命汤 and Xiao xu ming tang 小续命汤 were the three most frequently cited 
formulas in citations likely related to post-stroke spasticity. As for the ingredients in 
the formulas, fang feng 防风, dang gui 当归 and chuan xiong 川芎 were the three 
most frequently cited herbs, while the Chinese medicine functions of other herbs 
could be categorised into nourishing the Blood and treating Blood Stasis, tonifying 
the qi 气, Spleen or Kidney, eliminating Wind and unblocking the meridians.  
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Similarly, in terms of acupuncture points, although considering Chinese medicine 
syndrome differentiation, local and/or adjacent points were more commonly selected, 
with LI15 Jianyu 肩髃, LI11 Quchi 曲池 and LI4 Hegu合谷 the three most 
commonly reported acupuncture points in citations judged likely related to post-stroke 
spasticity. 
8.1.2 Systematic review of Chinese herbal medicine for post-stroke spasticity 
We then conducted a systematic review and meta-analysis to evaluate the add-on 
effects and safety of Chinese herbal medicine for post-stroke spasticity, specifically in 
terms of resistance in passive stretches as measured by the Ashworth Scale or 
Modified Ashworth Scale, motor function as measured by the Fugl-Meyer Assessment 
and activities of daily living as measured by the Barthel Index. Twenty-four (24) 
studies were included in the meta-analysis.  
Noting the quality concerns about the included trials, this review suggested that 
Chinese herbal medicine was a potentially effective and well-tolerated add-on therapy 
to reduce spasticity and improve daily activities. Specifically, oral Chinese herbal 
medicine with bai shao 白芍 and gan cao 甘草 was most commonly reported, while 
topical Chinese herbal medicine containing bai shao 白芍, dang gui 当归 and hong 
hua 红花 used in steaming therapy seemed the best option. Mild self-healing adverse 
events were reported in the intervention group with topical Chinese herbal medicine, 
but its connections to these adverse events has not been explored. 
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8.1.3 Systematic reviews of acupuncture and related therapies for post-stroke 
spasticity 
After the Chinese herbal medicine systematic review, systematic reviews and meta-
analyses were conducted to evaluate the effects and safety of acupuncture and related 
therapies for stroke patients with spasticity. Based on the results of the systematic 
reviews, it was found that, although Chinese herbal medicine demonstrated potential 
additional therapeutic effects for post-stroke spasticity, there was high clinical 
heterogeneity in terms of the herbs and formulas used among the included studies. 
As for acupuncture and related therapies (covering manual acupuncture, acupressure, 
moxibustion and electro-acupuncture), manual acupuncture and electro-acupuncture 
were more frequently used and studied. And compared to manual acupuncture, the 
frequency and intensity of electro-acupuncture can be standardised and repeated 
easily, ensuring participants in clinical studies receive the same amount of stimulation 
(Smith et al. 2010). Additionally, electro-acupuncture was found to be more effective 
than manual acupuncture in a previous systematic review evaluating acupuncture for 
post-stroke spasticity (Cai et al. 2017). Therefore, electro-acupuncture was selected as 
the intervention for further meta-analysis. 
Further, the systematic review and meta-analysis of electro-acupuncture summarised 
specific details of the study designs, basic characteristics of participants, electro-
acupuncture treatment protocols and outcome measures of the included studies, which 
would be helpful for further research in study design. 
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8.1.4 Pilot randomised controlled trial of adjunct electro-acupuncture for post-
stroke spasticity 
We then developed a study protocol for a single-centred, open-labelled, parallel pilot 
randomised controlled trial with a four-week treatment phase and a four-week follow-
up period in order to evaluate the add-on effects and safety of adjunct electro-
acupuncture for post-stroke spasticity, and conducted a pilot study to assess the 
feasibility of the full-scale trial. Twenty-five (25) patients were included in the pilot 
randomised controlled trial and data analysis. No significant between-group 
differences were detected for the Modified Ashworth Scale, Fugl-Meyer Assessment 
or Barthel Index scores, while 17 adverse events were reported but their causality was 
deemed not to be related to the electro-acupuncture intervention. Overall, the pilot 
trial suggests that a full-scale randomised controlled trial is feasible and manageable. 
Future studies are warranted to confirm the effects and safety of adjunct electro-
acupuncture for post-stroke spasticity. 
8.1.5 Significance 
The entire research project for post-stroke spasticity has been conducted in the 
following way: data mining of the classical literature; systematic review and meta-
analysis of Chinese herbal medicine; systematic review and meta-analysis of 
acupuncture (covering manual acupuncture, acupressure, moxibustion and particularly 
electro-acupuncture); as well as a pilot randomised controlled trial of electro-
acupuncture. This coherent study approach has not only summarised the synthesis of 
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results and identified the limitations of current evidence which had not been 
comprehensively evaluated, but had also assessed the feasibility and refined the 
methodology of a pilot randomised controlled trial, whose full-scale study is aimed at 
providing high-quality evidence of adjunct electro-acupuncture for post-stroke 
spasticity. 
8.2 Limitations 
8.2.1 Data mining of classical literature 
First, due to the large volume of Chinese medicine classical literature, data mining 
was limited to the book collection in Zhong Hua Yi Dian (ZHYD 中华医典 Version 
5.0) (Zhong Hua Yi Dian 2014), one of the largest classical literature databases for 
Chinese medicine. Compared to another database, the Chinese Materia Medica 
containing more than 6,000 books, the Zhong Hua Yi Dian (ZHYD 中华医典 Version 
5.0) (Zhong Hua Yi Dian 2014) was chosen for this project because it is electronically 
available, easily accessible and searchable. 
Second, search terms for data mining of the classical literature were selected from 
related textbooks and monographs, including names and symptoms of stroke and 
increased muscle tone, which on one hand might be influenced by changing 
terminology over time, and on the other hand could hardly cover all the related terms 
and might lead to omission in identifying citations. 
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Third, included citations were categorised into pools either possibly or likely related 
to post-stroke spasticity based on how similar the symptom description in the classical 
literature is similar to that in modern medicine. Although the selection criteria were 
predefined, objective bias was inevitable because judgement still relied heavily on the 
researchers’ understanding of the information provided by the citations. Different 
categorisation of the citations might influence the results for frequently cited Chinese 
medicine interventions in the classical literature. 
Fourth, caution should be given when considering the application of formulas, herbs 
or acupuncture therapies summarised from the classical literature in current clinical 
practice, because the efficacy and safety of these interventions are still in need of 
proper evaluation and confirmation by experimental and clinical studies. 
8.2.2 Systematic review of Chinese herbal medicine 
First, safety issues were inadequately reported among the included studies. Most of 
the included randomised controlled trials did not provide any information concerning 
the safety of Chinese herbal medicine treatment and none included a follow-up 
assessment. Therefore, there is insufficient evidence to evaluate the long-term safety 
of Chinese herbal medicine therapies and future studies are encouraged to address this 
issue. 
Second, concerns over the methodological quality of included studies limited our 
confidence in drawing the conclusion. For instance, improper randomisation and 
allocation in the included randomised controlled trials and lack of blinding could have 
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led to selection and performance bias, and might have resulted in overestimation or 
underestimation of the treatment effects. Additionally, none of the included studies 
applied a placebo-control design. Therefore, the placebo effect cannot be ruled out as 
part of the add-on effects of Chinese herbal medicine. Future studies with a rigorous 
study design are needed to confirm or otherwise the efficacy of Chinese herbal 
medicine. 
Third, inadequate reporting is not uncommon among the included studies, which 
might limit the translation of the synthesis results into further assessment and clinical 
practice. Future studies are recommended to report key items in accordance with 
CONSORT 2010 and its extensions for herbal intervention and Chinese herbal 
medicine formulas (Cheng et al. 2017; Gagnier et al. 2006; Schulz, Altman and Moher 
2010). 
8.2.3 Systematic reviews of acupuncture and related therapies 
Similar to the systematic review of Chinese herbal medicine, the results of the 
systematic reviews of acupuncture and related therapies, particularly the systematic 
review and meta-analysis of electro-acupuncture, were limited by the lack of long-
term safety assessment and relatively low quality in methodology and reporting. In 
contrast to studies with Chinese herbal medicine, a placebo-control design for 
complex interventions such as acupuncture, acupressure and moxibustion would be 
more difficult due to the potential physiological effects of sham and placebo 
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acupuncture (Linde, Niemann, and Meissner 2010; Hrobjartsson and Gotzsche 2010; 
Kaptchuk et al. 2000). 
Another concern over the synthesis results of the meta-analyses was the high 
heterogeneity across the included studies in terms of basic characteristics, 
acupuncture techniques and treatment protocols. Standardisation of treatment 
protocols might bring benefits in the comparison, synthesis and generalisation of 
similar studies. 
8.2.4 Pilot electro-acupuncture trial 
As a pilot trial, the study included only a small sample size to test the feasibility of 
conducting a full-scaled trial. Therefore, further analysis of how different basic 
characteristics affected the results was not practical. Nevertheless, the relatively short 
treatment phase and follow-up period prevented us from drawing a conclusion on the 
long-term safety of electro-acupuncture therapy. 
8.3 Implications for clinical practice 
Although the following implications are given based on systematic reviews of limited 
numbers of studies also limited by methodological quality, we hope that these 
findings will be considered in the context of clinical decision making and future 
research priority setting with a clear focus of developing stronger evidence to support 
effective use of therapies for this condition. 
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For Chinese herbal medicine therapy, the synthesised results from the subgroup 
analyses of the meta-analysis suggest that patients with spasticity within 180 days 
after stroke were more likely to receive additional benefits from the use of Chinese 
herbal medicine therapy. In terms of specific herbs, bai shao 白芍 and gan cao 甘草 
were the most frequently reported orally used herbs and a combination of topically 
used bai shao 白芍, Dang Gui 当归 and hong hua 红花 showed promising treatment 
effects. Steaming was observed to have better results than compression for post-stroke 
spasticity. 
In terms of acupuncture and related therapies, the following acupuncture points were 
frequently reported by the included studies: LI4 Hegu 合谷, SP6 Sanyinjiao 三阴交, 
SJ5 Waiguan 外关, LI11 Quchi 曲池, ST36 Zusanli 足三里, LU5 Chize 尺泽, SP9 
Yinlingquan 阴陵泉. For electro-acupuncture, we identified acupuncture points from 
the systematic review and meta-analysis of electro-acupuncture, and points could be 
selected depending on the treatment needed for the joints affected by spasticity, 
including LI4 Hegu 合谷, TE5 Waiguan 外关, LI10 Shousanli 手三里, LI11 Quchi 曲
池 (elbow), LI15 Jianyu 肩髃 (shoulder), GB34 Yanglingquan 阳陵泉, ST36 Zusanli 
足三里, ST40 Fenglong 丰隆 (knee), SP6 Sanyinjiao 三阴交 (ankle) and LR3 
Taichong 太冲 (toe joint). The number of acupuncture points with electrical 
stimulation ranged from two to 14 with an average of eight. 
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8.4 Implications for future research 
8.4.1 Potential active ingredients and mechanisms 
We conducted a general analysis of the mechanisms of frequently reported herbs, 
including bai shao 白芍, gan cao 甘草, dang gui 当归 and hong hua 红花. Related 
therapeutic effects might include neuroprotective activity, anti-inflammatory effects 
via inhibiting HMGB1 secretion and neurotoxicity by suppression of glutamate-
induced apoptosis, and anti-spasmodic activity through inhibition of 
phosphodiesterase and decreasing excitatory amino acid content etc. 
For acupuncture and related therapies, previous studies suggested the underlying 
mechanism of electro-acupuncture is that the stimulations generated at acupuncture 
points might send signals to the central nervous system to regulate the release of 
various neural and neuro-active components in order to help reach a new balance of 
stretch reflex (Wang et al. 2009; Zhang, Wang and McAlonan 2012). The 
neurochemical effects of electro-acupuncture might also be related to different 
peripheral and central pathways’ transmitting signals (Lee and Beitz 1992; Wang et al. 
2009; Zhang, Wang and McAlonan 2012).  
However, since there is no direct evidence on how the above Chinese herbal medicine 
ingredients and application on acupuncture points work, further mechanical and 
clinical studies are needed in order to discover how Chinese medicine therapies work 
individually and interactively. 
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8.4.2 Full-scale study of electro-acupuncture 
Based on the results of the pilot study, the electro-acupuncture treatment protocol is 
suggested to remain the same, since this protocol was developed based on the best 
available evidence and well accepted by both practitioners and participants. In terms 
of the recruitment and compliance of participants, recruiting patients from multiple 
trial sites may be helpful to increase their willingness to participate and their 
compliance, as well as reducing the time required for recruitment. Moreover, to 
ensure the implementation of the trial in accordance with the study design, the 
researchers at each medical centre need to be well trained and regular inspections for 
trial implementation and data monitoring are strongly encouraged. 
8.4.3 Other areas not addressed in this research 
Cost-effectiveness analysis was not conducted in our research, and there was no 
evidence of cost-effectiveness analysis of Chinese medicine therapies identified in our 
literature search of previous systematic reviews and clinical trials. But it has been 
discussed above that the direct cost for patients with spasticity post-stroke is nearly 
four times higher than for those without it (Lundstrom et al. 2010). Therefore, as well 
as evaluation of the efficacy and safety of Chinese medicine, it is essential to explore 
the cost-effectiveness of different Chinese medicine interventions in future studies to 
assist decision-making for policymakers and recommendations for guideline users. 
Overall, based on the synthesised results of this research, current evidence suggests 
that, as add-on interventions, various Chinese medicine interventions have the 
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potential to reduce spasticity, and improve motor function and activities of daily 
living after stroke. However, this conclusion is limited by low methodological and 
reporting quality of the included studies. Therefore, further research is critical to 
confirm the efficacy and safety of these Chinese medicine interventions.  
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Appendices 
Appendix 1 (Modified) (Modified) Ashworth Scales 
Score 
Ashworth Scale 
(Ashworth, 1964) 
(Ashworth 1964) 
Modified Ashworth 
Scale (Bohannon & 
Smith, 1987) 
(Bohannon and 
Smith 1987) 
Modified Modified 
Ashworth Scale (Ansari, 
et al. 2006) (Ansari et al. 
2006) 
0 No increase in tone No increase in muscle 
tone 
No increase in muscle 
tone 
1 Slight increase in 
tone giving a catch 
when the limb was 
moved in flexion or 
extension 
Slight increase in 
muscle tone, 
manifested by a catch 
and release or by 
minimal resistance at 
the end of the range 
of motion when the 
affected part is moved 
in flexion or 
extension 
Slight increase in muscle 
tone, manifested by a 
catch and release or by 
minimal resistance at the 
end of the range of motion 
when the affected part is 
moved in flexion or 
extension 
1+ Not applicable Slight increase in 
muscle tone, 
manifested by a catch, 
followed by minimal 
resistance throughout 
the remainder (less 
than half) of the range 
of motion 
Not applicable 
2 More marked 
increase in tone but 
limb easily flexed 
More marked increase 
in muscle tone 
through most of the 
range of motion, but 
affected parts easily 
moved 
Marked increase in 
muscle tone, manifested 
by a catch in the middle 
range of motion, but 
affected part easily moved 
3 Considerable 
increase in tone, 
passive movement 
difficult 
Considerable increase 
in muscle tone, 
passive movement 
difficult 
Considerable increase in 
muscle tone, passive 
movement difficult 
4 Limb rigid in 
flexion or 
extension 
Affected part rigid in 
flexion or extension 
Affected part rigid in 
flexion or extension 
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Appendix 2 (Modified) Tardieu Scales 
Tardieu Scale (Gracies et al. 2000) 
Grading is always performed at the same time of the day, in a constant position of the body 
for a given limb. Other joints, particularly the neck, must also remain in a constant position 
throughout the test and between tests. For each muscle group, reaction to stretch is rated at a 
specified stretch velocity with two parameters, X and Y. 
Velocity of stretch:  
V1: As slow as possible (minimising stretch reflex). 
V2: Speed of the limb segment falling under gravity. 
V3: As fast as possible (faster than the rate of the natural drop of the limb segment under 
gravity). 
V1 is used to measure the passive range of motion (PROM). 
Only V2 or V3 are used to rate spasticity. 
Quality of muscle reaction (X): 
0: No resistance throughout the course of the passive movement. 
1: Slight resistance throughout the course of the passive movement, with no clear catch at a 
precise angle. 
2: Clear catch at a precise angle, interrupting the passive movement, followed by release. 
3: Fatigable clonus (10 s when maintaining pressure) occurring at a precise angle. 
4: Infatigable clonus (10 s when maintaining pressure) occurring at a precise angle. 
Angle of muscle reaction (Y):  
Measured relative to the position of minimal stretch of the muscle (corresponding to angle 
0) for all joints except hip, where it is relative to the resting anatomic position  
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Modified Tardieu Scale (Boyd and Graham 1999) 
Velocity of stretch: once velocity is chosen for a muscle, it remains the same for all tests. 
V1 
As slow as possible (slower than the natural drop of the limb segment under 
gravity) 
V2 Speed of the limb segment falling under gravity 
V3 
As fast as possible (faster than the rate of the natural drop of the limb segment 
under gravity) 
Quality of muscle reaction (X) 
0 No resistance throughout the course of the passive movement 
1 
Slight resistance throughout the course of passive movement, no clear ‘catch’ at a 
precise angle 
2 
Clear catch at a precise angle, interrupting the passive movement, followed by 
release 
3 
Fatigable clonus (<10 s when maintaining the pressure) appearing at a precise 
angle 
4 Unfatiguable clonus (> 10 s when maintaining the pressure) at a precise angle 
5 Joint immovable 
Angle of muscle reaction (Y) 
Measured relative to the position of minimal stretch of the muscle (corresponding to angle 
zero) for all joints except hip where it is relative to the resting anatomical position. 
Lower limb: to be tested in a supine position, at the recommended joint positions and 
velocities. 
Hip Extensors (knee extended, V3) X Y (degrees) 
 
Adductors (hip flexed/knee flexed, V3) 
 
External rotators (knee flexed by 90º,V3) 
 
Internal rotators (knee flexed by 90º,V3) 
Knee Extensors (hip flexed by 90º, V2) 
 
Flexors (hip flexed, V3) 
Ankle Plantar flexors (knee flexed/extended by 90º,V3) 
Grading is always done at the same time of day, using a constant position of the body for a 
given limb. Other joints, particularly the neck, must remain in a constant position 
throughout the assessment and from one test to another. For each muscle group, reaction to 
stretch is rated at a specified stretch velocity with two parameters (X, Y). 
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Appendix 3 Composite Spasticity Index 
Composite Spasticity Index (Calota and Levin 2009) 
NAME: ___________________________ DATE: d/m/y____________ 
DATE OF BIRTH (d/m/y) __________ AGE: ____ DATE OF INJURY 
_________ 
DESCRIPTION OF INJURY AND TREATMENT HISTORY: 
_________________________________________________________________ 
_________________________________________________________________ 
MEDICATIONS: 
_________________________________________________________________ 
RANGE OF MOTION: WRIST: ________________ ELBOW 
__________________ 
EVALUATION 
TENDON JERK (BICEPS) 
0 No response 
1 Normal response 
2 Mildly hyperactive response 
3 Moderately hyperactive response 
4 Maximally hyperactive response 
RESISTANCE TO FULL RANGE PASSIVE JOINT DISPLACEMENT (e.g. 
elbow extension) 
* performed at moderate speed ( > 100°/s) 
0 No resistance (hypotonic) 
2 Normal resistance 
4 Mildly increased resistance 
6 Moderately increased resistance 
8 Maximally increased resistance 
CLONUS (wrist or ankle) 
1 Clonus not elicited 
2 1–3 beats of clonus elicited 
3 3–10 beats of clonus elicited 
4 Sustained clonus 
================================================= 
COMPOSITE SPASTICITY SCORE _____ / 16 
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Appendix 4 Fugl-Meyer Assessment (motor function) 
Fugl-Meyer Assessment (Sullivan et al. 2011) 
Motor function upper extremity 
Test Item Scoring criteria score 
I. Reflexes Biceps 0 – No reflex activity can be 
elicited 
2 – Reflex activity can be elicited 
 
Triceps  
II. Flexor 
synergy 
Elevation 0 – Cannot be performed at all 
1 – Performed partly 
2 – Performed faultlessly 
 
Shoulder retraction  
Abduction (at least 
90°) 
 
External rotation  
Elbow flexion  
Forearm supination  
III. Extensor 
synergy 
Shoulder add./int. Rot. 0 – Cannot be performed at all 
1 – Performed partly 
2 – Performed faultlessly 
 
Elbow extension  
Forearm pronation  
IV. 
Movement 
combining 
synergies 
Hand to lumbar spine 0 – No specific action performed 
1 – Hand must pass anterior 
superior iliac spine 
2 – Performed faultlessly 
 
Shoulder flexion to 
90°, elbow at 0° 
0 – Arm is immediately abducted, 
or elbow flexes at start of motion 
1 – Abduction or elbow flexion 
occurs in later phase of motion 
2 – Complete pronation and 
supination with correct positions at 
elbow and shoulder 
 
Pronation/supination 
of forearm with elbow 
at 90° & shoulder at 
0° 
0 – Correct position of shoulder and 
elbow cannot be attained, and/or 
pronation or supination cannot be 
performed at all 
1 – Active pronation or supination 
can be performed even within a 
limited range of motion, and at the 
same time the shoulder and elbow 
are correctly positioned 
2 – Complete pronation and 
supination with correct positions at 
elbow and shoulder 
 
V. 
Movement 
out of 
synergy 
Shoulder abduction to 
90°, elbow at 0° and 
forearm pronated 
0 – Initial elbow flexion occurs, or 
any deviation from pronated 
forearm occurs 
1 – Motion can be performed 
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partly, or, if during motion, elbow 
is flexed, or forearm cannot be kept 
in pronation 
2 – Performed faultlessly 
Shoulder flexion 90–
180°, elbow at 0° and 
forearm in mid-
position 
0 – Initial/flexion of elbow or 
shoulder abduction occurs 
1 – Elbow flexion or shoulder 
abduction occurs during shoulder 
flexion 
2 – Performed faultlessly 
 
Pronation/supination 
of forearm, elbow at 
0° and shoulder 
between 30–90° 
flexion 
0 – Supination and pronation 
cannot be performed at all, or 
elbow and shoulder positions 
cannot be attained 
1 – Elbow and shoulder properly 
positioned and pronation and 
supination performed in a limited 
range 
2 – Performed faultlessly 
 
VI. Normal 
reflex 
activity 
Biceps and/or finger 
flexors and triceps 
(this item is only 
included if the patient 
achieves a maximum 
score on all previous 
items, otherwise score 
0) 
0 – At least two of the three phasic 
reflexes are markedly hyperactive 
1 – One reflex is markedly 
hyperactive, or at least two reflexes 
are lively 
2 – No more than one reflex is 
lively and none are hyperactive 
 
VII. Wrist Stability, elbow at 
90°, shoulder at 0° 
0 – Patient cannot dorsiflex wrist to 
required 15° 
1 – Dorsiflexion is accomplished , 
but no resistance is taken 
2 – Position can be maintained with 
some (slight) resistance 
 
Flexion/extension, 
elbow at 90°, shoulder 
at 0° 
0 – Volitional movement does not 
occur 
1 – Patient cannot actively move 
the wrist joint through the total 
range of motion 
2 – Faultless, smooth movement 
 
Stability, elbow at 0°, 
shoulder at 30° 
0 – Patient cannot dorsiflex wrist to 
required 15° 
1 – Dorsiflexion is accomplished , 
but no resistance is taken 
2 – Position can be maintained with 
some (slight) resistance 
 
Flexion/extension, 
elbow at 0°, shoulder 
at 30° 
0 – Volitional movement does not 
occur 
1 – Patient cannot actively move 
the wrist joint through the total 
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range of motion  
2 – Faultless, smooth movement 
Circumduction 0 – Cannot be performed 
1 – Jerky motion or incomplete 
circumduction 
2 – Complete motion with 
smoothness 
 
VIII. Hand Finger mass flexion 0 – No flexion occurs 
1 – Some flexion, but not full 
motion 
2 – Complete active flexion 
(compared with unaffected hand) 
 
Finger mass extension 0 – No flexion occurs 
1 – Patient can release an active 
mass flexion grasp 
2 – Full active extension 
 
Grasp i – mcp joints 
extended and 
proximal & distal ip 
joints flexed; grasp is 
tested against 
resistance 
0 – Required position cannot be 
acquired 
1 – Grasp is weak 
2 – Grasp can be maintained 
against relatively great resistance 
 
Grasp ii – patient is 
instructed to adduct 
thumb, with a scrap of 
paper interposed 
0 – Function cannot be performed 
1 – Scrap of paper interposed 
between thumb and index finger 
can be kept in place, but not against 
a slight tug 
2 – Paper is held firmly against a 
tug 
 
Grasp iii – patient 
opposes thumb pad 
against pad of index 
finger, with a pencil 
interposed 
0 – Function cannot be performed 
1 – Pencil interposed between 
thumb and index finger can be kept 
in place, but not against a slight tug 
2 – Pencil is held firmly against a 
tug 
 
Grasp iv – patient 
grasps a can by 
opposing volar 
surfaces of 1st and 
2nd digits 
0 – Function cannot be performed 
1 – A can interposed between 
thumb and index finger can be kept 
in place, but not against a slight tug 
2 – Can is held firmly against a tug 
 
Grasp v – patient 
grasps a tennis ball 
with a spherical grip 
or is instructed to 
place fingers in a 
position with 
abduction position of 
the thumb and 
abduction flexion of 
0 – Function cannot be performed 
1 – A tennis ball can be kept in 
place with a spherical grasp but not 
against a slight tug 
2 – Tennis ball is held firmly 
against a tug 
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the 2nd, 3rd, 4th & 5th 
fingers 
IX. 
Coordinatio
n/speed – 
finger from 
knee to nose 
(5 
repetitions 
in rapid 
succession) 
Tremor 0 – Marked tremor 
1 – Slight tremor 
2 – No tremor 
 
Dysmetria 0 – Pronounced or unsystematic 
dysmetria 
1 – Slight or systematic dysmetria 
2 – No dysmetria 
 
Speed 0 – Activity is more than six s 
longer than unaffected hand 
1 – (2–5.9) s longer than unaffected 
hand 
2 – Less than two s difference 
 
Upper extremity total Maximum=66  
Motor function – lower extremity 
Test Item Scoring criteria Score 
I. Reflex 
activity 
Achilles 0 – No reflex activity can be 
elicited 
2 – Reflex activity can be elicited 
 
Patellar  
II. A. Flexor 
synergy (in 
supine) 
Hip flexion 0 – Cannot be performed at all 
1 – Partial motion 
2 – Full motion 
 
Knee flexion  
Ankle dorsiflexion  
II. B. 
Extensor 
synergy (in 
side lying) 
Hip extension 0 – Cannot be performed at all 
1 – Partial motion 
2 – Full motion 
 
Adduction  
Knee flexion  
Ankle plantar flexion  
III. 
Movement 
combining 
synergies 
(sitting: 
knees free 
of chair) 
A. Knee flexion 
beyond 90° 
0 – No active motion 
1 – From slightly extended position 
knee can be flexed, but not beyond 
90° 
2 – Knee flexion beyond 90° 
 
B. Ankle dorsiflexion 0 – No active flexion 
1 – Incomplete active flexion 
2 – Normal dorsiflexion 
 
IV. 
Movement 
out of 
synergy 
(standing, 
hip at 0°) 
A. Knee flexion 0 – Knee cannot flex without hip 
flexion 
1 – Knee begins flexion without hip 
flexion, but does not reach 90°, or 
hip flexes during motion 
2 – Full motion as described 
 
B. Ankle dorsiflexion 0 – No active motion 
1 – Partial motion 
2 – Full motion 
 
V. Normal 
reflexes 
(sitting) 
Knee flexors 0 – At least two of the three phasic 
reflexes are markedly hyperactive 
1 – One reflex is markedly 
 
Patellar  
Achilles (this item is  
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only included if the 
patient achieves a 
maximum score on all 
previous items, 
otherwise score 0) 
hyperactive, or at least two reflexes 
are lively 
2 – No more than one reflex is 
lively and none are hyperactive 
VI. 
Coordinatio
n/speed - 
sitting: heel 
to opposite 
knee (5 
repetitions 
in rapid 
succession) 
A. Tremor 0 – Marked tremor 
1 – Slight tremor 
2 – No tremor 
 
B. Dysmetria 0 – Pronounced or unsystematic 
dysmetria 
1 – Slight or systematic dysmetria 
2 – No dysmetria 
 
C. Speed 0 – Activity is more than 6 s longer 
than unaffected side 
1 – (2–5.9) s longer than unaffected 
side 
2 – Less than two s difference 
 
Lower extremity total Maximum=34  
Total motor score (upper extremity + 
lower extremity) 
Maximum=100  
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Appendix 5 (Modified) Barthel Indices 
Barthel Index (1965) (Mahoney and Barthel 1965) 
 With 
Help 
Independent 
1. Feeding (if food needs to be cut=help 5 10 
2. Moving from wheelchair to bed and return (includes sitting 
up in bed) 
5–10 15 
3. Personal toilet (wash face, comb hair, shave, clean teeth) 0 5 
4. Getting on and off toilet (handling clothes, wipe, flush) 5 10 
5. Bathing self 0 10 
6. Walking on level surface (or if unable to walk, propel 
wheelchair)  
0* 5* 
* score only if unable to walk 
7. Ascend and descend stairs 5 10 
8. Dressing (includes tying shoes, fastening fasteners) 5 10 
9. Controlling bowels 5 10 
10. Controlling bladders 5 10 
 
Modified Barthel Index (1981) (Fortinsky, Granger and Seltzer 1981) 
Independent Dependent  
I II III IV 
Intact Limited Helper Null 
10 5 0 0 Drink from cup/ feed from dish 
5 5 3 0 Dress upper body 
5 5 2 0 Dress lower body 
0 0 −2  Don brace or prosthesis 
5 5 0 0 Grooming 
4 4 0 0 Wash or bathe 
10 10 5 0 Bladder continence 
10 10 5 0 Bowel continence 
4 4 2 0 Care of perineum/ clothing at toilet 
15 15 7 0 Transfer, chair 
6 5 3 0 Transfer, toilet 
1 1 0 0 Transfer, tub or shower 
15 15 10 0 Walk on level 50 yards or more 
10 10 5 0 Up and down stairs for one flight or more 
15 5 0 0 Wheelchair/ 50 yards – only if not walking 
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Modified Barthel Index (1988) (Collin et al. 1988) 
Bowels 
0=incontinent (or needs to be given enemata) 
1=occasional accident (once/week) 
2=continent 
Bladder 
0=incontinent, or catheterised and unable to manage 
1=occasional accident (max once per 24 hours) 
2=continent (for over seven days) 
Grooming 
0=needs help with personal care 
1=independent face/hair/teeth/shaving (implements provided) 
Toilet use 
0=dependent 
1=needs some help, but can do some things alone 
2=independent (on and off, dressing, wiping) 
Feeding 
0=unable 
1=needs help cutting, spreading butter, etc. 
2=independent (food provided in reach) 
Transfer 
0=unable – no sitting balance 
1=major help (one or two people, physical), can sit 
2=minor help (verbal or physical) 
3=independent 
Mobility 
0=immobile 
1=wheel chair independent including corners, etc. 
2=walks with help of one person (verbal or physical) 
3=independent (but may use an aid, e.g. stick) 
Dressing 
0=dependent 
1=needs help, but can do about half unaided 
2=independent (including buttons, zips, laces, etc.) 
Stairs 
0=unable 
1=needs help (verbal, physical, carrying aid) 
2=independent up and down 
Bathing 
0=dependent 
1=independent (or in shower) 
Total (0–20) 
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Modified Barthel Index (2001) (Hobart and Thompson 2001) 
Item Response options 
0 1 2 3 
Transfer Unable, no 
sitting 
balance 
Major help (one or 
two people, 
physical), can sit 
Minor help (verbal 
or physical) 
Independent 
Bathing Dependent Independent (or in 
shower) 
(No response option) (No response 
option) 
Toilet 
use 
Dependent Needs some help, 
but can do some 
things alone 
Independent (on and 
off, dressing, 
wiping) 
(No response 
option) 
Stairs Unable Needs help (verbal, 
physical, carrying 
aid) 
Independent  (No response 
option) 
Mobility Immobile Wheelchair 
independent, 
including corners 
Walks with help of 
one person (verbal or 
physical) 
Independent 
(but may use 
an aid – e.g. 
stick) 
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Appendix 6 Functional Independent Measure 
Functional Independent Measure (motor) (Keith et al. 1987) 
 
Admission Discharge Follow-up 
Self-care 
   A. Eating    
B. Grooming    
C. Bathing    
D. Dressing – upper body    
E. Dressing – lower body    
F. Toileting    
Sphincter control    
G. Bladder management    
H. Bowel management    
Transfers    
I. Bed, chair, wheelchair    
J. Toilet    
K. Tub, shower    
Locomotion    
L. Walk/wheelchair    
M. Stairs    
Motor score    
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Appendix 7 Search terms for Chinese language databases 
Stroke-related search terms: 
颅内栓塞和血栓形成 OR 颅内栓塞 OR 颅内血栓形成 OR 脑梗死 OR 脑干梗死 
OR 颅内出血 OR 脑出血 OR 蛛网膜下腔出血 OR 急性脑血管病 OR 卒中 OR 脑
血管意外 OR 脑溢血 OR 脑梗塞 OR 脑血栓 OR 缺血性脑血管病 
Spasticity-related search terms: 
偏瘫 OR 痉挛 OR 关节挛缩 OR 肌张力障碍 OR 肌无力 OR 瘫痪 OR 半身不遂 
OR 康复 OR 运动疗法 OR 功能锻炼 OR 功能训练 
Chinese herbal medicine–related search terms: 
中医 OR 中西医 OR 中医疗法 OR 辨病论治 OR 辨证 OR 辨证论治 OR 辨症施治 
OR 汉方 OR 祖国医学 OR 传统医学 OR 传统治疗 OR 替代医学 OR 替代治疗 
OR 中国传统医学 OR 民族医药 OR 草药 OR 中草药 OR 中药 OR 中药疗法 OR 
中西药 OR 传统医药 OR 中成药 OR 植物药 OR 中医治法 OR 熏洗 OR 药浴 OR 
沐足 OR 足浴 OR 灌肠 OR 熨法 OR 药熨 OR 熨药 OR 热熨 OR 热敷 OR 敷脐 
OR 药枕 OR 药烘 
Acupuncture-related search terms: 
针刺 OR 灸 OR 针法 OR 刺法 OR 体针 OR 腹 OR 温针 OR 火针 OR 电针 OR 电
磁针 OR 梅花针 OR 水针 穴位注射 OR 经络注射 OR 穴位按压 OR 穴位按摩 OR 
指压穴位 耳压 OR 耳针 OR 耳穴 OR 耳豆 OR 埋藏疗法 OR 埋线 
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Study design–related search terms: 
系统评价 OR meta OR 荟萃分析 OR 系统分析 OR 综述 OR 进展 OR 概况 OR 现
状 OR 近况 OR 临床观察 OR 临床评估 OR 临床试验 OR 临床效果 OR 临床研究 
OR 疗效 OR 评价研究 OR 前瞻性 OR 随访 OR 对比研究 OR 多中心 OR 随机 
OR 对照 OR 病例报告 OR 病例研究 OR 病例分析 OR 病例报道  
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Appendix 8 Search terms for English language databases 
Stroke-related search terms: 
stroke OR cerebral infarction OR cerebral haemorrhage OR cerebral vascular disease 
OR cerebral thrombosis OR brain infarction OR brain hemorrhage  
Motor dysfunction–related search terms: 
hemiplegia OR hemiplegic paralysis OR semisideratio OR semisideration OR 
semiplegia OR spasm OR cramp OR motor OR mobility OR posture 
Chinese herbal medicine–related search terms: 
traditional Chinese medicine OR Chinese traditional medicine OR Chinese herbal 
drugs OR Chinese drugs, plant OR medicine, traditional OR ethnopharmacology OR 
ethnomedicine OR ethnobotany OR medicine, kampo OR kanpo OR TCM OR T.C.M. 
OR medicine, ayurvedic OR phytotherapy OR herbology OR plants, medicinal OR 
plant preparations OR plant extracts OR plants, medicine OR materia medica OR 
single prescription OR herbs OR Chinese medicine herb OR herbal medicine 
Acupuncture-related search terms: 
acupuncture OR meridians OR electroacupuncture OR moxibustion OR 
auriculotherapy OR plum blossom OR acupressure OR ear acupuncture OR ear 
acupressure OR acupuncture, ear OR acupuncture therapy OR moxa OR laser 
acupuncture OR seven star needle OR acupuncture analgesia OR acupuncture points 
OR electro-acupuncture OR electro acupuncture OR TENS OR transcutaneous nerve 
stimulation OR transcutaneous electric nerve stimulation OR transcutaneous electrical 
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nerve stimulation OR electro-stimulation OR electro stimulation OR 
pharmacopuncture OR point injection OR catgut embedding  
Study design–related search terms: 
randomised controlled trial: randomised controlled trial OR controlled clinical trial 
OR randomised OR placebo OR drug therapy OR randomly OR trial OR groups OR 
review article: systematic review 
Other studies:  
cohort study OR case-controlled study OR comparative study OR risk factor OR 
cohort OR compared OR groups OR case control OR multivariate OR case series  
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Appendix 9 List of herbs used in this thesis 
Pin yin 
name 
Chinese  
characters 
Common English 
name  
Scientific name Pharmaceutical 
name 
Ai ye 艾叶 Argy Wormwood 
Leaf 
1. Artemisia argyi Lévl. et Vant. Artemisiae 
Argyi Folium 
Ba ji 
tian 
巴戟天 Morinda Root 1. Morinda officinalis How  Morindae 
Officinalis 
Radix 
Bai jie 
zi 
白芥子 Mustard Seed 1. Sinapis alba L. 
2. Brassica juncea (L.) Czern. et 
Coss.   
Sinapis Semen 
Bai shao 白芍 White Peony Root 1. Paeonia lactiflora Pall. Paeoniae Radix 
Alba 
Bai zhi 白芷 Dahurian Angelica 
Root 
1. Angelica dahurica (Fisch. ex 
Hoffm.)  Benth. et Hook. f. 
2. Angelica dahurica (Fisch. ex 
Hoffm.) Benth. et Hook. f. var. 
formosana (Boiss.) Shan et Yuan 
Angelicae 
Dahuricae 
Radix 
Bai zhu 白朮 Largehead 
Atractylodes 
Rhizome 
1. Atractylodes macrocephala 
Koidz. 
Atractylodis 
Macrocephalae 
Rhizoma 
Ban xia 半夏 Pinellia Tuber 1. Pinellia ternata (Thunb.) Breit. Pinelliae 
Rhizoma 
Bing 
pian  
冰片  Borneol 1. Borneol (synthetic) Borneolum 
Syntheticum 
Bo he 薄荷 Peppermint 1. Mentha haplocalyx Briq. Menthae 
Haplocalycis 
Herba  
Cang 
zhu 
苍朮 Atractylodes 
Rhizome 
1. Atractylodes lancea (Thunb.) DC.  
2. Atractylodes chinensis (DC.) 
Koidz. 
Atractylodis 
Rhizoma 
Cao wu 草乌 Kusnezoff 
Monkshood Root 
1. Aconitum kusnezoffii Reichb. Aconiti 
Kusnezoffii 
Radix 
Chen pi 陈皮 Dried Tangerine 
Peel 
1. Citrus reticulata Blanco Citri Reticulatae 
Pericarpium 
Chi 
shao 
赤芍 Red Peony Root 1. Paeonia lactiflora Pall. 
2. Paeonia veitchii Lynch 
Paeoniae Radix 
Rubra  
Chuan 
shan jia 
穿山甲 Pangolin Scales 1. Manis pentadactyla Linnaeus Manis Squama 
Chuan 
wu 
川乌 Prepared Common 
Monkshood 
Mother Root 
1. Aconitum carmichaelii Debx. Aconiti Radix 
Cocta 
Chuan 
xiong 
川芎 Szechwan Lovage 
Rhizome 
1. Ligusticum chuanxiong Hort.  Chuanxiong 
Rhizoma 
Da zao 大枣 Chinese Date 1. Ziziphus jujuba Mill.  Jujubae Fructus 
Dan nan 
xing  
胆南星 Bile Arisaema  1. Arisaema erubescens (Wall.) 
Schott 
2. Arisaema heterophyllum Bl.  
3. Arisaema amurense Maxim. 
Arisaema Cum 
Bile 
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Pin yin 
name 
Chinese  
characters 
Common English 
name  
Scientific name Pharmaceutical 
name 
Dan 
shen 
丹参 Danshen root 1. Salvia miltiorrhiza Bge. Salviae 
Miltiorrhizae 
Radix et 
Rhizoma 
Dang 
gui 
当归 Chinese Angelica 1. Angelica sinensis (Oliv.) Diels Angelicae 
Sinensis Radix 
Dang 
shen 
党参 Tangshen 1. Codonopsis pilosula (Franch.) 
Nannf.  
2. Codonopsis pilosula Nannf. var. 
modesta (Nannf.) L. T. Shen 
3. Codonopsis tangshen Oliv.  
Codonopsis 
Radix 
Di 
huang 
地黄 Rehmannia Root 1. Rehmannia glutinosa Libosch. Rehmanniae 
Radix 
Di long 地龙 Earthworm 1. Pheretima aspergillum (E. 
Perrier)  
2. Pheretima vulgaris Chen 
3. Pheretima guillelmi (Michaelsen) 
4. Pheretima pectinifera Michaelsen 
Pheretima 
Di yu 地榆 Garden Burnet 
Root 
1. Sanguisorba officinalis L.  
2. Sanguisorba officinalis L. var. 
longifolia (Bert.) Yü et Li 
Sanguisorbae 
Radix 
Du huo 独活 Doubleteeth 
Pubescent 
Angelica Root 
1. Angelica pubescens Maxim. f. 
biserrata Shan et Yuan  
Angelicae 
Pubescentis 
Radix 
Du 
zhong 
杜仲 Eucommia Bark 1. Eucommia ulmoides Oliv. Eucommiae 
Cortex 
Fang 
feng 
防风 Divaricate 
Saposhnikovia 
Root 
1. Saposhnikovia divaricata (Turcz.) 
Schischk. 
Saposhnikoviae 
Radix 
Feng mi 蜂蜜 Honey 1. Apis cerana Fabricius  
2. Apis mellifera Linnaeus. 
Mel 
Fu ling 茯苓 Indian Bread 1. Poria cocos (Schw.) Wolf Poria 
Fu ling 
pi 
茯苓皮 Pared Skin of 
Indian Bread 
1. Poria cocos (Schw.) Wolf Poriae Cutis 
Fu ping 浮萍 Common 
Ducksmeat Herb 
1. Spirodela polyrrhiza (L.) Schleid. Spirodelae 
Herba 
Fu zi 附子 Prepared Common 
Monkshood 
Daughter Root 
1. Aconitum carmichaelii Debx.   Aconiti Radix 
Lateralis 
Praeparata 
Gan cao 甘草 Liquorice Root 1. Glycyrrhiza uralensis Fisch. 
2. Glycyrrhiza inflata Bat. 
3. Glycyrrhiza glabra L. 
Glycyrrhizae 
Radix et 
Rhizoma 
Ge gen 葛根 Kudzuvine Root 1. Pueraria lobata (Willd.) Ohwi Puerariae 
Lobatae Radix 
Gou ji 狗脊 Cibot Rhizome 1. Cibotium barometz (L.) J. Sm. Cibotii Rhizoma 
Gou qi 枸杞 Barbary Wolfberry 
Fruit 
1. Lycium barbarum L. Lycii Fructus 
Gou 
teng 
钩藤 Gambir Plant 1. Uncaria rhynchophylla (Miq.) 
Miq. ex Havil. 
2. Uncaria macrophylla Wall. 
3. Uncaria hirsuta Havil.  
4. Uncaria sinensis (Oliv.) Havil. 
5. Uncaria sessilifructus Roxb. 
Uncariae 
Ramulus cum 
Uncis 
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Pin yin 
name 
Chinese  
characters 
Common English 
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Scientific name Pharmaceutical 
name 
Gua lou 瓜蒌 Snakegourd Fruit 1. Trichosanthes kirilowii Maxim. 
2. Trichosanthes rosthronii Harms 
Trichosanthis 
Fructus 
Gua lou 
gen 
瓜蒌根 Snakegourd Root 1. Trichosanthes kirilowii Maxim. 
2. Trichosanthes rosthornii Harms 
Trichosanthis 
Radix 
Gui ban 龟板 Tortoise Carapace 
and Plastron 
1. Chinemys reevesii (Gray) Testudinis 
Carapax et 
Plastrum 
Gui zhi 桂枝 Cassia Twig 1. Cinnamomum cassia Presl Cinnamomi 
Ramulus 
Hai zao 海藻 Seaweed 1. Sargassum pallidum (Turn.) C. 
Ag 
2. Sargassum fusiforme (Harv.) 
Setch.  
Sargassum 
Hong 
hua 
红花 Safflower 1. Carthamus tinctorius L.  Carthami Flos 
Hua jiao 花椒 Pricklyash Peel 1. Zanthoxylum schinifolium Sieb. et 
Zucc.  
2. Zanthoxylum bungeanum Maxim. 
Zanthoxyli 
Pericarpium 
Huang 
qi 
黄芪 Milkvetch Root 1. Astragalus membranaceus 
(Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
2. Astragalus membranaceus 
(Fisch.) Bge.  
Astragali Radix 
Huang 
qin 
黄芩 Baical Skullcap 
Root 
1. Scutellaria baicalensis Georgi Scutellariae 
Radix 
Ji xue 
teng 
鸡血藤 Suberect 
Spatholobus Stem 
1. Spatholobus suberectus Dunn Spatholobi 
Caulis 
Jiang 
can 
僵蚕 Stiff Silkworm 1. Bombyx mori Linnaeus.  
2. Beauveria bassiana (Bals.) 
Vuillant 
Bombyx 
Batryticatus 
Jie geng 桔梗 Platycodon Root 1. Platycodon grandiflorum (Jacq.) 
A. DC. 
Platycodonis 
Radix 
Long 
nao 
龙脑 Natural Borneol Borneo (natural) mainly derived 
from   1. Dryobalanops aromatica 
Gaertn. f. 
a,b,c  
2. Cinnamomum camphora (L.) 
Presl 
a
 
Borneolum  
Lu jiao 
jiao 
鹿角胶 Deerhorn Glue 1. Cervus elaphus Linnaeus 
2. Cervus nipponTemminck 
Cervi Cornus 
Colla 
Lu lu 
tong 
路路通 Beautiful 
Sweetgum Fruit 
1. Liquidambar formosana Hance Liquidambaris 
Fructus 
Ma 
huang 
麻黄 Ephedra 1. Ephedra sinica Stapf 
2. Ephedra equisetina Bge. 
3. Ephedra intermedia Schrenk et 
C.A. Mey. 
Ephedrae Herba  
Ma qian 
zi 
马钱子 Nux Vomica 1. Strychnos nux-vomica L.  Strychni Semen 
Mai 
dong  
麦冬 Dwarf Lilyturf 
Tuber 
1. Ophiopogon japonicus (L.f) Ker-
Gawl. 
Ophiopogonis 
Radix 
Mo yao 没药 Myrrh 1. Commiphora myrrha Engl. 
2. Commiphora molmol Engl. 
Myrrha 
Mu gua 木瓜 Common 
Floweringqince 
Fruit 
1. Chaenomeles speciosa (Sweet) 
Nakai 
Chaenomelis 
Fructus 
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name 
Chinese  
characters 
Common English 
name  
Scientific name Pharmaceutical 
name 
Niu 
huang 
牛黄 Cow-bezoar 1. Bos taurus domesticus Gmelin Bovis Calculus 
Niu xi 牛膝 Twotoothed 
Achyranthes Root 
1. Achyranthes bidentata Bl. Achyranthis 
Bidentatae 
Radix 
Qiang 
huo 
羌活 Incised 
Notopterygium 
Rhizome or Root 
1. Notopterygium incisum Ting ex 
H. T. Chang 
2. Notopterygium franchetii H. de 
Boiss. 
Notopterygii 
Rhizoma et 
Radix 
Qin jiao 秦艽 Largeleaf Gentian 
Root 
1. Gentiana macrophylla Pall. 
2. Gentiana straminea Maxim. 
3. Gentiana crassicaulis Duthie ex 
Burk.  
4. Gentiana dahurica Fisch. 
Gentianae 
Macrophyllae 
Radix 
Quan 
xie 
全蝎 Scorpion 1. Buthus martensii Karsch Scorpio 
Ren 
dong 
teng 
忍冬藤 Honeysuckle Stem 1. Lonicera japonica Thunb. Lonicerae 
Japonicae 
Caulis 
Ren 
shen 
人参 Ginseng 1. Panax ginseng C. A. Mey. Ginseng Radix 
et Rhizoma  
Rou gui 肉桂 Cassia Bark 1. Cinnamomum cassia Presl  Cinnamomi 
Cortex 
Ru 
xiang 
乳香 Olibanum 1. Boswellia carterii Birdw.  
2. Boswellia bhaw-dajiana Birdw. 
Olibanum 
Sang ji 
sheng 
桑寄生 Chinese Taxillus 
Twig 
1. Taxillus chinensis (DC.) Danser Taxilli Herba 
Sang zhi 桑枝 Mulberry Twig 1. Morus alba L. Mori Ramulus 
Shan 
yao 
山药 Common Yam 
Rhizome 
1. Dioscorea opposita Thunb. Dioscoreae 
Rhizoma 
Shan 
zha 
山楂 Hawthorn Fruit 1. Crataegus pinnatifida Bge. var. 
major N.E. Br. 
2. Crataegus pinnatifida Bge. 
Crataegi Fructus 
Shan 
zhu yu 
山茱萸 Asiatic Cornelian 
Cherry Fruit 
1. Cornus officinalis Sieb. et Zucc. Corni Fructus 
She 
xiang 
麝香 Musk 1. Moschus berezovskii Flerov 
2. Moschus sifanicus Przewalski 
3. Moschus moschiferus Linnaeus 
Moschus 
Shen jin 
cao 
伸筋草 Common 
Clubmoss Herb 
1. Lycopodium japonicum Thunb. Lycopodii 
Herba 
Sheng di 
huang 
生地黄 Unprocessed 
Rehmannia Root 
1. Rehmannia glutinosa Libosch. Rehmanniae 
Radix 
Sheng 
jiang 
生姜 Fresh Ginger 1. Zingiber officinale Rosc. Zingiberis 
Rhizoma 
Recens 
Shi 
chang 
pu 
石菖蒲 Grassleaf 
Sweetflag 
Rhizome 
1. Acorus tatarinowii Schott Acori 
Tatarinowii 
Rhizoma 
Shi gao 石膏 Gypsum 1. Hydrated calcium sulfate  Gypsum 
Fibrosum 
Shi hu 石斛 Dendrobium 1. Dendrobium nobile Lindl. 
2. Dendrobium chysotoxum Lindl.  
3. Dendrobium fimbriatum Hook. 
Dendrobii 
Caulis 
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Chinese  
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Shi nan 石楠 Chinese Photinia 
Leaf 
Photinia serrulata Lindl. (Not available) 
Shu di 
huang 
熟地黄 Prepared 
Rehmannia Root 
1. Rehmannia glutinosa Libosch. Rehmanniae 
Radix 
Praeparata 
Su mu
a
 苏木 a Sappan wood 1. Caesalpinia sappan L. Sappan Lignum 
Tan 
xiang 
檀香 Sandalwood 1. Santalum album L. Santali Albi 
Lignum 
Tao ren 桃仁 Peach Seed 1. Prunus persica (L.) Batsch 
2. Prunus davidiana (Carr.) Franch. 
Persicae Semen 
Tian ma 天麻 dongguan 1. Gastrodia elata Bl. Gastrodiae 
Rhizoma 
Tian zhu 
huang 
天竺黄 Tabasheer 1. Bambusa textilis McClure 
2. Schizostachyum chinense Rendle 
Bambusae 
Concretio 
Silicea 
Tong 
you 
桐油 Tung oil Vernicia fordii (Hemsl.) Airy Shaw (Not available) 
Tou gu 
cao
b,c
 
透骨草 b,c N/A 1. Speranskia tuberculata(Bunge) 
Baill
b,c 
2.
 
Impatiens balsamina L.
c
 
Speranskiae 
Tuberculatae 
Herba
b
    
Tu bie 
chong  
土鳖虫 Ground Beetle 1. Eupolyphaga sinensis Walker  
2. Steleophaga plancyi (Boleny) 
Eupolyphaga/ 
Steleophaga 
Wang 
jiang 
nan 
望江南 (Not available) Cassia occidentalis Linn. (Not available) 
Wei ling 
xian 
威灵仙 Chinese Clematis 
Root 
1. Clematis chinensis Osbeck  
2. Clematis hexapetala Pall. 
3. Clematis manshurica Rupr.  
Clematidis 
Radix et 
Rhizoma 
Wu 
gong 
蜈蚣 Centipede 1. Scolopendra subspinipes mutilans 
L. Koch 
Scolopendra 
Wu mei 乌梅 Smoked Plum 1. Prunus mume (Sieb.) Sieb. et 
Zucc. 
Mume Fructus 
Wu shao 
she 
乌梢蛇 Black-tail Snake 1. Zaocys dhumnades (Cantor) Zaocys 
Wu wei 
zi 
五味子 Chinese 
Magnoliavine 
Fruit 
1. Schisandra chinensis (Turcz.) 
Baill. 
Schisandrae 
Chinensis 
Fructus 
Wu yao 乌药 Combined 
Spicebush Root 
1. Lindera aggregata (Sims) 
Kosterm. 
Linderae Radix 
Xi xian 
cao 
豨莶草 Siegesbeckia Herb 1. Siegesbeckia orientalis L.  
2. Siegesbeckia pubescens Makino  
3. Siegesbeckia glabrescens Makino  
Siegesbeckiae 
Herba 
Xi xin 细辛 Manchurian 
Wildginger Root 
1. Asarum heterotropoides Fr. 
Schmidt var. mandshuricum 
(Maxim) Kitag. 
2. Asarum sieboldii Miq. var. 
seoulense Nakai  
3. Asarum sieboldii Miq.  
Asari Radix et 
Rhizoma 
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Xing ren 杏仁 Bitter Apricot 
Seed 
1. Prunus armeniaca L. var. ansu 
Maxim.  
2. Prunus sibirica L.  
3. Prunus mandshurica (Maxim.) 
Koehne  
4. Prunus armeniaca L.  
Armeniacae 
Semen Amarum 
Xu duan 续断 Himalayan Teasel 
Root 
1. Dipsacus asper Wall. ex Henry Dipsaci Radix 
Xuan 
shen 
玄参 Figwort Root 1. Scrophularia ningpoensis Hemsl. Scrophulariae 
Radix 
Xue jie 血竭 Dragon's Blood 1. Daemonorops draco Bl. Draconis 
Sanguis 
Yin yu 茵芋 Skimmia japonica 1. Skimmia reevesiana Fort 
2. Skimmia arborescens Anders. 
(Not available) 
You 
song jie 
油松节 Tabularformed 
Pine Node 
1. Pinus tabulieformis Carr. 
2. Pinus massoniana Lamb.  
Pini Lignum 
Nodi 
Yuan zhi 远志 Thinleaf Milkwort 
Root 
1. Polygala tenuifolia Willd. 
2. Polygala sibirica L.  
Polygalae Radix 
Zao jia 皂荚 Chinese 
Honeylocust 
Abnormal Fruit 
1. Gleditsia sinensis Lam. Gleditsiae 
Fructus 
Abnormalis 
Ze xie 泽泻 Oriental 
Waterplantain 
Rhizome 
1. Alisma orientalis (Sam.) Juzep. Alismatis 
Rhizoma 
Zhi shi 枳实 Immature Orange 
Fruit 
1. Citrus aurantium L. 
2. Citrus sinensis Osbeck   
Aurantii Fructus 
Immaturus 
Zhu li 竹沥 Bomboo Juice 1. PhyILostachys nigra( Lodd.) 
Munrovar. henonis (Mitf.) Stapf ex 
Rendle 
2. Bambusa tuldoides Munro. 
3. 
Sinocalamus beecheyanus (Munro) 
McClure var.pubescens P.F.Li 
(Not available) 
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Appendix 10 PRISMA checklist for Chinese herbal medicine systematic review 
Section/topic  # Checklist item  Reported 
on page 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis or both.  Not 
applicable 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key findings; systematic review 
registration number.  
Not 
applicable 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4‒7 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
7‒8 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g. web address) and, if 
available, provide registration information including registration number.  
77 
Eligibility criteria  6 Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics (e.g. 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
79‒80 
Information sources  7 Describe all information sources (e.g. databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
77‒78 
Search  8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
Appendix 
7 & 8 
Study selection  9 State the process for selecting studies (i.e. screening, eligibility, included in systematic review 
and, if applicable, included in the meta-analysis).  
79‒80 
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Section/topic  # Checklist item  Reported 
on page 
Data collection 
process  
10 Describe method of data extraction from reports (e.g. piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
80‒81 
Data items  11 List and define all variables for which data were sought (e.g. PICOS, funding sources) and 
any assumptions and simplifications made.  
Not 
applicable 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level) and how this information is to be used 
in any data synthesis.  
81 
Summary measures  13 State the principal summary measures (e.g. risk ratio, difference in means).  82 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g. I2) for each meta-analysis.  
82 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. 
publication bias, selective reporting within studies).  
81 
Additional analyses  16 Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
82 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
83‒84 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g. study size, PICOS, 
follow-up period) and provide the citations.  
84‒104 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see 
Item 12).  
105‒106 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
118‒131 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
116‒129 
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Section/topic  # Checklist item  Reported 
on page 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15). 105‒106 
Additional analysis  23 Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
129‒131 
DISCUSSION   
Summary of evidence  24 Summarise the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g. healthcare providers, users and policymakers).  
132 
Limitations  25 Discuss limitations at study and outcome level (e.g. risk of bias) and at review level (e.g. 
incomplete retrieval of identified research, reporting bias).  
139‒141 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence and 
implications for future research.  
142 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g. supply of data); 
role of funders for the systematic review.  
Not 
applicable 
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Appendix 11 PRISMA checklist for electro-acupuncture systematic review 
Section/topic  # Checklist item  
Reported 
on page 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis or both.  Not 
applicable 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key findings; systematic review 
registration number.  
Not 
applicable 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4‒7, 143‒
146 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
7‒8 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g. web address) and, if 
available, provide registration information including registration number.  
143 
Eligibility criteria  6 Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics (e.g. 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
77 
Information sources  7 Describe all information sources (e.g. databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
77 
Search  8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
Appendix 7 
& 8 
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Section/topic  # Checklist item  
Reported 
on page 
Study selection  9 State the process for selecting studies (i.e. screening, eligibility, included in systematic 
review and, if applicable, included in the meta-analysis).  
79‒80 
Data collection 
process  
10 Describe method of data extraction from reports (e.g. piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
80-81 
Data items  11 List and define all variables for which data were sought (e.g. PICOS, funding sources) and 
any assumptions and simplifications made.  
Not 
applicable 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level) and how this information is to be 
used in any data synthesis.  
81 
Summary measures  13 State the principal summary measures (e.g. risk ratio, difference in means).  82 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g. I2) for each meta-analysis.  
82 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. 
publication bias, selective reporting within studies).  
81 
Additional analyses  16 Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
82 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
165‒166 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g. study size, PICOS, 
follow-up period) and provide the citations.  
167‒174 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see 
Item 12).  
174‒176 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
177‒185 
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Section/topic  # Checklist item  
Reported 
on page 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
177‒185 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  174‒176 
Additional analysis  23 Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
177‒185 
DISCUSSION   
Summary of evidence  24 Summarise the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g. healthcare providers, users and policymakers).  
191‒192 
Limitations  25 Discuss limitations at study and outcome level (e.g. risk of bias) and at review level (e.g. 
incomplete retrieval of identified research, reporting bias).  
198‒200 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence and 
implications for future research.  
201 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g. supply of data); 
role of funders for the systematic review.  
Not 
applicable 
  
342 
 
Appendix 12 SPIRIT 2013 checklist for electro-acupuncture pilot trial 
SPIRIT 2013 Checklist 
Section/item Item 
No 
Description Addressed 
on page 
number 
Administrative information 
Title 1 Descriptive title identifying the study design, population, interventions and, if applicable, trial 
acronym. 
Not 
applicable 
Title 
registration 
2a Trial identifier and registry name. If not yet registered, name of intended registry. /(TBC) 
2b All items from the World Health Organization Trial Registration Data Set. /(TBC) 
Protocol 
version 
3 Date and version identifier. Not 
applicable 
Funding 4 Sources and types of financial, material and other support. 241 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors. Not 
applicable 
5b Name and contact information for the trial sponsor. 241 
5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, 
and interpretation of data; writing of the report; and the decision to submit the report for 
publication, including whether they will have ultimate authority over any of these activities. 
Not 
applicable 
5d Composition, roles, and responsibilities of the coordinating centre, steering committee, 
endpoint adjudication committee, data management team, and other individuals or groups 
overseeing the trial, if applicable (see Item 21a for data monitoring committee). 
Not 
applicable 
Introduction 
Background 
and rationale 
6a Description of research question and justification for undertaking the trial, including summary 
of relevant studies (published and unpublished) examining benefits and harms for each 
intervention. 
202‒204 
6b Explanation for choice of comparators. 202‒204 
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Section/item Item 
No 
Description Addressed 
on page 
number 
Objectives 7 Specific objectives or hypotheses 205 
Trial design 8 Description of trial design including type of trial (e.g. parallel group, crossover, factorial, single 
group), allocation ratio, and framework (e.g. superiority, equivalence, noninferiority, 
exploratory). 
205 
Methods: Participants, interventions and outcomes 
Study setting 9 Description of study settings (e.g. community clinic, academic hospital) and list of countries 
where data will be collected. Reference to where list of study sites can be obtained. 
207 
Eligibility 
criteria 
10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study 
centres and individuals who will perform the interventions (e.g. surgeons, psychotherapists). 
208 
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when 
they will be administered. 
210‒209 
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (e.g. 
drug dose change in response to harms, participant request or improving/worsening disease). 
211‒212 
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring 
adherence (e.g. drug tablet return, laboratory tests). 
Not 
applicable 
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial. 205‒209 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (e.g. 
systolic blood pressure), analysis metric (e.g. change from baseline, final value, time to event), 
method of aggregation (e.g. median, proportion), and time point for each outcome. Explanation 
of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended. 
209‒211 
Participant 
timeline 
13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, 
and visits for participants. A schematic diagram is highly recommended (see fig 1). 
202 
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was 
determined, including clinical and statistical assumptions supporting any sample size 
calculations. 
212-213 
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Section/item Item 
No 
Description Addressed 
on page 
number 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size. 230 
Methods: Assignment of interventions (for controlled trials) 
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (e.g. computer-generated random numbers) and 
list of any factors for stratification. To reduce predictability of a random sequence, details of 
any planned restriction (e.g. blocking) should be provided in a separate document that is 
unavailable to those who enroll participants or assign interventions. 
205 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (e.g. central telephone; sequentially 
numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until 
interventions are assigned. 
205 
Implementation 16c Who will generate the allocation sequence, who will enroll participants, and who will assign 
participants to interventions. 
205 
Blinding 
(masking) 
17a Who will be blinded after assignment to interventions (e.g. trial participants, care providers, 
outcome assessors, data analysts) and how. 
205 
17b If blinded, circumstances under which unblinding is permissible and procedure for revealing a 
participant’s allocated intervention during the trial. 
205 
Methods: Data collection, management and analysis 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any 
related processes to promote data quality (e.g. duplicate measurements, training of assessors) 
and a description of study instruments (e.g. questionnaires, laboratory tests) along with their 
reliability and validity, if known. Reference to where data collection forms can be found, if not 
in the protocol. 
209‒211 
18b Plans to promote participant retention and complete follow-up, including list of any outcome 
data to be collected for participants who discontinue or deviate from intervention protocols. 
Not 
applicable 
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Section/item Item 
No 
Description Addressed 
on page 
number 
Data 
management 
19 Plans for data entry, coding, security, and storage, including any related processes to promote 
data quality (e.g. double data entry; range checks for data values). Reference to where details of 
data management procedures can be found, if not in the protocol. 
212 
Statistical 
methods 
20a Statistical methods for analysing primary and secondary outcomes. Reference to where other 
details of the statistical analysis plan can be found, if not in the protocol. 
213‒215 
20b Methods for any additional analyses (e.g. subgroup and adjusted analyses). 213‒215 
20c Definition of analysis population relating to protocol non-adherence (e.g. as randomised 
analysis) and any statistical methods to handle missing data (e.g. multiple imputation). 
213‒215 
Methods: Monitoring 
Data 
monitoring 
21a Composition of data monitoring committee (DMC); summary of its role and reporting 
structure; statement of whether it is independent from the sponsor and competing interests; and 
reference to where further details about its charter can be found, if not in the protocol. 
Alternatively, an explanation of why a DMC is not needed. 
211 
21b Description of any interim analyses and stopping guidelines, including who will have access to 
these interim results and make the final decision to terminate the trial. 
211 
Harms 22 Plans for collecting, assessing, reporting and managing solicited and spontaneously reported 
adverse events and other unintended effects of trial interventions or trial conduct. 
211 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be 
independent from investigators and the sponsor. 
211 
Ethics and dissemination 
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval. 215 
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Section/item Item 
No 
Description Addressed 
on page 
number 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (e.g. changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators). 
Not 
applicable 
Consent or 
assent 
26a Who will obtain informed consent or assent from potential trial participants or authorised 
surrogates, and how (see Item 32). 
/(TBC) 
26b Additional consent provisions for collection and use of participant data and biological 
specimens in ancillary studies, if applicable. 
Not 
applicable 
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared 
and maintained in order to protect confidentiality before, during and after the trial. 
203‒204 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators for the overall trial and each 
study site. 
Not 
applicable 
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual 
agreements that limit such access for investigators. 
212 
Ancillary and 
post-trial care 
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer 
harm from trial participation. 
211 
Dissemination 
policy 
31a Plans for investigators and sponsor to communicate trial results to participants, healthcare 
professionals, the public and other relevant groups (e.g. via publication, reporting in results 
databases, or other data-sharing arrangements), including any publication restrictions. 
Not 
applicable 
31b Authorship eligibility guidelines and any intended use of professional writers. Not 
applicable 
31c Plans, if any, for granting public access to the full protocol, participant-level dataset and 
statistical code. 
Not 
applicable 
Appendices 
Informed 
consent 
materials 
32 Model consent form and other related documentation given to participants and authorised 
surrogates. 
Not 
applicable 
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Section/item Item 
No 
Description Addressed 
on page 
number 
Biological 
specimens 
33 Plans for collection, laboratory evaluation and storage of biological specimens for genetic or 
molecular analysis in the current trial and for future use in ancillary studies, if applicable. 
Not 
applicable 
Notes: Amendments to the protocol should be tracked and dated. The SPIRIT checklist belongs to the SPIRIT Group and is reproduced by BMJ with 
their permission. 
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Appendix 13 STRICTA checklist for electro-acupuncture pilot trial 
Item Detail Page 
1. 
Acupuncture 
rationale 
(a) Style of acupuncture (e.g. TCM, Japanese, Korean, Western medical, Five Element, ear acupuncture, 
etc). 
198 
(b) Reasoning for treatment provided, based on historical context, literature sources, and consensus 
methods, with references where appropriate. 
198 
(c) Extent to which treatment was varied. 205 
2. Details of 
needling 
(a) Number of needle insertions per subject per session (mean and range where relevant). 205‒209 
(b) Names (or location if no standard name) of points used (uni/bilateral). 205‒209 
(c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level. 205‒209 
(d) Response sought (e.g. de qi or muscle twitch response). 205‒209 
(e) Needle stimulation (e.g. manual, electrical). 205‒209 
(f) Needle retention time. 205‒209 
(g) Needle type (diameter, length, and manufacturer or material). 205‒209 
3. Treatment 
regimen 
(a) Number of treatment sessions. 205‒209 
(b) Frequency and duration of treatment sessions. 205‒209 
4. Other 
components 
of treatment 
(a) Details of other interventions administered to the acupuncture group (e.g. moxibustion, cupping, herbs, 
exercises, lifestyle advice). 
205‒209 
(b) Setting and context of treatment, including instructions to practitioners, and information and 
explanations to patients. 
205‒209 
5. 
Practitioner 
background 
Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture 
practice, other relevant experience). 
206 
6. Control or 
comparator 
interventions 
(a) Rationale for the control or comparator in the context of the research question, with sources that justify 
this choice. 
205‒206 
(b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-
like control is used, provide details as for Items 1 to 3 above. 
205‒206 
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Appendix 14 Ethics Approval Notice from Guangdong Provincial Hospital of 
Chinese Medicine (translated English version) 
Date Apporval 
Number 
Changes Related revised 
documents 
28 October 
2016 
B2016-204-01 / / 
8 December 
2016 
B2016-204-02 The amount of transport 
allowance was added to 
informed consents 
1) informed consents 
27 February 
2017 
B2016-204-03 inclusion criteria (‘30 days 
post-stroke’ was revised to ‘30 
days to one year post-stroke’) 
1) trial protocol; 
2) Recruitment 
posters and 
documents 
18 August 
2017 
B2016-204-04 Outcome measure (Functional 
Independence Measure was 
replaced by Barthel Index) 
1) trial protocol; 
2) Case report form; 
3) SOP for 
investigators 
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Approval Notice (Translation Copies) AF/04-06.0/10.0 
Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine 
Approval Notice 
No. of approval notice: B2016-204-01 
Date 28 October 2016 
Location Room 2005-2006, 20th Floor, Research Building, Guangdong 
Provincial Hospital of Chinese Medicine, No 111 Dade Road, Yuexiu 
District, Guangzhou, Guangdong Province, China 
Funding Not applicable 
Research 
Project 
Electro-acupuncture for post-stroke spasticity: a randomised controlled 
trial 
Related 
documents 
1. Ethics review application form (Version 1.0, 20 September 2016) 
2. Statement of economic interests (Zehuai Wen) 
3. Study protocol (Version 1.0, 20 September 2016) 
4. Case report form, Electro-acupuncture treatment record form, 
Screening questionnaire, General information record form (Version 
1.0, 20 September 2016) 
5. SOP for investigators (Version 1.0, 20 September 2016) 
6. List of research fellows (Version 1.0, 20 September 2016) , 
Curriculum Vitae of principle investigator (Zehuai Wen) 
7. Notice and poster for recruitment (Version 1.0, 20 September 2016) 
8. Informed consent (Version 1.0, 20 September 2016) 
Affiliation of 
principal 
investigator 
Guangdong Provincial Hospital of Chinese Medicine, China-Australia 
International Research Centre of Chinese Medicine 
Research 
institutions 
Guangdong Provincial Hospital of Chinese Medicine, RMIT University 
Principal 
investigator 
Zehuai Wen 
Members of 
ethics 
committee 
Jun Liu, Xing Zeng, Xusheng Liu, Yan Li, Yini Luo, Bojian Chen, 
Yong Li, Likai Li 
Comments of 
ethics review 
According to the principle of ‘The Quality Control Standard for Drug 
Clinical Trials’, ‘Clinical Trial Ethics Review Guidelines’ of China 
Food and Drug Administration, ‘Ethical Review Methods for 
Biomedical Research Involving Human Subjects’ of National Health 
and Family Planning Commission of the People’s Republic of China, 
World Medical Association Declaration of Helsinki (2013), as well as 
International Ethical Guidelines for Biomedical Research Involving 
Human Subjects, the study ‘Electro-acupuncture for Post-stroke 
Spasticity: a randomised controlled trial’ was approved by the Ethics 
Committee of Guangdong Provincial Hospital of Chinese Medicine. 
351 
 
Statement of 
Ethics 
Committee 
The approval notice would also be stored for record. The ethics 
committee could be contacted if any disagreement on the feasibility of 
the trail (including the qualification of the investigators, equipment 
involved in the trial, or any other questions) is under concern. The 
ethics committee should be informed if there is an early stop, 
suspending, or completion of the study. Any severe adverse event 
should be reported to the ethics committee in time. Any revision to the 
study protocol or informed consent, or change to the principle 
investigator should also be reported to the ethics committee and a new 
ethical review would be required. Besides, any action against the 
consent of participants needs to be reported to the ethics committee. 
Reports of research progress or conclusion report need to be submitted 
to the ethics committee at least one month before the due date. 
Period of 
validity 
28 October 2016 to 28
 
October 
2018 
Frequency of follow-up 
ethical review 
Once a year 
Predicted date for next ethical review 28 October 2017 
Contact 
telephone 
Number 
+86-020-81887233 ext. 35943 Person to contact 
Xiaoyan Li 
Chief of the Ethics Committee 
Jun Liu 
Guangdong Provincial Hospital of Chinese Medicine (Sealed) 
Date: 28 October 2016 
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Approval Notice (Translation Copies) AF/04-06.0/10.0 
Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine 
Approval Notice 
No. of approval notice: B2016-204-02 
Date -   
Location -   
Funding -   
Research Project Electro-acupuncture for post-stroke spasticity: a randomised 
controlled trial 
Documents for 1. Ethics review application form for revising documents 
ethics review 2. Informed consent (Version 2.0, 5 December 2016) 
Affiliation of 
principal 
Investigator 
Guangdong Provincial Hospital of Chinese Medicine, China-
Australia International Research Centre of Chinese Medicine 
Research 
institutions 
Guangdong Provincial Hospital of Chinese Medicine, RMIT 
University 
Principal 
Investigator 
Zehuai Wen   
Review form  Quick review   
Members of Ethics 
Committee 
Yan Li   
Comments of ethics 
review 
According to the principle of ‘The Quality Control Standard for 
Drug Clinical Trials’, ‘Clinical Trial Ethics Review Guidelines’ 
of China Food and Drug Administration, ‘Ethical Review 
Methods for Biomedical Research Involving Human Subjects’ of 
National Health and Family Planning Commission of the 
People’s Republic of China, World Medical Association 
Declaration of Helsinki (2013), as well as International Ethical 
Guidelines for Biomedical Research Involving Human Subjects, 
the study ‘Electro-acupuncture for Post-stroke Spasticity: a 
randomised controlled trial’ was approved by the Ethics 
Committee of Guangdong Provincial Hospital of Chinese 
Medicine. 
Statement of Ethics 
Committee 
The approval notice would also be stored for record. The ethics 
committee could be contacted if any disagreement on the 
feasibility of the trail (including the qualification of the 
investigators, equipment involved in the trial, or any other 
questions) is under concern. The ethics committee should be 
informed if there is an early stop, suspending, or completion of 
the study. Any severe adverse event should be reported to the 
ethics committee in time. Any revision to the study protocol or 
informed consent, or change to the principle investigator should 
also be reported to the ethics committee and a new ethical review 
would be required. Besides, any action against the consent of 
participants needs to be reported to the ethics committee. Reports 
of research progress or conclusion report need to be submitted to 
the ethics committee at least one month before the due date. 
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Period of validity 28 October 2016 to 28
 
October 2018 
Frequency of follow-up 
ethical review 
Once a year 
Predicted date for next ethical review 28 October 2017 
Contact telephone 
Number 
+86-020-81887233 
ext. 35943 
Person to contact Xiaoyan Li 
Chief of the Ethics Committee Jun Liu 
Guangdong Provincial Hospital of Chinese Medicine (Sealed) 
Date: 8 December 2016 
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Approval Notice (Translation Copies) AF/04-06.0/10.0 
Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine 
Approval Notice 
No. of approval notice: B2016-204-03 
ate 27 February 2017 
Location – 
Funding – 
Research 
Project 
Electro-acupuncture for post-stroke spasticity: a randomised 
controlled trial 
Documents for 
ethics review 
1. Ethics review application form for revising documents 
2. SOP for investigators (Version 2.0, 22 February 2017) 
3. Notice and poster for recruitment (Version 2.0, 22 February 2017) 
Affiliation of 
principal 
Investigator 
Guangdong Provincial Hospital of Chinese Medicine, China-
Australia International Research Centre of Chinese Medicine 
Research 
institutions 
Guangdong Provincial Hospital of Chinese Medicine, RMIT 
University 
Principal 
Investigator 
Zehuai Wen 
Review form Quick review 
Members of 
Ethics 
Committee 
Yan Li 
Comments of 
ethics review 
According to the principle of ‘The Quality Control Standard for Drug 
Clinical Trials’, ‘Clinical Trial Ethics Review Guidelines’ of China 
Food and Drug Administration, ‘Ethical Review Methods for 
Biomedical Research Involving Human Subjects’ of National Health 
and Family Planning Commission of the People’s Republic of China, 
World Medical Association Declaration of Helsinki (2013), as well 
as International Ethical Guidelines for Biomedical Research 
Involving Human Subjects, the study ‘Electro-acupuncture for Post-
stroke Spasticity: a randomised controlled trial’ was approved by the 
Ethics Committee of Guangdong Provincial Hospital of Chinese 
Medicine. 
Statement of 
Ethics 
Committee 
The approval notice would also be stored for record. The ethics 
committee could be contacted if any disagreement on the feasibility 
of the trail (including the qualification of the investigators, equipment 
involved in the trial, or any other questions) is under concern. 
The ethics committee should be informed if there is an early stop, 
suspending, or completion of the study. Any severe adverse event 
should be reported to the ethics committee in time. Any revision to 
the study protocol or informed consent, or change to the principle 
investigator should also be reported to the ethics committee and a 
new ethical review would be required. 
Besides, any action against the consent of participants needs to be 
reported to the ethics committee. Reports of research progress or 
conclusion report needato be submitted to the ethics committee at 
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least one month before the due date. 
Period of 
validity 
28 October 2016 to 28
 
October 2018 
Frequency of follow-up 
ethical review 
Once a year 
Predicted date for next ethical review 28 October 2017 
Contact 
telephone 
Number 
+86-020-81887233 ext. 
35943 
Person to contact Xiaoyan Li 
Chief of the Ethics Committee Jun Liu 
Guangdong Provincial Hospital of Chinese Medicine (Sealed) 
Date: 27 February 2017 
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Approval Notice (Translation Copies) AF/04-06.0/10.0 
Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine 
Approval Notice 
No. of approval notice: B2016-204-04 
Date 18 August 2017 
Location – 
Funding – 
Research Project Electro-acupuncture for post-stroke spasticity: a randomised 
controlled trial 
Documents for 
ethics review 
1. Ethics review application form for revising documents 
2. Trial protocol (Version 3.0, 16 August 2017) 
3. SOP for investigators (Version 3.0, 16 August 2017) 
4. Case report form (Version 2.0, 16 August 2017) 
Affiliation of 
principal 
Investigator 
Guangdong Provincial Hospital of Chinese Medicine, China-
Australia International Research Centre of Chinese Medicine 
Research 
institutions 
Guangdong Provincial Hospital of Chinese Medicine, RMIT 
University 
Principal 
Investigator 
Zehuai Wen 
Review form Quick review 
Members of Ethics 
Committee 
Yini Luo 
Comments of 
ethics review 
According to the principle of ‘The Quality Control Standard for 
Drug Clinical Trials’, ‘Clinical Trial Ethics Review Guidelines’ of 
China Food and Drug Administration, ‘Ethical Review Methods 
for Biomedical Research Involving Human Subjects’ of National 
Health and Family Planning Commission of the People’s Republic 
of China, World Medical Association Declaration of Helsinki 
(2013), as well as International Ethical Guidelines for Biomedical 
Research Involving Human Subjects, the study ‘Electro-
acupuncture for Post-stroke Spasticity: a randomised controlled 
trial’ was approved by the Ethics Committee of Guangdong 
Provincial Hospital of Chinese Medicine. 
Statement of 
Ethics Committee 
The approval notice would also be stored for record. The ethics 
committee could be contacted if any disagreement on the 
feasibility of the trail (including the qualification of the 
investigators, equipment involved in the trial, or any other 
questions) is under concern. The ethics committee should be 
informed if there is an early stop, suspending, or completion of the 
study. Any severe adverse event should be reported to the ethics 
committee in time. Any revision to the study protocol or informed 
consent, or change to the principle investigator should also be 
reported to the ethics committee and a new ethical review would 
be required. Besides, any action against the consent of participants 
needs to be reported to the ethics committee. Reports of research 
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progress or conclusion report need to be submitted to the ethics 
committee at least one month before the due date. 
Period of validity 28 October 2016 to 
28
 
October 2018 
Frequency of follow-
up ethical review 
Once a year 
Predicted date for next ethical review 28 October 2017 
Contact telephone 
Number 
+86-020-81887233 
ext. 35943 
Person to contact Xiaoyan Li 
Chief of the Ethics Committee Jun Liu 
Guangdong Provincial Hospital of Chinese Medicine (Sealed) 
Date: 18 August 2017 
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Appendix 15 Ethics Approval Notice from Guangdong Provincial Hospital of 
Chinese Medicine (original Chinese version) 
日期 批号 修改 相关文件 
2016年 10月 28
日 
B2016-204-
01 
/ / 
2016年 12月 8日 B2016-204-
02 
在知情同意书中增加交
通补贴 
1）知情同意书 
2017年 2月 27日 
 
B2016-204-
03 
 
纳入标准之一’卒中后 30
天以后’修改为’卒中后
30天至 1年’ 
1）研究方案； 
2）招募海报和通
知 
2017年 8月 18日 B2016-204-
04 
次要结局指标之一’功能
独立性评分’修改为’巴
氏指数’ 
1）研究方案； 
2）病例报告表； 
3）研究者手册 
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Appendix 16 Notice of RMIT Registration of an Approved External Human 
Research Ethics Application 
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